CA2971626C - Gene editing through microfluidic delivery - Google Patents

Abstract

Gene editing can be performed by introducing gene-editing components into a cell by mechanical cell disruption. Related apparatus, systems, techniques, and articles are also described. The methods and systems of the invention solve the problem of intracellular delivery of gene editing components and gene editing complexes to target cells. The results described herein indicate that delivery of gene editing components, e.g., protein, ribonucleic acid (RNA), and deoxyribonucleic acid (DNA), by mechanical disruption of cell membranes leads to successful gene editing. Because intracellular delivery of gene editing materials is a current challenge, the methods provide a robust mechanism to engineer target cells without the use of potentially harmful viral vectors or electric fields.

Description

GENE EDITING THROUGH MICROFLUIDIC DELIVERY RELATED APPLICATIONS

[0001] This application claims the benefit of priority r to U.S. Provisional Application No: 62/102,347, filed January 12, 2015.

[0002] TECHNICAL FIELD

[0003] The subject matter described herein relates to gene editing by introducing gene-editing components into a cell by mechanical cell disruption.

[0004] BACKGROUND

[0005] Genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) and transcription activator-like effector nucleases (TALENs), have shown much potential in their ability to change the genetic code of cells. These technologies could thus enable novel insights in drug discovery and lead to the development of next generation gene therapies. Gene editing complexes, which include a protein 1 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 component and a nucleic acid component, e.g., deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) cannot readily cross the cellular membrane. Thus, delivery of such complexes has been a challenge. SUMMARY

[0006] The methods and systems of the invention solve the problem of intracellular delivery of gene editing components and gene editing complexes to target cells. The results described herein indicate that delivery of gene editing components, e.g., protein, ribonucleic acid (RNA), and deoxyribonucleic acid (DNA), by mechanical disruption of cell membranes leads to successful gene editing. Because intracellular delivery of gene editing materials is a current challenge, the methods provide a robust mechanism to engineer target cells without the use of potentially harmful viral vectors or electric fields. Moreover, the scalability and relative simplicity of the process make it suitable for broad adoption. The strategy and methods are suitable for genome engineering applications in research and therapeutics.

[0007] Accordingly, a method for delivering a protein-nucleic acid complex into a cell is carried out by providing a cell in a suspension solution; passing the solution through a microfluidic channel that includes a cell-deforming constriction; passing the cell through the constriction such that a pressure is applied to the cell causing perturbations of the cell large enough for said protein-nucleic acid complex to pass through; and incubating the cell in a complex-containing solution for a predetermined time before or after the cell passes through the constriction. An exemplary protein-nucleic acid complex comprises gene editing components. For example, the protein-nucleic acid complex comprises a Cas protein (such as a Cas9 protein) and a guide RNA (gRNA) or donor DNA. In other examples, the proteinnucleic acid complex comprises a TALEN protein, Zinc-finger nuclease (ZFN), mega nuclease, or Cre recombinase.

[0008] The methods and system is generally applicable to cytosolic delivery of complexes, e.g., a protein- protein complex, small molecule + RNA complex, etc.

[0009] A variety of target cells types are processed in this manner. For example, the cell comprises a mammalian cell such as an immune cell (e.g. , T cell) or a stem cell such as a hematopoetic stem cell. 2CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[0010] The microfluidic system may include a plurality of microfluidic channels. Each of the microfluidic channels of the plurality defines a lumen and is configured such that a cell suspended in a buffer can pass through the lumen. In some embodiments, microfluidic channels include one or more cell-deforming constrictions. In some embodiments, the diameter of the constriction is a function of the diameter of the cell. Thus, there may be many microfluidic channels within a microfluidic system of the invention. For example, the microfluidic system may include a plurality of the microfluidic channels arranged in parallel, e.g., 2, 5, 10, 20, 40, 45, 50, 75, 100, 500, 1,000 or more.

[0011] Microfluidic systems having a plurality of parallel microfluidic channels allow for the high-throughput delivery of payloads to cells. Many cells can be passed through each parallel channel one after the other. It will be understood that, depending on context, a reference to a “cell'’ herein may refer to more than one cell.

[0012] The diameter of the constriction is chosen depending on the dimensions of the cell type to be treated. In some embodiments, the cell may be primarily compressed by the fluid flow. In some embodiments, the diameter is less than the diameter of the cell. For example, the diameter of the constriction may be substantially or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 20-99% of the diameter of the cell. For example, the constriction is substantially 20- 99% of the diameter of the cell, e.g., a diameter of the constriction is substantially 60% of the diameter of the cell. Non-limiting examples of the diameter of the constriction include substantially or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 2-10pm, or 10-20pm. Different lengths of the constriction are also possible. Non-limiting examples of constriction lengths include substantially or about 10, 15, 20, 24, 30, 40, 50, 60, 70, 80, 90, 100, 10-40, 10-50, 10-60, or 10-lOOpm.

[0013] The subject matter described herein provides many technical advantages over methods that deliver components (or nucleic acids encoding the components) of the complex piecemeal. Most gene editing systems require complex formation to occur inside the cell, which may be an inefficient process. Advantages of delivering the RNA and Cas (such as Cas9) in complex form (or other protein/nucleic acid gene editing composite assemblies) include better efficiency and specificity compared to other methods. By obviating the need for mRNA or DNA manipulation to express the Cas protein (such as a Cas9 protein), one can reduce how much time the cell spends exposed to the protein thus reducing the chance of off- 3CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 target effects. Having the editing components delivered to the cell in complexed form also eliminates/minimizes the risk of the Cas (such as Cas9) complexing with other RNA strands in the cell and cleaving the wrong sites. For example, the RNA alone may be detected by intracellular and extracellular Toll-like receptor (TLR) and pattern recognition receptors, prompting an interferon response or other antiviral pathways. The complexed form does not interact with these pathways and can thus avoid undesirable side effects.

[0014] By complexing in vitro prior to delivery into a cell, one can precisely control the Cas (such as Cas9) and gRNA complexing reaction thus ensuring optimal functionality, while complexes forming in the cytosol may not be as efficient. For example, delivering the complex cytosolically ensures simultaneous interaction of Cas (such as Cas9) and gRNA with the target DNA. The complexes formed in vitro and delivered to the cell as described herein are fully functional and ready-to-go upon gaining access to the cytoplasm of the target cell.

[0015] The approach described here is relevant to any protein + RNA/DNA based system to guide the nuclease as the delivery process is independent of the exact size and composition of the complex and because complex formation of the editing materials occurs and is controlled in vitro under their optimal conditions.

[0016] Implementations of the invention may also provide one or more of the following features. Deforming the cell includes deforming the cell for substantially or about 1 ps to 10 ms, e.g., 10 ps, 50 ps, 100 ps, 500 ps, and 750 ps. Incubating occurs for 0.0001 seconds to 20 minutes or more, e.g., substantially or about 1 second, 30 seconds, 90 seconds, 270 seconds, and 900 seconds.

[0017] The pressure and speeds at which a cell is passed through a microfluidic channel may also vary. In some embodiments, a pressure of substantially or about 10-35psi is used to pass the solution containing a cell through a microfluidic channel. The speed may be adjusted for a variety of reasons, including to improve viability of the treated cells while maintaining high payload delivery. In some embodiments, the cell passes through the microfluidic channel at a speed of substantially or about 300mm/s, 400mm/s, 500mm/s, 600mm/s, 700mm/s, 800mm/s, 900mm/s, 100-300mm/s, 200-700mm/s, 250-400mm/s, l-1000mm/s, Im/s, 2m/s, 3m/s, 4m/s, 5m/s, 6m/s, 7m/s, 8m/s, 9m/s, lOm/s, 0.01-5m/s, 5-10m/s, or 0.01-10m/s. Where the cell is a plurality of cells, substantially or about 5, 10, 20, 30, 40, 50, 60, 4CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 90-95, or 80-99% or more of the cells may be viable after passing through the constriction. In some embodiments, the cells are viable for at least about any of one hour, two hours, three hours, four hours, five hours, six hours, seven hours, eight hours, nine hours, ten hours, twelve hours, eighteen hours, twenty four hours, or forty eight hours after passing through the constriction.

[0018] In some examples, a device of the invention includes 2, 10, 20, 25, 45, 50, 75, 100 or more channels. In some embodiments, cells are moved, e.g., pushed, through the channels or conduits by application of pressure. In some embodiments, a cell driver can apply the pressure. A cell driver can include, for example, a pressure pump, a gas cylinder, a compressor, a vacuum pump, a syringe, a syringe pump, a peristaltic pump, a manual syringe, a pipette, a piston, a capillary actor, and gravity. As an alternative to channels, the cells may be passed through a constriction in the form of a net. In either case, the width of the constriction through which the cells traverse is 20-99% of the width or diameter of the cell to be treated in its unconstricted, i.e., suspended, state. Temperature can affect the uptake of compositions and affect viability.

[0019] In certain embodiments, a temperature of 0 to 45°C is used during cell treatment, e.g., 0-25°C. In various embodiments, the methods are carried out at room temperature (e.g., 20°C), physiological temperature (e.g., 39°C), higher than physiological temperature, or reduced temperature (e.g., 0.1°C), or temperatures between these exemplary temperatures (e.g., 0.1 to 40°C).

[0020] In some embodiments relating to immune cells, treatment of unstimulated T cells, B cells and/or monocytes is carried out at temperature of 4-8°C, e.g., on ice. In another example, dendritic cells, activated T cells, and/or activated B cells are treated using the device at temperatures of 20-25°C, e.g., at typical ambient room temperature.

[0021] In some embodiments, following controlled injury (e.g., perturbations) to the cell by constriction, stretching, and/or a pulse of high shear rate, the cells are incubated in a delivery solution that contains the complex that one wishes to introduce into the cell. Controlled injury may be characterized as small, e.g., 200 nm in diameter, perturbation in the cell membrane. The recovery period for the cells is on the order of a few minutes to close the injury caused by passing through the constriction. The delivery period comprises 1-10 minutes or longer, e.g., 15, 20, 30, 560 minutes or more, with 2-5 minutes being optimal when operated at room temperature.

[0022] In some embodiments of the device and methods described herein, passage of stem cells or progenitor cells such as induced pluripotent stem cells (iPSCs) through a constriction channel does not induce differentiation, but does reliably induce uptake of compositions into the cell. For example, gene editing compounds are introduced into such cells without complications associated with the method by which the factor(s) was introduced into the cell.

[0023] The size and duration of temporary perturbations in cell membranes can be modified by adjusting various factors, such as the diameter of cell¬ deforming constrictions and the speed at which cells pass through the constrictions. Disclosures regarding the size and duration of perturbations provided herein should not be interpreted as limiting. Non-limiting descriptions of perturbations and recovery are provided in Sharei et al., (2014) Integr. Biol., 6, 470-475. In some embodiments, the perturbations of the cell membrane may be characterized by a maximum diameter of substantially or about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm. In various embodiments, perturbations of the cell membrane having a maximum diameter of substantially or about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm persist on the cell membrane for at least substantially or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 1-10 minutes or more (11, 13, 15, 18, 20 minutes or more).

[0024] In various embodiments, the diameter is less than the diameter of the cell. For example, the diameter of the constriction may be substantially or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 20-99% of the diameter of the cell. Non-limiting examples of the diameter of the constriction include substantially or about 4, 5, 6, 7, 8, 9, 10, 15, 20 4-10pm, or 10-20pm. Different lengths of the constriction are also possible. Non-limiting examples of constriction lengths include substantially or about 10, 15, 20, 24, 30, 40, 50, 60, 70, 80, 90, 100 10-40, 10-50, 10-60, or 10-100pm.

[0025] Many cells are between 5-20 pm in diameter, e.g. unstimulated T cells are 7-8 pm in diameter. For example, the diameter of the constriction portion is 4.5, 5, 5.5, 6, or 6.5 pm for processing of single cells. In another example, the size/diameter of the constricted portion for processing of a human egg is between 60 6 Date Regue/Date Received 2022-04-22pm and 80 pm, although larger and smaller constrictions are possible (diameter of a human ovum is approximately 100 pm). In yet another example, embryos (e.g., clusters of 2-3 cells) are processed using a constriction diameter of between 12 urn and 17 pm. In a non-limiting example relating to unstimulated T and B cells, the device comprises a constriction having a length of about 10, 15, 20, 25, 30, or 10-30 pm, a width of about 3, 3.5, 4, or 3-4 pm, a depth of about 15, 20, 25, or 15-25 pm, and/or an about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 5-15 degree angle. Examples of microfluidic devices useful for delivering payloads into immune cells are described in PCT International Patent Application No. PCT/US2015/058489, Delivery of Biomolecules to Immune Cells, filed October 30, 2015.

[0026] In addition to single cells, even very large cells, e.g., eggs (approximately 200 pm in diameter), clusters of cells, e.g., 2-5 cell clusters such as an embryo comprising 2-3 cells, are treated to take up target compositions. The size of the aperture is adjusted accordingly, i.e., such that the width of the constriction is just below the size of the cluster. For example, the width of the channel is 20-99% of the width of the cell cluster.

[0027] Cells or cell clusters are purified/isolated or enriched for the desired cell type. Dendritic cells or other cells, e.g., immune cells such as macrophages, B cells, T cells, or stem cells such as embryonic stem cells or iPS, used in the methods are purified or enriched. For example, cells are isolated or enriched by virtue of their expression of cell surface markers or other identifying characteristics. Dendritic cells are identified and isolated by virtue of their expression of the Pintergrin, CDllc or other identifying cell surface markers. With regard to cells, the term “isolated” means that the cell is substantially free of other cell types or cellular material with which it naturally occurs. For example, a sample of cells of a particular tissue type or phenotype is “substantially pure” when it is at least 60% of the cell population. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% or 100%, of the cell population. Purity is measured by any appropriate standard method, for example, by fluorescence-activated cell sorting (FACS).

[0028] Payload compositions such as polynucleotides, polypeptides, or other agents (e.g., Cas9 and gRNA) are purified and/or isolated. Specifically, as used herein, an “isolated” or “purified” nucleic acid molecule, polynucleotide, polypeptide, 7 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 or protein, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. Purified compounds are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. For example, a purified compound is one that is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% (w/w) of the desired compound by weight. Purity is measured by any appropriate standard method, for example, by column chromatography, thin layer chromatography, or high-performance liquid chromatography (HPLC) analysis. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally-occurring state. Examples of a an isolated or purified nucleic acid molecule include: (a) a DNA which is part of a naturally occurring genomic DNA molecule, but is not flanked by both of the nucleic acid sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner, such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Isolated nucleic acid molecules according to the present invention further include molecules produced synthetically, as well as any nucleic acids that have been altered chemically and/or that have modified backbones.

[0029] Complexes are prepared from purified modules or components, e.g., purified protein(s) and purified nucleic acids (RNA and/or DNA). Thus, the ratios of the components are controlled and tailored as desired to achieve a desired gene editing result. The present method is particularly suitable for delivery of sensitive payloads, e.g., protein-RNA/DNA complexes, e.g., complexes that are 40 kDa, 50 kDa, 75 kDa, 100 kDa, and up to 120, 130, 150, 200, 250, 300 kDa or more.

[0030] Surfactants (e.g., 0.1-10% w/w) are optionally used (e.g., poloxamer, animal derived serum, albumin protein) in the flow buffer. Deliver}7 of molecules into cells is not affected by the presence of surfactants; however, surfactants are optionally used to reduce clogging of the device during operation. 8CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[0031] In some aspects, the device is made from silicon, metal (e.g., stainless steel), plastic (e.g., polystyrene), ceramics, or any other material suitable for forming one or more appropriately sized channels or conduits. In some aspects, the device is formed of materials suitable for etching micron scaled features and includes one or more channels or conduits through which cells pass. Silicon is particularly well suited, because micro patterning methods are well established with this material, thus it is easier to fabricate new devices, change designs, etc. Additionally, the stiffness of silicon can provide advantages over more flexible substrates like Polydimethylsiloxane (PDMS), e.g., higher delivery rates. For example, the device includes 2, 10, 20, 25, 45, 50 75, 100 or more channels. The device is microfabricated by etching the silicon. Cells are moved, e.g., pushed, through the channels or conduits by application of pressure. A cell driver can apply the pressure. A cell driver can include, for example, a pressure pump, a gas cylinder, a compressor, a vacuum pump, a syringe, a syringe pump, a peristaltic pump, a manual syringe, a pipette, a piston, a capillary actor, and gravity. As an alternative to channels, the cells may be passed through a constriction in the form of a net. In either case, the width of the constriction through which the cells traverse is 20-99% of the width or diameter of the cell to be treated in its unconstricted, i.e., suspended state.

[0032] Various implementations of the invention may also provide one or more of the following clinical and research capabilities. Quantitative delivery of gene¬ editing complexes or components thereof to cell models for improved screening and dosage studies can be achieved. The method could be deployed as a high throughput method of screening protein activity in the cytosol to help identify protein therapeutics or understand disease mechanisms. The devices and techniques are useful for intracellular delivery of gene-editing complexes to a specific subset of circulating blood cells (e.g. lymphocytes) or even whole blood; high throughput delivery of complexes or components thereof into cells, especially oocytes and zygotes; targeted cell differentiation by introducing gene-editing (optionally together with genetic material such as donor DNA) to induce cell reprogramming to produce iPS cells; delivery of DNA and/or recombination enzymes into embryonic stem cells for the development of transgenic or mutant stem cell lines; delivery of DNA and/or recombination enzymes into zygotes for the development of transgenic or mutant organisms; dendritic cell (DC) cell activation; iPS cell generation; creating mutations in normal or diseased cells (such as cancer cells) to study the contribution of one or 9CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 more genes to cellular function and/or disease; and stem cell differentiation. Skin cells used in connection with plastic surgery are also modified using the devices and method described herein. Methods of delivering gene-editing proteins disclosed herein may also be used to generate CAR-T cells or to genetically modify hematopoietic stem cells (HSCs) for treating genetic and other diseases. In embodiments relating to HSCs, a subject may receive an autologous, syngeneic, or an allogeneic edited HSC. In various embodiments, cells of a subject may be ablated before the subject receives a gene-edited cell. For example, bone marrow cells of a subject may be ablated with radiation or chemically before the subject receives a gene-edited HSC. In some embodiments, a gene associated with beta thalassemia or sickle cell anemia is edited using a method or composition disclosed herein. Cells processed ex vivo or in vitro, i.e., outside of the body of a subject, in accordance with the invention are useful for subsequent administration to a subject in need of treatment or diagnosis of a pathology. In alternative embodiments, in vivo cell processing is carried out.

[0033] In various embodiments, the SHP2 gene is edited/mutated to reduce the activity thereof or knock out or reduce SHP2 expression. In such embodiments relating to gene editing in T cells, the T cells become less responsive to immunosuppressive signals and have increased activity toward tumors. In such embodiments, the T cells may be more responsive to tumor antigens and more effective at treating cancer.

[0034] Aspects of the present subject matter relate to the rapid and transient delivery of protein-protein as well as protein-nucleic acid complexes, e.g., gene-editing complexes to cells. A nucleic acid component of the complex comprises a deoxynucleic acid (DNA), ribonucleic acid (RNA, e.g., mRNA, gRNA) or other double-stranded or single stranded nucleic acid compounds, respectively. For example, the delivery of a gene-editing complex (e.g., a ribonucleoprotein (RNP)) may achieve gene editing faster than if an expression vector encoding components of the gene editing complex (e.g. a Cas protein and a gRNA) was delivered to the cell. For example, the gene may be edited (e.g., mutated or replaced) in the cell 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1-4 hours sooner than in a corresponding cell that has received microfluidic or electroporation-mediated delivery of an expression vector that encodes gene editing complex components. 10CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[0035] Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments. Thus, all combinations of the various elements described herein are within the scope of the invention.

[0036] Related apparatus, systems, techniques, and articles are also described.

[0037] The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims. DESCRIPTION OF DRAWINGS

[0038] FIG. 1A and IB are schematic diagrams of a microfluidic system in which cells are exposed to the delivery material (payload) after passing through the constriction;

[0039] FIG. 2A and 2B are schematic diagrams of an embodiment of a microfluidic system in depicting parameters such as channel depth, width, and length.

[0040] FIG. 3A and 3B are a series of flow cytometry plots (FIG. 3A) and a bar graph (FIG. 3B) of the recombination efficiency for K562 reporter cells that had genetic editing material delivered to cell cytoplasm using the microfluidic device illustrated in FIGS. 1-2. For the reporter used, there is a frame-shifted GFP gene in the cell line. To perform the editing the Cas9 gRNA complex and a donor oligonucleotide would be delivered. The complex would cut near the GFP site and the oligonucleotide would insert itself into the cut site. Successful insertion of the oligo would correct the gene and result in GFP expression which is what is seen in this figure. Thus, in this assay something turned on upon gene editing as opposed to turned off. A gene would be expected to be turned off in instances where a gene (or depending on the context, a nucleotide or portion thereof) was being deleted in the absence of a donor oligonucleotide.

[0041] FIG. 4 is a series of FACs plots showing P2 microglobulin component of MHC class 1 (B2M) expression vs. delivered dextran for four different cell populations obtained using FACS. The delivery of the RNP using the 30-4 chip at 90 psi results in a 54.4% reduction in B2M expression as compared to the endocytosis control whereas the 10-4 chip at 90 psi results in a 25.2% reduction in B2M expression. B2M expression on the CAS9 control is not significantly different 11CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 than the endocytosis control. The longer constriction chip results in more delivery of the RNP complex and a larger reduction in B2M expression.

[0042] FIG. 5 is a series of FACs plots showing reduced B2M expression in a dose dependent manner determined by FACS as a measure of functional editing with the indicated conditions.

[0043] FIG. 6 shows a FoxP3 genomic sequence running from the first sheet of FIG. 6 to the last sheet of FIG. 6 (SEQ ID NO: 56). Exons belonging to FoxP3 are shown in underlined and highlighted letters. Other exons within this region that do not belong to FoxP3 are shown in non-underlined highlighted letters.

[0044] FIG. 7 shows a FoxP3 translated amino acid sequence (SEQ ID NO: 57). Alternating exons are underlined and non-underlined. Bold with italics indicate a residue overlap splice site.

[0045] FIG. 8 shows a SHP1 genomic sequence running from the first sheet of FIG. 8 to the last sheet of FIG. 8 (SEQ ID NO: 58). Exons belonging to SHP1 are shown in underlined and highlighted letters. Other exons within this region that do not belong to SHP1 are shown in non-underlined highlighted letters.

[0046] FIG. 9 shows a SHP1 translated amino acid sequence (SEQ ID NO: 59). Alternating exons are underlined and non-underlined. Bold with italics indicate a residue overlap splice site.

[0047] FIG. 10 shows a SHP2 genomic sequence running from the first sheet of FIG. 10 to the last sheet of FIG. 10 (SEQ ID NO: 60). Exons belonging to SHP2 are shown in underlined and highlighted letters. SEQ ID NO: 60 is also as follows: AGGCTCAAGCAATCCTCTCACCTCAGCCTCCCGAG'IAGCIGGGACTACAGGCGCGCGCCA CCACGCCCGGCTAATTTTTGTATTTTTTGTAGAGATGGGATTTCACTATTTTGCCCGGGC TGGTTCCCAACTCCTGGACTCAAGCGATTCGCCCGCCTCAGCCTCCCAAAGGGAAGTGCT GGGATTTCAGGCGTGTGCCACCGCTCCCACCCCAAAGTAGTATTTATTGTAATTATTATT ATTATTTTGAGACGGAGTCTCGCTCTATTGCCAGGCTGGAGTGCAGTGGCGCGATCTCGG CTCAATGCAACCTCTGCCTCCCGGGTTCAAGCGATTCTCCTGCTTCAGACTCCCAAGCAG CTGGGACTACAGGCGCCCCCCACCACGCCAGGCTAATTCTTGAATTTTTAGTGGAGACGG GGTTTCACCATGTTGGCCAGGATGGTCTCGATCTCTTGACCTCGTGATCCGCCCACCTCG GCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCAGCCTATTATTATTTTT TTAGGCAGTGTCTTGCCCTGTCGCTCAGGGTGTAGTGCAGTGGCGTGATCACGACTCACT GCAGCCCCGACTTCTCGGGCTTAAGTTATCTTCCCGCCGCAGCCTCCACGCCCGTACT TTTTTGCATTTTTTGTAGAGATGAGGTCTTGCTTTTTTGCCCAGGCTGGCCTCGAACTCC 12CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TTGGCTTAAGCGAACCTCTTGCCGCAGCCTCCCAAAGTGTTGGGATTACGGGCGTGAACC accgcgcccagcctactatctttatcttacac-aaagaaaagaatggaggaaaccgAGO*B CGGAGACAGTAGGTAATTTCCCCAAGGTTCCACAGCTAATGAGTGGAGCGGCGATTTGTG GAACGAAATGAATGAAATCGATGTGGCAGCGGGCCCGGACGGGTCGGTGGCGTAGACGCG GAGCGCGCAGCTCACACCTGGCGGCCGCGGTTTCCAGGAGGAAGCAAGGATGCTTTGGAC ACTGTGCGTGGCGCCTCCGCGGAGCCCCCGCGCTGCCATTCCCGGCCGTCGCTCGGTCCT CCGCTGACGGGAAGCAGGAAGTGGCGGCGGGCGTCGCGAGCGGTGACATCACGGGGGCGA CGGCGGCGAAGGGCGGGGGCGGAGGAGGAGCGAGCCGGGCCGGGGGGCAGCTGCACAGTC TCCGGGATCCCCAGGCCTGGAGGGGGGTCTGTGCGCGGCCGGCTGGCTCTGCCCCGCGTC CGGTCCCGAGCGGGCCTCCCTCGGGCCAGCCCGATGTGACCGAGCCCAGCGGAGCCTGAG CAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCGGGAGGAACATGACATCGCGGAGTCAC gagccccgaggggcccggcgcgggcctcggcccggccaccgccgcgttcggttagccccg TCCGGAAGGGGGCGCCCCGGCCGGGCTTCGGGCTCCCGCCCCGGGTCGGGGTTGGGGGCC GGTTCCCTCCTCGTCCCCTCGCCCTCCAGGGGCCGGGGGCCGGCCCCACCGCGCCCCCAC CCCTCGGGTCCCCATTCATTTCCTGCCTCCCCGAGTTCCGGCTGCGGCAGCCCCGGGGAT GCCCGTCAGGCCCGGGGCAGGTAGAGCCGCCGAGGGAACCACGGGTGCCAGCGGCCAGGC TCAGCGCCGCATTCCTGACCCATTGCCTCATGAGAATTGCCTCATGGTGATTCCGAAATA ACCCTGCTCACTTGGGGAGGCTCCTTGGGACACGAGAGGGGAGTTGCGCGGGGCCGGGCC CCCAGTGGTCTAGTCGTTCTGGCTCACTGTGCCACTTTCGTGCATTTGGGGACTTCACGC AGGACCCCTGACCCTTTTATATGCCTCTTTGTGTCTTCTTTTCCTCCTACCCCTCACGTG CCAGAAATGGAAAAACTGACTGTATCTGCAGCCACTAGAAGTATTTCCTTCCTCTGCGAT CTTCGCTTTGGGAGATGGAAAGGAAGGGAGCCGCATCTCGTTATTTAATCCTTCACTGCA ACCTTAACAGTCAGGTCACTTTACTGGTACCCGTTTTATGGATGAGGAAACCGAGGCCCA GAAGCAACATGCTAGTAAATGACAAGATTTGAAACTTAGGAGGATTAGTGAGTTAATGAG ATCCTTTGAAAGGTCAGGGTAATACTACTACTAATAGCTAACATTTGCTTAGTTCTGACC ACAGCCCTATCAGATGGCTAGTATTATCCCCATTGTAAAGATGAGTAAACCGAGTTTCAG AGGTTAAGTAAATTGCCTAACCTCACAGCTAGTAGGTGGTGGAGACAGAATCCCTACTTT TAATCACTATGTTGCTTCTATTATTTTGTAACTATTGCTAACCATTTGTAAGCCTTAATT TTGTTGTCAAACAGTAGTGTGACCTGTTGTTTTCAGATAGTGATCCTGCTATTTTGTATA GTCACTCTATATACCACTCACACTTAAGACCCATTGTCTATTCTTTTCCATGATTGTTCA ATTATGGTCACTGTCTCAGACATTTAAAAAACGATTCAAGCTATTGAGGCTATTTGAATG AGATTTTCTTTTCTTTTTTTCTTTTTTTTTTTGGAGACGGAGGCTCACTCTGTTGCCCAG GCTGGAGTGCAGTGGCGCAATCTCGGCTCACCACAATCTCCGCCTCCTAGGTTCAAGCGA TTCTCCTGCCTCAGCCTCCCAAGTAACTAGGACTACAGGCGCACCACTATGCCCGGCTAA TTTTTGTATTTTTAGTAGAGACAGGGTTTCACTATGTTGGCCAGGCTGGTCTCAAACTCC TGACCTCGTGATCCGCCCGCCTTGGCCTCCCAAAGTGCTGGAATTACAGGCGTGAGCCAC CGTACCCAGCCTGAATGAGATTTTTCAAAATATTAGGAATGTCTCCTCCAAACACACCTG 13CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCATGTTATTCATACATGGATCTGGAATTTAAAAAGGGGAGAAAAAGAAAACTGAGAACT CGTAGGAAGTGAGTGACTTGGACAGGTCGGTTGGCAAGTGCTTACAGATCTGGGTAATAT ATAACTGCATTTCAACAGAACAGTGTATAGCCTCAAATGTTCTAATTCTTTAGGGAGCTT TTAAATAAACAGTTGTCTATTCTTTAATCTGTCAAATAGTCATTGAGCCTTTTGTTCCTG GTGTCTGCTCTTCCAGACAAGTAAGGATCTGCTGCTTTAGGAGACATCAGACGGGGCTGG GGGTTGGGAAAAGGTCTGGGTAGTAATAGACCCTACATTGTCCAGTTTGTTCATTTAGAA GCATAGAAGTGTGGGCATAGTCAAAGTAGCAAGTGGTAAAGATGACAGTTTGAAATGGAG TAATTCCTTCTCCCCTCCAGCCCTGGTATTATGCACCACCCAAAAAGCCGGGTTATGAAC ATAATACACATAATTTTGAATGATTCATTATTTTTTGGAITATAAGCCTGTTTTATTTGT TAACCAGCCTTAATGAGGTATAAATGACATGCAATTAATTGCATATATTTAAATGTACAA TTTGATCAGTTTTGACATACATATACACTTGGGAAACCACCACCATAGTCAAGATAATGA ACACATCTATCACCCCTGGTAATTTTGCCTTATGTTCTTTATAATCCTTCCTTTGTTCTT AGGCAGCCACTATTCTGCTTTCTGTCACTATGTATTAGTTTGCATTTCCTAGAATTTTAT TTTTAAAAATTTTAAAATTGTTTGAATAGAGATGGGGTCTCACTGTGTTGCCCAGGGCAG TCTCAAACTCCTGGGTTCAAGTGATCCTCTCACCTTGGCCTCCTGAAGTGTTGGGATTAT AGGCATGAGACACCCTGCCCAGCCCTAGAATTTTATTATIATTGTTATTATTGTGTTTTT TTGAGATAGGGTCTCACTTTGTTGCCCAGGCTGGAGTGCAGTGGTGCAATCACTGCAGCC TTGTTTTCCTAGGCTCAATCCATCCCCCCTCCTCAGCTTTCCGGTTACTGGGGCTACAGG TGTGCACCACCACACCCGGCTAATTTTTGTATTTTTTTATAGAGACAGGGTTTTGCCATG TTGGCCAGGCTGGTCTCAAACTCCCGGGCTCAAGCGATCTTCCTGCCTCGGCCTCCCAAA GTGCTGGGATTACAGGCATGAGCTATTGCGTCCCGCCTTCAAATTACTTTAACCTAGTAT TAATTCATTCAACAGGAAGTTAATGAGCCAGGCAGGATAAAGCAGTAAGATAGGAAAATA TTGCTATTTTCATGGCTGAGAGAGAGCAGACAAACACATGACTAAATAGGGCAATTTCAG GTAGTAATAAATTCTAGGAGGGAAAAAATCCCACAGAAATGTGAGGATGGGAGAATGCAG TTAGTTTTGATAGGTGGTTTAGAGAAGGTGATCGTGTGAGCTGACACCTGAATGACAATT AGTAGTCTGAATTTTGTTTTGCTTAATTATCAAAATAACICCTCTTGGGTTCGGCTTTTA TATGCATCCAGTAATTAAAATGTAAGTATATTCAATGTACTGATATCTCTCAGCATCATA GGTAGGAAAACTAAGGCATTCAGCAATTAAGTGACTCCTCCCTTGATCATGTAGCAGTGA TAGTACTGGATTTAGATTTTGAGGTTGCTTCTCTGCCCTITTCTGCCTTTGTGAAACCAA CAAAGCTGCCTGTATTTTCCAACTCTTCCTTCAGCATGTGGTACCTCCTTTACATCTGTT TTTGTTGCTCTGAAATCCATACGCGACGATGAGCTGAGAGGGGCAGAAAATTGAGCTTGT TCTGAGACTGGAGGCTTTTGGTTTATCTCTTGCAGGTCAAGTACATTTTGTCCTGGGCTC TCCCTGGTGGCCACGTTTGTTTATCTCCTGCGGGAGTAAATAAACTTGCCTTGCTGAAAA ATAACAGTTCTGTGTCTTTGCAGTGGAAACTGGGATGTCTTTATTAACGTTAGGTCCTGA TGTAAGGCCAAGTTTTTGGTTAGAGTTGCTCAAGTGCAGAGGCCACTGCTAAGATGACTT ACCCCTCGTGTCCATGGTCAATGTGGAGACTGTTAIGAGIGGCACATGATGCTGGAAAAG CAGAGCCAACTCATGTTTGTAATTGTCCTAGCAGGCCGTGGTGTACTTTGTTAGGCAGCC 14CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ACAGAACAATAGAGAAACTCAGCTTATTCCCCTTCCCTCTGGGAAACACAGACAGTACTT GCCATCCAACGCCAATGTTTTTAAGGAAGAAAGAGGCAAAAAGTGATGTTGGCAAGGTCT CTGGGAGTTGTGGACCCCAACCAAGGATTGGAGACCCTGAAATGGATTCAGATGCCCTAA AATGCAGCCCAGTTCATTACTATGAATTTTGGAGGACTTTGTGCCTTGAGCAAATGTGTA TATGTGACGCTCTTTGACAACACTGAAATAGGAAAAATACTATCCATGTTCGCGAGGAGC ACTGAATTTAGAGAGGGAGACAGACTTTTATGCCAGCATCAAATGAATTTGATAAAGCTA GTACCAAAATGAAATTTGAAATTTTTTTTTTTTGAAATAGAGTCTTACTCAGTCACCCAG GCTGGAGTGCAGTGATACAATATTGGCTCACTGCAACCTCCACCTCTTGGGTTCAAACAA TTCTTGTGCCTCAGTCTCCTGAGTAGCTGGGATTACAGGIGCGTGCCACCATGTCTGGCT AATTTTTATATTTTTAGTAGGGATGGGGTTTCACCATGTTGGCCAGGCCGGTCTTGAACT CCTGGCCTCAAGTGATCTGCCCACCTTGGCCTTCCAAAGTGCTGGGATTATAGGCATGAG CTACCACACAAGCCTGAAATTTGAAATGTATTGGTATAGAATATACTGTTTAGAATGTAT GTGTATATATGTATATTTGTATACTCATATAAACACAAATACACATTGTATGTGTTTCTG TAATATGTATATCTGTCTACACATACATGTATATACACACATACAATGTCTTTTTTTTTT TTTTTTTTTTTTGAGACAGGGTCTTACCCTGTTGCGCAGGCTGGAGACTGCAGTGGCATA ATCTTGGCTCACTGCAGCCTCGACCTCCTGGGCTCAAGTGATCCTCCCATCTCAGCCTCC TGAGTAGCTGGGACTGACTACAGGCACGTGGCATCAAACTTGTCCAATTTTTCTATTTTT TTGTAGAGTTAGGGTCTTGCTCTGTTGCCCAGGCTGGTCTCAAATTCCTGGGCTCAAGCT GTCTGCCTGCCTCGGCCTTCCAAAGTACTAGGATTACAGATGTGAACCACTGTACCTGGC CTTTACAATGTCTATTTTAAAGATAATGGTTCAAGTTTTTATCATCCCACTGGCCTACTC TAATGAAACATCTATCCATTCATTGAAGAATTATTTATGGTGGGATAACTCTGTGCCAGG TACCGTGCTAGGCATTGAGTATTCCAGGTTTTAGGAAACAGCACATGCAAAAGTGCTGAA GTGGGAGAAGATCTCGGAGTGATTGAAGGCTAGGAGAGAGCAAGTGTGGGAGCTGTGAGG CTGGGAAGGTGGGAGGTAGGTGGGAGCAGACCACATAGGGATTCTTAATGTCTTTAGTGT CATGTGGACCATGGAGAGGAGTGTAGATTGTATTTTTAGAGCAATGCAAAATCATAGAAG GATGTGATCGGGGGAGTGGCATGAGCTGATCTATTTAAAAATATTTCTCTGGCTGCTGTG AAGGAAGGATTGTAGGAGGCAGGAGTAGATTCAGGGAGATGAGACAAGTGATGAGAGAGG CTTTGAACTTGGGTAAAAGTAGTTTGTGGAAAGTCTTTTTTGGAGGTAGTTTTTGTTTAT TGCCTTGTCATCAAAGCAGAGATGCTGACCAATGAAACTCCATGAGAAAATAGTGATTTA TAAAGACATATCTATGCACTGCCATTAAAAAGCTGCTTGGAAAAAAAGGATAAAAAGCTG CTTTAACAACTTTTTTTTTTGAGATGGGGTCTTACTCTGTCACCCAGGCTCACGACCTCA GCTCACTGCAACCTCTGCCTCCCAGGCTCAAGCATTCTCCCACCTCAGCCTCCCGAGTGG CTGGGACTGCAGGCACACGCCACCATGTCAGGCTAATTGTGTGTGTGTGTGTGTGTGTGT ATGTGTGTGTGTGTGTGTGTGTGTGTGTGCTGGGACTGCAGGCACACACCACCATGTCAG GCTAATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTA TGTAGAGATGGGGTTTTGCCATGTTGCCCAGGCTGGTCTCAAAATGTTGCCCAGGCTGGT CTCAAACTCCTGAGCTCAGGTGATCCACCCGCCTCGGCCTCCAAAGTGCTGGAGATTACA 15CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GACGTGAGCCACTGTGCCCACCTAACAACTTTAAAAAAATTTTGAGATTTAGTAGGATAT TTATTGCATTATTGTTGAGATGGCAAAATATTGGAGACAACTGAAATGTTCATCAGTGGG GGGGGCTAGTTAAATGAAATACAGTGTAGCATGCATTAGAACACTTTTCAAGAATTTAAC TTTTTTTGTAGCCTTTTACTTATAATGCTTGTCCCTATTGATGCCTTTTTTTTCAGCATG ACTTACTCTTTTACTATAGGATATTAAAATTTAATTAGATTAGAAATGAGGAATATTCTT GTAATCTGTAGAAAGTAACAAACTATAAACTTATTCCCCAAGAACAAATATAATAATTTT TCTGGAGTAGCAGGTAAGAAAGATATAAATTTATATGTATACAAGAAACTGAAATTAGAC TTTATACATTTAAAGGTTACAAGTGCAGTTTTATTACATGAATGTATTATCCAGCATTGA AGTCTGGGCTTTTAGTGTAACCAGCACCTGAATAACATACATTGTACCCATTAAGTAATT TCTCATCCCTCAAACCCCTCCCACCCTGAAATTAGACTTTGGATCCCTAGTTTAAATTCC ACCCCTCTCTTTTTTTGAGACAAGGTCTCACTCTGTCACCCAGGCTGGAGGGCAATGTTG CAA.TGATAGCTTACTGTAGCCTCAACCTCCTGGGCTCAAGGGATACACCCTCCTCAGCCT CCTGAGTAGCTGGAACTGCAGGCGTGCACCACCACATTCAGCTAATTTTTTGATTTTTTT ATAGAGATGAGGTCGGAACTCCTGGGCTCAAGCGATTCTCCCCAAGTGCTGGGGTTACAC ACATGGGCCACTGCCCCCAGCCTAAACCTCCTTTCTCAGTATAGCAGCCTTGAGATGAAG TTCCTGAAATTACTGGCCAGCTTGACTGTTTCCCCACATCACTGGAGGAGGGGGATGCAT AGATAAAACAAAATATTCAGCATCATTGTATTTTCTTTTTGTTTCATCAGCATCTTTTTT TAAAACTCACTTGACATAAGTCCCTAGCCTCAAAGAGTAAAGCCTTTGCAGAATCTGCAT TCAGATTTCGGGTGTGATTTCCTGACAGATAGTTCAGGTTTGTAAACTCTTTTTTTTTTC TTTGAGACAGAGTTTCACTCTTGTAGCGCAGGCTGGAGTGCAGTGGCACCATCTTGCCTC ACTGCAACTTCTGCCCCCTTGATTCACGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTG GGATTACAGGCATGCGCCACCACACCTGGGTAATTTTTGTATTTTTAGTAGAGATGGGGT TTCACCATGTTGGCCAGGCTGGTTTTGAACTCCTGACTTCAGGTGATCTACCTGCCTCAG CCTCCCAAAGTGATGGGATTACAGGTGTGAGCCACCGCAGCCGGCCAAAACTTTGTTTTT TTTCCTCTTTTTGTTGCTGAGAAATGTAAACTCTTACAGACACAAATTATGTCTCCCATT TTTTAAAACCCACTCAACACAGGGGTCATGTGTAATAGGCCCTGGAGCTTATTTTAGACA TTGATTTGAGGCTCTTTTCCCCAAGTGCTGGTTTGTGTGTGTGTGTATGTGTGTGTAAGT CTTTCTATGAGATGAGTGGTACCTACCTGGGCTGTGTGATCTTTTTTATTTTATTTATTT TATTTTTGTAGATACGAGGTCTCACTATGTTGCTCAGGCIGGTCTTGAACTCTGGGGCTC AACCTATCCTCCCTCCTTGGCCTCCTAGAGTGCTGAGATTACAGGTGTGAGCCACTGCAC CTGGCCAGCGATCCTTAATAAATATAGATAATGGCCGGGCGTGGTGGCTCACACCTATAA TACCAGTACTTTGAGGGGCCGAGGCTGGCAGGTCACCTGAGCTGAGGAGTTTGAGACCAG CCTGGGTAACGTGGGTGAAACCCTGTCTCTACAGAAAATAGAAAAATTAGCCAGGTGTGG TGGTGCATGCCTGTAGTCACAGCTACTTGGGAGGTTGAGACAGGAGAATTGCTTGAACCT GGAAGGTGGAGGTTGCAGTGAGCCGAGATCGTGTCTTTGAACTCCAGCCTGGGTGACAGA GTGAGACCTTGTCTCAAAAAAAAATATAGATATAGGCTGGGCGTGGTGGCTCACACCTGT AATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCAGGAGGTCAGGAGATCGAGACCAT 16CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCTAGCTAACATGGTGAAACCCTGTCTCTACTAAAAATACAAACAATTAGCCAGGCCTGG TGGTGGGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCC GGGAGGTGGAGGTTGCAGTGAGCCGAGACTGTGCCACTGCCCTCCAGCCTGGGCGACAGA GCGAGACTCTGTCTCAAAAAAAAAAAATCTATATATCTATATATCTATATCTATATAGAT ATAGATATAGATAATGCCAGATGATGGCTGGTTAGAAGGGATTGTCAGGGGCTGGCAGGT TTTGCAGGTGTTAGAATGAGCAAGATGAGGAGAAGGATGCTTACTTCCCTCTCCTTGTAA CTCTCTACCCCCTCCCCTCAGTGTTTTTTTATTTTTATTTTTATTTATTTATTTTTTTTG AGACAAGGTCTTGCTCTGTCACCCACACTGGATTGCAGTGATGCAATCATAGCTCATTGA AGCCCAAACTCCTGGGCTCAAGTGATCCTCTTGCCTCAGCCTCCCAAGTAACTGGGACCA CAGGTGCGTACAACTATGCCCAGTTAAGTTTTTCATTTTTTATACAGACGGGGTCTTGCT ATGCTGTCCAGGCTGGACTTGCACTTCTGGCTTCAAGTGATTCTCTTGCCTCAGTTTCCC AAA.GTGCTGGCATTATGGGCATAAGCCACTGTGCCTAGCCCATCAGTGTCTTTTTATCCT TTACTCCTATCAAAATTCATTCACTCAGCAGCCATTGATCAAGTGCCTACTATATACATG TTGAGGACTGGAAATTTATTTGTCTCTTCTCATCTTATCTGGACCCTCTGTGTTAATTGT AATTAACTGTAATCATTCTGTATTAATTGTAATAAACTTGTTGATAAACTCAAATGAGGC CATACCGTTTTGCCACTTCCCCTCCTTCCAGGTTATATGGATGTACTTACATTGCAGGTT TCATTTGTTGGTTCAGTTTTTAAACTAAGCCCTATTGTGTCAAATTATGCTAGGTGTGAG ATGGGGAGTTCAAGCTGTGTGTTGTCTTTTTTTTTTTTTTTTTTTTTGCCTCACTTACTA ATATACAAGCGCTTATAACCTTTGAGGCTGGCCCTATACATTAAGATTTTTATTAATTCC ACTGTTCTTTATCTTCTCTTACTAAGTTCTCAGGGTCGAATGAACTCTAACTGCTCCTTG CTAGTGATAAGCAAGTTGCAAATTACAGAATTGTCAGTGATTGAATACACGTATTAAACC TGTAACTGGGAAGCATTTTTGGTAATTATGAATACTTTTGGAAAAAAAAAAGCTATGGAA GGAAAGTTTAAAATCTACGAAAGCTCAAGTAGATGGTCATGGAATAGCTATTTCAATTTC TAACTATATATTACTTATTTATTTATTTATTTTTGAGACGGAGTTTAGCTCTTGTTGCCC AGGCTGGAGTGTAATGGCGTGATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAGC TATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTATAGACATGTGCCACCACGCCAGG CTAATTTTGTATTTTTAGTAGAGACGGGGTTTCTCCACATTGGTCAGGCTGGTCTCGAAC TCCCAACCTCAGCTGATCCGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGA GCCACCGCGTCCGGCCTCTTAACTATTGTTTGAAATAATGTAGAGACAGCTCCAGAGCCA TGAAGAAGTGTATGAAGAAGCAGTGTTAGCTTAAATGACATACATGTCACAATTGCCTAT GTGAAACTATCATAATTATGCATGAGAAGTATCTATCCTGCATAACCTCCACCAATAATA ATAATGTTAATAATAGTGAAAACTAATGTTTATTAAGTCCTTACTGTCTCCAGCCTCTGT GCTAAATACTGGTTACTAAGTTTCCCTGAAAATACTATTCTCATCTGTTTGTTCTTAATA ACAGGATAGCATAATTGTAAGTTGTAAATGAAATAATACAGTTTATGTAATAAAAGGGTA AAAGAGAAGACCACCTACCTTATCTTCTGTTGCTGATCTGGATGGATGTAGGTGGTGTTT ACCTAGTTTCACCTTTGGCAGTTGAAACTACTTTTITTTITTTTTTTTTTTTTTTTAAGA GACAGGGTGGGCCAGGCGCAGTGGCTCACGCCTGTAATCCCCGCACTTTGGGAGGCTGAG 17CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCGGACAGATCACTTGAGGTCAGAAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCT GTCTCTACTAAAAATACAGAAAAATTAACTGGGTGTGGTGGTACACACCTGTAATTCCAG CTACGTGGGAGGCTGAAGCAGGAGAATCGCTTGAACCCGGGAGTGGAGGTTGCAGTGAGC TGAGATTGTGCCACTGCACTCCAGCCTGGGTGACAGAGCAGGACTCCGTCTCAAAAAAAA AAACAACAACAAAAAAAGAAATTTTTAGAAATATGAGATGAGAGCAAGAATGAGGGTATT AAAAAGAAATTTTTAGAACTAAATAGCAGAAIGTAATGGIGAAAAGTTTGATTTCTCAAG TCTGCTTTGCACACAGGCATGTGGCAAACATTCAGTAAGTATAGCTGTAATTTTAACCAG CTGTAATGTATAATAGCCAACATATGAGATTTTTCTTTTTTCTTTTTTGAGACAGAGTCT TGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCACCATCTCGGCTCACTGCAACCTCTGCCT CCTGAGTTCAAGTGATTCTTGTGCCTCAGCCTCTCAAGTAGCTGGGATTACAGGTGTGTG CCACCACACTCGGCTATTTTTTGCATTTTTAGTAGAGATGGGGCTGGTCTTGAACTCCCA GCCTCAGGTGATCTGCCTGCCTCAGCCTCCCAAAGTGCTGAGATTACAGGTGTGAGCCAC AGCGCCTGGCCATATATTGCTTTTTTCTTATTATCAGAGCCAGTTCATAATTGTGGAAAA ATAGTGTTTGTAACAATGTAAGTATGGATAAATCATCTTTTTAATTTTGTGATTCATATA GGTTTGTTGTTGTTGTTGTTGTTTTGTTTTTATCTTGAGACAGAGTCTTGGTCTGTCACC CAGGCTGGAGTGTAATGGCACAACCATGGCTCACTGCAGCCTCAGATGCCTGGGTTCAAG CAATCCTCCCGTCTCAGCCTCTAGAGTAGATGGGACCACAGGTGTGGGCCACCATGCCTG GGTAATTACAAAACTTTTTTTTTTTTTTCTAGAGATGAGGTCTCACTATGTTGCCCAGGC TGGTCTCAAACCTTTGACCTCGCTTCAGCCTTTAGAGTAGCTATGACTATAGGCATGTGC CATCACCCAGCTAATTAAAATTTTTTTTCTTTTTTTTTTTGGTGGAGATGCGGTCTTACT TTGTTACCCAGACTGCAAGTTAGTTTCAGATATCAACATTTGGTGTTTCCAAATGCACGG GGAGGCTTTGGAGCAAGTTTTTGGCTCATATGCATAGGTGTCCTAGACATTCACTTTGCA AATTCTTATTAAAATGAGTAGAGTAGCATACAGATAGGGAAAAATATCCTTGTCAGTACC ACCGATTGGGTGAGAAGAGACTGTATATTAAAAACAATGACCATCTTTTTGCCACATAAA TTGCTGGTGGGGCCAGTTTGAAGAGGGCTTTGTCAGCTGCCTTCTGCCTCTTCCTCTTGA GTACGTGGAGTTGGAGTCATCCTTGACAGCCTCCTGTTGACACCACCCGGGTCACAGATG TGAAACTGTGTGGATGTAGGAGAGAGCAGTGATGGGGCTTACCCCAAGGTTGCTCTTCCT TCCCTCTGGCCACAAATGTTTAGTAAGGAACTGCTCTGTATTAACCATTTGCTAGGGGCT GCAGATACGGTGGTGAAGAAATAGACATGTTCCTACTCGGGATGCTGAGGTGGGAGGATT GCTTGAGCCCAGGAGTTGGAGCTGCAGTGAGCCATGATCACACCACTGCACTCCAGCCTG GGGGACAGAGCGAGACCCTATCTCTAAAAAACAATAAAAGAAATAGATGTGTCCTTCACC CTCATGGAACTGCCAGTCTAGCCTTCAACCTGGTGACTGTAGAAATGTGTGATTAGATGC TATATTGCCATGTTGAGTGTCACCCCTGAGAAGCAGGGTTTTTTTTGAGAAGGTAGGATG GGGGATCTGACTGTGGGACCACCAGAGGGAAAAGCACATGTAAAAGCTGCGTGTACCAAC TGGAGGAAATCGGAGACGTGATCAGAGAACCAGAGTCAACCAGGGGCCATGCCGTACAGG GTCCTGTTAAGATCTGTGACTTTTTTCTAAACGTTITCTICTGGATAACATCTAAATTTC TAGTTCCAAATGTGAAACTCCAAGGGCGTTCTGTGCTAAACATTTTGCATGTATTAATTA 18CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATTTCCACCACACAACATTGCTGTGAATTAAGACAGTTTCTAAGCATGGCAAGAAACCCA GAAATCATAATGGAAAAATCTGATAAATTTAACAATGCCAACATGAACCTCTGTAGGAAA AAAAATACCACAGACTAAAAAGGGGGGAAAAAAACCAC-AGACAAATATTTGCAACACATA CAGTAAAGGGTAATTTTCTGGTTATATCAAGAGCTCCTAGAAATCAGTAAGAAAAAAAAT CTAATAGGAAATGAGCAACGACAAACTGACAACTCATAGAAAAGGAAACACAAGTGGTCT GAAAACATGAAAAAGTGCTCAGTCTGAGAAAGAAATGCAAACTAACATGGTACCATTTTC CATTAATCAGATAGACAAAGATGAAAGAGTTTGGTAATGTATGTAGTATTGGCACAAGTG AGGGAAAACAGGGGATTTCACACTCTATGCCCGTCCAAACCAGTACCTTATTTTGAGGGT GGTTTGACAATATTTGTCAAAATAAAAAAATTATATATAGTCATTTGCCACATAATGATG GTTCAGTTGATGATGGACGGCATACATAATGGTGGTCCCATAAGAATATAATGGGCTGGG TGCAGTGGCTCTCACCTGCAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATTGCCTG AGGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTGCTAAAAACA TACAAACAATTAGCCAGGCATGGTGGCGGGTGCCTGTAATCCCAGCTACTCAGGAGGCAG AGGCAGGAGAATCGCTTGAACCCGGAAGGCGGAGGTTGCAGTGAGGTGAGATTGGGCCAC TGCACTCCCATCTAGATGACAAGGCAAAACTCCATCTCAAAAAAAAAAAAAAAAAAGAAT ATTATGGGCCCAGCCACAGTGGCTCACACCTGTAATCCCAGTACTTTGGTAGGCCAAGGC AGGAGAATCATTTGAACTCAGGAGTTTGAGACTAGTGGGGACAACATAGCAAGACCCCAT CTCAAAAAAAAAAGATTATGGTGGAGCTGTCCTGTATA.GACATACCATTTTTAACTTTTT TTTTTTTTGAGATGGAGTCTTGCTGTGTCACCCAGGCTGATGTGTAGTGGCGTGATCTGG GCTTACTGAAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCTTCCTGAGTA GCTGGGACTGCAGGCGCAGGACACCATATCTGGCTAATTTTTATATATTTAGTAGAGATG GGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCTCAAGTGATCCGCCTGCC TCAGCCTCCCAAAGTGCTGGGATTACAGGCATTAGCCACCATTTACAGGCACCTGGCCAC CATTTTTAATCTTTTATATTGTATTTAAACTGTACCTTTTCTATGTATGGATGTGTTTAG ATACACAAATACCATTGTGTTACAGTTACTTACAGTATTCAGTACAGTAGCATGCTGTAC AGGTGTGTAGCCTAGGAGCAATAGGTTATACCATATAGCCCAGGTGTGTAGTAGGCTCTG CCATCTAGGTTTGTGTAAGTACGCTCCATGATGTTACCACAGTGACGAAATCGCCTAATG ATGCATTTCTCAGAACATATTCCTGTTGTTAAGCAATGCATGACCGTATCTTGACAAAGC CATTTTATTTCTAAAACTTTAATTTTACAGATTTATTTGIAAAAGTATGTAAAAATGATT GTAAAGGATATGTTCTGCTGCATTATTTGTAATAACAAAAAACCAGAGGATAACATAAAT GTCCTATAAGAAGGGTTAGATTATGGATGGCACATTCATACAATGGGGTATTATGTAGCC ATTGAATAAAAGGGTACTGGCTGGGCGCAGTGGCTCATGCCTATAATCTCAACACTTTGG GTGGCCAAAGAAGGAGGATTGCTTGAAGCCAGGAGCTTGGGGCCAGCCTGGGCAACATAG CAAGACCCTATCTCTACAAAGGAAAAATAAAACAATTAGCCAGGTTTGGTATTGGACACC TTCATGGTCCCAGCTACTGAGGAGGCTGAGATTGGAGGGATCGCTTGTGCCTGGCAGGTT GAGGCTGTAGTGAGCCATGATTGTGCCACTGCACTCCAGGCTGGGAGATAGAGTGGGACC CTATCTCAAAAAAACAAAAACAAAAACAAAACCTCCTGTAAAATGTCAAGAAGTCCTAGA 19CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TGTGGGCCAGGTGTGGTGGCTCACACTTGTAATCCCTGCACTTTGGGAGGCTGAGGCCAG GAGTTTGAGACCAGGCAGAGCAAGATAGCAAGACTCCATTTCTACAAAAAATAAAAAAAA ttagttgggcatagtggtgcattcctgtagtcccagctactcaggaggctgaggtgggag GATTGCTTGAGCCTGGGAGGTTGAGGCTGCAGTGAGCCATGATCACACCTCTGCACTCCA ACCTGCGCAACAGAGTGAGACCCTGTCTCTAAAAACAACAACCAAAAAAACCCAGCAAAG TACTGATAAAGATCTTTGGCTGGGCGCAGTGGCTCACACCTGTAATCCCAACACTTCAGG AGGCTGAGGCGGGCAGGTCACAAGATCAAGAGATCAAGACCATCCTGGCCAACATGGTGA AACCCGGTCTCTACTAAAAATACAAAAATTAGCTGGGCATGGTGGCGTGCACCTGTAGTC TCTGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGTGGCAGAGGTTGCAG TGAGCCGAGATCACGCCACTGCATTCCAGCCTGGCGAGAGAGCAAGACTCCGTCTCAAAA AAAAAAAAAAGAGAGAAAGATCTTCAAGTTGTAGTATGTGAAAAAATCAGGGTGTAAAAC AAGAGAATCCCATTTGTGTGTGTGTCGAGTGTGTTTCACACAGGCTCAGAGGGAGTAGTG TGTATATGCACATGAACATACGTGTCAGTGTATATATGTATATATACAAGGTTGTGGGTT TGTTTGTTTTTTTTGAGACAGAGTCTTACTCTGTTGCCCAGGCTGGGGTGCAGTGGTGCA ATCTTGACCCACTGCAACCTTCACCTCCCAGGTTCAAGTGATTCTTGTGCCTCAGCCTCC CAAGTAGCTGAGACTACAGGCACGCACCACCATGCCCAGITAATTTTTGTATTTTTAGTA GAGATGGGGTTTCATCATGTTGCCCAGGCTGGTCTGGAACTCCTGGCCTCAAGTGCTCTG CCCGCCTTGGCCTCCGAAAGTGCTGTTGCCCAGGCTGGAGCTCAGTGGCACAATCGCAGC TCACTGCAACCCCGACGTCCCAGGCTCAGGCAATCTTTCCGTCTTAGCTTCCCAAGTAAC TGGGACTACAGGTGTGTGCCATCAATGCCCCACCAATTTTTTAATTTTTTGTAGAGATGG GGTTTCCCTACGTTGCCCAGGCTGATCTTGAACTCCTGGTCTCAAGCAATCCTCCCACCT CAGCCTCCCAAAGTGCTGCGATTACAGGTGTGAGCCACCTTGCCCTGCCCTGTACAAAGA TCTGCATAAAAGCAGTTAATAATACTATGTTTGAGGCTGCCATCACAGGGGTGAGGTCAA GGACAAGTGTGAGAAATTCTTTTAGAATCTATTTTAAAAAAAGAAGAGATGACAGTGGTG ACAGTCAGGGAACAGATAAGCAGGTAGATTGTGGGGGTCTAGGCTGTCTAACTGGTGTTT AAAATGAAGCAACCGCTGAGCCTGCTGTATTICATTTAATGGAGACTAGTAAAACAACAG CCAGAAATTCTTCACTTTCCATCTAAGAGAGGCAAAAGTTATTTTCCCTTCAATAACCTG GGACTGTAGGATTAAGGTTTTTTTTTTTTTTTTTTTAAATACTACAATATGACTACCAGT ATAATTTAAAAATGATTAGAATTCTATTTGAGTAAGAAAIAGGTGTCTGCCTGAAGTAGA CAGTCACTGAAGTCACTAAGTGGCAAAAGACAGAAAAAAAATTGAAAGTAGGAAACAATC AGCAGATATGATACCAAACATGAGCTGTCAGTGATAATGGATTAAGTCCTTCAATAATGG CTGAGCCAGATGGAATTAAAAGAAAAAATCCAGGCCGGGCATGGTGGCTCACACCTGTAA TCCCAGCACTTTGGGAGGCTGAGGTGGGAGGATCACTTGAGTCCAGGAGTTTGAGACCAG CCTGAACAACATAGTGGGACCCCATCTCTATTTTATAAAAATATTTTGAAAAAAGAAAAA AAAATTCAGTTGTGTTCTGCTTTAAAAAGACAAATTGGCACAGAATGTCAAAGAATAAAT AAAACAAACATGGGCAAAAGAGATTCAGGTGGTACCAATATCGGGCTAAGTAGCATTCAA GATAAAGATTATTAAATAATAAGTTAGTTAATACTAGAGTAATTGCATATTAATGAAACA 20CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TAATCTATGGTAGAGATATTATAGTCAATAATTGTTTTATGTATTCATTAAGGTAACAAC AAGCAAACAAGCTTTAATAGTTTTAAATGCTTTATATGCTTTATAGTTCTTTTATGTGCA TTAATTCATTAATTCTCATTTCCTATGAGGTAAACACTATTATTATCCACATTTTACAGA TGTAAAAACCGAAGCAGAGAGATTAATTAGCTTGCCCAGGAGATGTGGCATTCTGGGATT TGAGACAGTGGTTTGGCTCTGTAGGTTGCTTCAATAACCAAGAGATGCTTCAAATCAGAT TTTTAAAATATGTTTTTCAGAAGCATTTTCCTGATACTTCTCCCCTTACATGGGTGTTAG TCTTTTGGGTTGAAAAACATGAGTAAGTGCTAGAAGAGCAAAATATGCATCCAGATTTAA TAGTATGTCTGTTTTTCTGAGCCTTGGCATTTCATTGCTTTTATAATAGAAATGAAGGCT TTTTTTTTTTTTTGGCTGAGAATAGCACTGAACTCAGTGGGAGGGACTGTGGGTTGTAAG TTGTCCGCCTCTGAATGGAGTTGAATTTAAGTTTCTTGGTTTCCAAAGAATGATTGATTT AAAGACCCTCAAATTGCAAGTTAGAACTGACTTCAGTCCTTGAGGTTTTTTACCATTTAA TGAATAATTAAATTTATGGTAATAAATGGTAATAAATGGTAAAAATGGTAATAAATTTTA CCATTTAATGAATTTTTCTTAAAAAGCAATTGAATTGTTGATGAAAGGTGATGTTAAAAT TATCCCAGATTTATCAATCTTTTTTTTATTGCCCCTGGATTTTGAGTCATAGAAAGCCTT TCCTTATTCTAAGGTTAACAAGACATTCACCCATGTTTTCCTCTAGTATTGCATTGTTTC ATCTTTTACGTTTATTATTTATTTTATTTTATTTTTTTGAGACAGGGTCTCACTGTGTCA CTCAGGCTGGAGTGCAGTGGAATGATCTTGGCTCACTGCAGCCTCTGCCTCCCGCCTCCC GGGTTCAAGCGATTCTGCTGCCTCGGCCTCCCAAGTAGCTGGGATTACAGGCACCTGCCA CCGCGCCTGGCTAATTTTTGTATTTTTTTTTTAGTACAGATGGGGTTTTGCTGTTGGCCA GGCTGGTCTCGAACTCCTGACCTTAAGTGATCCACCCGCCTTGGCCTCCCAAAGTGCTGG GATTACAGGCATGAGCCACCGTGCCCGGCCTAAAATTTATTCTGATATGTGATATGATGT ATGGTTCTAACTACTTTGTTACGGTGCATTATTTTCTAAATGTGGTATTGGATTCTTTTA TATTTTGTTTAGAAGTTCTGCATCAATATTCATGAGTACCATTGGTCTCTGTTGTTTTTC TTGTGCCATCTTTATTGGTATAGGTATCAGTGTTATATTTAGTTTGTAAAAGGAAGTTGG AAGTTTTCCTTTCTTTTTAGTACTCAGGAATGATTTTAAGAATTGAGACTATTTGGTCTT TGAAGGTTTGGTAGAAGTCCATTGGGAATCCATCTGGGCCTGGTGATTTTCTGTGCGGTA GTTCCTTAATTGTTTTCCCTATTTTTTCTTATTTTTAATCAGGTAGCCTCTGAACCAGAA TAGGTTCAGAGAGGCTCCCTCTATTTTTTTTAATACAAGTTGGTCTGCCTAAGTTTTCTT ACTCTAATGGGTTAATTTTTGTAGACTGCATTTCCCTGAAAAATTACA.CGTTTGTTCTAG GTTTTCTGACTTATTTCCACAACTTTTTAGTCTTTCCCCCTGGAATCATGCCCCTTTCCA TAAACAGGACTCTGATGTACCTGAAGTATTTTCACACTTCGGGTGGACTTTCTGTTTCTG GGGGTGGTTTTAGAGCAATTTTAGGCCTGCCACTAGCTACCCTGTTCTCTACACCATGCT GTTTTTCTCAGAATGCTCTTCTTTTGCACAAAGGCTTGGAGTAGGAGGTTGAGCAGTCAC TCACTGACGTTTGGTATATTTTCTTTTTTTTGCTTACAGGTAATCTGGAAGTTTGGGCAT TCTCTTTAAGTTGAGGGTGTGGTTTTCATGTCATTTTATTTGTTTATTGTTTTCTTGTGT GTGTTTCTTAGAGACAGGGTCCCACTCTTGCCCTGGCTGGAGTGCAGTGGCGTCTTGATC ATAGCTTACTGCATCCTCAAGCTGCTGGGCTTAGATGAACCTCCCACCTCAGCCTCCTGA 21CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GTAGCTGGGACTACAGGAGCACACCACCATACCTAATTTTTTTTTTTTTGAGACGAAGTC TTGCTCTGTCCCCCAGATTGGAGTGTAGTGGTGCAATCTCGGCTCACTGCAACCTCTGCC TCCCGGGTTCAAGCGATTCTCTCACCTCAGCCTCCCGAGIAGCTGAGACTGCAGGTGCAT GCCACCATACCCGGCTAATTTTTGTATTTTTTAGTAGAAACAGGGTTTCACCATGTTGGC TAGGCTGGTCTCAAACTCTTGACCTCAAGTGATCCACCCACCTTGGCCTCCCAAAGTGCT GGGATTACAGGCTTGAGCCACTGTGCCTGGTCCCTGGCTAATTTTTAATTTTTTTGTAGA GATGGGATCTTGCTATGTTGCCCAGGCTGGTCTTGAACACCTGGCCTTAAGCAATCCTCC CACCCTAGCCTGCCAAAACACTGGGATTTACAGGCATGAACCATTGTGCCTGGCTTGTTT TGTTTTTAATTCTATGTTGTTTTTGAAGGATGTATGGGGAGAGATGGATTTAGGCAATCA TCGTTGTCCTTGGCTACCTGAAAGTCCAGGCACTCTTCTAGATACTTTATAAATATTAAC TCATTTTATCCTCTCAACAACACTATGACATGGGTACTGTTACACCTTCCATTTTATAGG ACTTAACAGAGAGGTTAAATATGTAGCCCAGGGTCACAGAGAGCTGGGCTTCAGACCAAG ACAATCTGGCACCAGAGTCTATGTGGCTACCCCIAAGGCITTGCCACCATGTGTTAGTGA TTCTCAGCCTGTCATTTGGGGAGGGGATTGCCCTTTTTTTTAAACTTTTTAAAAAATTTA TTCTTATTTTATTATATTTTTGAGACAGAGTCTCCCTCTTTTGCCGAGGCTGGAGTGGAG TGGTGTGATTTCAGCTCACTGTAACCTCTGCCTCTGGGGITCAAGTGATTCTCATGCCTC AGCCTCCCAAGTAGCTGGGATTACAGTTGCCAGCCACCATGCCCAGCTAATTTTTGTATT ATTATTATTATTATTTGAGACGGAGTCTCGCTCTTTTGTTCAGGCTGGAGTGCAGTGCTG TGATCTCGGCTCTCTGTAACCTTCGTCTCCTGGGTTCAGGTGATTCTCCTGCCTCAGCCT CCGGAGTAGCTGGGACTATAGGCGCGCACCACCATACTTGGCTAATTTTTTGTATTTTTA GTAGAGACGGGGTTTCACTATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGAT CTACCTGCCTTGGCCTTCCAAAGTGCTGGGATTACAGGTGTGAGCCACCATGCATGGCTG GATTGTCCTTTTTTAAAAAAAAAAACAAAAACAAAAAAAAAAACCCAAACCATAAACCCA ATATTCTG/YAAGATTTGGTCTCCACACCTGTGTTATATAATAATTAGTTTTTCCATTTTT TTCCTCTTGGTAGAAGGCACATATGCCACTCAGTTTCCAGTTGCCACACCCAATTAACAT AATTGTTTTGCAGCCAAAAGCAAAAGAGAGT'IGACATITIAATTAGCTTATGTAGGTAGA CAAATTGAGGCCTAATGTAAGAGTTTCATTATACCTTTTTGAAAAACTATAAATAGCTAG AAGCCAGTTGTCATTACTTTTTGATTCCTTAGAATTCTGGGCATCTTTCATCTGGAACCA CAGATGAAAGAAGCTGCAAGGAAGGATTTTTTTTCTTAACGGAATAGTTTAACCATTCTG AATGCAAAAGTATTGGATGCTAGAATAATAGGTATCACATAAATTGAGGTTGACGTTTTC CCGGGTGAAATTCTATTCTGTCTCAATTTTCCTTTTTTTTTGAGACGGAATCTTGCTCTG TCGCCCAGGCTGGAGTGCAGTGGCATGATCTCGGCTCACTGCAAGCTCCACCTCCTGGGT TCATGCCATTTTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGGGCCTGCCACAAC ACCCAGCTAATTTTTTTGTATTTTTAGTAGAGACGGGGTTTCCCAGGATGGTCTCAATCT CCTGACCTCGTGATCCGCCTGCCTCGGCCTCCCAAAGTGCCGGGATTACAGGCGTGAGCC ACTGTGCCTGGCCTTTTTTTTTTTTTTTTTTITTT'ITTT'ITAAGACAGAGTCTCGCTTTG TTGCCTAGGCTGGAGCGCAGTGGCATGATCTCAGCTTATTGCAACCTCCGCCTCCCGGGT 22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TCAAGTGATTCTCCTGCCTCAGCCTCCCGAGTATCTGAGATTACAGATGTGTGCCACCAT GCCTGGCTAATTTTTGTATTTTTAGTACAGATGAGGTTTTGCCATGTTGCCCAGGCTGGC CTCAAACTCCTGACCTCAGGTAATCCTCCTGCCTCAGCTCTTCCCAAAGTGCTGGGATTA TAGGCATGAGTCACCGGGCCCAGACTCAATCTTCTGACAAGCTCTCAGAGAGAGTAAAAA GCAAATGAATATTTCATTATTTTGATCTGAGCTTTACGATTTTTCTTTTCTTTTCTTTTT TTTTTTTTTTTGAGATGGAGTTTTGCGTTGT.IGCCCAGGCTAGAGTGCAGTGGTGGCGAT CTTGGCTCACCGCACCCTCCGCTTCCCGGGTTCAAGCGATTCTTCTGCCTCAGCCTCCTG AGTAACTGGGATTACAGGCATGCGCCACCATGCCCGGCTGATTTTGTATTTTTAGTAGGG ACAGGGTTTCTCCATGTTGGTCAGGCTGGTCTTAAGCTCCCGACCTCAGGTGATCCACCT GCCTCGGCCTCCCAAAGTGCTGGGATTACAAGCATGAGCCACCTTGCCCAGCCTTTTTTT TTTAAATCTGAGAAGAGGTCTTGCTCGATTGCCTAGGCTGGAGTGCAGTGGTGCGATCTC TGCTCACTGCATTCTCTGCCTCCCAGACTCAAGCAATCCTCCCACCTTAGCCTCCTGAGT AGCTGGGACTACAGGCATATGCCACCACACCTGGCTAATGTTCGTATTTTTTTGTAGAGA CAGGGTTTTGCCATTTTGCCCAGGCTGGTCTTGAACTCCTGACCTCAGGTGATCCTCCCA CCTTGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCTGGTCTCCTTCAC TGTTGTAAGATACTTGAATTGGGTCAATATTTGTGGAGAAGTCTCTTAAAAGTTCACTTG ATTGTCAGTACTAGAACTCTACATTTAATATTGACATATTCCTGGGAGCATTTCAGAGCA TTCTATTAGCTTAGAAAGGTCCAGGATAATTTGACTTTAGAAGTTACTGTTACCATGAAT CTCAATGACTTTTGAAATCCATGAAGAATATCTTTTTTTTTTTTTTGAGACGGAGTCTCA CTCTGTCGCCCAGGCTGGAGTGCAGTGGTGATCTGGGCTCACTGCAAGCTCCGCCTACTG GGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCACATGCCAC CACGCCTGGCTAATTTTTTTGCATTTTTAGTAGAGAGGGGGTTTCACTGTGTTAGCCAGG ATGGTCTCGATCTCCTGACCTTGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATT ACAGGCGTGAGCCACCGCGCCTGCCCAAGAATATCTTTTTGCTGGTAACTAGAGAGGACT CCTCTGAAGCAGATGCCATTCATGATGGATTTCATCATTTATGGGTTTTAAAAAACATTT TATTTTGAAATAATTTCAAATTTAAATAAGAGTTGCAAAATAGTACAAATAATTCGTGTT AACTTTTCATCCAGATTTACAAGTCAACCTTATACAGGTTGAGTATCCCTTATCCAAAAT GCTTGGGACCAGAAGTGTTTTGGATTTCAGATTTTTTCGAATTTTGGAATATTTTTATTA TATACTTAAGCATCTCTAATCCCCAAATCTCAAATCTGAAATATCTGAAATGCTATGATG AGCATTTCCTTTGAGTGTTATGTGGGCACTTTTTAAATTTATTTAATTAATTTATTTTTT GAGATGGAGTATTGCTCCATCACCCAGGCTGGAGTGCAGTGAGCGATCTTGGCTTATTGC AAACTTCACCTTCTGGGTTCAAGTGATTCTCCTGCCTCAGCCCCCTGAGTAGTTGGGACT ATAGGCGCTTGCCACCACGGCCGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCAC CGTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGGTCCACCTGCCTCCGCCTCC CAAAGTGCTGGGATTACAGGAGTGAACCACCGCGCCTGGCCATGGATTTTGCAGCATTTT AGATTTGGGATACTCAACCTGTACCATGTTTACTCTCTCICCTCTCTCTCTCTCTCTTTT TATATATATATATATATATATATATATATATATATATATATATATATAAATTATATATAC 23CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ACTACACATATATGTATGTATATGTATGTATTTTATATATAAAATACATATCTACATATA AAATACACATGTATATATACATGTGTACATATATGTGTCTCTATATTTAAGTTTTGTTGG AACCACTTGAGGGTAAGTTGCAGACATGGCGTCTCATTGCTCCAAAATACTTCAGTGTGT ATTTCTTAAATACAAGGACACTTGGTTACATAACCACAGTATATCACCAAATGTATATTA TAACAAGACTACCATCAAATCCTTATATCTCTTTCAAATTGTTTTAGTAATATCCTTATA GCAAAAGACAAAACAACAACAAAAACTGTTCCCTTTTATITTGTTTGTTTTGGTCCATTA TATGTCCAGGTTATGCATTAATGCATTGTGTTACTTGCTAAGTCTTGTTACTGGCCTTTA ATTAGGATATTTCTTTGCATCCCGCCAAACTCCTCTTCATGGTTGTATCTTTTTTTTTTT TTTTGGAGATGGAATTTTGCTTATGTTGCCCAGGCTGGAGTATAATGATGCGATCTTGGC TCACTGCAACCTCCGTCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAAC TGGGATTGCAGGCCTGCGCCACCTTGCCCAGCTAATTTTGGAATTTTGTGAGACGGGGTT TTGCCATGTTGGTCAGACTAGTCTCGAACTCCTGACCTCATGATCCGCCCGCCTTGGCCT CCCAAACTGTTGGGATTACAGGTGTGAGCCACTGTGCCCGGTCTTTTTTTTTTTTTTTTT GAGACAGGGTCTTATTCTGTTGCCTGGCCTGGAGTGCAGTGGTATGATCTTGGCTCACTG CAACCTGGACCTCCTGGGCTCAGGCGATCCTCCCACCTCAGCCTCCTTAGTAGCTGGGAC TATAGGCACACACCACCATGCATGGCTAATTTTTATATTITTTTGTAGAGACTGGGTTTC GCCATGTTGCCCAAGCTGGTCTTGAACTCCTGGGCTCAAGTGATCCACCTGCCTTGGCCT CCCAAAATGCTAGGATTACAGGTGTAAGCCACTGCGCCTGGCCCTAATTTTTGCATTTTT TGTAGAGATGGGGTTTCACTATATTGCCCAGGCTGGTCTTGAACTCCTGGGCTCAAGTGA TCTTCCCATCACAGCCCCCTAAAGTGCTGGGATTATAGGCGTGAACCACTGTGCCTGGCT GAGGATTAAGTTTCAACCTCAGGGGAGCGGCATTCAAACTATAGCATTGTCCTTTAGTGA CTGGCTTAGTTCACTTAGAATGTTTGTCTATTCATCCATCTATAGACACTGTTTTCTTTC ACCTTTTGGCTTTGCAAATAATGCTGCTGTGAATATGAGTTATAGAAAAATACCAATTTG AATCCGTGTTTTCAATTACTTTGAGTATATACCTGGAAGTGGAATTTCTGGATCATATGG TACTTCCAAGTTTTTTTTTTTTCTTTTTTGAGACAAGGTCTCACTCTGTCACCCAGGCTG GAGTGTAGTGGCACGATCTTGGCTCACTGCAACCTCCGCCTCCCGGGTTCAAGCGATTCT CCTGCCTCAGCCTCTCAAGTAGCTGGGATTACAGGCACGCGCCACCACGCCCAACTAATT TTGTATTTTTAGTAGAGATGGGTTTCTCCATGTTGGTCAGGCTGCTCCCGAACTCCCGAC CTCAGGTGATCTGCCTGCCTCAGCCTCCCAAAATTCTGGGATTACAGGTGTGAGCCACCG CACCTGGCCTCCATGTTTCAATTTTTAAACAAACAATTAGTTAAAAAAATAGGAAACTAA GAGAATGAACTATTTCCTGTTTTATTCAGTGGGTTATAATCTGTTACTATCATTGTTTAT TTTGAGGTACAAATTGTCCCTACTTTGGCCAGCAGAGGATCCTGCAGTTTGTCTCCTGTG TCCTTTTCATAGCTCCTTGTTGGAACTCTTACTGGCCCACAATAGGATGTTCCAAGTTCA TCTTCTTACTTTTACTGCCCCAACGCTGGGATCAGCCATTTCTTCAAGGAGGCCAGTTCC TTTCATTGGAGAATGGAAAACCCAATATGTAGAAACCAAGATAGAGGTGTTAGGTGTGAT TGCTACTGGAGTGTCATTGCTTCCAAACCCTTTCAGAAGAGACCTAGGAAATGTGTGTGT GTGTGTATATATATATGTGTGTGTGTGTGTGTATTCATAAAAGCACATACACATACACAT 24CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ACCCCGAAGCATGTATTTCTGTATTATTATTATTTTTTTGAGATGGAGTCTTGCTCTGTC GCCCAGGCTGGAGTACAGTGGCACGATCATGGCTCACTGCAACCTCTGCCTCCTGGATTC AAGCAATTCTCCTGTCTCAGCCTCCTGAGTAGCTGGGATTACAGGTGTCCACCACCACGC CCACCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCACATTGGCCAGGATGGTCT TGAACTCCTGACGTCAAGTGATCTGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTATAGG CGTGAGCCACTGTTCCCATCCAGAAGCATACATATCTATITCTATATCTACATTTCTGTC TTTACATGTATATATTAAAAATTACAGTTTGCACTAATACCTCCAATTACAATCTAACAT CATGGGATTTATTCTGGCTTTCTCCCTTCTCATATTTGTGTCTCCCCAACAGTGAGAAAC CTGGCTTGCTATCCTCAACATGGTAACTTATTTATTAAGAAACTTATTCTTTTTTTTTTT TTTTTTCTGAGATTGAGTTTCGCTCTTGTTGCCCAAGCTGGAGTGCAGTGGTGTGATCTT GGCTCACCGCAACCTCTGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCTTCTCAAGT AGCTGGGATTACAGGCATGCACCACCATGCCCAGCTAATTTCGTATTTTTAGTAGAGATG GGTTTCTCCATGTTGGTCAGGCTGCTCTGGAACTCCCGACCCCAGCTGATCTGCCTGCCT CGGCCTCCCAAAGTCCTGGGATTACAGGCGTGAGCCACCGTGCCCTGCCTCTAGTTTATT TATTTTTATTCCATGTGCTCAGTCTTGCGAGCACGTGGTCTGTTTTCTTGGGCCTGGCCC CCTCAGTGCACTGTCTTAATACCCTAGCCCCCAGTCCCTCTGATCATATCCCCAGACACC CCTACTGAATCCCAGGTCTCTACCAAGGGAAAGGCAGGGAGGAGGCATTGACCAAGGAGA AGAGGGGGAAGGGACAGGGAAGGTCTTGATTTGTATTTTCTAAAATTTTCTACTCTGCTC ATAATGCGTCTTAGCTGTGTTGTTGTGGAAAGTAGTGCTGACAGTGTCTTGTTTTTTTAT TACTTACTTTGTCTTTCTTTT ATGGTTTCACCCAAATATCACTGGTGTGGAGGCAG AAAACCTACTGTTGACAAGAGGAGTTGATGGCAGTTTTTTGGCAAGGCCTAGTAAAAGTA ACCCTGGAGACTTCACACTTTCCGTTAG TTGGAATGAAAAGAGAGGATCCTGAGA GTGTTTTCTAGGTAGGAAGTGGTAAAACCATGCTTGGATAGCTTGCTGCCTGCATTTCGA GTTTGAAGGCCTTATCTGAGCCCTGGGCTGCCTTCAGGGTTTGGGGAGTGGCCTCCTGGA CATTTAGCAGAAGAGGAGTAAGGAGGGCCCTTCTTCTCCCTCTGAGACCTCATGGAAGGT GAGTTGGAGCAGGTCATAGAAGTTCTTAAGCCCTCCAGTGCTTGAGACTTGTTCCACACA TCTTGAACCTGGTTTCTGCATTTTTCTTTTCCTTCCTGTTGATTTATTTAAAAATTTTAT TTCTTTTCAATTTTTTTTTTTTTTTAAATAGAGGTGGGATCTTCCAATGTTGGCCAGGTT GGCCTTGAACTTCTGGCCTCAAGCAATCCTGCCTCGGCCICCCAAAGTGTTAGGATTACA GGCGTGAGCCACTATGCCTGGCCTTCTTTTTTTGAGACAAGCTGTTGCTCTGTTGCCCAG GCTGGAGTGCAGTGGTACGATCACAGCTTACAGCAGCCTTGAACTCCTGGGCTTAAGTGA TCCTCCCGCCTCAGCCTCCCGGGTAGCTGGGACTCCAGGCTTGTGCCACCATGCTCAGCA TTTTTAAAAAATATTTTTTGTAGAGATGAGGTCTCACTGTATTACCAAGGCTGATCTTTA ACTCTTAGCCTCAAGTGATCCTCCTGCCTCAGCCTCCCAAAGTGTTGGGATTACAGGCAT GAGCCACCACACTCAGACTTTGTTGACTTCTTAATAAGAAAAATACTTGTTAAGAGTTTC TTCAGATCACTTTCCTTTATCAACAAGTAAAACATGACTGAGGAAGTTGTGGTCCCCTTT GCTTCCCTGCCCAGGCCCGTTTCCCTCCCTCTTTCCCCAGAGGAAACCACCAAGAGGTTG 25CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCATATATTCTTCCTGAACGTGTTTTTATAGTTGTACTGCACTTGTACTGTGTATGAACA ATATAAAGTTGGTTTGTGTGTTTAAAAAATTCACATACATGGATTTATAATGTATGTATC ATTTTGCAACTTAAAAATTTTTTTTTGAGCTCCATGCTGATTGATAACGATCTATTTTTT TTTTTTGAGATGGAGTTTCAGTCTTATTGCCCAGGCTGAAGTGCAATGGCGTGATCTCAG CTCACTGCAACCTCAGCCTCCTGGGTTCAAGCTATTCTCCTGTCTCAGCCTCCGGAGTGG CTGGGATTACAGGTGCATGCCACCATGCCCAGCTAATTTITGTATTTTTAGTAGAGATGG GGTTTCACCATGTCGACCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCTGCCTGCCT TGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCTACCATGCCTGGCCTTTTTTTTTTT TTTTTTTTGAGACAAAGTCTTGCTCTTTTTCCCAGGCTGGAGTGCAGTGGCCACAATCTT GGCTCACTGCAACCTCTGCCTCCTGAGTTCAAGCAC-TTCTCCTGCCTCAGCCTCCTGAGT AGCTGGGATTACAGACATGTACCACCATGCCAAGTTAATTTTTGTATTTTTTGTAGAGAC TAGGTTTTACCATGTTGGCCAGGCTGGTCCTGAACTCCTGACTTAAAGTGATCCATCTGC CTTGGCTTCCCAAAGTGCTGGGGTTACAGGCATGAGCTATCGCGCCTGGCCTGAGAAATC TCATTCTTACTCCTACTCCCTTGCACACTATCTCCATTCTGTAGGTAGCCATTTCTATTA ATTTCTTGTTTACCCTTCTGTGTTTCTTTCATTCTTTTTCTTTTTTTCTTTTTTTTTTTT GAGACAATCTTGCTCTGTTGCCCAGACTGGAGTGCAGTGGTGTGATCTTGGCTCACCGCA ACCTCCACCTCCTGGGTTCAAGTGATTTTCATGACTCAGCCACCTAAGTAGTTGGGATTA CAGCGCCTGGTGTACACTACCACACCCAGCTAATTTGTGTATTTTTAGTAGAGATGGGGT TTCACCATGTTGTCCAGGCTAATCTCCAACTCTTGGCCTCAAGGGATCTGCCTGTCTCAG CCTCCCAAAGTGCTGGGATTATAGGCATGAGCCACCATGCCTGGCCCTATGTTTCTTTTT ATAAAAATAAGCAAATTAATATTTTTATTACTATTTTCCTTTTATTTTTACACATCAAGT AGAACATTAAATATATTTCTCTGTAATTTTTTTCAGTTACCTAAATCTTTTAGTGATCTC TCTCATCTTTTTAATCAGCTGGATCGCATTCTATCATGTGAATATTTTATAACTTCTATA TACTGTCACCAGCAGGTAGCGATTTAGTTGTGTCTAATATTTTAAAATGATATATAATGC CTCAATGAATATAGTAACCTTTTGCATATATTGTTTTGTGCTTTGGGATAACACTACCTC GTATTGGAAACTGTGTCATTACATGTGTCTTIAAAATTACATGTGTCTTTTTATTTTTAT TTTTATTTTTTTTGAGTGGGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAGTGGTGAG ATCTCGGCCGACTGCAACTTCCGCCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC CCAGTAGGTGAGATTACAGGTGCCTGCCACCACGCCCAGCTAATTTTTGTATTTTTAGTA GGGACGGGGTTTCACCATGTTGGCCAGGCTGGTATCGGTCTGCTGACCTCAGGTGATCCT CCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGACGTGAGCCACCATGCCTGGCCATCA CTTTTTTTTTTTTGTTAATTGGTGGATAGTGGGCGGGGAGAGTGGCTCACGCGTGTAATC CCAGCACTTTGGGAGGCCAAGGCAGGCGGCGGATCATGAGGTCAGGAGACCAATACCATC CTGGCTAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAAAATTTAGCTGGGCGTC GTGGCGGGCGCCTGTAGTCCCAGCTACTTGGGAGGTTGAGGCAGGAGAATGGTGTGAACC CGGGACGTGGAGCTTGCAGTGAGCCAAGATTGCACCACTGCACTCCAGCCTGGGTGATGG AGTGAGACTCTGTCTCAAAAACAAACAAACAAACAAAAAAATTGCTGCATAGTATTCCAT 26CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TGTATGAGTAGTAACACAACAATTTTTATAATGCATAGTATTCCATTGTATGAATAGTAA TGTAGCACTATTTGTTTATACATTTTTATGATTAAAAAACAAAATGTTTTTCTATTATGA ATAAAGTGGCAATGAATATTTTTGTACAAGTGTTTTGGTAGCTATACAGTTATTGTCACT TAATATATGCAATTCGATAGGCCAGTCATTCAAAATAGAAGATATACAAGGTAGGCCGGG CGTGGTGGCTCACGCCTGTAATCTCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACCTG TGGTTAGGAGTTTCAGACCAGCCTGACCAACATGGAGAAACCTCATCTCTACTAAAAATA CAAAAGTAGCTGAGCGTGGTGGCGCATTCCTGTAATCCCAGCTTCTTGGGAGGCTGAGGT AGGAGAATCACTTGAACCTGGATTTATAATGTATGTAAATCCACCGCGAAGGTTGCGGTG AACCGAGATCACGTCATTGCACTCCAGCCTGGGCAATAAGAGCGAAACTCCATCTCAAAA AAAAAAAAAAAAGATATGCAAGGTAAAGATACTAATAAAGACCTTTGTGTTGAGTTGGTT GACATGTGGTTATTTCACCCATCGTATTTCTTATAGGGAATAGGTAAATTCGTTCCTTGG GTTTCTTTCAACACTTAGGTAAAATCCGACGTGGAAGATGAGATCTGATTTTACTGGTGT AACTCTTTATTTGTCCCCTTGCCTCCCTTTCCAATGGACIAITTTAGROAaOtOajiW GTCACCCACATCAAGATTCAGAACACTGGTGATTACTATGACCTGTATGGAGGGGAGAAA TTTGCCACTTTGGCTGAGTTGGTCCAGTATTACATGGAACATCACGGGCAATTAAAAGAG AAGAATGGAGATGTCATTGAGCTTAAATATCCTCTGAACTGTGCAGATCCTACCTCTGAA OGTCAGTAACATTTTAGTGACCACAAAGTCTGCTGCTCCCTTGTGCCCTGAGTGTCAGA AATGCATGACGGTCTGTGTATGACTCTCTGACTCCAAAGGCTTGTGACTGTTTTTTGAGC TGTAATCTTTAAAGAATTACTAAAGTGAGACTAATAGCATCAAATTATTTTCAGAGTACC TTTTTCCTGCAAAAGTTTTAATCAGTGTTACTTACACTCATCCTATAGGGGTTGCATACC ATTCCTGCATATACTTGGTACGTGTATTAGTTTTAAGACTTATTGAACTTCAGCAGATAA TCTTTGAGAGTTATTAGAGGAAAACAAATGATAATGGAGACACCAAAATAGCAGCAGTTT TCTATGGTGGCTCTCGACCAGTTATTCAGCAATGTCACCAACAGATGTCAGTTTAAGCTC AGAAGTGGAAAAGCAGAGAGCTCAGAGGGTCAGCTTTTTCATCAGTTCTTTTAATGTTAT CACCACAATTATGTGAGAATGACCTTGCTTAGAGAAAATTATGTTATTTTCGAGATCTTT CCCCCTGTGTTGGAACTAGGCTGATGAAAGCATGGGCTTGACTTATTTATTGATTGTATT CGTTTTGTACATTCCCAATCTCCTCTCTGACTTGGTGCAAATTCAGGATCTCTTAGTTAG TTTGTATATTTTGTGTCTTCAGGTATGATTTTTTCAGCTTATACCTTTATGTCAGTGCTA TTATGTGCTGATAATTTGTTTCTCTAGCTACCACCGTAGCTTCAGGCAAAAGGCTGTCAG CCAACTCTGTACAGTTTATTTCTAAATTTTACTGTTTTCAGTTGAGTATGGATGAAGAAT AACTCAAAGTTTATTCTTTTGATGATGAGCCCTTAACACCACCTGCCATGATAGTACTTG CTTTCTGACCAAGATCCTGAGGGAAAAAGCCACTTTATTATTAGAACTATGTTAAGATGC TTCCCAAAAAACATGGAGCAGTATTGTCTCAAAGTCTGTCCTTGGATGGCTTTGGATGCC TACATCAGGACTGTCTGATGTGCTGGTTAAAATGCAGATTCCTGGGCCTCATTCAGACTT ACATGTATTGATATTGCTGGTTGTGGAGCCTGGGAATTCATATTTTTAGCAAAATCCCTC ATTTTTACTCCAAGTCTTATGTGCATTATACAGTTIGAGATGATCACCCAGGATATAGTC CAAAGACACTGGAGGCTGTTGAAGTATAGGTTGTATATATGGAAAAGGTTGGAATGTTTG 27CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AATTAATTTATAATGAAGATCCTTTTTAATTGAGTGTTCACATGCCAAGGCAAGGACAAA CATTCAAAATGATTTTCTGTCTCTGTTACAACTTTTTCTTTCTTTTTTTTAATTTATTTA TTTGAGATGGAGTCTCACTCTGTCACCCAGGCTGGAGTCAAGTGACGCGATCTCGGCTCA CTACAACCTCCGCCTCCCAGATTCAAGTAATTCTCTTGCCTCAGCCTCCCGAGTAGCTGG GACTACAGGCATGTGCCACCATGCCCAGTTAATTTTTGTATTTTTAGTAGAGACAGGGTT TTGTCATGTTTGCCAGGCTGGTCTCAAACTCCTGAACTCAGGTGATCCGCCCACCTTGAC CTCTCAAAGTGCTGGGATTATAGGCGTGAGCCACCGTGCCTGTCTCTATTACAACTTTTT ATTACAACTTCTTTATTTTGACTTTATTTTTACAAATTATTTATTTATTTTTTTTGAGAT GGAGTTTCGCTCGTCACCCAGGCTGGAGTGCAATGGTGCGATCTCAGCTCACTGCAACCT CCGCCTCCCAGGTTCAAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGG CACTTGCCACCACACCCGGCCAATTTTGTATTTTTAGCAGAGACAGGGTTTCACCATGTT GGTCAGGCTGGTCTCGAATTCTTGACCTCAGGTGATCCACCTGCCTCGGCCTCCCAAAGT GTTGGGATTACAGGCATGAGCCACCACGTCCGGCCGACTTTTATTTTTTTTTCTTGAGAC AGGGTCTTGCTCTGTCACCCAAGCTGGAGTGCGGTGGCATGATCATAGCGCACTGCAGCC TCGACCTCCTGGACTCAAGTGATCCTCCTGCCTCGGCCTTGTGTATAGCTGGGATTACAG GCAGTTGCCACCATGCCAGGCTAATTTTTAATTGTTTTGIGAAGATGGGGATTTCACTGT GTTGCCCAGACTGGTCTTGAACTCCTGGCCTCAAGTGATCTTCCTGCCTTGGCCTTCCAA AGTGTTGGGATTACAGGCATAAGCCACTATGCATGGCCTGTAACTTCTTTAAATGGCTAT AATTAAACAGTTGGTCCTTTTAAGATTGGGCAATGGACGAATGGCAAATTGCATTTTTAA AAGAGGAGGGATTTAAAAAAAAACAGGAAAGATTGGGGCATTTGTCTCTAAAGGACTGTG GACTCATTTAAGAAGTTTAGTGGTCATTCTTACCATCTTTGTGGTTTTTCCTGCCTGCAT GGGATGCAGATTTTCTGTCTCAGGTGGGATTGATCAATCCCTTGGAGGAATGTGTCTACT TTTTAATTGTGTTTAGGAGAGCTGACTGTATACAGTAGTTTTGTGAAAGAACAACATGAA CCCATAGTAGAGCTAAATTCTTTTTTATTTTTTAAAAACTTTAGi^ijilljOiBOO CTCTCTGGGAAAGAAGCAGAGAAATTATTAACTGAAAAAGGAAAACATGGTAGTTTTCTT GTACGAGAGAGCCAGAGCCACCCTGGAGATTTTGTTCTTTCTGTGCGCACTGGTGATGAC AAAGGGGAGAGCAATGACGGCAAGTCTAAAGTGACCCATGTTATGATTCGCTGTCAG':TA AATCTCCAGTTGAAAAATGGGTCTGGCAAGATGTTACCTTTGGGTGATTTTTCTGCTGAC AGAAGACAGACACCATTACATTCAAAGTCAGATTGTCTTITATTTATTTATTTATTTATT TATTTATTTGAGACAGGGTCTTGCTCTATCACCTACAGATGGGGTTTCACCACGTTGGGT CTGGTGACCCAAATCTTTGGGTGATTTTTCTGCTGGAAGAGGACAAACACCATTACATTC AAAGTCAGATTTTCTGTTTTTTTTTTTTTTTTGTTTTTGTTTTTTTAATATTCATTTGTT TATTCATTTGAGACTGGGTCTTGCTCTGTCACGCAGGCTGGAGTGCAACCTCCCTGGGCT CAGTTGATCTTCCCTCAGCCTCTTGAGTAGCTGGGACTACAGGTGTGTGCCACCATGCCC AGCTAGTGTTTGTATTTTTTGTGGAGATGGTGTTTTGCCGCATTGCCCAGTGTGGTCTTG AACTAGTGCTCAAGAGGCCTGCCTCCTTCAACCTCTCAAAGTGTTAGGATTACAGATGTG AACTACTGTGCCTGATCCAAAGTCAGATTTTCTTTGCTTACTTAGTCAAGTTCGTCTATG 28CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CTTTTATTATACTTAATATATTAGTATAGTTACTGTATTAGTATATTAGCATATTTAATA TATTATTATACTTATCATACTTGAGTATATTGAGTATATTTACACTTTTAGTATATTTGT ATACACACACCACATTTTTATTATTTATCTTTTTTTTGAGACAGAGTCTCCCTCTGTCTC CCAGGCTGAAGCACAGTTGGCTCACTGCAACCTCTGCCTCTTGGGCTCAAGTGATTCTCG TGCCTCACCCTCCTGAGTAGCAGGGATTACAGGTGTCCACCACCAAGCCTGGCTAATTTT TGTATTTTTAGTGGATATGGGGTTTTACCATGTTGGCCAGGCTGGTCTCGAACTCCTGAC CTCAAATGATCTGCCCGCCTTGGCCTCCCAAAGTGCTGGAATTACTGGCGTGAGCCACTG CACCCAGCCTATTATCTGTCTTTTGATGGACATTTAAGTTGTCTCTATATACTAGCTATT GTGAATAATGCTGCAGTGAACATGAGAGTGCTTGAAAACACTAATGTAACATAAAGGTAA CAAATAATAAATGTCATGTGTTTATCTT GAACTGAAATACGACGTTGGTGGAGGA GAACGGTTTGATTCTTTGACAGATCTTGTGGAACATTATAAGAAGAATCCTATGGTGGAA ACATTGGGTACAGTACTACAACTCAAGCAG I GAGCAGATTGGAAAGCTCAAGCTTTCTC CTTAAAAACTTAAAACAAATCCTAATAGAGAATTTTGCAAACATACAGAGGTAGACAGAA TAGTATCATCAGCCTCCATGTACCCATTGCAGCTTCAACTATCAAATCTTTTTTTTTTTT TTTTTTTTTGAGACAGTCTTACTCTGTCACCCAGTCTGGAGTACAGTGTTGCAATCTTGG CTCACTACAACCTCTGCTTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAG CTGGGACTACAGGTGCCCACCACCATGCCCGGCTAGTTTTTGTGTTTTTAATAGAGATGG GGTTTCACCATGTTGGCCTGGCTGGTCTTGAATTCCCGACCTCAGGTTTTCTGCCCGCCT TGGCCTCCCGAAGTTTTGGGATTACAGGCGTGAGCTACCACGCCCGGCCCTAAATCTTTT CTTATTATGATTCCACTCACTGACTGCCGCTATAGTACTTGGAAACATATTCCAGATTTA TATTATTCCCATATTTATCTGTAAAAGGCATTACAGAGGTTCTTTTTTTTTTTTTTTTTT TTTGAGATGGAGTTTTGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCGTGTTCTTGGCTCA CTGCAACCTCTGCGTCCCGGGTTCAAGAGCTTCTCCTGCCTCAGCCTCCTGAGTAGCTGG GATTATAGGTGGTGCCACTACACCCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTT CACCATGTTAGCCAGGCTGGTCTTGAACTCCTGACCTCAAGTGATCTGCCTGCCTCAGCC TCTCAAAGTGCTGGGATTATAGGCATGAGCCACTGCATCIGGCCTAAGGCTGTACAGAGT TTTAAAGCAAGTTTTCATTATAGATCCACTTCTGGTTACCTTTAGGTAACCTCACTTATT CACTTTGGCATTGTTGCTATTTCAAATTTCACCTTTATGATAGTGGAAAATGATATAATC TCTCTAAATAATGTGGTCTATTCATAAAGAAAAATAGGCITGAATTTATATCAGCAGAGT AAAGTGTATGTGAAGACTGAAGAAAGATACATTTTCTGGCTGAACAGAAAACACGGTGAA ACGATTTGAAAACTTTTATTGTGAATTACAGGGTCCTATGAACCCTCTGTCCGTGCCTTT ATGAATATCAACATAGACATGTTTTTTTTTTTTTTTTTGCATTAACACCGTTTTCTGTAA TATTTTCTTTATTTGACATCAACTGCTGTACTCGATCAGC^tiOeOC^C^aOW^ AATGCTGCTGAAATAGAAAGCAGAGTTCGAGAACTAAGCAAATTAGCTGAGACCACAGAT AAAGTCAAACAAGGCTTTTGGGAAGAATTTGAG "AAGTTATTAAAAAACTGTTTTTACG TGAGTTGTTATATCCTATTTTTAGTGGAGGAGAAGTTGCICTTGTGTTTGGAATTGGACC TGAGAGACTTGAAACTGACGTCCTTTTTTAATTCGGCCATTGATTGACACGGAGCAAGTT 29CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCTGAGAGGGCTTCTTCGAAACAGAAGAGCATTGTGTTCTGAGGGAAGGGAGTTGGCAGT GAGTAGTCAATGGATGTGCTAGCCGCTCCATTTGGCTCTTTTGGTTTGGACTGGTGGCAA AATCTCAGAGAAACAAAAGGATCTAATTTCTTCGAAAGATTTCCAGCATGCACTGGGGTC TTTAGAAACAATCTATAGCCTTAGTGCAGCAAATGAGTATGAGTAAAAGAGAAACACCTT GTGGTGGCTTTTTTTTTTTTTTTTTTGAGACAGGGTCTCGCTCTGTCGCCGAAGCTGGAG TGTAGTGGCGTGATCTCGGTTTACTGCAGCCCCGTCCTCCCTGGGCTCAAGTGATCTTCC CATCTCAGCCTACTGAGTAGCTGGGACTACAGGCACATGCCCCTATGCCTGGCTAATTTT TGTATTTTTGGTAGAGATGAGGTTTTGCAGTGTTGCCCAGGCTGGTCTTGAACTCTTGGG CTCAAGTGATCCTCCTACTTAAGCTTCCCGAGTAGCTGGGACTACAGGCACACGATACCA TGCCCATCTAATTTTTGTATTTTTTTGTAGAGATGGGGTTTTGCAGTGTTGCCCAGGCTG GTCTTGAACTCTTGGGCTCAAGTGATCCTCCAGCTTTGACGTGCCAAATGTGGTGGCTTT AATTTCAGAGTTCAAATTGATAACTCTGGTAAGTTAAGTGAACTGATTTCTTTTTTTTTT AAATTATTTTTGTTGATTATACTTTAAGTTCTGGGATATATGTGCAGAACGTGCAGGTTT GTACATAGGTATACATGTGCCATCATGGTTTGCTGCACACATTAACCCATCATTTAGGTT TTAAGTCCTGCATGCATTAGGTGTTTGTCCTAATGCTCTCCCTCCCCTTTAATGCATCAG TGAAAAAGTGATGATAGGCTGGGCGTGGTGGCTCACTCCIGTAATCTCAGCACTTTGAGA GGGTGAGGCAGGTGGACCACTTGAATCCAGGAGTTTGCCCCCATCCCCAGACAGTGTGTG TGATGTTCCCCTCCCTGTGTCCATGTGTTCTCATTGTTTGGTTTTCTGTTCCTGTGTTAG TTTGCTGAGAATGATGGTTTCCAGCTTCATCCATGACCCTGCAAAGGACATGAACTCATT CTTTTTTTATGGCTGCATAGTATTCCATGGTGTGTATGTGCCACATTTTCTTTATCCGGT CTATCATTGATGGGCATTTGGGTTGGTTCCAAGTCTTTGCTATTGTAAATAGTGCTGCAA OsosSOgSgOsatatgtctttatagtagaatgttttataatcctttgggtatatac CCAGTAATGGGATTGCTGGGTCAAATGGTATTTCTGGTTCTAGATCCTTGAGGAGTCACC ACACTGTCTTCCACAATGGTTCAACTAATTTACACTCCCACCAACAGTGTAAAAGCATTC CtATTTCTCCACATCTTCTCCAGCATCTGTTGTTTCCTGACTTTAAGTGAACTGATCTCT TTCCTGAAACTAACTTGGGTTGGAGAATGTCCCTGATC-GGAATGTGCTGTGTTCCCATTG CACTCTTCTATATCACTTACCCATTGACAATGTGATCTCTTTCATTTTCTCCTCATCCAT TTGACAGAAAACTTCAAAAACAAGGATTCTGGCATATTTACCTTTGCAGTTGTCCCCAGC ATGTAGCACGGTGCCTAGTACACAGAAGAAACTCCATAAATGTTTGTTGAATGAGATTTA CATTTAACTCATGTTTACATCATTTTATTTTCCTGTTCTGTTTTATGGGAATGATTATTC TATGCTTTTTGAGGACTACAATTTATAAATATTTGTGGATTGAATGAATAAGTGAATACT GGGCAAATAAAGTCCTTTTAGCCAGAGTATGTCTGAACAACTTGCTGAGATAGATATGAT TTCCCATTTTCCAGCTGAGGGGCCTAAGGGAGGTTAAGTAAATTATTCAATCTTCATACC ACAGTTTTTGTTTTGTTTTGTTTTGTTTTTTTTCCTCCTGAGACAGAGTCTCACTTTGCT GCCATACTGGAGTACAGTGGTGCAATCATAGCTCACTGCAGCGTCCAACTTCTGGGCTCA CGCCATCCTCCCACCTCAGCCTCCTGAGTAGCTGGTACTACAGGTGTGCACCACCATAGC CGGCTAATTTTTCATTTTTTGTAGATATGGGGTCTCACTGTGTTACTCAGGTTGGTCTTG 30CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AACTTCTGAGCTCAAACAATTCTCCTGTCTTGGCCTCTCAAAGTGTTGGGATTACAGGTG TGAGCCACTGTGCCCGGCCCATACCACAGATATTGATTGAATTCCAGCAGTGGGGAGGAG TGTGGAATAGAACATTCTGAGTCCTTGCTCAACATTAGTGAACAGAGACTTGAATTTGAG TTTATTCTCTCATCCCAGGCTTCGCGTTAGGCTCTGAAGACACTAGTGAACAAGACAGAC AGGGTTACTGCCTTTAAAGGGAGCTTTTAGTTGAGAGAAGGAAAACAGTGATGAAAAGCA TCAGTGAAAAAGTGATGATAGGCTGGGGCGTAGTGGCTACTCCTGTAATCTCAGCACTTT TAGAGGGTGAGGCAGGCAGCTCACTTGATTCCAGGAGTTTGAGACCAGGCTGGGCAACAT GGTAAAACCCCGTCTCTACAAAAAATACAAAAAGTAGCTGGGTGTGGGGGTGCGCACCCA CAGTCCCAGCTACTCTGGGGGTTGAGGTGGGAGGATTGCICGAGCCTGGGAGATTGAGGC TGCAGTGAGCTGAGATCACGTCACTGCTCTCCAGCCTGAGCAACAGAGCCAGAACCTGTC CCAAAAAAAAAAAAAATTGATGATAAACATAGTGAGACAGAATTTTGAAATCTCAGCCTC ACTGTTGCCTTCCTTGTCCCCTGCCTGCCTAAATAATAAAAGGCAGCATTTCAGCAGTCA TTCATTTCATTACTTTCACTTCATTTCACCTTCATAAAGCCTCATGAGGTAAGATGGGAA GATACAGAAGTTTTAGAAACCGCTCATCAAAATTGAATGGAAAGCCGATTGTTCCAAAAC TTTTTAGTGTGGAAAATTTCTATTATATGCAAAAGTAGAGAGAATGGGATAGTTATAGCA GTATACCTGACACCCAGCATTAACAACTGTTGATAATATGGCCAATCTTTTTCGACTCTG CCCCACTCACTTCCCCAGCCCTGACTTGTCTTGAAGCAAATACTTTTTTTTTTTTTTTGA GATAGAGTTTTGTTTTGTTTTGTTTTTTGTTTTTGAGATGGAGTCTCACTCTGTCCCCCA AGCTGGAGTGCTGTGGCTTGATCTTGGCTCACTACAACCTCCGCCTCCTGGGTTCAAGTG ATTCTTGTGCCTCAGCCTCCTGAGTAACTGGGATTACAGGTGTGTACCACCATGCCCAGC TAATTTTTGTATTTTTAGTAGGGACAGGGTTTTCACTATGTTGGCCACGCTGGTCTCAAA CTCCTGACCTCAGGTGATCCGCCTGACTTGGCCTCCGAAAGTGCTGGGATTGTAGGTGTG AGCCACTGCTCCCGGCCTTGAAGCAAATCTTAACACATCATTTCGTCTGTAACTATTTTA TTTCAAAAAATTATAACCTGAATAGCATTATCATATCTAAAACTATTAACAGTATTTCCT TAATATTAACACATATCAGTCACATTTTCCTGATTGCTACACACACACACACACACACAC ACACACACACACTTGCAATTTGTGTTTTTTTCTTTTTAGATGGATCTCACTCTGTTGCCC AGGCTGGAGTGCAATGGTGCATTCTCAGCTCACTGCAACCTCCACCTCCTGGGCTCAACT GATTCTCTTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTGCCCACCACCTCACCTGG CTAGTTTTTGTATTTTTAGTAGAGGTGGGGTTTCACCATGTTGGCCAGGTTGGTCTCAAA CTTCCGACCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATG AGCCACTGTGCCCAGCAGCAATTTGTTTGAATTGGGAGTGCTTTCTTCCACCTTGATTAT GAAAAAATTTCAAATGTGTATAAAACAGATTCATATAAAGGATCCTGATATGCCATTATC AGCTTTATCAATTATCCCTGTCATCATATTTTTTATTTATAAATATTTCAATATTTGTGG AATCCTTAAAAATGCATCACATAACCCAACATTGTTCATATTATACCAATTGTCTTATAA TTTAAAAATATTTTGTTCAATCATTTTTCAGATAAGCTTCACACACTGTGGTTGGCTAAG TCTCATAATATTTCTGTTGTAAAAATCTTAAGTCTGGGCGTGGTGGCACACGGCTGTCAT TCCAGCACTTTGGGAGGCTGAGGTGGGCGGATCACGAGGTCAAGAGATCGAGACCATCCT 31CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGCCAACATGGTGAAACCCGGTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTAGT GCGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGAA GGTGGCAGTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTAGAGACAGAGTGCG GCTTCATCTCAAAACGAAACAAAACAAAACAATCTTAAGTCTCTTAGAATACTTTGATGC CCCTTCCATCTCTCTTTTTCTGTCTTCCTTCCCCCTCTCCCTGTCTTTTCTGCTGTTGAA GAAAGCAGATCATTTGTCCTGAGAGTTACTTATAGTCTGAATTTTGCTGAGTGCCTCTCT GTGGTGGACTTAAGCATGTATCCATCCCTTATATTTCTTGTAAGTTGATATATCTAGAGA CTTCATTGGATACAAGTTTTCTTTGGCAAGATAGCATGTATGGTGGTGTATCAGGAGGTG TTTATGTCCTGTTGTTTCTTCTCTGATTTTCTTAGCAGCICCTGATCATTATTACTTAGA TCCATTAATTCATAAGGGACTATATGGTAGTGATATTGTAATTTTATCATTCTTCTTCAT TTGTTAGGTTGGCATATTTCTATAAAAAGCTTTTCATCGCCGAGGGTTGATTTTTTCCTT CTTACTAAGCAGTTTTCTTTTCTTTTTCTTTTTTTTTTTTTTGAGGTAGGTCTCACTGTG TTGCTCAGGCTGGTGTGCAGTGGCGCAAACACACAGTTGCGAACTCTTGGGCTGAGGTGA TCCTCCTGCCTCAGTTTCCTGTGTAGTTGGGACCACAGGTGCATGCCACCATGCCTGGCT AATTTTTTGATTCTTTTGTAGAGATGAGGTCTCACTTTATTTCCCAGGCTGGTCTTGAAT GTCTGGGCTCAAGCAATCTTTCTACCTCAGCCTCCTGAGIAGCTGGGACTACAGGCACAT ACCACCATGCCCAGCTAATTTTTTAATTTTTATTTTTAGTAGAGATGTGGTCGTATTATG TTGCTCAGGATGGTCTCGAACTGCAGAGCTCAAGTGATCCTCCTGCCTCAGCCTCCCAGT GTGCTGGGATTATAGGTGTACTACAGGCAAGAGCCAATGAGCCTGGTCAGATTTTTTTTT CCTGATTTGAAATCTGTTATGGGTTCAATTGATACTTCCAAATCAAACTCAGGGTTTCAG GATTTTTACTAACCTCATTGATCTTACCCATGTATCTCCTTTCTCTAATGCCAAAAATCC TACTTCTTGAAGCCATAATAAGATTATTCATTTGTTTTATCCCACATTACACACAACAAT CTTAGAATAATGACTTCCCAATAATATGATTAGTGAAAACAGTTTAATTTTTTTTGCGCT TTTCAAAAAAATCCTTCAGAGATGTGTAGTCAAGTTACTGTATTCTGCTGGGCACAGTGG CTCACGCCTATAATCCCAGTACTTTGGGAGGACAAGAAGGGAGGATCGCTGGACCTCAGG AGTTTGAGACCAGCCGGGGCAATATAGTGAGACCCTGTCICTACAAAAGAAAATTAAAAA TTAACCAGACATGGTGGCATGTCCCTATAGTCCCAGCTATTGAGAGGCTGTGGCGAGAGT AGGCTTAAGCCCAGGAGTTTGAAGCTGCAGTGAGATACGATTGTGACACTGTACTCTAGG GTGACAGAGCAGGGACCCTGTTTTTAAAAAAAAAAAATGAAAAAACTTCCTGTGCCTTAG ACTCATTTGTAATCGTCCTTCTCTCTGTGTGGCTATATGCTAACTGGGTATATGGTTAGT TTATTTGTTTCATTTAAAAAATCTCTTTCTGTTAAGTTTTATTTATAATTACACAAATAC TGGCTTTGATAGTCAAATTGAAAAAACAAAGTGTATTCAAAGAAGTCTACCTTCTATCCT TGTCCTTTCCTATGTTTTAGCCATAGTATAAAAAGTTATGGTTTATCATTATATTTCAAA AATATAAGAAGATATTCCCATATCCCACTTTTTCTTAAACAGTAGCATAACTTTACATAC TTTTTTCTAACCTTGCTTTTTTAAATATCCTGGACATCCTGGATATCCATAATAGTGTCT AGAGATAGTCTTCATTCTTTTTTTACTGTATAGTAATCCACTGTGTACTTGTACCATAGT TTATTCAACCTATTGATGGGCATTTGGGTAGTTTCCAAATGTATCACAGAGAGGATTACA 32CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GTGAATAGCCTTGTGTATGCATCCTGCTTTACTTTTGCTGACTACTGGTAATATTAACAT TTTTTATGTTCTGTATTTAAAAAATGGTGGTTATTATTCATCTATAACTTTTATTATACA TGACTTTGGTTAGCATGCTTTAACCTTTTAGCATAACATTTGCAAGCTACTTGTTTT/VAT TAAAATTTTGGTTAAATGTAAAAAATAGTGAGCTATTTTGTAATCTAGATTCAATAGAAT CTTATACTTCCTTTACAAATGATAGCTGAGTTGATCATTTGTGTAAATGACTGTGAACTT AAAAATTACAGCATTTTTTAAAATAAATTTTITTAACATITTAAAATTATTTAAAATAAT AGACACACAAAGTAAAAAGAGAAGAAAAAAAAAAGAGACAGGGTCTTGCTATGTTGCCCA GGCTGGTCTCAAACTCCCAGGCTCAAATGATCCTCCTGCCTTGGCCTCCTAAAGTGTAAG CCACCACACTTGGCAAAAATTAGTTTCTTTAAAACAAAAACATTACAGGTTATCTGGTAC CATGGTAGCTTCTTTAACACTAGGTTCACTTAGAACAAAGCTTAGGAACAAAGTCAGACT TTCACAAAGAGCTTGTGTGGCAATGGGGTATTTTTTGCAAATTCCATTGGTGGGGTCAAG ATGTGAGTTTAGAAGGAACTCTTAGCCTGACTCTTCTGGCCATGGAAAAAGATGGTTGCT TCTAAATGCTGACCTGGTGATTTTACACTGTCACATCTCAAATTGTGGTCATCTTTTATA CATTATTAACAACAAAAGGGAAAAATTGAGTTGACTTTAAGAGGAAGTGGAAAATAACGA GATCACATCTGTACTCTACAGGCTCTCCACAGAGGTCAGACTGAGGTGGTAAAATTGTTG TGCACTAAATTAGGGCATTAACGTTTCATGGAAACTGAAGCTATATCTAAATAGCTGATG GCCTGCTTTCTAGATCTCCTATATACCTGCTTCTCAAATTCAGTCTGTTTTAAAAAATTG CCCTTTGAGGTTGGAACCAGCGAAATAAGGCTGAAAACAGAATAAGCCATTATTGAAAAA ATTAGGAACTTGGAAGCAGATACTCATAATCTAAATCCTCTGAAGCTAAAGTTTGATCCA CAATAGCAAAGCATTATCATTTTAGTGATTGTACCTTAGTTGTTTCCTGGCAGGTGATAA ATTTGGGATCACTTTCTTCTTACAGTGTGCTCTGATAGTCTTTAAAACAAACCAGAGCTC TAAATTGTAATGCCATTGGTAATTTAACTCTGATTTGTCTCTATGCCTGTCTCCTGGTGT TCTGTAAAATTCTACACGTCATTTCAGGTATCACTATCCAGAAGACGTTACTTTTGCCTT TGATGCACTTTAAAATGTGAAGTCTCTTGTGAAGCTCTTTGGTTATTTTCTCCTTTGCTG CTGAAATAAATTCAGGTTGATGATTTTCTTGTAGGATATGTTGTGTGATCTAGACATTGC AAACCCAAGTCTTTGATTTTTTTTTCCCTACAGATTGCCIGTTTCTTTTTTATTTTAATT TTTATTAGTTATTATTATTTTTGAGATGGAGTCTCACTCTGTCACCCAGGCTGGAGTGCA GAGGTGTGATAGCTCACTGCAACCTCCACCTCCCGGGTTCTTGTGCCTCAGCCACCCAGG TAGCTGGGATTACAGGCACGTACCACCACTCTCAGCTAAITTTTTTGTATTTTTAGTAGG GATGGGATTTCTCCATGTTGGCCAGGCTGATCTCAAACTCCTGACCTTAAGTGATCTTCC TGCCTTGGTCTCTGAAAGTGTTGGGATTACAGGTGTGAGCCACTGTGCCTGGCCAGTTAT TAATTTTTTTAAAGAGATGGGGTCTCACTATCTTGCCCAGGCTGGAGTGCAGTGGCTCTT TACAGGCACTGTTGTAGTGCACTGCAGCCTTGAACTCCTGGGCTCAAGTGATCCTCCTGA GAGGCTGGAATTACAGGCACACACCACTGTGTCCAACAGATTGCCCATTTGTGATCTGTG TAAATATCTCTCACTTCCTGCAGTATCTCTGCTCAAGAATGTAAAGAGATGGATAATATT TTTAGATTTGTTGAAACAAAGTAAAGTTCTGCTCAAATGAGAATGACACTAACTAAATGA AAAGGCCGGTTATAATTCTGTAATTTTGTGCCTGCAATGTGTGTGTTATTGTACACTTGA 33CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATCGGCCCTGTGCATTGTGGCGAGGTGCATATTGCATGGTTGTATTGAAAAGGTGCTTGG GCCGGGCGTGGTGGCTCACACCTGTAATCCCAGCAATTTGGGAGGCTGAGGCAGCTGGAT TACCTGAGGTTAGGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACCCTGTTTCTAGTA AAAAATACAAAAAATTAGCTGGGTGTGGTGGTGGGTGCCTGTAATACCAGCTACTAGGGA GGCTAAGGCAGGGAGAATTGCTTAAACCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATTG TGCCACTGCACTCCAGCCTGAGTGTATCACAAAAAAAAAAAAAAAAGGTTTTTGCCCTCT CTCTGTGCCTGCTGCTCCCTGTTGAGTCCTATAGGCCTGAGCTGCCAGGGGGTACTGTGG GCTGAGACTGGACATTGCAACCGACTGCAAGGCACCGTGGGACCCAGGTTGTGGATGGAC TGTCTCTCGGGCTTTCTTCTTTCCATTCATCTTCCTCCTCTAACTCCCCTCTGTATCCAG TATCCTTGCTCTCCATACACCTGCTTCATTCTTTTTCCTTCAGTAGATTTTTCTGCTTCT TGACTTACAAACCCTACTTCTAGCCCCTTTCAGATATTGAAACTAGCAACTTTCAGGCTT TGTACCAAAGTCTCAGAGATTCTCATTGACTCGGATGCCATCCATCTCTAGTCCAAAGAA CAATGTCAAGGACATGAACATGTGGAACAAAAGTGTCTGCTGTGGACACCTTTGGGGAGA AATAGTTTTCAGTGATGAGGGTTGTAGTGAGTTGGGCAGATATCCCAAAAATATCTGCCA AAAACTATAGACACTTCTGGTTGCAGTGACTTATTCCTTCCTTCATTCAGCAAATACTGA TTGAACACCGACTGTATGTCTGGATCTATTCTAGGTTTTGGGGGTGGAGCAGTGAACAAA TCAGTCTTTATCTTTATAGAGTGTACAGTCAAGTGGGAGAGACAGGCAGTAAACAAAGAA ACAGTTCAATATTCAATCTGTGAGATGGTGATAAGTGCTACAGAGAAAACAAACTAGTGT AAGATAAAAAGGGTGTTTTGATAGGCCTTTACTATTTAGGTCTCTTTGATAAGGTGGCAT TTGAACAAAGCTCTGAAGGAAATAATGGAGCCAACCATGCATATAACCTCAGGGAGAACA TTCTAGGTAGAGGGAACAGCAAGTGCAAAGGCCCTGAAGTGGGGGTTTGTTTACCTTGTT GCACAATCTGCACACAGGCCAGTACAATTGGAATGGATGGGAAATGTAAAAGAGAGAAGT TGAAAAGGCCAGGTGCAGTGGCTCATGCCTACAATCCCAGCATTTTGGGAGGCTGAAGTG GGAGGAATTTGAGATCAGCCTGGGCAACAGAACCAGACCTCGGGCTAATTTTTGTATTTT TAGTAGAGACAGGGTTTCACCATATTGGCCAGGCTGATCTCAAACTCCTGACCTCAGGTG ATCCTCCTGCCTCAGCCTCCCAAAGTGCTAGGATTACAGGTGTGAGCCATGGCCCCCAGC CGTATCTTTGTCTTAAAAAGTAATCTCTGTGCTTGGTAGGCCAAGAATTTAAAATATAAA AAATTTAAGAAAGAAAAAAAATAAGTAAAGTAACTATACAGGTTGGTCTGGCCGTAATGG TGAGTGTCATTATTTTTCTTCCCTAGGTATTTTGGCTCTGTTGCTCAGAGCAGTGCAGGC GAAATGGTCATTAGGGCATCGTCATGGTGCCTGGGGATGCCTGGCTCAGCCAGTTTATTT TCTGTCTGCCTCTCTCCTTGGTCCTTTTCCTCCACTTTCATTCATGAAATTCTAGTCAAG AGCTGGGTCCAGTGGTTTTCAATCCAAGGGCTTTGGAAGCCTCTGGGGTCTATTTTGGTC ATTGCAGTCACTGGGCTGCTGCTCCTGGCATTTAGGTTGGCAGGGGTCTGGGCTGGGAAG CAGGAATGTTCAGTGGCCATAAATGTAAGGGTTGGTCTTACATTTACATAAGGGAGACAA TGAAAACTTAACTCCTCCACAGTAGTGGAGTAGTGCCGTTGGGTACTCACAGTCAGTAGT GCCGTTGGGTACTCACATGTACAACATGGATCAGGACATTGACTTTCTGTGGATACCTTT TAATAGTTTATTAGATGTGTTAGGCTGTTTTGCACTGCTCTAAAGGAATATCTGAGTCTA 34CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGTAATTTATAAAGACAAGAGGTTTAATTGGCTCATGGTTCTGAAGGCTGTACAAGCATG GCTCCAGCATCTGCTTCTGGTGAGGGCCTCAGGAAGCTTCCGGTCATAGTGGAAGGCAAA AGGAGGGCAGACGATCACATGGCCGGAGTGGTGGCAAGGGTGGGGTGGGAGCCACGCTCT TTTTTT^TTTTATTTTAATTTGAGACAGTGTCTCACTCTTTTGCCCAGCCTGGAGTGCA GTGGCGTGATCTCAGCTCACTGCAGCCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCT CAGCCTCCTGAGTAGTTGGGACTACAGGCGCGCATCACAATGCCCAGCTGATTTTTGTAT TTTTAGCAGAGACAGGGTTTCACCATGTTGGCCAGGCTGGTCTCGGACTCCTGATCTCAA GTAATCCGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACTGCGCAC GGCCACCACACTGTTTTAAACAACCAGATTGCACGTGAACTTAGAGTGAGAACTCACTGT GAGGATGGCACCAAAACATTCATGAAGGATCCACCACCTTCCTTTAGGCCCCACCTCCAA CACTGGAGGTCATATTTCAACTTGAGATTTGGAGGGGACAGACATCCAAACCGTATCATT AAA.TTTAATAGTTTTATGCAGTTTTTTTGGCTCTAGATCTGTTTAGACTCCTGCAGTCAG GTGTCTGTAACTAGCCTCTGGTCCTTTTTGAGAGTTCACAGTTTGGTGCAAACCCTTTGG ATGTATTATTTGGGAAAATGGGATATCTGGCAGCCTGTGTCCCTGCTTTACATTATCCTT TTTGCTGCCTGCCCCAAGCCTCCTCATTAGCATCCCTGCCAAGGCCAGTGGAGAAGGATG GAGATGCGGTGACATTCAGCTTGACAGGTCATTAGCAGCITTTGTGCCCTAGGGACTGCT GGTGGGAGGGAGGTTGTGGAAGATAAACCCTGACAGGAATGTATTCTCCTCGAGGGCAGG GTTTATTTGATATTTTTCTGGAGCTTAGAACCATAAGCCTGGTGCTGGGGAGGAAGCGCC CTTAGCATTTGGTAGCCTCTGTGGGCAGAGCATGGAAAGTCACAACTTCTGAATTGTTTG TATTTTCAGTCTCACTCTAGATGGATGGCATCTTCTGCTATGGGAAATGAAATATGTTTA GGCAACTTGAGTCCCAGGTGCAGATGAGGCTGGGCTAATTGGTGCACTAGGGAAGGAGCC GGGGGAGAGATGTGCTGTTAGCTATTATCAATCTGTGACAACTGTCAGCTGCTGGCAGTT AGCACCCACCTGAGCCTGGGATGCAGGGGTGCCTCTCCTGTCCTCTGTGGAAGCCTCTGG ACCCAGCAGCCATCTTGACTGTGCACTGTTCAAGCCCCAAGTCCGCCTGGAAGAGGTGAT TGAGAACTTACTGCAGGATAAGGAAAGCGCAGGACAGGTGCAGTGGCTCACGCCTGTAAT CTCAGTGCTTTGGGAGGCTGAGGCCGGAGGAGGGCTGGAGTCCTTGAGTGCGAGACCAGC CTGGGCAACATAGTGAGACCCTGTCTTTACAAAAAGGAAAAGAATTAGCCAGATGTGGTG GTGCGTGCCTGTAGTCCCAGCCACTCAAGAGGCTGAGGTGCGAGGATCACTTGAGCCCAG GAGTTTGAGGTTACAGTGAGCTATGATCATACCACTGCAITCCAGCCTGGGTGAGAGAGC ATGACTCTGTCCCAACAACAAAAAAAAAGATTAAGGGAAGCCTCTGGCAGACCTGATGAT GGGTGGCCCAGCCAAAATGAGTATTGATGAGGATTTCCCTGGTCTGGAACTCTGAATTTA GTCTGGCAAAGTATTCCCTTTGTGTTGTGAGATGATTCTTGGTGTTACCCCATCACGGTA GGTAAGATGAATTAGCAAATGAGAAAGGCTTTCTCTTTTTCATCCTTATCTAGTCCGTAG ATGAAGCCTGAAGAAGGTCTCCATATGGTAGTAGTAAGTGTTTAACATCTACCTCTAACA CTTGCCTGTGTCTTTTTTTTTTTGCAAAGCCTCAGGAATGCCCCAGTATCTAGGTAGAAT TTGATAATATTTCATTTTTGTTATATTCCCTTTTCIGTTTAGCTTCTATATACAGCAAAA TGAAAAAATTTTTAAAATTTGTGCAAGTAAGGGCAATTTCTTTTTTCTTTTTCTTTTTTT 35CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TTGAGACAGGGTCTTGCTCTGGCACCCAGGCTGGAGTGCAGTGACACAATCTCGGCTCAC TGCAACCTCTGCTTCCTGGGTTTAAGCGATTCTCCTGCCTCAGGCTTCCAAGTAGCTGGG ATTACAGGTGCCTGCCACCACTCCCAGCTAATTTTCATATTTTTAGTAGAGACCAGGTTT TGCCATGTTGACTGGGCTGGTCTTGAACTCCTGACCTCAGGTGATCCATCCACCTTGGCC TCCCAAAGTGCTGGGATTATAGGCTTGAGCCACTGGGCCTGGCTGAGGCAGTTTCTTTTT GAAATATATTTTGTGAAGGAGAAAAAGAGGAGTTCAGTTIAAAGAAACAAATGAGATAAG AGGTGGTATGCAGAGATGCCAAAGCATCTTGAAGGTGCTTTTTTTTTTGGAAACAGAGTC TTGCTTCATTGCCCAGTCTGGTCTGCAGTGGTGCAATCATGGTTCCCTGCAGCCTTGACC TTCTGGGCTCAAGTAATCCTCCCACCTCAGCCTCTCAAGIAGCTGGGACTACAGATGCAT GCCACTATGTCTGGCTAATCTTTAAATTTTTTGTAGAAGCCAGCTCTCACCATATTGCCC AGGCTGGTCTTGACCTCCTGTCCTCGAGCAAAAATACCGATTTTGATTAAGTCTGGGGTA GGACCTGGGGCTGGGATTCTAACCAGCTCCCAGGTGGTGCTAATGCTGCTGGTCTACAGA CCACACGTGGAGTAGCCAGTGTAGAGTTCATGTAGCAATAGTGATGTCATAGAAATAGCC AGTATCTGTATACTTGCTTTGTTGTATGTCACGCACTGTATAGTGATGTACATGCATCTC ATTTGACCCTCACCCCGCCCCTTTGGGGGTAGAAAGGATTGTGCTCATTTCACACTCAAG GAAACTGAGGCACAGACAGGCAAAGTAGCTTGGCGAAACAGAAAGGAACTTAGAGGCAGG CCCTGATTAGCTCAGAGACTAGAAGGCCTTGTGCGTCATCCTGAACAGCTTGGACTTGAT CTTGAAGGTGGAGGGAGAAATTGAAGGGTAATTAAACAGGAACTGTAGGAAATTCACCTT GCATAGTGATTGCTTTGGCCACGTGTGCCCTGCCACCGCCCCCCCACCTCAGTGAAGTGT CATGCGAAGTTGGGTTCGTAAATGAAGGCCCGAATGCTTTCCTGACAAGTTTGTTTTAAA TCAAGCTGCTAATTAGTCCCAGTCCCCCTCCCCCGGTATGTATTTTTTTGTTGATGTCGT TTCACTTCATTTAGTTGAAGTGATTGATTCAGTTCAGTGTTTGAACTTCTTTTTGAACCT CACCTTAATAACCTGTCTAAACATCAAGGTTAAACCTTCTTGCTAACACAGCAGTATTGC TTGGTAAGACTGGCTCACAGTCCAAGGAAATGCTTGCCCAGAGAGGGCAAACTGCCTTAA CTCCTTAACCTGAGCTCATTAAAAAAAATTCAAATGACTGATTCCTTGTCACAGTTCTAC CTACATTGTTTTTATTTTTGTCCAGGTTTCAGCTAGTTAAATGCTTTTGTGATGAGCTTA TGTCCAGGCTGAAGGTTGCATTTTGAAACTGAGCGTCAAATACCAATTTAAAGTCCAGAC CTTTACACTTGTGAAATTCAGATAAATGAAATGGAAATAAAACAGGGCTGCTGTGTTGTG AAATATGACTGTGTTTTTCCTTGTAGGACTCTTTGAGGGIAGCCATTTTGGCATTTTATA TATAAATTTTCTTTTCTTAGCCTACCTTTTACTTTCTTGATTTGCCTATTTGTGATTTCC CATTAAACACTAGGCTTTTTGTAAACCAATTATCCCTTGAAATTGACTTTTTTTTTTTTT GAGACAGGATCTTGTTTTGCCACACAGGCTGGAGTGCCGTGGCTCCATCATATGATAAAC AGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGACCCTGTCTTATTTAAAACA AAAAAAGAAGAAGAAAAAAAGAATATAGATCACAGCTGTTATTTGTATATGCTACGCCAA TCCTTGTTGGGTTTCATTCTTTATAATTGTTATTTTTAAAGATTTTTCTTATGAATATTC TATTGTTTCATTGTAGAAAATTTAAGGGAGAACACAGTGGGAAAAAAAAAACAAGAAAAG GACTTCATAATCCTGCTACCCTGGGAGAAAAAAAAAATCACCATTACCTATTTGGTTCTT 36CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CTCCCACTTTTTTTTTTTTCGAGATGGAGTCTCCCTTTGTTACCCAGGCTGGAGGGCAGG GACGTGATCTTGGCTCTCTGCAACCTCTGCCTCCTGGGTTCAAGCGATTCTCGTGCCTCA GCCTCCCGAGTATCTGGGATTACAGGGGTGTGCCATCACACCTGGCTAATTTTTGTATTT TTAGTAGAGACGGGGTTTTGTCATGTTGGCCAGGCTGGTTTGTTGGCCATGTCTGGTTTT TTGTCATATTGGCCAGTCTGTTTGTCATGTCAGGCTGACATGTTTTGTCATGTTGGCCAG GCTGGTCTTTAACTCCTGACTTCAGGTAATCCTGAAGTGCTAGGATTATAGGCGTGAGCC ATTGCACCTGGCCTTCTGCCTTTTTTTTAAAGAAAAAAAATTAAAACATTTTTTTCTTTT TAAGATAGCGTCTCATTTTGTTGCCCAGGCTGGTCTTGAACTCCTGGGCTCAAGTGATCC TCCAGCCTCAGCCTCTGGAGTAGCTGGGACTACAGATGCACATCATGGTGTCCTTATGCC ATTTCTTTTGTACGTAGGTGAATGCAAGTGTATGATTACATCATATGCTATTTTGGAGGT TTGACTTTCTTTTCACTTTCATCATCTTTCCAAGGTGTTATTTTCCTAGTACATCTTTTT AAATGGACATAGAACATTCTTTTGTATGAACAAACAATAGTTTTATTTAGGCGGTCCTTT CCTGTTGGACATTTATATTATTTTCAGCATTTCTCCACAGTTGTTGCAGCATTCAGATGA ACCTTCTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTTTCGCCCAGGCTGGAGTGCAG TGGCACAATCTCTCCTCAAGTGATTCCTGTGTCACCCTCCCACGTAGCTGGGATTACAGG TGCCCATGTCTGGCTAATTTTTGTGTTTTTGGTAGAGCTGTGGTTTTACCATGTTGGCCA GGCTGGTTTCGAACTCCTGCCCTGAAGTGATCTGCCCACCTCAGCCTCCCAAAGTGTGGG GATTACAGGTGTAAGCCATCACGCCTGACCCAGATGAACATTCTTGTAGCTATCGCACAC AATTCTGAACATTTCCTAGGATGAATTCCTTAAAGAAGTAATGCTGATCCAGGCTTTTTT CTTTTTCTGTGACTCTTTGACACGTAATAATATTGACTTTTCTTTCTTTCCAGACOgA6 AACAACAGGAGTGCAAACTTCTCTACAGCCGAAAAGAGGGTCAAAGGCAAGAAAACAAAA ACAAAAATAGATATAAAAACATCCTGCCCT I AAGTATCAATATTCCGCTCAGTAATAGT CACTCTTGGAGATTTTGATTCCTAGCACCTCTGTACCTTTCCTCAGGGTCGTGTGCTCTT GTTAGCACATCGGAGGCCTTAGCTTCTTTAATTGCAAGCAGTTTCCAAAATAATCAACCA TGGTGGGTGTTGATGACTTCATTCACTGAGCTCCCGTGATGCTGATTACTGAGTAAAGTT GCCACTAGGTGGCTTTGTCTGTGGTTGGTTCCTTCTGTTAATTAATTTTCTGTCTGCCCA AGATAGATCATCTCAAGGCTTGGGATCTCTCAGTGTCAGGGACCTTAGGGTGCCAGATTT GTGTCTTGACTCCTCCTCACTGGGCCTGTGAGTCCTGGGTAAGGCCTGCCTCCTTTCTGG GACTCAGTTCCCTTAAGTGGGAAACAGACAAACACCTCCIGAGGGCTCCTAGAACTGTTC TGCTTGCTGATCCCCTGAGCTCAAGTTACTGGAGAAAGGGTATATACCTAAACTGCTCAG AAGAAGACTTTGTGGGCCGGGCGCAGTGGCTCACACCTGTAATCCCAGCACTTTCGGAGG CCGAGGCAAGCGGATCACCTCTGATCAGGAGTTCAAGACCAGCCTGGCCAACATGGTGAA ACCCCATCTCTACTAAAAATACAAAAATTAGCCATATGTGGTGGTGTGCGCCTGTAATCC CAGCTACTCGGGAGGCTGAGGCGGGAAATTGGTTGAACCCAGGAGATGGAGGTTGCAGTG AGCCGAGATGTGCCATTGCACTCCAGCCTGGGTGACAAGAGCAAAACTCCGTCTCAAAAA AAAAAAAGGAAGACTTTGTGAATATTCGCAAAGCTGTAAAGCTGTACCTTTCAATTTTTT TTTGAGACATAGTCTCACTCTGTTGCTCAGGGTGCAGTCACAGCTCACTGTAGCCTCAAC 37CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CTCCTGGGCTCAAGCGATTCTCCCACCTCAGCCTCCTGATTAGCTGGGACAATAGGCAGG CACCAGTACACCTGGTTGATTTTACAGTTTTTCTGTAGGCCGGCGCAGTGGCTTACGCCT GTAATCCCAGCACCCTGGGAGGCCGAGGTGGGCGGATCACCTGAGGTTAGGAGTTCGAGA GTAGCCTGGCCAACATGGTGAAACCCCATCTCTATTAAAAATTACAAAAATTAGCTGGGC GTGGTGGTGGATGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCTGAGGCAGGAGAATC GCTTGAACCTGGGAGGCGGAGGTTGCAATGAGCCGGAGGIGCTATGTGCACCACTGCACT CCAGGCTGGGCGACAGAGTGAGACTCTGTCTCAAAACAAAAAACGATTTAAAAAATAATA AAATTTTTTCTAGGGCGGGGTCTCCCTATGTTGCCCAGGCTGGTCTTGAACTCCTGGGCT CAAGTAGTCCTCCTGCCTCAGCCTCCCAAACTGTTGGGAITACCAGTGCAAGCCATTGTG CCTGGCTGTACCTTCTGTAACACCCAAATGCCACCTGGCAAAGCCCAAGTTGAATCATGA GGAAAAAAGGCCTGGAAGGATGTAGACCTTCCTTTTTTCTACTTATTTATTTATTTATTT TTGAGATAGGGTCTTACTCTGTTGCCCAGGCTGGAGTGCAGTGGCATGATCATGGGTCAC TGCAGCCTCAACCTCCCGGGCTCAAGTGGTCCTTCCCACCCCAGCCTGCAATGTAGCTGG GACTACAGGCATGTGCTACCATGCCCAGCTAATTTTTGTATTTTTTGTAATTATTTTTTT TGTAGAGACAGGGTTTCGTCATGTTGCCTAGGCTGGTCTCGAATTCCTGGGCTCAAACGA TCTGCCTGCATCGGCCTCCCAAAGTGTTGGGATTACAGGIGTGAACCACTGTGTCTGGCT ATATCTTCTGTAACACCCAAATGCCACCAGGCAAAGCCCAAGTTGAACCAGGAGGGAAAA AGGCCTGGCAGGATGTAGGCCTTGCATGAGGATCTCAGAAACTGCACTAAACCAGTCACA GTTCCTCTCTCCCGAGGTCTAACTCTATGCTGAACTCTTTGCATTTTTATCTCACTTAAT CCATATCACATGCACAGGAAGGAAGCATTCGTAGTATCCTGGTTTCCTAGACCATTTTAG CAAGGTTATAAGTGAAGGGGAGTGGGTGGGAGAACTGGCACTAGAGCCCCCAAAGTCACT GTTCTTAGCACCACTCTAATGCATGGGGTTCTCCATTGATGTGCTATGCAAGGCAGTGCA CTGAGGAGAAAGGAAGGAACATTTACAACTTCTCTTTATTTATATCCTGTCCCTAAAAAA AAAAGAAAAAGAAAAATTTGTCTGAGGCCTAGATTGATTGCAGGGAGTGCATAATGTTTT ATTGATTGATTGATTGATTGTATATAGAGATGGGGGGTCTCACTATATTGCCCAGGCTGA TCTCGAACTCCTAGGCTCAAGCAATCCTCCTGCTTTGGCITCCCAAAGTGCTGGGATTAC AGGCATGAGCGACTGCACCTGGCTATGCATACTATATTTATCCAACTTACAAATAAGGCT TGCTTGCCTGTAGTGCATATGTGTATACATTTCAGCATAGAAAAACTGTGTGATTGGGGG TTGTGATCAAATTTGGAGAGCATTGCTCTCATGTCTTATCAGGTCAGAGTCATTTTGTCA AATCTTGTAAACCATTCTTTGTGTGTGTCTATGCATGAAACATAGTCTTTCTCTTTCTGC ATGCATATGTACATATACATGGTATATATGTATATCATATCTACATGGATATTGTAATGT ATATGTATGAGGATGGGGGAAAGTGGAGACATTTGTAATACTGAGAAAAGGCAGTGAGGA ATTTGCAGAGAAGCAGTTTGAGCTGTAGCATGGTACTAGTGACCTTGAGGAAGCCTTATC CTTTTTTTTTGGAATTTATTTTTTCAATTTTTAGAAATAGACAAGAGTTTCTCTATGTTG CCCAGGCTGGTCTTGACCTCCTGGGCCCAAACTATCCTCCTGCCTTGGCTTCCCAAAGTG CCAGGATTAGAGGTGTGGACCACCATGCCTGGCCACCTTGTCCTTTCTATGTCTAAGTTG TGACATCTGCTCAGGGGTCAGGTGGTATTAAATGGTATAAAATGTATGGGAAAGTGAAGG 38CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GATCAATGGTATGCAGTATCTAAATAGAATATCGCTTTTTCCTCCCTTAAAGGTCTCATT CAGATGTTTCCTCTGATGAACATCTCATTTCCTTAAAGATGAGGAGTCTGAAGCAAAAAA GACATTATTCTTTTAAGACACATGGCTGTCTTACTAATTCCCATTGCAAAATATGTTGTT TAGGTAGAGCACTCAGATTTTTATACGAATAATAGACTTTTGTACAGAATTTGGACAGTT GATACTATCAGAGCCTTGTGATATTCCACTGCATTATGCTTCACTAAAAAATACCTGGCT GGGTGCGGTGGCTCACAACTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGCAGATCAC CTGAGGTCAGGAGTTCAAGATCAGCCTGGCTAACATGGCAAAACCCCATCTCTACTAAAA ATACAAAAATTAGCCAGATGTGGTGGCACGCTCCTGTAATCCCAGTTACTCAGGAGGCTG AGGTATGAGAATTGCTTGAGCCCAGGAGGCAGAGGTTGCAGAGAGCCGAGATAGTGCTAT TGCACTCCAACCTGGGTGACAGAGGAAAACCCTGTCTCAAAAAATAAATTTAAAACAACA ACAACAACAACAACAAAAACCCCTCTTTATTATGGAAATTTTCAAATATATTCAAGAGCA TAAAGAACCCACATGTACCCATCACCCAGCTTCAACAATTATCAACTCATGCCCAGTCTT GGTTTCATCTATACTCTGATCCACATCTCCTCTCTCCTTGAATTATTTTGAAGCCCATCT CAGACATCATGTCATATATGTATACTTCAATCTTCTTTTTTTTTAAAACTCCCCCTCCCC TTTTCTTTTTTCTTGAGACTGTGTCTCACTCTGTCATCCAGGCTGGAGTGATCTTGGCTC ACTGCAATGTCCGCCTCTCGGGTTCAAGCGATTTTTGTACCTCAGCCTCCCTAGTAGCTA GGATTACAGATGTGGACCAACATGCCTGGCTAATTTTTGTATTTTTAATAGAGACAGGGT TTTGTCATGTTGGCCAGGCTGGTCTTGACCTCCTGACCTCATATGATCCACCTGCCTTGG CCTCCCAAAGTGCTGAAATTATAGGCCACTGCGCCCAGCCCAAAATTTCTTGGTTTGAAA TAATTTTGGAACTCATAAGAAGTTACACATATAGTAGAGAGAATTTTCTTGTACCTTCTC TGAGCTTCCTATATACCCAATGATAACATCCTATATACCCATAGTATATGATCAAAACTA GGAAATTGTGAAGATGGCATTTTGAGACATCAGGCAGTGTTCACGTTACTGTTTTGCTTA CCTGGGCTTTAATTTTTATGTGTTTTTTTTTCAATCATTGAATGAACAAAACTTGGACTA GGCTGGGGAGTAACTGATTTGAACTGTTTTTTCCTGAAGCAGTCCAGGACTTATGTGACC GTGGTCTCTTTTTCTTCTAGi^GOBOTOliiOOfrCi|ABB2GQBG|Gl||B^ TGAGCCTGTTTCAGATTACATCAATGCAAATATCATCATG 1AAGCTTTGCTTTTCACAG TGTTTTCTGACCATACATTTCTAGCCTATTTTTGTATTTTAAATCCTTCCTCATGTCCTG AAAGTAACTTTAAGGTGTTTGAAGGATTTTCTTCCTAAATTTC ... CCTGAATTTGAAAC CAAGTGCAACAATTCAAAGCCCAAAAAGAGTTACATTGCCACACAAGGCTGCCTGCAAAA CACGGTGAATGACTTTTGGCGGATGGTGTTCCAAGAAAACTCCCGAGTGATTGTCATGAC CACAGAAACTTCTTTTCTGCTAAACTGTT TTTAAAGTATCAGACATGTCAGATTGGCCATGTTTAGGAATTGAATAAATGAATTAAGCT TACTGTAACTGATTCTCTGGAAAAAAGGGACTAGGAGAAATTTGATTATGTTATTCCTTG GTGTAGTTTTCTTTATGTTTCTTCTGCTTGGGATTTGTTGAGCTTCTTGGCTCCATGGAT TTGTAGTTTTCCTTAAATTTGGATAATGTTCAGTCTTAGTTTCTTCAGATACATATCCTG GGCTGGGCATGGTGGCTCATGCCTGTAGTCCCAGCACTGIGGGGTGTTGAGGTGGGCGGA TCACTTGAGGTCAGGAGTTTGAGACCAGCCTGGGCAATGTAGTAAGACCCCATCTCTTAA 39CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAAAAAAAAATGTACCCTGCACAACCTTGTCCTAGGACAGCAGTCATACGTGTATTAGAC TACTTGAAGTTGTCTCATAGCCCACTGATACTTGGTTTATTTTATTCAGTTTTTTCTCCC CGTGTTTCATTTCG/kATAGCTTCTTTTGCTATGTCTCCAAGTTAATCTTCTGCAATATGT CATCCGCTCTTAATCCTATCCAGAGTATTTTTCATCACAGACATTGTATTTTTCATCTCT AGAAGTGTTAATGTCATCTATAGCTTTCCTTTTAACATGTGTAGCATTTTCCTTACCTTT TGAATGTATGGAGTATTTCTGTTGTTGTTTTITGTTTTGIAGAGACAGGGTCTCGGTCTG TTGCCCAGGCCGGAGTGCAGTGGCATGATCTCAGCTCACTGCAGCCTCTGCCTCCCGGTT CAAATGATTCTCATGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGTGCGTGCCACCACG CCTGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTTGCCATGTTGGCCAGGCTGGTT TTGGAACCCCTGAGCTTAGGTGATCCACCTTCCTTGACCTCCCAAAGTGTTGGGATTATA GGTGTGAGCCACCATGCCTGGCCATGTTGTCTGTTTTAATTAACTCTGCCTAACTGTCCT CCCAAATGGTTGCTGCAGTGCTCACTCCCACCAGCAGCACCTGCCTAGGACTCATTACTC CATACTCTTCAAGACACTTCAGATTAAAAAAATAAATTGTAACACCCCACACCTACAGAA GAGCGGACAGATCTTATTGAGTGACAGCCCTCTGTGTTATCTCAAAGTGAGCCCACCATG GTGGTTTTTTTTTTAAATATGGAAAAGTTCTGTGTTTTTGTTTGTGTTCTAGTGAAAGTT CTTTTTTAGATATCCTTTAATTGGTTTATATAAGATTTTATGTGGAATGTAGCAGTCATA CCTATAAATTAAACCTAAGGCAGATGGAGAACTTTGGAGTTGAGCCTTCCTACTGTAATT TTCATATTGGATGTGAAGGGCAGTGTGATTTTCATAAGACTTTCATTGTTGTACTCCTAG TTGGTATACTTCTGAATACCTTTGAGGCCAGTTCTGGTCATCGTGAAACAAAGGTTTCCT TCAGCAAATGCCTGTGGTAACATTAGGTGTTCTTGAATTAATGGACCAATGAAAACATCT TTGTAGTTTCTGCTTCAGGCAAGGGTTTTTTGCCCTAAATGTGGATAGGAAGAATGAAGC CCTTCATCCTCCTTTTTGCCTGATTATAGCTATAGGAGGTTCACCTGTTCTCAGAAGACA TGAGGATTGTGAAGAGAGGGGTCTTGTGTTGCTTCAGAGGAATCAGTATCAGTCCCTTTC AGAAGCTCTCCTGGATAGACAGGCATTAGGGCCAAATCACTCTGCCCCACCCCTCACCAC CATGTCCTACTCTCTGCTCCCTGTCTCATTCTTCCTCTTTACTTTGGTGGTGCCGAGAGG ATGACATGATGGGTATTGATTCTCTCCACAGACCTTTCTGACATCCTACTTTCAGTATCC CCCCAGTGCACAGAAGACAAGCCAGACTGTGGACTGTGTTTGATTCCTGGGCTCTATTTT AAAAGACAGTGTATTAGTTCTCACATTTTAGAATTTGTTTGCCAAGGTTTCCACGGGAGT TTAGAAACTAGGGGGAGGGCTGATGTTTAAAGTTAGCTAAAATGTTCTTTTCAGGGTCAT GATTTAATTTTATATTCTCTGGTGAGTTCCCTATAGTGACTGGGAGCAGTCCTCAGTCTT GATTGGCCAGTGACAGCATAGAGTACAATTAATATTAGGAGTGCTCATTTGGGGAAACTA AAATTTGCATCAAATCTGTCAGAGGTGTTTGGATCTACAAAATACCGGAGGGAAAGCTGA ATTGAGAATCATAATAAATAAAAGACCACATCGTTCTTTTTTTTTTTTTTTTTTGGGACT GTATCTTGCTCTGTCACTCAGGCTGCAGTGCAGTGGCACTATCTTGGATCACTGCAGGCT CCGCCTCCCGGATTCAAGCGATTTTCCTGCCTCAGTGCCTGAGTAGCTGGGATTACAGGC GTGTGCCACTACACCTGGCTAATTTTTGTAATTTTAGTAGAGACAGGTTTCACCATGTTG GCCAGGCTGGTCTCAAACTCCTGGCCTCAAGTGATCCACCCGGCTTCCCAAAGTGCTGGG 40CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATTACAGGCGTGAGCCACTGCGCCCAACCAAGACCACATCCTTTTATTGAACGTTCCTCC TACCATGTTTTCTTTTTTCTTTCAATTAATCATTGACTCATTGACTCTCACTGTTGATGT CTGTAGCTGCTCTCTTATTTCCAGTTTTATAGCTGTAAATTTCTCTGTCTTCCTAAGATA CAAGGTAAATTTCTCTTGCTGATATTGGTGGTTTTGGAAAGTGAGTGGTGTGGATGACTG CCCAGAAAACAACAGAACACAAAAGCATTCTCTGCCCAGAACACATCACCAAATAGATAC AAACTCATCTCTTACTGAGTGAAATAGCTTCCTTTTTGGCAGCAAGAATGATTTTCTTGG TGCCATATTTTTCAATCCGCCTGCTCTTGAAGCCAGCAGCTATTGCAGACTTGGCATTCC CAGGCACCCAGTTAAGGGAAAGTGACGTGTAGAGGAGGTATCAGATGGGTCTGGATATAG AAAAAGCAGCTGGTTCAAAACCCCATGGGCTGCCTTTCTGTGATAGAGTTATTCACACTT GGGTTAGATAAGGCACAGAGTCCTCCTACACTGGTGCGGAAATGAAACAGACAGTCTGGC TCGTTGGGCAGCCTAGCCTCCTCCAGAATCTGTGCTTGCCTTCCCTATGGAGTGACTGGT AGATCTTAGAATTCAGACCTCAGTGGTTGCTAGCCAGCACTCTCACATTGGTTGGTCCTT CTCTCTGCATCTTTGATTCTTTAGAGATAGATAAACCAAGCACCGAGTCTCCTTTGACAT GTGCTTGGAACAGACACCTGCACGAGCTGCCTTTCTCCTCCCACTTCTGCCTGGTCTTCC AAACACCTGCTTTTCTTGTTTGAACTCTTCCTTTTTTTTTGAGACAGAACCTCTCTCTGT CACCCAGGCTGGAGTGCAGTGGCATGATCTCAGCTCACTGCAACCTCTGCCTCCCAGGTT CAAATAATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGTGCCTGCTATCACG CCTGGCTAATTTTTGTATTTTTAGTAGAGACACGGTTTCACCATTTGGCCAGGTTGGTCT CAAACCTCTGGTCTCAAGTGATCTGCCCGCCTCGGCCACCCGAACTGCTGGGATTACAGG CATGAGCCACTGCGCCCCAGCTGATTCTTTACAGATAAACAAACATTGACTCTGCTTTGA CATGTGCTTGGATCAGGTAACTGCACCAGCTGCCTTTCTCCTCCCACTTCTGCCTGGTCC TCCGAATGCCTGCTTTTCTTATTTGAACTCTTCTGTCCTTTTCTGAAAACCTAACAGATG CGAAACAGGCCATTTTCCATGTTGGTGGTTATTAAGCAAGACTTGAACATTTGTTTGTTG CTTGTTTAGGCTTTTATTTCAGAGTTCACAGAATTAACTTTCTTTTTTTCTGATCTCTTC -';AGTAAATGTGTCAAATACTGGCCTGATGAGTATGCTCTAAAAGAATATGGCGTCATG CGTGTTAGGAACGTCAAAGAAAGCGCCGCTCATGACTATACGCTAAGAGAACTTAAACTT iOOB££BWCiWGTAAGTATATTGTCGTATTCTAGAGACTTTGGGAACTGTTGATGG TGTGTAGGAATTCAGGGTCTTGCCGTTACTCATGTTTGCATACATGCATGCATTCGCTCA CTCATTGATTCAGTAGCCATTTATTAGCTTCCTTCTATGIGCCAGGTACAGTTTAAGCAG TACTGGTACATTGTGAACAAGGCAGGTAGTGTTCCTGCCCTCATCGAGCCTAGGGAGATA GACAATTTAAAAACAAATAACTGGCCAGGCGCCGTGGCTCAGGCCTGTAATCCCAGCACT TTGGGAGGCTGAGGTGGGTGGATCGCTTGAGCCGGGGAGTTCGAGACCAGCCCTGGGTGG GAGACTGGGATAGGGTGACCTGAGTGGCTACAAGGTCTGTTAGGAGGCCTCCGCAGGGGC CTATGTTGATGGCCTCCTCTCCAAGTATCCACAGACTTCAGCAGTTGTTCTTTTTTGTTC CTTCCTTTGGAATGGAATATTATATAAAATGGCAGAATAAACTGGAAGAGAAGCAGTAGA TGTGAGAGGTGCCGGGGGGTGAAGTCTGCAGGATGTGGGGATTGTTTGGCTTTTGGAGGA GGAAGGAGGGATTCAAGACACATTGTAGAGGTTTGAGTCTGAGCGGACAGTGGTGCTGTG 41CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCAGACACCACAAAAGCTGGAAGGAGAACTGATGTGGGCAGTGATTTGTTTTCTTCTGGA TGTGTTCAGCTGGGCATCTGAACAGTCATGTGGACATTCATCTATTCATTCAGAGATATT TGTTCAATGACCTCTTGGTTCCTGGCACCATGCTGCTTGCTGGAGATAGAGCTGGGGAAC AAAACAGATGGAATCCCTGCACTCCCAAGTGTACACTATACTGGCCAGTAATCTACCAGC CCAGTAATTGCACATATAAATATATCATTATAAACTGTAATCAGGGCTAGAAAGAAAAAA TGCAGGAGTTTAGGGTTCATTTGGAGGGGGAAGGGACTTITTTTTTTTTTTTTTTGAAAC AGAATCTTGTTCTGTCACCCAGACTGGAGTGCACTGGTGCATTCACGGCTCACTGCAGCC ACAACCTCCTAAGCTCAAGTGATCCTCTCACCTCAGCCTCCCATGTAGCTGGGGGCTACA GGTGTGTGCCACCATGCCCACCCAATTGTTAAATTTTTTATAGAGACGGTTGTCTCATTA TGTTGCCCAGGCTGGTCTTGAACTCCTGGGCTTAAGCGATCCTGCTGCCACATGCAGCCT CCCAAGGTGCTGGAATTACAGGCGTGAGCCAGCGCACCCGGCCAAGGGAGGGGAGGTTCT TAA.GGCATAGGGAACAATGTGTTTGAGTCAGCAAAGGAGGTTGTGGGGGTTTGTCCTAAG TGTGGIAAGCAGCCAGAGTTGGATTTAAGTTTTTAAGAGATTCCCCTCCACCCTGTAGAG ACTGGAGGGGGCAGGAGTTGTTCTAGGGATTAGGACCAATTTGGAGGTAGTGCAGCCGTC AGAGTAAAAAATAATAGGGATTGAACTAGGCCAGTGCCCAGGGTGCCTGAAAGAAGAGGA CCCAGTAGAGCTGACTGGAGGCAGACATGCAGGGATTCAGTGAAGGAGTGTACCAAGGGC GAGGGTGGTGTGCAGGGTGACTGGCAATTTTCTAGCTTGAGAAAGGTCCGGGGGGATGGC AGTGGAGTTGAGGAAGCTGGGAGGATCAAGGACCTTTTTGTGAACACACAAAGTTTGAGA TGCCTTGGACACATTGAAGTGGAGCGGTCAGGGAGGCAAGGGTGGAGGTGGGATGCGGAG GGGAGGTGGGATGCAGAGCGTCGTGGATGGATCAGTTTTGCTCGATAGAGGGACATGTTT TTCTGTGGCAACAGGAGGGCAAAAGGAGAAGGTGGCCACAGATGCCGGTAGATGAGCTGA GAGTGATTGTATTCCCTATCCTCTCGGAAGCTTGAGGCAAGGCCATCAACAGACAATCAG AGGGAATAAGAAGAGATAGAATATATGAAGAAAGGGAGAAAAGATGAAATCGTAATTGTG TAGCAGGGCAAGAAGTCCAGAAATTTCTGTGCTGTGCCAAGTTCCCAGTTGAGGCGGTGA ACATGAAAATATACTGATACCCATTGCCTGGTTTTTCTCCAAGGACACTTGGCTCCTAGG GCACAAAACAGAAAGTACGTGGTTTGTCCAGGCCGAGGGCTTTGCATAGTTGCAGTGGAT GGAGAGGAGGTCAAGGAATGGAGGCACATGGTAGAGAGAGACTGTCCCCAGAGCACGGGG ACTCCTGGCCGGATGAGGGGGACAGGGGCAGGAGGAGGCAGGTGGAAAGTAGAGGGAGGG CTCAGTGGTCTGGAGGCTACAGGAAGTGACGGGGGGACCAGAAGGAGCTGGAAACCAGTG TGGTTGTGGCCCAGGGTGGGATGTTTGGATTTCTGATGTCAGAGAGGGTCCAGTCCTTCT GATGATGGGGAGGGGTGGAGGCTGAATCTATGGTAGAGATAGTGAGAGGAACTGGAACAA TGTAGCTGTCAAGTGGAAATGGGAGAAAGGGCTGGGCGTGGTGGCTCACGCCTGTAATCC CAGCATATTGGGAGGCTGAGGCAAGAGGATCGTGTTAGCTCAGGAGTTCTGGGCTGCATT GAGCTGTGATTGTGCCACTGCACTCCAGCCTTGGCAACAGAGTGCCCAGTTAAAAATAAA AATAAAATAAAATAAAAAAATTAAAAAAAAAAGAAGAAGAAAAAAGAGAAAAGTGTCCTT TTACATCCCTTTTAAAAATGTCACTTAAGGCTGGGCAAAGTGGCTCATGCCTGTAATCCC TGCACTTTGGGAGGCTGAAGTGGGTGGATTACTTGAGGTCAGGAGTACAAGACCAGCCTG 42CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCCAACATGGCGAAACTCCTTCTCTACTAAAATTAGCTGGATGTGGTACATGCCTGTAGT CCCAGCTACTCGGGAGTCGAGTCTGAGGCCCAAGAATTGCTTGAATCGGGGAGGCGTAGG TTGCAGTGAGCTGTGATCAGGTCACTGTGCACCAGCCTGGATGACAGAGTGAGACTCTGT CTCAAAAAAAAAAGTCACTTAGCTTAGATTGTCTCTACATATATAGGAAGAAGATGTAGG AATGAATGGTGCTGCTACAATTACGTCATCTGGATAGACCCAGAAACATGATACTTTTTG gttttctgtagccttggtgccattgttgatctttattaaitatcattatcctcaaaatag CCATAATGTGCTGAGTCTCTTCCTATTTGCTGGGCAGAGGCTGAGTATTTCAGCGAGCTC ACTGAGTCCTTAAAATTGCATTATGATAGAGAGAAAGAGATTATTATTTGCATTTTGCAA AATGAAGAAATTGAGGTTTAGAGATACCCAAGGGCCACGIGAGTGTGAGTGCCTGGAATT GGAGCCTAAATCTAGTCATCTGATAGCAAAGCCTGTTTTCTTATCTGCTTTGCATTAAAT ATAAGTTTAAAATAGAACAATACTGGCCAGGCTGGGTGGCTCACGCCTGTAATCCCAGCA CTTTGGGAGGTCGAGGCAGGCAGATCACCTGAGGTCAGGAGTTTGCAACCAGCCTGGCCA ATATGGCGAAAGAAACCCCATCGCTACTAAAAATACAAAAATTAGCCAGGCATGGTGATG TGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGCTTGAACCCGGGAG GCAGAGGTTGCAGTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGCAACAGAGTAAG ACTCTGTCTTGGAAAAAAAAAAAAAAAAGAATGATACTAIAGTCTGTGTTTATATGGTGG GGAAGGTTGAGTATCAAAAAAATAACAAAGAGGAATGAATGTCTTAAGTGAATGCCTGTT TCCCCATCTGCTTCCTCTTCTGCTGGGAGGAGAGACCTGGATCCCTAGAGGTTTCAGTTG CCTCCAGAGCTGAGTGCCACAGGGATGCAGGGGAATAGGGATGTTACCTGTCGCTGGTAA TTCAGAGAGATGATTCAGGGTATAGTTACCTGAAAGAACAAATTGCCATGCCAGACGTCT TGGTTCTTATGACAGAGGCAAAGAGTTGCCTCCAGGATTGCCCAAAAGGAGACGAGTTCT GGGAACCTCACGAAGAGGACCTTTCAGTGGAACCTGGGGAGATTCTCTTCCTCTCCATTG GATTTAGGAAAGCTTAGAACCGGGTGATTCCTCAACCTCTTGATTTATTTAATTCTTTTC 1 - TTTTTCTTGGCTCTACTCCAGGGGAATACGGAGAGAACGGTCTGGCAATACCACTTT CGGACCTGGCCGGACCACGGCGTGCCCAGCGACCCTGGGGGCGTGCTGGACTTCCTGGAG GAGGTGCACCATAAGCAGGAGAGCATCATGGATGCAGGGCCGGTCGTGGTGCACTGCAGG TGACAGCTCCTGCTGCCCCTCTAGGCCACAGCCTGTCCCTGTCTCCTAGCGCCCAGGGCT TGCTTTTACCTACCCACTCCTAGCTCTTTAACTGTAGGAAGAATTTAATATCTGTTTGAG GCATAGAGCAACTGCATTGAGGGACATTTTGATCCCAAGGCATATTTCTCCTAGACCCTA CAGCACTGCCATTGGCCATGGCCATGGCAACATGCTCAGTTAAAACAGCAAAGACTAAGT CAGCATTATCTCTGAGTCCACCAGAAGTTGTGCATTAAACAACTTCATCCTGG TCTGCA GTTTCTCCTTATTCTTCATGATGTTTGCTTTGTAGCTGTTGACTGCTTTGTAGGTATTGA GGTGGTGGGGGTGTGGTGGAAATAGGCCTGACTCTTGAGGATCCCTTAAGTCATTTTTGC TTGGTTCTCTTTTTCCTTCTTTTCTTCTACTCTTCTATGATTCATCTCTTTGATTGTGAT TCTGTTCTCTCTCTCTCTCTCTCTTTTTTTTTTTTCGTTTTTGAGACAGAGTCTTGTTTT GTTGCCCAGGCTAGAGTGCAGTGGTGCCATCTTGGCTCACTGCAACCTCCGCCTCCCGGG TTCAGGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGCATCTGACACTA 43CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CGCCCGGCTAATTTTTGTATTTTAATAGAGACAAGGTTTTGTCATGTTGGCCAGGCTGGT CTCGAACCCTTGACCTCAGGTGATCCACCTGCCTTGTCCTTCCAAAGTGCTGGGATTACA GGTATGAGCTACCATGCCCGGCCCATTCTGTTCTCTTCTACCATAAATATATTTCTCCCC TAACACTATATTTGTTTGCTTCACAAGATTCCAGCTGCTTTTCCACCAAGGCCTTTGATG GAAGCTGTGCTGTGACCTCTGTAATGAGTCTGTGGGCTGCTGATTCTCCAGTTTGGGCTT CATGATTATACTGGGGAATATTGGGTTTCCTAAATCTCAITCATTTCTTGGGCAAGTAGA TATATGTGAAAGTGTTTATTTGTCCAGTTGTTAAAGAAGCTACCATTTATTGAGCCAGCC TCTGAGCACAATGTTTTTTGTTTTGTTTTGTTTTTAATTTTTAAAATTATTTACTTCTTC TATTTCAATAACTTTATTATTATTATTTTTTGAGACAGAGTCTCACTCTGTCACCCAGGC TAGAGTGCAATTGAGCGATCTTAGCTCACTGCAACCTCTGCTTTCTGGGTTCAAGCAATT CTCATGTCTCAGCCTCCCGAGTAGCTGGGATTACTGGTACGTGACAACATGCCTGGCTAA TTTTTGTGTTTTTAGTAGAGACGAGGTTTTGCTATGTTGGCCAGGCTGGTCTGGAACTCC TGGCCCCAAGTGATCCTCCTGCCTCGGCCTCCCAAAGTGCTGGTATTATAGGTGAGAGCC ACTGCGCCCGGCCCTCTTTCAGTAATTTTGATGTATTTTTTTGTATATGATTCCTGTTTC ATTCTGTCCAACCAGCACTCTGTATGGTATGTGCTGTTGTCCCCATTTCACAGATGCAGA AATTAAGGGTCAGAGAGGTTAAGGGACTTACCTCAGGCACGTTGTACTGGAGAAGCTGAA CTCCAAGAGCAGGTTTGGGCTGACTCCAAAGCCCTATGCTTTTTGCCAACATATTTTCAA ACATAAATAGACAATTTTATAAATAGCTCCAAAGAGTAGACATTGTTTCTGTTGATATTA ATGGCTTGGTTTTGAGTCTGAAACCCCCATGAATGATTCTGTTGTCCCTGCTTTTTGTCC TGCCOATGCTGGAATTGGCCGGACAGGGACGTTCATTGTGATTGATATTCTTAT TQOlg&rCAGAGAGAAAGGTGGGTCATCTGGTGGGCAAGAAGCGACAGTTTCTGTTTT TAGTTTATGGAAGGAAAGTGCTCACGAAAACAGTCTGGGGAAGAGAGGTTGAATGGGAAA ATTCTTTCACAAAAATCTGGGCTGAAGACTTCAGTGTGTCTGCCTGAGAACAGAAGTGAC ACTATTTGAGCTTTTGGCATAAAATGAAGTCTAGGAGCTGCAGAACCCACTGCCATGGCC TTTTGTTGCATACACAGTGGTGGTCTCTATCCAGCCACCTGACCTTGTTTACAGTATGGG GTGATTTGTTGGCAAGTGAGGGAATCCTGACTTCTGCCACTTCGTTATTTATGTAGTCTT CTGGGATCATTGGTATTGGTCAGAAGTTCAACACTGTAGCCATTGCAACATGCTCAGTTA AAACAGCAAAGACTAAATTAGCATTGTCTCTGAGTCCACTAAAAGTTGTGCATTAAACAA CTTCATCCTGGCTCTGCAGTTTCTCTTTATTCTTCATGAIGTTTCCTTCGTAGGTQiO CTGCGATATTGACGTTCCCAAAACCATCCAGATGGTGCGGTCTCAGAGGTCAGGGATGGT CCAGACAGAAGCACAGTACCGATTTATCTATATGGCGGTCCAGCATTATATTGAAACACT ACAGCGCAGGATTGAAGAAGAGCAG. CAGCCTGAGGGCTGGCATGCGGATTCTCATT CTCTTGCTAGGCCTCTTGGATACGCTCTCCTTTTGAGCAGGAGGACAGGCTCTGATAGAC AACTGTTTGATTTCGGAATGGGAAACAAACTCCCAACTAAAAGGGCCTCTGGAAACTGTC AATTATTCTCCACTTCTCAGCTCTGATTTTTCACTGCAGAGGAGCTTAGGGAAGGGCACC ATCCTATCAGCCTGGCCTGCCAGATTGAAGAACTGCCATGCAGAAAGGTTCTGATGTTCT CAGGCTCATGTGGCAAGCGTAAAACTCAAAGCCTTGAAGTTTCTAGCCTGTTCCAGCCTT 44CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GATCCAGGCCATGTTTATCCTGATTCCATCCTTTAAAACGAATGCCTCACTCTTAATAGC GCACGGCAGTTTGAACCACTAATTTGGTCGAGTTGGAAACAGTGAAATTTCAATTTTAAT AAGCTGTGCATAATGAAGAGGAATGTGGAATTGGAGCCTTTCCATCTGAAGCTATTCATA ACAGGCACAAAGCTGAGTTAATTAGGAATATGCTGAGATGAAGGAAATGAGGAGAGCTGC tcttttgggggctgtgcttctctccccaacccctcaaccccattgccatgctgcagatgg GGTGGTGTCTAAACATCAGTGGCGAGTGCCTGCATTACTCTGCTCGTTGCCTTCCAGAGA ACTCAGCTTCTCCAAATGCTGAGCTCTTTTCAGAATGGGACCTGCCACCAGTATTTGAAA GATTTCTAGCCTAGCAGAACAGCAGCCACGTTATCAAAGTTTGGTTGGCCAAAGGAAGGT ACTTGCTAATTAGTTTAGTAGGTTTTCAGTCCGCACAGACATACGGGATTGTTTTATTGT ACATAGACATCTTCAGAAACAGTGTATGTATAGAAATGTAAGGTCAAAATTTGAACCTCA GTGCTTTAAATCTGAATTTGTATTAACTGATATGAAATATTTAGACGGTTACTTTATTTT ATATCTGTCTTCCATTATACTTAATTTGGCTCAAGAATAGTTAGGCAAAAAGTTGCCCAA AGAGAAGGATCTCCTAGTAAATACAAAGAGAATGTAACATAGTTGCTACAAGTTGGAGCA TGTTCAGGGATGTCTTTTTTTTTTTTTTTTTTTGAGAGAGAGGTCTCTCTCTGTTGCCCA GGCTGGAGTGCAGTGGTGTAATCATGGCTCACTGCAGCCTCAATCTCCCAGGCTTAAGCG ATCCTCCCACCTCAGCCTCCCAAGTAGCTGGGACTATAGGCATGCGCCACCACACCTAGC TAATTTTCGCATTTTTTGTAGTGTCACAGTTTCGCCATGTTGCCCAGGCTAGTCTCGAAT TCCTAGGCTCAAGCAGTGCTTCTGCCTCAGCCTCTCTGAGTAGTTAGGACTACAAATTTG TGGCTCCATGCCCGGCTAATTTTTTTATCTTTATTTTGTAGAGACAAGGTCTCACTGTGT TGCCCAGGCTAGTCTTGAACTCCTGGGCTCAAACAACCCTCCCACTTTGGGTTTCCAAAG TGCTGGGATTACAAGTGTGAGCCACTGAGCCCAGTGACCTCTGGGTTTTAAAAATGTGTA GGCTTCAATTATTTATTTTAAAAAATGAAATCCTGCAATATATAGTTTTCTGCGTTGTGT GGTTTGAATCAATCTGGGAACTGGCTTGCTGGCTGATTGTGGTAAAGTAAGAAGTACTTA ATTTAGTAGAAAGTTTAAATGGCAGACATAACATTAAACCCAGCTGATTTATAAATGAAG CAAAAGAACAAAACTCATTCAGGATAATTGGTTATTCTAAAATACAGTCATTTCTAAAAT TATGAAGTGTTCAGGACCTTTGGGAGTGAAAGAATTTGCIAAAGAAGGATCAGTGAAAAA AAGGAATGATGGGTGAAGAGCTGTGGAGAAGGAAGAGAAGAAACAGCACAAGGAAGGAAG AATATAAAATCAGATGTGGGAATCCAGGGGAAAGTGCAAACGAAGCAAGATTGAGAAAAT TCTCAAGTTTTTATAAACAGTTCTCACACTCTGCCAGTTCCTTGGAGGTAGACTTTTTTG TTAACTTCCAACTACAGTAGTGAAAAAAAAAAAAAAACCCTCAAATTTGCAAAAGCAGTC TGTGGAATTTTCTTTACCCAGCTTTCCTGACTGTTAACTTTTTAGCACACTTAACTTTAT CATTCGTTTATTCTCTCTGTTTAAAATTAAAAATGTAAATTTTAAAAAGTAAAATGTTTG TTGGTTACAAACATTTATACCCCTTTGTCTCTAAATATCATTTCATTTTAAAAAATGAAT AATCTAAGCCTACACATTCTAAAATGTGTATATTTTCTAAAAATAAGGGCATTCTCTTAC ATAACCAATGTCACAATTATTTGATACAGTGATCAAAATCAGGAAACTAACATTGATATA ACACTATTATCTAACCTACAGACCATCTTCAAATTITC-TCCTGCTAGTATCTTTTATGGG TCCAGGGTCACACAGTGCATTTGGCTATAATGTATCTTTTTTCTCTTTTTTTGAGACAGG 45CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GTCTCACTTTGTTGCCCAGGTTGGAGTGCAGTGGTGCAATTATGGCTCACGGCAGCCTTG ACCTCCTTGGGCTCAGGTGATCCTCCCACCTCAGCCTCTCGAGTAGCTGGAGACCACAGG TGTGCACCACCATGCCTGGCTAAGTTTTGTATTTTTTGTAGAGATGGAGCTTCGCCGTGT TGCCCCGGCTGGCCTTGAACTCCTGGGCTCAAGTGACCCTCCCGCCTTGGCCTCCCAAAG TGCTGGGATTACAGGCGTGAGTCACCACACCTGGCCAGTTATTAGTATGTTTAGTCTCTT TAATCTGGAACAGTTTCTCAGTCATTCTTTAITTTTCATGACCTGGATGTTTTTGAAGAG TTTAGGCCAGCTATTTAGCAGAATGCCTTTCAGTTTGGATTTGTCCAGTGTTTTCTCTTG ACTATATTCTAGTCATGCATTTTTGGCAGGACTGTCACAGAAATGTTGTTGTAGTCTTCT TAGTACATCACATCAGGTACACACTGTTGATCTGATTCAITACTAGTGGTGTTAACTTTG ATCACTTGAATAAGGTGGTGTCTGTCAAATTTGTCCACCGTAAAGTTACTTGAGCAAAAC GTAGCTGGGACTACAGGCGTAGCAAAAAATGTAGCAAAAAGTAGTATTTTTGCTACATTT TTTTTTTAGGAACAAAGTATTTTTCCCTTTTAAGTTAATCTCTTGTCCATAAAGTTATTA tttttcccttttaagttaatatcttgtgggtagataciggagactgcgtaaattacctat TTCTCATAATACTTTTTTTTTTTTTGAGATGGAGTCTCGCACCGTCTCCCAGGCTGGAGT GCAGTGGTGCAATCTCGGGTCACTGCAAGCTCCACCTCCCGGGTTGACGCCATTCTCCTG CCTCAGCCTCCCAAGTAGTTGGGACTACAGGCGCCCGCCATCACACCTGGCTAATTTTTT GTATTTTTAGTAGAGACGGGGTCTCACCGTGTTAGCCAGGATGGTCTTGATCTCCTGACC TTGTGATCTGCCCGCCTTGGCCTCCCAAAGTGCTGGGATTACAGATGTGAGTCACTGCGC CCGGCTCTCATAATACTTTTTGCCTACTAATTTTATATTCATTGATTAAATTCTTGCCTG AAAAAATTATTACTGTGGTATTTGCCAAATGGCAATTTTCTGTTTCCATCATTGCCTTTC CCCCGCTTTTAAAAGTATAAGTGACAAAGAAAAACTGTATATAAAGTGTACACCATGATA TTTTGATATATGTATACTTTGTGAAATGATTATCAAAATTGAGTTAAATAATGCATCCAA CATCTCAGTTACTTTTTTTTTTTTTIGAGACAGAGICTTGGITTGTCACTAAGGCTGGAG TGCAGTGCCACAATCTCGGCTCATTACAACCTCCACCTCCCAGGTTCAAGTGATTCTCCT GCCTTGGCCTCCCCAGTAGCTGGGATTACAGGTGCCCACCATCACACCCGGCTAATTTTT GTATTTTTAGTAGAGGTGGGGTTTCACTACG'ITGGCCAGGCTGGTCTCGAACTCCTGACC TCAAATGATCCTCCCGTCTCAGCTTTCCAAAGTGGTGGGATTACAGGCGTGAGCCACTGT GCCCGGCCACTCTTAGTAAATTTTAAGTGTACATTTTTTTTTTTTTTTTTTTGAGATGGA GTCTCACTTTGTCACCCTGGCTGGAGTGCAGTGGCATGAICTTGCCACACTGGAACCTCT GCCTCCTGGGTTCATTCAGGTGCTTCTCCCACCTCAGCCTCCCAAGTAGCTGAGACTACA GGTACCCGCCACCATGCCTGGCTAATTATTGTATTTTTAGTAGAGATGGGGGTTCACCAT GTTAGCCAGGCTGGCCTCAAACTCCTGACCTCAGGTGATCTACCCACCTCGGCCTCCCAA AGTACTGAGATTACAGGCATGAGCCACCACACCGAGCGAGATTACGTTAGTATTAACTAT AATCACCATGCTGTACATTAGATCTCCAAAATGTATTCATCTTATGTAACTTCAAGTTTG TACCCTTTGACCAAAGTCTCCTTGTTTTCCCTACCCCCAACCCCTGGTAATCACTGCTTT AATCTCAGTTTTTATGAGTTTGACTGGTTTAGATTCCACATACAAATGAGATCAGGCAGT GATGGTTTATTTCACTTAGCATAATGTCATCCATGTTCTTGCAAATGACAGGATTTTCTT 46CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CTTTTTAMACTAATATCCATGCTGGACACGGTGGCTCATGCCTGTAATCCCAGCACTTT GGAAGGCTGAGGAGGGTGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACAT GGTGAAACCCCATCTCTACCAAAAATATAAAAAATTAGCTGGATGTGGTGGCGCACACCT GTGATCCCAGCTACTTGGGACACTGAGGCAGGAGGATCGCTTGAACCCGGGAGGCGGAGG TTGCAGTGAGCCAAGATGGTGCCACTGCACTTTAGCCTGGATGTTGATGTTGTTCCACTT GTTTATTTTTATTTTGTTCCCTGTGCTTTIGGTATCAAAICCTAAAAACCATTGCCATGA CCATTGTCATGTTACTTTCCCCATATGCTTTCTTCTAGAACTTTTAAGGTTCATCATTCC CTTTTCTGTTTTTAGTTGCAAGCCTACTATAAGGAAGGGCTTTTCTTTCTTCCTTATTTA TTTATTCATGTCTATCAGAATGGGCACCTTACTACTATTITTGTTGTTATTGCTTGAATT GACTTGAATTTGGCTAGTGGAAACCTTTTCAGATCGGGTACTCTGTCCTTTTGATCTCTT TCCATTTTCAAGCACTTCTTTAGACTTAAGATGGTCTAGGCTCATCTTCTCCTTTCCCAG CCATTTTTCAAAGGAACCTGATTCCTTTTAGTGAAGAGGAGTATTTTGAAACCAAGATCT GGGCACTGGGTCTACTTGTTTGTACTGGTACAGTGTTCTTTGAATTGCTAATTAGCTGAT CAATTACTGCTCTATTTGAGTTCCCTCTTTCTAAAACCTCACATATGTGTACAGACGGTC CCTGACTTATGATGGTTCGACTTATGATTTTTGATTTTATGATGGTTTGAGAGCAATACA TCCATTCTGTTTTTCACTTTTCATTCAACACTTTATTTTAAAATAGGGATTGTGAGATGA TATTGCCCACGTGTAGGCTAATGTAAGTGTTCTGAGCACGTTTAAAGTAGGCTAGGCTAA GCTGTGGTGTTTGGTAGGTTAGATATGTTAAATGCATTTTCGACTAGTGATATTTTCAAC TTATGATGAGTTTATTGGGATGTATCCCCATAAAGTCGAGGAGCATTATACATATCTCTG TATAACAGAGTGAGTTCCTTATACCTTTCATCCACTTTCCCCTGAAGTTAACATTTTACC TAACCATGATACATTTATCAAAACTAAAACATTAACATCAATACATTGCTATTAACTAAA CTAGAGTTTAATTGGATTTTGCCAGTTTTCCAATGAATATCCTTTTTCTGTTCCTTGATC CAATTCATGGTCACACACTGAGTTTGGTCACTTGTCACTGTAGTCTTCTCCAATCTGCGA CAGCTTCTTAGGCTTTCCTTGTTTTTCATGTACTCTTGACGATTTTTAAGAGTACTGGTC AGATATCTTGTAGGATATCCCACAACTTGTGTTTAATCTTATGTTTTCTCATGATTAGAC TTGAGTAATGGATTTTTGGGAAGAATACCACAGAGGTATATTGTTAAGTGTTCTCATCAC TTGGAGGTAAATGTTATCAACATGGCCTGGTGATGTTAAACTTGTCAGTTTGTTTAGTTA GTATCTGCCAGATTTTTCTCACTGCATAATTACAAATCCTCCTTAACTTATGATGGGGTT ACAGCCTGATAAGCCCATCATAAATTGAAAATATCATAAGTCAAAAATGCATTTAATGCA TCTAAACTACTAAACATCACAGCTTAGCCTAGCCTGCCTTGAACGTATTCAGGACACTTA CATTAGCCTACAGTTGGGCAAAATCATCTCATGGGAAGCCTGTTTTATAATGTGTTGCAT ATCTTATGTAATGTGTTGAGTACTGTACTCAGAATGAAAAACAGAAGGGTTGTATTGCTT TTGCACCATCATAAAATCAAAAAAACCATAAGGCAAACCATCATGAAGTTGGGGACTGCC TGTACTTTTTTCCTCTTTCCCTGTTCAATTCCTTGGAAGAAAGTCATTTAGTTCAGACCA TACTCAAGAAAAGGGAAATAAAGCTCCATCTCTTGGAGCTTAATTGAAACTGGAATGACT AGTTTCTATATACATTATTTAGAATCCTTTTGTAAGAAAGATTTGTTCCTTCTCTCCATT TATTTATTCCATTATTTATATTGATAGAGACGCATGTACATTTATTTTATACTTTGGGTT 47CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATAATCTATTTTTCTTGCTCAAATTGTTACAGCTTTGGTCACTGGGAGGTTCTTCAGATT GGCTCCTGTGTCATTTGACATGTCCCCACCCTCTCGTTTCTGAGTACTTCTCTACTTTGG CATTACAAAAGAWI"I'CCAGGCTCCICTTATATITITCCCTGCCGCAGCCCTAGAATCAT CCATTTTTCTATGGTGCCCTGGTTCCTTTTACTTTAGATGGGGGTTTAGAAACCAATCTG GGTGTTGGGTGTGCTCATTGCTACTGGAATCACTGCTTCTAGGCCCTCTCAGCAGATAGA GCTAGAAAACATATGGCTGTATATGAATCCAIGGATTCAIATATATCTATAATTGTTTTC TGTATCTGGCCATCTATATATATATTAAGCTAAACATGAATTCATACTGATGTCTCAGAC TCGAATCCATTGCCGCAGGGCTCATTCTTGCCTTCCTCTTGCTTATTTGTGACTTCTTTC TCTAACAGGGAGAAACCCCAGTCTCATTATCACCAACCTATCTACTCATTTGTTCAACCC TGGTATAGGTGTAAAGTAGTTTCAGAATTACTAACCTATACCCATGTGAGAATTGTATTT GCACTTCTTGTTTGAAGGAAATACATACAACACAGGTAGCGTCTCTACACTTCAGTATAC AGAGATCTGAACAGTGTTCTCTCTGAGTGAATCATATTGCAGGACAGAAATTACTTTTAA AAATTCTGTAATGGGTCAGGCCTATAATCCTAGCACTTTGGGAGGCTGAGGTGGGCAGAT CACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAAAATGGTAAAACCCCATCTCTACAA AAAATACAAAAATTAGCCAGGCGTAGTGGTGTGTGCCTGTAATCCCAGCTACTCAGGAGG CTGAGGCACGAGAATCACTTGAACCTGGGAGGCAGAGCTIGCAGTGAGCTGAGATTGAGC CACTGCACTCCAGTCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAAAAAAAA AATTCCATAATGATAGCAGAGCTGGAATAGAAATGGGATTGCACAGGCTGAATCTGAGTT GTTGCAACAGTAAACGAGCAAGATTTAAACTGGCCTTGTGTAGCACTTGCTATTTGGCTC CTCATATTTTATTAGACGCTTATTCTTTTTTGTTTGGTGTCATTCCTTTGAGAAATATTT GAGTGCCTTTTCTGTTGCAGACATTGATTAGATGCTGAGGTTGTAACAATGAAGAAGATA GCCATCGCTGTTGCCTCATGGAACTGAAGTTTTACTAGATGTAAAATTTGAGTTAACATG AGGCCGTGCCCCTATGTGCCCTATTGTTTCTTCACACAGCTCCCTTCATCTCCTTGGTCC AATGAAAAGGTTTTTTCATACTTGTTCATTCATTCCTGCATTAATTAAAGTAGGTTGTAC TGTGCCAGGCACTGGGAATATTTAAGTAGTTGTGTTCCTGAATTGGAAATGAATCCAGCA TGGTTGGAGTAGAAGGAGCTGGGGGGCAATGTGGAGTGTGATGGGGAGATTGGAAAAGTA AGCTGAGACCAGATTTTTCAGTTTGGAGGGAGAGGTGGGCCTTGTAGGCCATATTACAGA TTGTAGACTTTATTTGGAGGGACATGGAAGTCATTGAGGAGTCTGAAGCAGGGGAATGAC ATAAAAAGATCCTCATTTTAGGCCGGATGTGGTGGCTCACGCCTGTAATCCCAGCACTTT GGGAGGTTGAAGTGGGTGGATTGCTTGAGGCCAAGAGTTTGAGACTAGCCTGGGCAACAT GGTGAAACCCTGTCTCTATCAAAAATACAAAAATTAGCTGGGCATGGTGGCTCACACCTG TAGTCCCAGCTACTTGGGAGGCTGAGGCATGAGAATCGCTTGAACCCGGGAGGCAGAGAT TGCAGTGAGCCGAGATTGTGCCACTGCATTCCAGCCTGGGTGACAGAGTGAGACTTCGTG TCAAAAAAAAAACAAAAAACCCCTCATTTTGAAAGGGAACCCTGGCTTGAGGGTGAAGAA TGGGTGGGCACTAGGCTAGAGCAGCTGCAGGGTCAGTGAGGAGCTGCCGCAGTGCTGCAC GTGAGAACCCGTCATGGTTTGGTCAGGGTGGGCAGGACTGACAGTGAGCACAGAGCGAAG TAAAACCAGCAAAATTTCATGATTGGATAGTGGAAGGAATCATGGTGTTTGTAGTCTTCA 48CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AATGTGAACCCAGAGTGCACTGGACAAGTAGTCTAGGCTGCTCTGTAACCAAGGCAAGTG TTTTCATTTTACCCTCTCTTCCTGCTCTTGGCCTTTGGATTTTTTGTAATTTAAGGTTTA TGAATGTAATGAGTTAGTTAACATGGAAAGATACTTAATACGAGATGATTTTGGAGTCTT GTGATCAATACCTTCTCTCAATCTTGGGTGTGTGTCAGTTGGCAAGGCCATAAAATTTGT TATAAACATTGCAGAAGGCTTGGTTACTGTGCTGTGACGTTGAATTTGGGTGGAGATAGA TGAATTTCAGTTGATTTTCTAGGCTTCAGAAACACATTAGCCTCTAGTCCACAAACACAA ATCAAAACAAAACAATCCCTATTCCCTGAGCATTTCTCTTGATCTATAACACAGCCTGGG CTGTCACAGTACTAAGACAAGCCCATCTGATTTGTGAGTCAGTTTTATTTCTTGGTCTTC TACATAAGCTAAAAAGTTTCAACATTTTAATGCTTTTCCITGGATTCCTTTGAGTCATTG AAGTAATTCCTGTTTCATTTGTACTAATTATTCCACACTAGAAAATTCTGTTGTAATCAC TTTATGTATTAATAGAAATACTGATTTTTATTTTCAAGGAAGTATTGAGTAGGGAGGGGG AAA.TAGGGATTTGCTGTTCAATGGGTATAGAGTTTCAGTAATACAAGACAAAAAACTTCA GAGATCTTCTATACAGCAGTGGGTATATAGTTAACAATACTC-CACATCTAACAGTTTGTT AAGAGGGTAGATCTCATGTCATGTGTTTTTAAAAATTGCTTTTAAAAAAAGTATCGAGTA AAAAAGCAGTTTTACTCCTCAGTTTCTATTTATATTTAAAATTTTTATTTAAAAAGTGAG TTGAGATTTTTAAACCTCAGGATAAGTTTTATTTTTTAAAAAATTTATTTTTTATTATTT TTTGAGATGGAGTCTCACTCCATCTCAAGTCACCCAGGCTGGAGTGCAGTGGTGTCTTGG CTCACTGCGACCTCTATCTCCCAGGTTCAAGTGTTTCTGCTGCTTCAGCCTCCTGAGTAG CTGGGATTACAGGTCTGCACCACCACGCCTGGCTAATTTTTGTA.TTTTTAGTAGAGATGG GGTGTCACCATGTTGGCCAGGTTTGTCTTGAACTCCTAACCTCAAGTGACCACCTGCCTT GGCCTCTCAAAGTGCTGGGATTACAGGTATGAGCCACAGTGCCCGGCGGGATAAGTTTTA AAATAATATTCTCTGCTGGCTGGGCATGGTGGCTCATGCCTGTAAACCCAGCACTTTGGG AGGCTGAGGCAGGAGCATCACTCGAGGCCAAGAGTTTC-AGACCAGTCTGGGCAACATAAT GAGACCCCCTCTCTACAAAAAATAAAAAAAATTTGGCTGAGTGTGGCATGTTCCTGTAGC TATCGGGAGGCTGAGATGGGAGGATTGCTTGAGCCCAGGAGTTTGAGGCTGCAGTGAGCT ATGATTGCACCACTGCGCTCTAGTCTGGGTGACAGTGTGAGACCCTGTCTCTTAAAAAAA AAAAAAAAAAAGGCCAGGCACAGTGGCTCAGGCCTGTAACCCCAGCACTTTGGGAGGCCG AGGCGGGTGGATCACTTGAGGCCAGGAATTTGAGACCAGGCTGGCCAACATGATGAAACC CCGTCTCTACTAAAAATACAAAAATAAGCTGGGTGTTGTGGTGCACACCTGTAATCCCAG CTACTTGGGAGGCTGAGGGAGAGAATTGCTTGAACCTGGGAGGCAGAGGCTACAGTGAGC CGAGATCACACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACTCCATCTCAAAAACAA CAACAACAAAAAAACCAAATGTTCTTGCCAATTCTTCCATTTAATATTTAATTTTGAATT ATATTGTATCTTTCTAAGGATTGTTTCTTATATAAGCAAAGATTTTTCAGTGCTAAACAT TTACGACTGCTATTCAGAAATGGTTATTTACAAGTCTTTTTGTTTTAAGAAAATGGCTGT TCAAAAAATTAAAATAGTATATAAACCAAACAAAATATTTTTGCTTTGGATGTCTGTTTT GCAGCTTCTTCCCTACACTATAAGTTCTTACTGACTGCTITATCACTTAATAAATTGGTT TGGCTACTTTAACAGAGGCAAATAGTATCAGGCAAAAAATTATTTTTTATTTTTATTTTT 49CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TGAGACAGTCTCACTCCATCACCCAGGCTGCAGTGCAGTGGCCTGATCTTGGCTCACTGC AACCTCCACCTCCCAGGTTCAAGCGATTCTCATGCCTCAGCCTCCTGAGTAGCTGGAATT ATAGGCATGCACCACCACACTCAGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTTGC CATGTTGACCAGGCTAGTCTTGAACTCCTGACCTCAAGTGATCCATCTGCTTTGGCCTCC CAAAGTGCTGGGATAACAGGCATGAGCCACCATGCCCAGCCCTATTTTTTATTTTTTAGA GATGGGTCTCGCTTTTTAGAGATGGGTCTTGTTGCCCAGGCCAGAGTGCAGTGGTGCGAT CATAGCTTACTGCAGCCTTGAATTCCTGGGCTCAAGCAATTCTCCTGCCTCAGCCTCCCG AGTAGCTGGGACTACAGGCCTGTGCCACCAGGCCTGGCTTGTACATTAGTATTTGATATG GCTACCCTAAGGGCAATCCTATAGTGAAGTCAACATTAGATAATGATGCTCATCTGATGG ATTAGATTTTCAGAGTTGGCTGTTTCCAGGTGCCTATAGGAGTAGAAAAGGGTGACAAAC CTCCTAACTAGATGTCCTACCAAATATAGTTCACTCCACATCTGAGATGAGACTGCATGA CTGCTGGTTTTCTTTGCCTTTTCCCCCCCAGGGTATCATCAGAACCAAAAATAAAGTTTT AAAGGTGGGTCAGGTGTGTGTTGGCTCATGCCTGTAATCCTAGCACTTTGGGAGGCTGAG GCAGGTGGATCATCTGAGCTCAGGAGTTCAAGACCAGCCTGGCTAATAACATGGTTAAGC CCCATCTCTACTAAAATACAAAAAGTTAGCTGGGCATGGTGGTGGGCACCTGTAATCCCA GCTACTCAGGAGGCTGAGGCATGAAAATCGCTTGAACCCCAGAGGCGGGGGTTGCAGTGA GCCGAGATCATGCCACTGCACACTAGCCTGAACAACAGAGCAAGGCTCTGTCTCCAAACA AACAAAAATGGTGCCAGAGTCTTTTCCAGGGCTGAGGGGAGATACAATGAAGTGTGTTAT TTTTTCTGATAAGAGTGCTACCATCTTTCATTCTTGTGTGCCATTTCTAGTTGGGGTGAA TTTGTTTTCGGAGTTCCTTTCCCAGCTGTTTGCCTGAAAAACCATGAAATGTGTTCCACA TGAACTATGAAATGATTAGATGCTAATGTGGCAAAGAAAGTGTGAATTCTCTTGTAGAAA CAGGGACATTTGGTTCGGTACAGTAAGTTGTTAATGCGTGACTCTGTGCTTTCAAATTCT GTGGTTCAAAAGTACTTTTCACTCCTACTGTGTATTTACCTTGAGAAGGTGAATCCCCTA ACAATTTGGTCAATGTATCAGTATTCTCAACCCGTCTATCAATTTTTTTTTCTTTCTCCC TCTTTTTTCTTTTTTTGGGCAAAATACCTTTTTTGCTTTTTATCCCCTTAAAATAACCAT TGTCCCTCACATGTGCACTCTTCCAAATTTC AAAAGCAAGAGGAAAGGGCACGAATAT ACAAATATTAAGTATTCTCTAGCGGACCAGACGAGTGGAGATCAGAGCCCTCTCCCGCCT TGTACTCQAACGCCACCCTGTGCAGA 1AGTGCTGAAGGAAATTCTTTTTACCTGG TCATGGTGGTTTAAAAAGGTTTAAAAAACAAAAACAAAAACAAAACACAAGTTTGTAGCA CATGCCTTTCACTGGTGCACGTTCCTGTTGCCCTACTGTTAGTGTATCTGTGACTGGTGA TATCTATTGATTGTGTTAATGCTATCTCAACCACGTTTTAATTTTCCTAAGCTGGCCAGG CACGGTGGCTAACGCCTGTAATCCCAGTGCTTTGGGAGGCCGAGGTTCATGGATTACTTT GAAGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAAT ACAAAAATTAGCCGGGCATGGTGGCGCATGCCTGTAATCCCAGCTACTCAGGAGGCTGAG GCAGGAGAATCGCTTGAACCCAGGAAACGGATGTTGCAGTGAGCCGAGATCATGCCACTG CACTCCAGCCTGGGCGATAGAGTGAGCCTCTGTCTAAAAATAAAATAAAATAAAATAAAT TCCTAAACTGAAGGCTGACTGCTATGCTAGCTAGGATTATATGGGATTTTAAGTATATCA 50CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGTGGTGGTTCTCCAAGAAGAATCTAATTTTTCTTTTGATGGGCTGGGGATTGTAACAAA GGAAGGTCATATGTCTTAATGATGTGTTAAGGCTCTTTGCAAAATCAAAGTAAATAAATT GACCACTAATGTGTCAGCCCAGCCAIGTTCTGCICATTTGCCACCAGTCAACAGAAATCT ACTTTGGGTGTTTAAACCAGGAGTCAGCAAACTACAGCTCACAAGGCCAGATGTGGGCCA TGGCCTGTTACTGTATGGCCTGTTAATGGTTTTAAAGGGTTGTAAAACAAAAGAACACAA AACAAAGACCCAATAACAAAACAAAGCCCGAAGAAIAATATGCGACAGAGACCATGTATG GCATATAGAGCCTAAAATACTGACTCTCAAGCCCTTCCCAGAAATCCTTCCCGACTCCTT GTTGAAAACACGGTAGGAAAGCATTTGTCAAATTGAGGATATGAATAGCAATTGTAAGTT ATTATTTTTCTATATATTCGAAAGTCACTTGCTAGTATAACATTTACCTTTTATTTTTCC CTAAGAATCTTCTCTCTGTTTGCTTTCGACATGGATTTTTAAACCCCTGCAGATTTTAAT ATTCTATATAAATGTTTTAGGTGGCATATATGAGGTTTGTATTAACATTTGCTTTCTATT TAACATTGAAATGAAATTATACAGCAGAGGTATTTTCTCGTCCAAGTTGCCACTTCTTTC TATCTTTTTTCTTTTCTTTCCCAGTGGACIGCCIGGGAAAATTGATATTTTAAATTGCTC TCTGCAATAATTTGCAATGGAACTGGAATGCCAGGGTTCTGAGTCCTTGCCAGACAGCTC GTCCCTCCTGTTGGCATGACTGAGTCAGCTGTCATGATTCCCTCAGTACCAGTGGCATGC CTGTGACAGACAGCCTGTCTGCCTTTCATTCCCGTCGTCICCCTTGTAGGGTTCAGATCC AGGATACACTGGTCCTGGAGCCCCTCTCAGCCTGGCACCCACAGCTGCTGGGTTCCTTAC TCTCCTGGACTGCTCTGATGTCATCTCCCTGCTCAGCAGAAAGAAGTCTGGGATCTTGAT GCTTTGGCCCTCTGTCCTAGGCCCTAAACCACCCATTC-CCCTTCACATAACCTGAGCTGG GGCTAAATAGATCTCTCATCACTGCCTGCCTGCTCCTGTATTTTCCCTTCTTGGAGCTTT TGCCTGTTCAGATCCCTCTACTGGAAATTAATAGGATTTCATTCTATGTGTGCATTTCCA ACCTTTCTTCACAGTGCGATCCAAATGCCTCATCCTACAGGCCTCCTTAAAACAACCTGC TttCTGCCAGACCCCAGGGAGCACCAGGACTIGAGGCTTITATTGCACTTCTGTTGTTTT TTTGAGATGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCACGATCTCTGCTCA CTGCAACCTCCATCTCCCGAGTTCAAGAGATTCTTCTGCCTCAGCCTCTCAAGCAGCTGG GACTACAGGCATGTGCCATGACACCCGGATAATTTITGTATTTTTAGTAGAGACGGGGTT CACCATATTGGCCAGGCTGGTCTCAAACTCCTGACCTCGTGATCCACCCACCTGGGCCTC CCAAAGTTCTGGGATTACAGGCGTGAGCCACCATGCCCAGCGTTATTTCACTTCTGCCTC TGTAATTATATTGCTGTATGGCTATCTCTTCTCTCCCTGGGAATGTCAGGTCCTAGGCAC AGGAACTGTGTCTGTACCATATCTGGTGCCCAAAGAATGTAGTATGTGTTTTATAGATAT CATGTAAGCTTAAACAGCGTGGTCTACATTTTTGTAAATGTCTTTCTTTTTCTTTTCTCT AAATGAGAGAAGACAGTGCTAGAGTCTATGAAAACGTGGGCCTGATGCAACAGCAGA AAAGrTTCAGATGAGAAAACCTGCCAAAACTTCAGCACAGAAATAG^^^iCAAA GTGCTCTATTGGTTAATTGTTTATATAATTGGCAGTATTTTTAAGCAGGCAAGCAATTTG GGAATGTTTTAGCAAAGTGTACCATAATTGAGTTTTACAAACCAGGCTCCTTTTTCCTCT CCCTGTACTTCTTTTTCCAAGATGGTTTTAGITTAGAGT'ICATTAAACATTAAAATCAAA CACAGAATTAATTCTGCATGAGGCAAGGCTAGCACTTATTCCAGAGAAATGGCTGATACT 51CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGTGGTAGAGTGCAGGTATCACTGTTCCTGCAATTTTTATTAGAGTTGGTTAGCCCAGGC TGTGCTGGGGGATGATCTGTAGGGATCTGGGAAGCATCGGGACTCAGCACTGGGTGGTTG GGAGTCAGGAAGCCTGAGTTCTCATTTCAGTCAGTCTCTGACCAACTGTGTGGCATGGGG TGCTAGACCACTTGGCTGCCGACTGGGTCACCGACATCCCTTCCAGCTCTGCTGCTGGAA ATTCATCTCTCCCATATGTTGCCTCCCCATCAATTACGTTTTTTAAGTGTGACCCAAGTA TATGATGTATGTTTTCATGATAAATTAGAAACTTATCTGGGCATGGTGGCTCATACCTGT AATCCCAGCACTTTGGGAGGCTGAGGTGGGCGGATCACCTGAGGTCAGGAGTTCGAGACC AGCCTGACCAACTAAAATAGTAGAGACCAACCCGTCTCTACTAAAAATAGAAAATTAGCT GAGCATGGTGGTGCATGCCTATAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAGGCAG CGGTTGCAGTGTGCCAAGATCGCGCCATTGCACTCCACCTGGGCCACAAGAGTGAAACTC CATCTCAAAAAAAAAAAAAAAAAAAAAAAAACTCAGTGTCAGTATTTCATGTCGAAATTC CACTTCAATGGGTAGTGTAGTTAAAAGCTCTAAGTCTACCTTAAAATCACCTAATGCTTT GTTAAGCTTTTAGATATATGTTCCTTAAAAACTCTIAACITATTTCTTCCCCAGQQGG ACTTTCACCCTCTCCCTAAAAAGATCAAGAACAGACGCAAGAAAGTTTATGTGAAGACAG AATTTGGATTTGGAAGGCTTGCAATGTGGTTGACTACCTTTTGATAAGCAAAATTTGAAA CCATTTAAAGACCACTGTATTTTAACTCAACAATACCTGCTTCCCAATTACTCATTTCCT CAGATAAGAAGAAATCATCTCTACAATGTAGACAACATTATATTTTATAGAATTTGTTTG AAATTGAGGAAGCAGTTAAATTGTGCGCTGTATTTTGCAGATTATGGGGATTCAAATTCT AGTAATAGGCTTTTTTATTTTTATTTTTATACCCTTAACCAGTTTAATTTTTTTTTTCCT CATTGTTGGGGATGATGAGAAGAAATGATTTGGGAAAATTAAGTAACAACGACCTAGAAA AGTGAGAACAATCTCATTTACCATCATGTATCCAGTAGTGGATAATTCATTTTGATGGCT TCTATTTTTGGCCAAATGAGAATTAAGCCAGTGCCTGAGACTGTCAGAAGTTGACCTTTG CACTGGCATTAAAGAGTCATAGAAAAAGAATCATGGATATTTATGAATTAAGGTAAGAGG TGTGGCTTTTTTTTTTTTCTTTTTTCCAGCCGTTGACCAATTATAGTTCGGCTGTTGACT GAGAAGTTTGTGGTGGGAAAACGTTTGCCATATTTTCTTTGCATTTGAATAATTGTCTTG TACTTAGAAAAAAGGCGTCTATGAATGACCAGTGTTTTTGGTCGCCAAATGTTGCTGACA AACTTATCCCAAAACTTTAGTGGCTTAAAAAAACCTGCCCCCAACTGTTAGTCAATCTGA GCTGGGCTCAGCTGGGCTGTTCTTCTGCCAGCCTGCAGGTGGCCACTCATGTGGTCAGCA GGTCGGCGGAGAGACTGGGATGGCTGGGCTTCTCTCTCTGCCTGCAGTCCTGAGTCTCTC CTTCTTCGTGTAGTCTCTTTCAGTGGCCTGGCTGGCAGGGTAGCTAGACCTCTCACATGC AGCTCAGAGCTCCCAAGAGCTCAAAAGCAGAAATGGCCAGGCCTTCTGAAAACTTAAGTC CAGAATTGTCACAGTGTCCCTTCTACTTCCCTCTATTGATGATGATGATGATGATGATGA TGATGATGATGATGATGATGATGGTTTTTTCTAATCAGAAGAAAGCTGGGGTATGCCCTC TACTTACTAAACAAGTCACAAGCCCAGCTCAGATTCAAGAAAAGGGTGTGAAGTAGAGGT GCAGTTAAGTGGGGGGCCACTAGTCTAACAGACGGTCACAACCAGTGCCATGGAAAACCA AGGATATTAGCAAAAGCAGAAGTTGCTAGTGACCTTGGGAAGCCGAAGCTGCTTACAGTA GCTGGGACAAGCTGAAAGTCAGACTAAGAAATAAAGAGAGGGCCTTCAAGAAGCTTCCTG 52CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 aatgatttctgctagccctgagcctatttttggaaccagcacttggggaaactgatcttg TGAGGATGGATGTGTTTAGGGACACAGGGCTTTTGAGAGCAGCACCACCCCACTGGGGCA TCCCCAGACTTGGGAAACGTGACTCTTTCTTAATGCCACTGGGTTTTAGTCAGGCCACAG TGAGAAGGAACAGCCCTAACAGGCCTCCAGCCAGGTTGAATGAGCTCATTTTTGTTGTAG CCAACCAGTAAGATTTGCTAATGTTCTACATTAAGTGCCTTCTCCAAAGACATCCCTCTT TGCCTCATATGTTGAATCATCCAGTGCGGATATTTCAATGAAAATATCATTGGTTGACTT TTGTGATGGTAATAATGCTATGGCATCTTTGCCATGAAGTTGTGGCCTCCTTGGATTCTT CTGACTTTGGCTTCTGAAAGGAAGGCCTAGATCCAGCCCTGGTGGTAGTTCCTTTCTGAG GTCTCTCAGTCCCTTGAGACTTTGGGGTAGTTTGGCTGCCATTCTCACTGACAAAATGTA TATCAGCCCCCACCTCCACCCCCCAATATTCCTTGAACTTTGAATTGCTTCAGAACACAG GTGTGGCCTGAAGGTATTCCCTTATTAGGGAAGTGTCACTGCTGTCTTCTAGTCAAACTT GTAAAGAAAAAGATTCCAGTTCAGTATTTGCAGCAAGAAGCTTGAATGCTGTTCTTTTTA TCGCATTGTTACATCGACTCATTCTCCATTTTGCTTTGGTTTTGTCTTGACTTGACTTGA CTTTGGGGGTAAAGTCTTTCACCAGCACACAAGAGTTTGATTGTACAAATATATCTTCTG CATTAACATCTCTGCCTGTTGCTTAAGATCAGTTGCTTTTATACTCAGAATGGAAATACC TGATCTTGGCTAGTTTTGTTATAAGATATTGATTTCATTTAGATTTCCCTCCACGAGGTC AGCAAACTATCATGTTCTTATGTAAACTTAGGCCAAGGCCAGAGTTATCATAGTCCCTAG GTTGCTACGGCTTATCATGTGCTTGGTAAAAGGTGATCGCAGGTTCTCAGACGAGTTTAC TTTACATGAGATGGAATCAGGCAGAGAGGCTGGGATGATGGAGAAAGCTCGAGGTGAAGT TTTAAAAAAAAAGTTGTGGAAAGGAAAGTTCCAAAGAGGTGGTTTCTGAGGAAGTCAGAG CGCCCAGGGCCAGAGCAGTCAGTAATGGGTGAATGAGGTTGTTTGGAAAGTCGGTGTGAC AGACACATGGATGCCATCTACTTCTAGGTTGCTGGTGGGTATTAAATATGCACAATATTC CATAGCTCACTGAGGATTTTAAAATTATAAGCATAGGATTTTATATTTTGGGGTGAAAGA ATTATCTGGCACATTAGGTATTGGAGTTTAAAAAAAAAGCCAAATTTCACAGTCTTAATA ACTTTTTTTAAAAAAAACTAAAAGGCGCTTCATGTCCAGTGTGTGGCCCTTCTGAAACTT ATGGTCATCTCTCCCACTGAAACCAAGGTCTTTTCAAATGTGGCTAAATGGGGATGAGGA GACACGGGTAGGACTTTCTTGGTGTGTGTGCATTCTTTAAAGAGCCAAGTTGCTTCGGGG AAACAGCCAGGAAAATGGTCAAGATTATTTTTAGAGGTTATTTTATTGGGGATTTTAAGA ACTAATAACATCTTGAGTTATTTTTAATTCAGGGGGATGTGGAAAGGTTTGCAATTGTCA AGTGTTTTGTTGTAGCTTAGTATCCATAAGGGAAACTTAGACTATAGACATAACTACAAA GCCAGTGCAGCTTTTGTTTTCTGTATGTTGTTGGGGGATCAACTTTCACACATAGCAAGC ACATGGCCTCCCTGATGTCAGGATGCCTTTGTTAGGATCTGTATTTGCCCTTAATTTTGT TGAAATCTTTTTTCCTTCTTCCTCTTGAAAAGTTCCAAAATATAGTTTATTGTATCTTTC ATCACTAAAAATTTGTTCCTTTTTCACTATGGGCAGTTCACACAAGGCAAAAACTATTGA ACAGTTGGTTTTAGTGTGTTGTATAACTTTGCTGTATATCAAACTAATTTTGACAAGTTT TCATCCTAAGCCTCAAATCATGTAATTAATAATTTGCCTGTTTATTTATGACCTAATTGT GATTCTTTTATTAATAAAAGCTAATGGGAAAAGGATCCCTGATTAAGCTGATGACTAGAC 53CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CTACAATTAATTTTCCTGCAGTATATGAAGTATTGTACCAGAGTATTAAAAGATATGTAA TATTTTATTGATAAATCTATCCTTTAAAAGGAATACGTTTTAGGATGTCATCATTTTGAT GTGAATCATGTAAATGTTGATAATATGCTGTTTATTATACATTTAGTGTTTCAAGAGATT CACTTAATTGCCTTTTTGCCCACGTATATTATGTAGTCTATTTGCAACTGTTCTTAAAAA AATGACATTAAAAGAATAGTTTATGTAGAGAAACATTAGTGGATGTTAATTGTCTCCCCA CCTATATTTATGGGTGTTAGCGCAACTGCTTTGCTAGTTGCAAAGCTGTATTATCAGAGT AAAAGTGTATTTGTAAACTGTATGGGAACTAAAAATTAGGAATAAAACCATTTTCTTATA HBtGGCATTTGTCGTTTGCTTCATCAGAAATGTCCAGGAAAAAAATGGGATTATTGGTC ACTCCACCTCTCACACTGGCAAAATACTGACATTTAGCAGCTCTTATCTAGAAGTGACTT GGAACATAGAATAAAGGCATGAGTTCCTGAAGAATTCATTGAGTGTTTCCTGTAGAAATA GCTTTAGGAGATAGGGAGTTCTATCTGGGAGAACATATGAGTAACTCAAGAGTAAAAAGT ATAGTCTGTGTAAACTATAGAAGAAATGCTGGGCATGGTGGCGCGCCCCTGTAATCTCAG CTACTTGGAGGCTGAGACGGGAGGATTCCTTGAACCCAGGAGCCCAGGAGTTTTAGACCA GTCTGGGTAACATAGTGAGACCCTTTCTCACCTACTCTCACTGCATGCCCCCCAAAAATA TATATGTGCGCGCACGCGCGCGCACACACACATACACACACACACACACACACACACACA CAGAGGAAATTGTTAGAAAACACACAGAACTGAATGTAAATAGTATTAGGTGGGAATAAG AAGTAAAGGGATGGTAAGGAGGCTTGGAGGAGGAGTAAATTATCTGCTATGGGACATCAG CTC

[0048] FIG. 11 shows a SHP2 translated amino acid sequence (SEQ ID NO: 61). Alternating exons are underlined and non-underlined. Bold with italics indicate a residue overlap splice site.

[0049] Like reference symbols in the various drawings indicate like elements. DETAILED DESCRIPTION OF THE INVENTION

[0050] Protein/nucleic acid complexes or assemblies are difficult to manipulate due to their fragility and requirement for structural integrity (e.g., 3-dimensional conformation. Genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, transcription activator-like effector nucleases (TALENS), and others, have shown much potential in their ability to change the genetic code of cells. However, their activity is highly dependent on structural and conformational integrity.

[0051] Zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are examples of a class of gene editing tools. These chimeric nucleases are composed of programmable, sequence-specific DNA-binding 54modules linked to a nonspecific DNA cleavage domain. ZFNs and TALENs enable a broad range of genetic modifications by inducing DNA double-strand breaks that stimulate error-prone nonhomologous end joining or homology-directed repair at specific genomic locations (Gaj et al., 2013, Trends Biotechnol. 31(7):397-405).

[0052] Numerous publications describe the use of viruses, mRNA and plasmids to code for the Cas9 and/or gRNA and/or donor oligonucleotides (where relevant). Compared to these methods, the methods and systems described herein utilize a different strategy - delivery of the protein itself, complexed with the guide RNA. This process is fundamentally different, because it does not require the cell to translate/transcribe anything for the editing to work. For that reason, and because the protein/guide complex has a short half-life, the approach of the invention results in faster and more efficient editing with fewer off-target effects. Other approaches such as liposome mediated protein delivery, microiniection, and cell-penetrating peptides (CPP).

[0053] One example of liposome mediated protein delivery uses GFP fused to Cas-9, has also been used (Zuris et al., 2015, Nature Biotechnology 33:73- 80). The GFP is capable of complexing with conventional lipofection agents (e.g. lipofectamine) due to charge interactions and appears to mediate a gene editing response. The main advantages of the invention relative to this approach are: 1) does not require a fusion protein 2) does not require lipofection agents which can have toxicity, endosome escape problems, and issues/problems translating to primary cells.

[0054] Microinjection mediated complex delivery is characterized by extremely low throughput and can be difficult to implement for most mammalian cell types. The latter drawback is highlighted by the fact that the work was done with embiyos, i.e., cells that are much larger than a fibroblast or a T cell (cells which are desirable target cells for gene editing endeavors). By enabling high throughput and ttanslatability to smaller primary cells, e.g., fibroblasts, T cells, stem cells, the methods described herein have a big advantage.

[0055] A CPP-based strategy does not involve a complex. One example of such as strategy is described in Ramakrishna et al., 2014, Genome Res. 24(6):1020- 7. CPP mediated delivery of individual components is also associated with drawbacks. Conjugating a CPP to the guide and Cas9 requires extra modification that 55 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 may inhibit function, limit scalability. CPP mediated delivery is known to go through endocytosis and is inefficient or ineffective in many primary cells (particularly immune cells). Target cells and payload compositions

[0056] Any gene can be manipulated using the gene editing strategies described. Some target genes/proteins are particularly relevant in clinical disease and thus gene editing of such target genes/proteins is useful for therapy. Examples include C-C chemokine receptor type 5 (CCR5): prevent human immunodeficiency virus (HIV) infection; major histocompatibility complex class I (MHC-I): reduce graft vs. host disease; cluster of differentiation 1 (CD1): reduce graft vs. host disease; programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PDL-1), Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), interferon-regulatory factor (IRF) protein family, TLR protein family, pattern recognition receptors (PRRs): modulate immunity to enhance or dampen effector/antiviral responses; forkhead box P3 (FoxP3): eliminate Treg mediated tolerance; cluster of differentiation 80 (CD80), cluster of differentiation 86 (CD86) and other costimulatory molecules: knockout costimulation abilities to promote tolerance; T cell receptor (TCR), B-cell receptor (BCR): eliminate endogenous TCR or BCR to allow for engineering of T cells and B cells with desired specificity; oncogenes (e.g., Kras, Myc, Tp53): cancer therapy. In another example, targeting transcription factors is used to change cell fate, e.g., delete FoxP3 to remove Treg type function. Delete nuclear factor-kappa B (NF-kB), t-bet, Eomesodermin (Eomes), etc. to alter T cell differentiation.

[0057] A protein coding sequence for forkhead box P3 (FoxP3) is as follows:

[0058] ATGCCCAACCCCAGGCCTGGCAAGCCCTCGGCCCCTTCC TTGGCCCTTGGCCCATCCCCAGGAGCCTCGCCCAGCTGGAGGGCTGCACC CAAAGCCTCAGACCTGCTGGGGGCCCGGGGCCCAGGGGGAACCTTCCAG GGCCGAGATCTTCGAGGCGGGGCCCATGCCTCCTCTTCTTCCTTGAACCCC ATGCCACCATCGCAGCTGCAGCTGCCCACACTGCCCCTAGTCATGGTGGC ACCCTCCGGGGCACGGCTGGGCCCCTTGCCCCACTTACAGGCACTCCTCC AGGACAGGCCACATTTCATGCACCAGCTCTCAACGGTGGATGCCCACGCC CGGACCCCTGTGCTGCAGGTGCACCCCCTGGAGAGCCCAGCCATGATCAG CCTCACACCACCCACCACCGCCACTGGGGTCTTCTCCCTCAAGGCCCGGCC TGGCCTCCCACCTGGGATCAACGTGGCCAGCCTGGAATGGGTGTCCAGGG 56CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGCCGGCACTGCTCTGCACCTTCCCAAATCCCAGTGCACCCAGGAAGGAC AGCACCCTTTCGGCTGTGCCCCAGAGCTCCTACCCACTGCTGGCAAATGGT GTCTGCAAGTGGCCCGGATGTGAGAAGGTCTTCGAAGAGCCAGAGGACTT CCTCAAGCACTGCCAGGCGGACCATCTTCTGGATGAGAAGGGCAGGGCAC AATGTCTCCTCCAGAGAGAGATGGTACAGTCTCTGGAGCAGCAGCTGGTG CTGGAGAAGGAGAAGCTGAGTGCCATGCAGGCCCACCTGGCTGGGAAAA TGGCACTGACCAAGGCTTCATCTGTGGCATCATCCGACAAGGGCTCCTGCT GCATCGTAGCTGCTGGCAGCCAAGGCCCTGTCGTCCCAGCCTGGTCTGGC CCCCGGGAGGCCCCTGACAGCCTGTTTGCTGTCCGGAGGCACCTGTGGGG TAGCCATGGAAACAGCACATTCCCAGAGTTCCTCCACAACATGGACTACT TCAAGTTCCACAACATGCGACCCCCTTTCACCTACGCCACGCTCATCCGCT GGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAATGAGATCTAC CACTGGTTCACACGCATGTTTGCCTTCTTCAGAAACCATCCTGCCACCTGG AAGAACGCCATCCGCCACAACCTGAGTCTGCACAAGTGCTTTGTGCGGGT GGAGAGCGAGAAGGGGGCTGTGTGGACCGTGGATGAGCTGGAGTTCCGC AAGAAACGGAGCCAGAGGCCCAGCAGGTGTTCCAACCCTACACCTGGCCC CTGA (SEQ ID NO: 62)

[0059] Src homology region 2 domain-containing phosphatase-1 (SHP1) is also known as tyrosine-protein phosphatase non-receptor type 6 (PTPN6). A protein coding sequence for SHP1 is as follows:

[0060] ATGGTGAGGTGGTTTCACCGAGACCTCAGTGGGCTGGAT GCAGAGACCCTGCTCAAGGGCCGAGGTGTCCACGGTAGCTTCCTGGCTCG GCCCAGTCGCAAGAACCAGGGTGACTTCTCGCTCTCCGTCAGGGTGGGGG ATCAGGTGACCCATATTCGGATCCAGAACTCAGGGGATTTCTATGACCTGT ATGGAGGGGAGAAGTTTGCGACTCTGACAGAGCTGGTGGAGTACTACACT CAGCAGCAGGGTGTCCTGCAGGACCGCGACGGCACCATCATCCACCTCAA GTACCCGCTGAACTGCTCCGATCCCACTAGTGAGAGGTGGTACCATGGCC ACATGTCTGGCGGGCAGGCAGAGACGCTGCTGCAGGCCAAGGGCGAGCC CTGGACGTTTCTTGTGCGTGAGAGCCTCAGCCAGCCTGGAGACTTCGTGCT TTCTGTGCTCAGTGACCAGCCCAAGGCTGGCCCAGGCTCCCCGCTCAGGG TCACCCACATCAAGGTCATGTGCGAGGGTGGACGCTACACAGTGGGTGGT TTGGAGACCTTCGACAGCCTCACGGACCTGGTGGAGCATTTCAAGAAGAC GGGGATTGAGGAGGCCTCAGGCGCCTTTGTCTACCTGCGGCAGCCGTACT ATGCCACGAGGGTGAATGCGGCTGACATTGAGAACCGAGTGTTGGAACTG 57CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AACAAGAAGCAGGAGTCCGAGGATACAGCCAAGGCTGGCTTCTGGGAGG AGTTTGAGAGTTTGCAGAAGCAGGAGGTGAAGAACTTGCACCAGCGTCTG GAAGGGCAGCGGCCAGAGAACAAGGGCAAGAACCGCTACAAGAACATTC TCCCCTTTGACCACAGCCGAGTGATCCTGCAGGGACGGGACAGTAACATC CCCGGGTCCGACTACATCAATGCCAACTACATCAAGAACCAGCTGCTAGG CCCTGATGAGAACGCTAAGACCTACATCGCCAGCCAGGGTTGTCTGGAGG CCACGGTCAATGACTTCTGGCAGATGGCGTGGCAGGAGAACAGCCGTGTC ATCGTCATGACCACCCGAGAGGTGGAGAAAGGCCGGAACAAATGCGTCC CATACTGGCCCGAGGTGGGCATGCAGCGTGCTTATGGGCCCTACTCTGTG ACCAACTGCGGGGAGCATGACACAACCGAATACAAACTCCGTACCTTACA GGTCTCCCCGCTGGACAATGGAGACCTGATTCGGGAGATCTGGCATTACC AGTACCTGAGCTGGCCCGACCATGGGGTCCCCAGTGAGCCTGGGGGTGTC CTCAGCTTCCTGGACCAGATCAACCAGCGGCAGGAAAGTCTGCCTCACGC AGGGCCCATCATCGTGCACTGCAGCGCCGGCATCGGCCGCACAGGCACCA TCATTGTCATCGACATGCTCATGGAGAACATCTCCACCAAGGGCCTGGAC TGTGACATTGACATCCAGAAGACCATCCAGATGGTGCGGGCGCAGCGCTC GGGCATGGTGCAGACGGAGGCGCAGTACAAGTTCATCTACGTGGCCATCG CCCAGTTCATTGAAACCACTAAGAAGAAGCTGGAGGTCCTGCAGTCGCAG AAGGGCCAGGAGTCGGAGTACGGGAACATCACCTATCCCCCAGCCATGA AGAATGCCCATGCCAAGGCCTCCCGCACCTCGTCCAAGAGCTTGGAGTCT AGTGCAGGGACCGTGGCTGCGTCACCTGTGAGACGGGGTGGCCAGAGGG GACTGCCAGTGCCGGGTCCCCCTGTGCTGTCTCCTGACCTGCACCAACTGC CTGTACTTGCCCCCCTGCACCCGGCTGCAGACACAAGGAGGATGTGTATG AGAACCTGCACACTAAGAACAAGAGGGAGGAGAAAGTGA (SEQ ID NO: 63)

[0061] Src homology region 2 domain-containing phosphatase-1 (SHP2) is also known as tyrosine-protein phosphatase non-receptor type 11 (PTPN11). A protein coding sequence for SHP2 is as follows:

[0062] ATGACATCGCGGAGATGGTTTCACCCAAATATCACTGGT GTGGAGGCAGAAAACCTACTGTTGACAAGAGGAGTTGATGGCAGTTTTTT GGCAAGGCCTAGTAAAAGTAACCCTGGAGACTTCACACTTTCCGTTAGAA GAAATGGAGCTGTCACCCACATCAAGATTCAGAACACTGGTGATTACTAT GACCTGTATGGAGGGGAGAAATTTGCCACTTTGGCTGAGTTGGTCCAGTA TTACATGGAACATCACGGGCAATTAAAAGAGAAGAATGGAGATGTCATTG 58CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGCTTAAATATCCTCTGAACTGTGCAGATCCTACCTCTGAAAGGTGGTTTC ATGGACATCTCTCTGGGAAAGAAGCAGAGAAATTATTAACTGAAAAAGG AAAACATGGTAGTTTTCTTGTACGAGAGAGCCAGAGCCACCCTGGAGATT TTGTTCTTTCTGTGCGCACTGGTGATGACAAAGGGGAGAGCAATGACGGC AAGTCTAAAGTGACCCATGTTATGATTCGCTGTCAGGAACTGAAATACGA CGTTGGTGGAGGAGAACGGTTTGATTCTTTGACAGATCTTGTGGAACATTA TAAGAAGAATCCTATGGTGGAAACATTGGGTACAGTACTACAACTCAAGC AGCCCCTTAACACGACTCGTATAAATGCTGCTGAAATAGAAAGCAGAGTT CGAGAACTAAGCAAATTAGCTGAGACCACAGATAAAGTCAAACAAGGCT TTTGGGAAGAATTTGAGACACTACAACAACAGGAGTGCAAACTTCTCTAC AGCCGAAAAGAGGGTCAAAGGCAAGAAAACAAAAACAAAAATAGATATA AAAACATCCTGCCCTTTGATCATACCAGGGTTGTCCTACACGATGGTGATC CCAATGAGCCTGTTTCAGATTACATCAATGCAAATATCATCATGCCTGAAT TTGAAACCAAGTGCAACAATTCAAAGCCCAAAAAGAGTTACATTGCCACA CAAGGCTGCCTGCAAAACACGGTGAATGACTTTTGGCGGATGGTGTTCCA AGAAAACTCCCGAGTGATTGTCATGACAACGAAAGAAGTGGAGAGAGGA AAGAGTAAATGTGTCAAATACTGGCCTGATGAGTATGCTCTAAAAGAATA TGGCGTCATGCGTGTTAGGAACGTCAAAGAAAGCGCCGCTCATGACTATA CGCTAAGAGAACTTAAACTTTCAAAGGTTGGACAAGGGAATACGGAGAG AACGGTCTGGCAATACCACTTTCGGACCTGGCCGGACCACGGCGTGCCCA GCGACCCTGGGGGCGTGCTGGACTTCCTGGAGGAGGTGCACCATAAGCAG GAGAGCATCATGGATGCAGGGCCGGTCGTGGTGCACTGCAGTGCTGGAAT TGGCCGGACAGGGACGTTCATTGTGATTGATATTCTTATTGACATCATCAG AGAGAAAGGTGTTGACTGCGATATTGACGTTCCCAAAACCATCCAGATGG TGCGGTCTCAGAGGTCAGGGATGGTCCAGACAGAAGCACAGTACCGATTT ATCTATATGGCGGTCCAGCATTATATTGAAACACTACAGCGCAGGATTGA AGAAGAGCAGAAAAGCAAGAGGAAAGGGCACGAATATACAAATATTAAG TATTCTCTAGCGGACCAGACGAGTGGAGATCAGAGCCCTCTCCCGCCTTGT ACTCCAACGCCACCCTGTGCAGAAATGAGAGAAGACAGTGCTAGAGTCTA TGAAAACGTGGGCCTGATGCAACAGCAGAAAAGTTTCAGATGA (SEQ ID NO: 64)

[0063] Other targets include areas of the genome that can have a plasmid or donor DNA inserted into them so that the target cell can express a new gene, e.g. a 59CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 recombinant. TCR, a recombinant BCR, Chimerica Antigen Receptor, fluorescent protein, reprogramming factors.

[0064] In some embodiments, a genomic sequence is edited in a coding region. In certain embodiments, a genomic sequence is edited in a non-coding region.

[0065] In various embodiments relating to FoxP3, a genetic region upstream of FoxP3 may be edited. In such embodiments a region where a transcriptional repressor of Foxp3 might bind is edited. For example a site about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 0.5-2.5, or 0.5-5kb upstream of the FoxP3 transcriptional start site may be edited. Treating Subjects

[0066] Aspects of the present invention relate to editing the genomes of a plurality of a subject’s cells. In various embodiments, cells are removed from a subject, receive a gene-editing complex using a method of the present subject matter, and then are reintroduced back into the subject. For example, mutant cells may be produced in a process involving delivery of a gene-editing complex as described herein. The mutant cells may be heterozygous or homozygous for a mutated allele a gene involved in a disease. In certain embodiments, the mutant cells are null for the gene involved in a disease.

[0067] Cells, such as stem cells (e.g. hematopoietic stem cells) from bone marrow, or circulating immune cells in whole blood, may be treated using methods and devices described herein. Cells may be genetically modified to reduce the expression of a receptor for a pathogen (such as a viral or bacterial pathogen) or a toxin (such as a microbial pathogen toxin). Since a gene-editing protein complex or components thereof may be directly introduced into target cells without the need for expression, no transgene delivery is necessary. This approach has important advantages over traditional gene-therapy approaches, which suffer from aberrant expression, insertion, and silencing, as well as variable delivery of transgene copy number.

[0068] In one embodiment, a gene-editing complex that targets the C-C chemokine receptor type 5 (CCR5) gene is introduced into a blood (such as a CD4+ T cell) or bone marrow cell (such as a hematopoietic stem cell) of a subject who is infected with human immunodeficiency virus (HIV). The gene-editing complex may be designed to mutate the CCR5 gene such that cells receiving the gene-editing complex no longer express CCR5 or express CCR5 at a reduced level. In one 60CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 example, hematopoietic stem cells expressing a version of CCR5 that binds HIV (or that produce progeny that express the CCR5) are removed from the subject, modified to no longer express a version of CCR5 that binds HIV, and then are transplanted into the subject. In another example, CCR5-expressing CD4+ T cells of the subject receive a gene-editing complex using methods and devices described herein such that the CD4+ T cells no longer express a version of CCR5 that binds HIV. The modified CD4+ T cells are then returned into the subject. Such treatment of the CD4+ T cell may be performed in whole blood from the subject. In these and other embodiments, bone marrow cells or blood cells are modified to no longer express a version of C-XC chemokine receptor type 4 (CXCR4) to which HIV binds. Similarly, cells of a subject may be modified to have reduced CCR5 expression to treat or prevent an infection associates with Yersinia pestis (bubonic plague) or Variola major (small pox).

[0069] Subjects, other than humans, containing cells modified by methods and devices disclosed herein are also provided. Such subjects include non-human vertebrate, amphibian, mammalian, and primate subjects. Non-limiting examples include Danio sp., Fugu sp., Xenopus sp., Mus sp., Rattus sp., and others. Introducing Gene-Editing Proteins and Complexes into Cells

[0070] The delivery of pre-formed protein complexes allows for the study of cellular processes without genetic modification of the cells being studied. The present subject matter is useful for delivering protein complexes and gene editing complexes to cells, including CRISPR.

[0071] The advantages of delivering protein complexes using the methods and devices described herein include the controlled and temporary introduction of test agents for the study of cell and protein complex function. Since transgene expression and cellular assembly of complex components is not needed, the timing and ratios (protein:RNA) of complex function can be controlled. Additionally, the transient nature of delivery enables the observation of changes due to temporary function, rather than prolonged expression which may result in off-target or secondary effects. From an in vivo homing perspective and a gene expression format, microfluidic delivery has far fewer side effects (1O-fold) on treated cells rather than electroporation.

[0072] For example, microfluidic delivery results in fewer aberrant and non-specific gene expression changes compared to electroporation. Additionally, the 61CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 structural and functional integrity of microfluidically squeezed cells is preserved compared to electroporation-mediated cargo delivery. As an example, an increased number of T cells exposed to microfluidic delivery ex vivo (and then introduced into a subject in vivo) home to lymph nodes compared to T cells that have undergone electroporation. Cells (e.g., T cells) treated by electroporation and then administered into a subject are more likely to be cleared from the subject compared to cells treated by microfluidic delivery. Such clearance is related to altered/aberrant gene expression following electroporation that marks such cells for destruction or clearance by the body. Target cells and Payload Compositions

[0073] Any eukaryotic, e.g., mammalian such as human, cell can be processed using the microfluidic device to alter the cell membrane for introduction of protein/nucleic acid complexes or assemblies into the cytosol of the target cell. Exemplary target cells include Lymphocytes/Immune cells: DCs, B cells, T cells, Natural killer cells (NK cells), neutrophils, basophils, eosinophils, innate lymphoid cells, monocytes, macrophages, hematopoietic stem cells, common lymphoid progenitor cells; Stem cells: Embryonic, mesenchymal, induced pluripotent; Other primary cells: Fibroblasts, hepatocytes, cardiomyocytes, neurons, epithelial, epidermal, endothelial, pancreatic islet cells; as well as Cell lines, e.g., cell lines for disease studies: T cell clones, Jurkat cells, HeLa cells, Human Embryonic Kidney 293 (HEK293) cells, U2OS cells, Chinese Hamster Ovary (CHO) cells. Prokaryotic cells can also be processed. The dimensions of the constriction of the device are tailored depending on the cell type to be processed.

[0074] In some embodiments, the cell is a prokaryotic cell. In other embodiments, the cell is a eukaryotic cell. Non-limiting examples of eukaryotic cells include protozoan, algal, fungi, yeast, plant, animal, vertebrate, invertebrate, arthropod, mammalian, rodent, primate, and human cells. The cell may be a cell, e.g., of a unicellular organism or a multicellular organism. The cell may be, e.g., a primary eukaryotic cell or an immortalized eukaryotic cell. In some embodiments, the cell is a cancer cell. In certain embodiments, the cell is other than a human cell. For example, a composition for treating cancer and/or a method of treating cancer or preparing a composition for treating cancer, comprises treating immune cells using the gene¬ editing methods described herein to reduce the expression/production of immune 62CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 suppressing signals from tumor cells. An example includes reduction or SHP-2 knockout for increasing immune activity towards tumors.

[0075] In various embodiments, a cell may be in a mixture of two or more cell types or a plurality of cells may be a mixture of two or more cell types. A mixture of cell types may be a co-culture of multiple cell types (such as two or more of those disclosed herein) or a mixture of cell types that naturally occur together, such as in whole blood.

[0076] In some embodiments, the cell is a peripheral blood mononuclear cell. In various embodiments, the cell suspension comprises a purified cell population. In certain embodiments, the cell is a primary cell or a cell line cell.

[0077] In some embodiments, the cell is a blood cell. In some embodiments, the blood cell is an immune cell. In some embodiments, the immune cell is a lymphocyte. In some embodiments, the immune cell is a T cell, B cell, natural killer (NK) cell, dendritic cell (DC), Natural killer T (NKT) cell, mast cell, monocyte, macrophage, basophil, eosinophil, or neutrophil. In some embodiments, the immune cell is an adaptive immune cell such as a T cell and B cell. In some embodiments, the immune cell is an innate immune cell. Exemplary innate immune cells include innate lymphoid cells (ILCs; ILC1, ILC2, ILC3), basophils, eosinophils, mast cells, NK cells, neutrophils, and monocytes. In some embodiments, the immune cell is a memory cell. In some embodiments, the immune cell is a primary human T cell. In some embodiments, the cell is a mouse, dog, cat, horse, rat, goat, monkey, or rabbit cell.

[0078] In some embodiments, the cell is a human cell. In some embodiments, the cell suspension comprises a cell other than a human cell or a nonmammalian cell. In some embodiments, the cell is a chicken, frog, insect, or nematode cell.

[0079] Any physiologically-compatible or cell-compatible buffer system can be used as a solution to bathe/incubate the cells and process the cells through the device. For example, phosphate buffered saline (PBS), Opti-MEM®, Roswell Park Memorial Institute (RPMI), Dulbecco's Modified Eagle's Medium (DMEM). A reduced serum or serum-free media or buffer composition is preferable. The buffer or medium is chosen based to maintain and preserve the health or viability of the target cell and/or the effect on gene expression. For example, in some cases the presence of calcium in the buffer is desirable to promote or support mRNA expression. 63[0080] Payload compositions include a protein-nucleic acid complex or assembly. Exemplary complexes include components or modules of a gene editing system as described above, e.g., nuclease/guide nucleic acid combination or assembly. For example, gRNA:Cas9 molar ratio ranges from 1:100,000 to 100,000:1, e.g., a preferred range, 1:10 to 10:1, e.g., 1:1 or 1:2, 2:1. Complex concentration in the buffer to facilitate delivery (molar concentrations) typically ranges from 1OOmM to InM, e.g., IOuM to lOOnM. Complexes can be mixed with cells before going through constriction or afterwards. Microfluidic Delivery of Gene Editing Complexes

[0081] In order to effect gene editing manipulations, Cas protein (such as Cas9 protein), guide RNA and donor DNA can be delivered to a cell through mechanical deformation using, for example, a microfluidic platform (e.g., as described in U.S. Application Publication No. 20140287509, filed April 17, 2014; PCT International Application No. PCT/US2014/051343 filed August 15, 2014; PCT International Application No. PCT/US2015/060689 filed November 13, 2015; and PCT International Application No. PCT/US2015/058489 filed October 30, 2015).

[0082] FIGS. 1-2 illustrate an example microfluidic system that can be used for the delivery of genome editing protein, RNA, and DNA. The microfluidic system 5 includes a channel 10 defining a tubular lumen. The microfluidic channel 10 includes a constriction 15 that is preferably configured such that only a single target cell 20 can pass through the constriction 15 at one time. Preferably, the cells 20 pass through the channel 10 suspended in a solution buffer 25 that also includes delivery materials 30, although the delivery materials can be added to the solution buffer 25 after the cells 20 pass through the constriction 15. As the cell 20 approaches and passes through the constriction 15, the constriction 15 applies pressure (e.g., mechanical compression) to the cell 20, squeezing the cell 20 (e.g., shown as cell 20i). The pressure applied to the cell by the constriction 15 causes perturbations (e.g., holes) in the cell membrane (e.g., cell 20j). Once the cell passes through the constriction 15, the cell 20 begins to uptake the material in the solution buffer 25 through the holes, including the delivery material 30 (e.g., cell 2O3). The cell membrane recovers over time, and at least a portion of the delivery material 30 preferably remains trapped inside the cell. 64 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[0083] In some embodiments, the device comprises a constriction length of about 5 pm to about 50 pm or any length or range of lengths therebetween. For example, the constriction length ranges from about 5pm to about 40pm, about 5pm to about 30pm, about 5pm to about 20pm, or about 5pm to about 10pm. In some embodiments, the constriction length ranges from about 10pm to about 50pm, about 20pm to about 50pm, about 30pm to about 50pm, or about 40pm to about 50pm. In some embodiments, the constriction depth ranges from about 2um to about 200um or any depth or range of depths there between. For example, the constriction depth ranges from about 2pm to about 150pm, about 2pm to about 100pm, about 2pm to about 50pm, about 2pm to about 25pm, about 2pm to about 15pm, or about 2pm to about 10pm. In some embodiments, the constriction depth ranges from about 10pm to about 200pm, about 25pm to about 200pm, about 50pm to about 200pm, about 100pm to about 200pm, or about 150pm to about 200pm. In some embodiments, the angle of the entrance or exit portion of the constriction ranges from about 0 degrees to about 90 degrees or any angle or range of angles therebetween. For example, the angle is about 5, about 10, about 15, about 20, about 30, about 40, about 50, about 60, about 70, about 80, or about 90 degrees or more. In some embodiments, the pressure ranges from about 50psi to about 200psi or any pressure or range of pressures there between. For example, the pressure ranges from about 50psi to about 150psi, about 50psi to about 125psi, about 50psi to about lOOpsi, or about 50psi to about 75psi. In some embodiments, the pressure ranges from about 75psi to about 200psi, about lOOpsi to about 200psi, about 125psi to about 200psi, about 150psi to about 200psi, or about 175psi to about 200psi. In some embodiments, the device comprises a constriction width of between about 2pm and about 10pm or any width or range of widths therebetween. For example, the constriction width can be any one of about 3pm, about 4pm, about 5pm, about 6pm, or about 7pm.

[0084] The data described below was generated using the following materials and methods. Complexes were made as follows: Mix lOpl of Img/ml nuclear localization signal (NLS) tagged Cas9 protein with 5pl of Img/ml guide RNA. Incubate on ice for 20 min to allow complexes to form. For delivery, target cells are suspended at 10 million cells/ml in serum-free media. Cells and Cas9-gRNA complexes are mixed immediately before device treatment such that complex concentration is ~0.15mg/ml. Cells are treated by the device using pressure, temperature, chip design and buffer conditions specific to the target cell type. For 65example, for primary human T cells, pressure is approximately lOOpsi, on ice, through a 30pm length, 4pm width constriction. After a 2 min incubation post-treatment, cells are diluted in media and washed to remove undelivered complexes. Cells are then cultured to allow for gene editing to occur (e.g., 1, 2, 5, 12, 24 hours or more (for nonclinical applications, timeframe depends on assay readout, e.g., 24 hours or later). For clinical use, e.g., for patient therapy, the cells could be injected back into patient immediately after device treatment. Optionally, the cells are incubated in vitro for a time (e.g., 1, 2, 5, 12, 24 hours or more) prior to injecting the cells into a patient recipient. Temperatures, concentrations, iterations of the molecules vary depending on the target cell type.

[0085] FIG. 3 is a series of flow cytometry plots and a bar graph of the recombination efficiency for K562 reporter cells (American Type Culture Collection (ATCC)® CCL-243™, bone marrow-derived cells derived from patient with chronic myelogenous leukemia; lymphoblast morphology) that had genetic editing material delivered to cell cytoplasm using the microtluidic device illustrated in FIGS. 1-2. At top are flow cytometry plots of K562 reporter cells that had a protein Cas9, site¬ specific gRNA, and donor oligonucleotide delivered. A CRISPR complex is ~150kDa. These reporter cells had an mCherry gene and thus would normally appear in QI of the plots. If the site-specific DNA cleavage and insertion of donor oligonucleotide is successful it would lead to expression of green fluorescent protein (GFP), i.e., cells would appear in Q2. At bottom is a quantification of recombination efficiency based on flow cytometry for multiple device conditions as compared to endocytosis (inlet) and untreated (NC) controls. Delivery' of Cas9 protein, guide RNA and donor DNA by cell squeezing led to successful changes in the genome of reporter cell lines. These data indicate that delivery of gene editing components (in the form of a complex or assembly) by mechanical cell disruption leads to effective changes in the genome.

[0086] Delivery of TALEN proteins or mRNA, zinc finger nucleases, mega nucleases, Cre recombinase or any other enzyme capable of cleaving DNA can also be delivered to the cytoplasm of a cell by mechanical disruption of the cell membrane. An exemplary TALEN genome-editing system, including exemplary' TALEN proteins, is described in Ding et ah, (2013) Cell Stem Cell, 12, 238-251. Ding et al., (2013) Cell Stem Cell, 12, 238-251 describes non-limiting examples of generic TALEN amino 66 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 acid sequences to recognize 15 base pair sequences. Non-limiting examples of generic TALEN amino acid sequences are: 1 - C’W ' sSLidiKL £ineI mx>su CAnyiiTKAnnnnK:AAKKe?>£S>^ QLTS.LNSKTNCRriAVLSVEELUY^^^^^ (SEQ ID NO: 65) x X- H- .>:. .. -.— -... .... - X„— x.—1.—... X...X..... .....1 ....... ' xx A- 'x;' UJQAhGLTREw7VR':ASXSKJGKQX££7 VORLi.tXGAQ^ LGQAHGLTeGWYAiRSKX'XiKyAL^^^ X V ' " ' XX x ' XX A "V, < x V, 'V XX . XX " 'x\ >,b . ? xX x>X -C' x’X >X - . >x 1 j x s''t-’ ^^EX-Xl .,'A X-X-— ' -'•••xV •. _. E 'x.^a/t-i..- GyiVDTKAYSGG»3LPn>QAD£?«BTv'EEK<ZrRDKHLBPNEWKy"PS.3V”EFKFLWSG^ QLTSLJiHITRCRGAVLSvKELLiqGEtnKAGTiAiAEVRRKFNin^ (SEQ ID NO: 66)

[0087] In SEQ ID NOS: 65 and 66, to recognize C: XX = HD; to recognize T: XX=NG; to recognize A: XX = NI; and to recognize G: XX = NN except in the last position where XX = NK. Underline indicates N-term and C-term of TAL effector.

[0088] Although a few variations have been described in detail above, other modifications or additions are possible. For example, genetic editing material can include TALEN proteins, TALEN mRNA, zinc finger nucleases, mega nucleases, Cre recombinase or any other enzyme capable of cleaving DNA delivered to the cytosol by mechanical disruption of the cell membrane. 67Delivery of RNA and Cas9 in Complex Form

[0089] The results achieved were surprising in view of numerous factors that could potentially have impeded successful gene editing by microfluidic delivery of the gene complexes. For example, the Cas9-gRNA complex may have caused a Toll-like receptor (TLR) mediated or other PRR (pattern recognition receptor) mediated response that would have inhibited gene editing function and/or survival but this potential problem was not observed. Since the complex is not guaranteed to be stable once it enters the cytoplasm, it could have been degraded and rendered non¬ functional, but surprisingly, the delivered complexes were still able to edit.

[0090] The integrity of the gene editing complex was preserved using microfluidic based, cell-squeezing delivery to the cell. The complex does not have the same physical/chemical properties as a gRNA alone or protein alone and thus it was uncertain if the delivery process would behave the same in the context of delivering a complex vs. its individual components. Complexes are larger and less stable than their constituents. Complexes may fall apart due to, e.g., shear forces. Additionally, complexes may not survive membrane transit or in the cytosol because some other elements may break the complexes up before they are functional or have an opportunity to act on cellular targets. Complexes also have a different charge distribution which may affect the ability of a complex to be delivered. Shape and thus transport properties can also change compared to complex constituents. The delivery methods successfully preserved the structural and functional integrity of the complexes.

[0091] The shear forces involved with the delivery process could potentially have disrupted the Protein/gRNA complex and rendered it non-functional but surprisingly the delivery system was effective to introduce the complexes into the cell and the gene editing still worked. Il was also not obvious that the complex would still have the appropriate nuclear localization behavior as compared to an uncomplexed Cas (such as Cas9) protein alone with NLS; however, the behavior and function was preserved throughout the process as demonstrated by the gene expression results described above.

[0092] The CRISPR-Cas system is known in the art. Non-limiting aspects of this system are described in U.S. Patent No. 8,697,359, issued April 15, 2014. 68 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[0093] Non-limiting examples of Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments the CRISPR enzyme is Cas9, and may be Cas9 from S. pyogenes or S. pneumoniae. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. In aspects of the invention, nickases may be used for genome editing via homologous recombination.

[0094] Non-limiting examples of Cas9 amino acid and cDNA sequences are provided below.

[0095] The amino acid sequence of a Streptococcus pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2. This amino acid sequence is:

[0096] MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKV DDSFFHRLEESFLVEEDKKHERHP1FGN1VDEVAYHEKYPT1YHLRKKLVDST DKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEEN PINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFK 69CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 SNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGY AGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPH QIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFT VYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFK KIECFDSVEISGVEDRFNASLGTYHDLLK11KDKDFLDNEENED1LEDIVLTLTL FEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGK TILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGS PAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERM KR1EEGIKELGSQ1LKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS DYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLN AVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNI MNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIV KKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVA KVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNE QKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRID LSQLGGD (SEQ ID NO: 1)

[0097] SEQ ID NO: 1 may be encoded by the following nucleotide sequence found in the European Nucleotide Archive under accession number AAK33936.2:

[0098] ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACA AATAGCGTCGGATGGGCGGTGATCACTGATGAATATAAGGTTCCGTCTAA AAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATC TTATAGGGGCTCTTTTATTTGACAGTGGAGAGACAGCGGAAGCGACTCGT CTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTG TTATCTACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTT CTTTCATCGACTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATG AACGTCATCCTATTTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGA AATATCCAACTATCTATCATCTGCGAAAAAAATTGGTAGATTCTACTGATA 70CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAGCGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTC GTGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGG ACAAACTATTTATCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAA AACCCTATTAACGCAAGTGGAGTAGATGCTAAAGCGATTCTTTCTGCACG ATTGAGTAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTG AGAAGAAAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGTTTGA CCCCTAATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGC TTTCAAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTG GAGATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTA TTTTACTTTCAGATATCCTAAGAGTAAATACTGAAATAACTAAGGCTCCCC TATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAGACTTGACTC TTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATC TTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGC TAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGG ATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGGT GAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAAAA GACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTAT GTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAA GTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATAAAG GTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAAAATC TTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAGTATTTTA CGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAAGGAATGCGA AAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTC TTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGATTATTT CAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTGAAGATA GATTTAATGCTTCATTAGGTACCTACCATGATTTGCTAAAAATTATTAAAG ATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAGGATATT GTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACT TAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAAC GTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGATTAATGGTA TTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGAAATCAGAT GGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGTTTGACA TTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGGCGATAGTTT 71CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ACATGAACATATTGCAAATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTA TTTTACAGACTGTAAAAGTTGTTGATGAATTGGTCAAAGTAATGGGGCGG CATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCAGACAAC TCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCGAAGAA GGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTTGAAAA TACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAG AGACATGTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTGATTATG ATGTCGATCACATTGTTCCACAAAGTTTCCTTAAAGACGATTCAATAGACA ATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAAATCGGATAACGTT CCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGACAACTTCT AAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACGAAAGCTG AACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAA TTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAATTTTGGATAG TCGCATGAATACTAAATACGATGAAAATGATAAACTTATTCGAGAGGTTA AAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAAAGATTTCC AATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGCGT ATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAACTTG AATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGA TTGCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAAAATATTTCTTT TACTCTAATATCATGAACTTCTTCAAAACAGAAATTACACTTGCAAATGGA GAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAAT TGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCA TGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATTC TCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCG TAAAAAAGACTGGGATCCAAAAAAATATGGTGGTTTTGATAGTCCAACGG TAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGGAAATCGAAG AAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAATTATGGAAAGAAG TTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAGCTAAAGGATATAAGG AAGTTAAAAAAGACTTAATCATTAAACTACCTAAATATAGTCTTTTTGAGT TAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGGAGAATTACAAAA AGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATTTTTTATATTTAGC TAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAAAA CAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCA AATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAA 72CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGTTCTTAGTGCATATAACAAACATAGAGACAAACCAATACGTGAACAAG CAGAAAATATTATTCATTTATTTACGTTGACGAATCTTGGAGCTCCCGCTG cttttaaatattttgatacaacaattgatcgtaaacgatatacgtctacaa AAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATG AAACACGCATTGATTTGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO: 2)

[0099] The amino acid sequence of a Streptococcus thermophilus Cas9 protein may be found in the UniProt database under accession number Q03JI6.1. See also, Sapranauskas et al., (2011) Nucleic Acids Res. 39:9275-9282. This amino acid sequence is:

[00100] MTKPYSIGLDIGTNSVGWAVTTDNYKVPSKKMKVLGNTSK KYIKKNLLGVLLFDSG1TAEGRRLKRTARRRYTRRRNRILYLQEIFSTEMATLD DAFFQRLDDSFLVPDDKRDSKYPIFGNLVEEKAYHDEFPTIYHLRKYLADSTK KADLRLVYLALAHMIKYRGHFLIEGEFNSKNNDIQKNFQDFLDTYNAIFESDL SLENSKQLEEIVKDKISKLEKKDRILKLFPGEKNSGIFSEFLKLIVGNQADFRKC FNLDEKASLHFSKESYDEDLETLLGYIGDDYSDVFLKAKKLYDAILLSGFLTV TDNETEAPLSSAMIKRYNEHKEDLALLKEYIRNISLKTYNEVFKDDTKNGYA GYIDGKTNQEDFYVYLKKLLAEFEGADYFLEKIDREDFLRKQRTFDNGSIPYQ IHLQEMRAILDKQAKFYPFLAKNKERIEKILTFRIPYYVGPLARGNSDFAWSIR KRNEKITPWNFEDVIDKESSAEAFINRMTSFDLYLPEEKVLPKHSLLYETFNVY NELTKVRFIAESMRDYQFLDSKQKKDIVRLYFKDKRKVTDKDIIEYLHAIYGY DGIELKGIEKQFNSSLSTYHDLLNIINDKEFLDDSSNEAIIEEIIHTLTIFEDREMI KQRLSKFENIFDKSVLKKLSRRHYTGWGKLSAKLINGIRDEKSGNTILDYLID DGISNRNFMQLIHDDALSFKKKIQKAQIIGDEDKGNIKEVVKSLPGSPAIKKGI LQSIKIVDELVKVMGGRKPESIVVEMARENQYTNQGKSNSQQRLKRLEKSLK ELGSKILKENIPAKLSKIDNNALQNDRLYLYYLQNGKDMYTGDDLDIDRLSN YDIDHIIPQAFLKDNSIDNKVLVSSASNRGKSDDVPSLEVVKKRKTFWYQLLK SKLISQRKFDNLTKAERGGLSPEDKAGFIQRQLVETRQITKHVARLLDEKFNN KKDENNRAVRTVK11TLKSTLVSQFRKDFELYKVREINDFHHAHDAYLNAVV ASALLKKYPKLEPEFVYGDYPKYNSFRERKSATEKVYFYSNIMNIFKKSISLA DGRVIERPLIEVNEETGESVWNKESDLATVRRVLSYPQVNVVKKVEEQNHGL DRGKPKGLFNANLSSKPKPNSNENLVGAKEYLDPKKYGGYAGISNSFTVLVK GTIEKGAKKKITNVLEFQG1SILDR1NYRKDKLNFLLEKGYKDIEL11ELPKYSLF ELSDGSRRMLASILSTNNKRGEIHKGNQIFLSQKFVKLLYHAKRISNTINENHR KYVENHKKEFEELFYYILEFNENYVGAKKNGKLLNSAFQSWQNHSIDELCSS 73CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 FIGPTGSERKGLFELTSRGSAADFEFLGVKIPRYRDYTPSSLLKDATLIHQSVT GLYETRIDLAKLGEG (SEQ ID NO: 3)

[00101] SEQ ID NO: 3 may be encoded by the following nucleotide sequence found in the European Nucleotide Archive under accession number ABJ66636.1:

[00102] ATGACTAAGCCATACTCAATTGGACTTGATATTGGAACG AATAGTGTTGGATGGGCTGTAACAACTGATAATTACAAGGTTCCGTCTAA AAAAATGAAAGTCTTAGGAAATACGAGTAAAAAGTATATCAAAAAGAAC CTGTTAGGTGTATTACTCTTTGACTCTGGAATCACAGCAGAAGGAAGAAG ATTGAAGCGTACTGCAAGAAGACGTTATACTAGACGCCGTAATCGTATCC TTTATTTGCAGGAAATTTTTAGCACAGAGATGGCTACATTAGATGATGCTT TCTTTCAAAGACTTGACGATTCGTTTTTAGTTCCTGATGATAAACGTGATA GTAAGTATCCGATATTTGGAAACTTAGTAGAAGAAAAAGCCTATCATGAT GAATTTCCAACTATCTATCATTTAAGGAAATATTTAGCAGATAGTACTAAA AAAGCAGATTTGCGTCTAGTTTATCTTGCATTGGCTCATATGATTAAATAT AGAGGTCACTTCTTAATTGAAGGAGAGTTTAATTCAAAAAATAATGATAT TCAGAAGAATTTTCAAGACTTTTTGGACACTTATAATGCTATTTTTGAATC GGATTTATCACTTGAGAATAGTAAACAACTTGAGGAAATTGTTAAAGATA AGATTAGTAAATTAGAAAAGAAAGATCGTATTTTAAAACTCTTCCCTGGG GAGAAGAATTCGGGGATTTTTTCAGAGTTTCTAAAGTTGATTGTAGGAAA TCAAGCTGATTTTAGGAAATGTTTTAATTTAGACGAAAAAGCCTCCTTACA TTTTTCCAAAGAAAGCTATGATGAAGATTTAGAGACTTTGTTAGGTTATAT TGGAGATGATTACAGTGATGTCTTTCTCAAAGCAAAGAAACTTTATGATG CTATTCTTTTATCGGGTTTTCTGACTGTAACTGATAATGAGACAGAAGCAC CTCTCTCTTCTGCTATGATAAAGCGATATAATGAACACAAAGAAGATTTA GCGTTACTAAAGGAATATATAAGAAATATTTCACTAAAAACGTATAATGA AGTATTTAAAGATGACACCAAAAATGGTTATGCTGGTTATATTGATGGAA AAACAAATCAGGAAGATTTCTACGTATATCTAAAAAAACTATTGGCTGAA TTTGAAGGTGCGGATTATTTTCTTGAAAAAATTGATCGAGAAGATTTTTTG AGAAAGCAACGTACATTTGACAATGGTTCGATACCATATCAGATTCATCTT CAAGAAATGAGAGCAATTCTTGATAAGCAAGCTAAATTTTATCCTTTCTTG GCTAAAAATAAAGAAAGAATCGAGAAGATTTTAACCTTCCGAATTCCTTA TTATGTAGGTCCACTTGCGAGAGGGAATAGTGATTTTGCCTGGTCAATAA GAAAACGAAATGAAAAAATTACACCTTGGAATTTTGAGGACGTTATTGAC 74CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAAGAATCTTCGGCAGAGGCCTTCATTAATCGAATGACTAGTTTTGATTTG TATTTGCCAGAAGAGAAGGTACTTCCAAAGCATAGTCTCTTATACGAAAC TTTTAATGTATATAATGAATTAACAAAAGTTAGATTTATTGCCGAAAGTAT GAGAGATTATCAATTTTTAGATAGTAAGCAGAAGAAAGATATTGTTAGAC TTTATTTTAAAGATAAAAGGAAAGTTACTGATAAGGATATTATTGAATATT TACATGCAATTTATGGGTATGATGGAATTGAATTAAAAGGCATAGAGAAA CAGTTTAATTCTAGTTTATCTACTTATCACGATCTTTTAAATATTATTAATG ATAAAGAGTTTTTGGATGATAGTTCAAATGAAGCGATTATCGAAGAAATT ATCCATACTTTGACAATTTTTGAAGATAGAGAGATGATAAAACAACGTCT TTCAAAATTTGAGAATATATTCGATAAATCCGTTTTGAAAAAGTTATCTCG TAGACATTACACTGGCTGGGGTAAGTTATCTGCTAAGCTTATTAATGGTAT TCGAGATGAAAAATCTGGTAATACTATTCTTGATTACTTAATTGATGATGG TATTTCTAACCGTAATTTCATGCAACTTATTCACGATGATGCTCTTTCTTTT AAAAAGAAGATACAGAAAGCACAAATTATTGGTGACGAAGATAAAGGTA ATATTAAAGAGGTCGTTAAGTCTTTGCCAGGTAGTCCTGCGATTAAAAAA GGTATTTTACAAAGCATAAAAATTGTAGATGAATTGGTCAAAGTAATGGG AGGAAGAAAACCCGAGTCAATTGTTGTTGAGATGGCTCGTGAAAATCAAT ATACCAATCAAGGTAAGTCTAATTCCCAACAACGCTTGAAACGTTTAGAA AAATCTCTCAAAGAGTTAGGTAGTAAGATACTTAAGGAAAATATTCCTGC AAAACTTTCTAAAATAGACAATAACGCACTTCAAAATGATCGACTTTACTT ATACTATCTTCAAAATGGAAAAGATATGTATACCGGAGATGATTTAGATA TTGATAGATTAAGTAATTATGATATTGATCATATTATTCCTCAAGCTTTTTT GAAAGATAATTCTATTGACAATAAAGTACTTGTTTCATCTGCTAGTAACCG TGGTAAATCAGATGATGTTCCAAGTTTAGAGGTTGTCAAAAAAAGAAAGA CATTTTGGTATCAATTATTGAAATCAAAATTAATTTCTCAACGAAAATTTG ATAATCTGACAAAAGCTGAACGGGGAGGATTGTCACCTGAGGACAAAGCT GGTTTTATTCAACGCCAGTTGGTTGAAACACGTCAAATAACAAAACATGT AGCTCGTTTACTTGATGAGAAATTTAATAATAAAAAAGATGAAAATAATA GAGCGGTACGAACAGTAAAAATTATTACCTTGAAATCTACCTTAGTTTCTC AATTTCGTAAGGATTTTGAACTTTATAAAGTTCGTGAAATCAATGATTTrC ATCATGCTCATGATGCTTACTTGAATGCCGTTGTAGCAAGTGCTTTACTTA AGAAATACCCTAAACTAGAGCCAGAATTTGTGTACGGTGATTATCCAAAA TACAATAGTTTTAGAGAAAGAAAGTCCGCTACAGAAAAGGTATATTTCTA TTCAAATATCATGAATATCTTTAAAAAATCTATTTCTTTAGCTGATGGTAG 75CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGTTATTGAAAGACCACTTATTGAGGTAAATGAGGAGACCGGCGAATCCG TTTGGAATAAAGAATCTGATTTAGCAACTGTAAGGAGAGTACTCTCTTATC CGCAAGTAAATGTTGTGAAAAAAGTTGAGGAACAGAATCACGGATTGGAT AGAGGAAAACCAAAGGGATTGTTTAATGCAAATCTTTCCTCAAAGCCAAA ACCAAATAGTAATGAAAATTTAGTAGGTGCTAAAGAGTATCTTGACCCCA AAAAGTATGGGGGGTATGCTGGAATTTCTAATTCTTTTACTGTTCTTGTTA AAGGGACAATTGAAAAAGGTGCTAAGAAAAAAATAACAAATGTACTAGA ATTTCAAGGTATTTCTATTTTAGATAGGATTAATTATAGAAAAGATAAACT TAATTTTTTACTTGAAAAAGGTTATAAAGATATTGAGTTAATTATTGAACT ACCTAAATATAGTTTATTTGAACTTTCAGATGGTTCACGTCGTATGTTGGC TAGTATTTTGTCAACGAATAATAAGAGGGGAGAGATTCACAAAGGAAATC AGATTTTTCTTTCACAGAAGTTTGTGAAATTACTTTATCATGCTAAGAGAA TAAGTAACACAATTAATGAGAATCATAGAAAATATGTTGAGAACCATAAA AAAGAGTTTGAAGAATTATTTTACTACATTCTTGAGTTTAATGAGAATTAT GTTGGAGCTAAAAAGAATGGTAAACTCTTAAACTCTGCCTTTCAATCTTGG CAAAATCATAGTATAGATGAACTCTGTAGTAGTTTTATAGGACCTACCGG AAGTGAAAGAAAGGGGCTATTTGAATTAACCTCTCGTGGAAGTGCTGCTG ATTTTGAATTTTTAGGTGTTAAAATTCCAAGGTATAGAGACTATACCCCAT CATCCCTATTAAAAGATGCCACACTTATTCATCAATCTGTTACAGGCCTCT ATGAAACACGAATAGACCTTGCCAAACTAGGAGAGGGTTAA (SEQ ID NO: 4)

[00103] An example of a Cas9 protein comprising a nuclear localization signal (GGSGPPKKKRKV; SEQ ID NO: 5) at the C-terminus thereof has the following amino acid sequence:

[00104] MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKV DDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDST DKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLF1QLVQTYNQLFEEN PINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFK SNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGY AGYIDGGASQEEFYKF1KP1LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPH QIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFT 76CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 VYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFK KIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTL FEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGK TILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGS PAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERM KRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS DYDVDHIVPQSFLKDDS1DNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQrrKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLN AVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNI MNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIV KKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVA KVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNE QKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRID LSQLGGDGGSGPPKKKRKV (SEQ ID NO: 6)

[00105] In some embodiments, a Cas9 nickase may be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce non-homologous end joining (NHEJ).

[00106] As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III) may be mutated to produce a mutated Cas9 substantially lacking all DNA cleavage activity. In some embodiments, a D10A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity (where the amino acid numbering is as in SEQ ID NO: 1). In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01%, or lower with respect to its non-mutated form. Other mutations may be useful; where the Cas9 or other CRISPR enzyme is from a species other than S. pyogenes, mutations in corresponding amino acids may be made to achieve similar effects.

[00107] In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as 77CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database", and these tables can be adapted in a number of ways. See Nakamura, Y., el al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, Pa.), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme corresponds to the most frequently used codon for a particular amino acid.

[00108] In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler 78CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 Aligner), CluslalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence¬ specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.

[00109] A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. Exemplary target sequences include those that are unique in the target genome. For example, for the S. pyogenes Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXGG MMMMMMMMNNNNNNNNNNNNXXAGAAW where NNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be a deoxynucleotide) has a single occurrence in the genome. A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGG where NNNNNNNNNNNXGG (N is A, G, T, or C; and X can be a deoxynucleotide) has a single occurrence in the genome. For the S. thermophilus CRISPRI Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXXAGAAW (SEQ ID NO: 7) where NNNNNNNNNNNNXXAGAAW (SEQ ID NO: 8) (N is A, G, T, or C; X can be a 79deoxynucleotide; and W is A or T) has a single occurrence in the genome. A unique target sequence in a genome may include an 5. thermophilus CRISPRI Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXXAGAAW (SEQ ID NO: 9) where NNNNNNNNNNNXXAGAAW (SEQ ID NO: 10) (N is A, G, T, or C; X can be a deoxynucleotide; and W is A or T) has a single occurrence in the genome. For the S. pyogenes Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXGGXG where NNNNNNNNNNNNXGGXG (N is A, G, T, or C; and X can be a deoxynucleotide) has a single occurrence in the genome. A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGGXG where NNNNNNNNNNNXGGXG (N is A, G, T, or C; and X can be a deoxynucleotide) has a single occurrence in the genome. In each of these sequences ”M” may be A, G, T, or C, and need not be considered in identifying a sequence as unique.

[00110] In some embodiments, a guide sequence is selected to reduce the degree of secondary structure within the guide sequence. Secondary structure may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A. R. Gruber et ah, 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62). Further algorithms may be found in U.S. application Ser. No. 61/836,080.

[00111] Aspects of the present subject mailer relate to delivery of CRISPR/ CRISPR/CRISPR from Prevotella and Francisella 1 (Cpfl) gene editing complexes or components thereof (e.g., CPfl proteins). Examples of human codon optimized Cpfl-family proteins are provided below. Human Codon Optimized Cpfl-family Proteins

[00112] Non-limiting examples of Cpfl-family protein sequences, and aspects of CRISPR/Cpfl gene-editing, are described in Zetsche et al., Cell 163, 759- 771, October 22, 2015. 80 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00113] Francisella tulurensis subsp. Novicida UI12 (FnCpfl; pY004)), including NLS and HA tag:

[00114] MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEK RAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDNLQ KDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDN GIELFKANSD1TDIDEALEIIKSFKGWTTYFKGFHENRKNVYSSNDIPTSHYRIV DDNLPKFLENKAKYESLKDKAPEA1NYEQIKKDLAEELTFDIDYKTSEVNQRV FSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQIN DKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTV EEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLE YITQQIAPKNLDNPSKKEQEL1AKKTEKAKYLSLETIKLALEEFNKHRDIDKQC RFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIK DLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNK IRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVM NKKNNKIFDDKAIKENKGEGYKKIVYKLLPGANKMLPKVFFSAKSIKFYNPSE DILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFR FSDTQRYNSIDEFYREVENQGYKLTFENISESYIDSVVNQGKLYLFQIYNKDFS AYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAK EAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEI NLLLKEKANDVHILSIDRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNY HDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIWF EDLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQ LTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFS KFDKICYNLDKGYFEFSFDYKNFGDKAAKGKWTIASFGSRLINFRNSDKNHN WDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTIL QMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDADANGAYHIGLKG LMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNNKRPAATKKAGQAKKKKG SYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 11)

[00115] SEQ ID NO: 11 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a Human influenza hemagglutinin (HA) tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00116] SEQ ID NO: 11 may be encoded by the following nucleotide sequence: 81CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00117] ATGAGCATCTACCAGGAGTTCGTCAACAAGTATTCACTG AGTAAGACACTGCGGTTCGAGCTGATCCCACAGGGCAAGACACTGGAGA ACATCAAGGCCCGAGGCCTGATTCTGGACGATGAGAAGCGGGCAAAAGA CTATAAGAAAGCCAAGCAGATCATTGATAAATACCACCAGTTCTTTATCG AGGAAATTCTGAGCTCCGTGTGCATCAGTGAGGATCTGCTGCAGAATTAC TCAGACGTGTACTTCAAGCTGAAGAAGAGCGACGATGACAACCTGCAGAA GGACTTCAAGTCCGCCAAGGACACCATCAAGAAACAGATTAGCGAGTACA TCAAGGACTCCGAAAAGTTTAAAAATCTGTTCAACCAGAATCTGATCGAT GCTAAGAAAGGCCAGGAGTCCGACCTGATCCTGTGGCTGAAACAGTCTAA GGACAATGGGATTGAACTGTTCAAGGCTAACTCCGATATCACTGATATTG ACGAGGCACTGGAAATCATCAAGAGCTTCAAGGGATGGACCACATACTTT AAAGGCTTCCACGAGAACCGCAAGAACGTGTACTCCAGCAACGACATTCC TACCTCCATCATCTACCGAATCGTCGATGACAATCTGCCAAAGTTCCTGGA GAACAAGGCCAAATATGAATCTCTGAAGGACAAAGCTCCCGAGGCAATTA ATTACGAACAGATCAAGAAAGATCTGGCTGAGGAACTGACATTCGATATC GACTATAAGACTAGCGAGGTGAACCAGAGGGTCTTTTCCCTGGACGAGGT GTTTGAAATCGCCAATTTCAACAATTACCTGAACCAGTCCGGCATTACTAA ATTCAATACCATCATTGGCGGGAAGTTTGTGAACGGGGAGAATACCAAGC GCAAGGGAATTAACGAATACATCAATCTGTATAGCCAGCAGATCAACGAC AAAACTCTGAAGAAATACAAGATGTCTGTGCTGTTCAAACAGATCCTGAG TGATACCGAGTCCAAGTCTTTTGTCATTGATAAACTGGAAGATGACTCAG ACGTGGTCACTACCATGCAGAGCTTTTATGAGCAGATCGCCGCTTTCAAG ACAGTGGAGGAAAAATCTATTAAGGAAACTCTGAGTCTGCTGTTCGATGA CCTGAAAGCCCAGAAGCTGGACCTGAGTAAGATCTACTTCAAAAACGATA AGAGTCTGACAGACCTGTCACAGCAGGTGTTTGATGACTATTCCGTGATTG GGACCGCCGTCCTGGAGTACATTACACAGCAGATCGCTCCAAAGAACCTG GATAATCCCTCTAAGAAAGAGCAGGAACTGATCGCTAAGAAAACCGAGA AGGCAAAATATCTGAGTCTGGAAACAATTAAGCTGGCACTGGAGGAGTTC AACAAGCACAGGGATATTGACAAACAGTGCCGCTTTGAGGAAATCCTGGC CAACTTCGCAGCCATCCCCATGATTTTTGATGAGATCGCCCAGAACAAAG ACAATCTGGCTCAGATCAGTATTAAGTACCAGAACCAGGGCAAGAAAGAC CTGCTGCAGGCTTCAGCAGAAGATGACGTGAAAGCCATCAAGGATCTGCT GGACCAGACCAACAATCTGCTGCACAAGCTGAAAATCTTCCATATTAGTC AGTCAGAGGATAAGGCTAATATCCTGGATAAAGACGAACACTTCTACCTG 82CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GTGTrCGAGGAATGTTACTTCGAGCTGGCAAACATTGTCCCCCTGTATAAC AAGATTAGGAACTACATCACACAGAAGCCTTACTCTGACGAGAAGTTTAA ACTGAACTTCGAAAATAGTACCCTGGCCAACGGGTGGGATAAGAACAAG GAGCCTGACAACACAGCTATCCTGTTCATCAAGGATGACAAGTACTATCT GGGAGTGATGAATAAGAAAAACAATAAGATCTTCGATGACAAAGCCATT AAGGAGAACAAAGGGGAAGGATACAAGAAAATCGTGTATAAGCTGCTGC CCGGCGCAAATAAGATGCTGCCTAAGGTGTTCTTCAGCGCCAAGAGTATC AAATTCTACAACCCATCCGAGGACATCCTGCGGATTAGAAATCACTCAAC ACATACTAAGAACGGGAGCCCCCAGAAGGGATATGAGAAATTTGAGTTCA ACATCGAGGATTGCAGGAAGTTTATTGACTTCTACAAGCAGAGCATCTCC AAACACCCTGAATGGAAGGATTTTGGCTTCCGGTTTTCCGACACACAGAG ATATAACTCTATCGACGAGTTCTACCGCGAGGTGGAAAATCAGGGGTATA AGCTGACTTTTGAGAACATTTCTGAAAGTTACATCGACAGCGTGGTCAATC AGGGAAAGCTGTACCTGTTCCAGATCTATAACAAAGATTTTTCAGCATAC AGCAAGGGCAGACCAAACCTGCATACACTGTACTGGAAGGCCCTGTTCGA TGAGAGGAATCTGCAGGACGTGGTCTATAAACTGAACGGAGAGGCCGAA CTGTTTTACCGGAAGCAGTCTATTCCTAAGAAAATCACTCACCCAGCTAAG GAGGCCATCGCTAACAAGAACAAGGACAATCCTAAGAAAGAGAGCGTGT TCGAATACGATCTGATTAAGGACAAGCGGTTCACCGAAGATAAGTTCTTT TTCCATTGTCCAATCACCATTAACTTCAAGTCAAGCGGCGCTAACAAGTTC AACGACGAGATCAATCTGCTGCTGAAGGAAAAAGCAAACGATGTGCACA TCCTGAGCATTGACCGAGGAGAGCGGCATCTGGCCTACTATACCCTGGTG GATGGCAAAGGGAATATCATTAAGCAGGATACATTCAACATCATTGGCAA TGACCGGATGAAAACCAACTACCACGATAAACTGGCTGCAATCGAGAAG GATAGAGACTCAGCTAGGAAGGACTGGAAGAAAATCAACAACATTAAGG AGATGAAGGAAGGCTATCTGAGCCAGGTGGTCCATGAGATTGCAAAGCTG GTCATCGAATACAATGCCATTGTGGTGTTCGAGGATCTGAACTTCGGCTTT AAGAGGGGGCGCTTTAAGGTGGAAAAACAGGTCTATCAGAAGCTGGAGA AAATGCTGATCGAAAAGCTGAATTACCTGGTGTTTAAAGATAACGAGTTC GACAAGACCGGAGGCGTCCTGAGAGCCTACCAGCTGACAGCTCCCTTTGA AACTTTCAAGAAAATGGGAAAACAGACAGGCATCATCTACTATGTGCCAG CCGGATTCACTTCCAAGATCTGCCCCGTGACCGGCTTTGTCAACCAGCTGT ACCCTAAATATGAGTCAGTGAGCAAGTCCCAGGAATTTTTCAGCAAGTTC GATAAGATCTGTTATAATCTGGACAAGGGGTACTTCGAGTTTTCCTTCGAT 83CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TACAAGAACTTCGGCGACAAGGCCGCTAAGGGGAAATGGACCATTGCCTC CTTCGGATCTCGCCTGATCAACTTTCGAAATTCCGATAAAAACCACAATTG GGACACTAGGGAGGTGTACCCAACCAAGGAGCTGGAAAAGCTGCTGAAA GACTACTCTATCGAGTATGGACATGGCGAATGCATCAAGGCAGCCATCTG TGGCGAGAGTGATAAGAAATTTTTCGCCAAGCTGACCTCAGTGCTGAATA CAATCCTGCAGATGCGGAACTCAAAGACCGGGACAGAACTGGACTATCTG ATTAGCCCCGTGGCTGATGTCAACGGAAACTTCTTCGACAGCAGACAGGC ACCCAAAAATATGCCTCAGGATGCAGACGCCAACGGGGCCTACCACATCG GGCTGAAGGGACTGATGCTGCTGGGCCGGATCAAGAACAATCAGGAGGG GAAGAAGCTGAACCTGGTCATTAAGAACGAGGAATACTTCGAGTTTGTCC AGAATAGAAATAACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGC AAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATC CCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCCT AA (SEQID NO: 14)

[00118] Lachnospiraceae bacterium MC2017 (Lb3Cpfl; pY005), including NLS and HA tag:

[00119] MDYGNGQFERRAPLTKTITLRLKPIGETRETIREQKLLEQDA AFRKLVETVTPIVDDCIRKIADNALCHFGTEYDFSCLGNAISKNDSKAIKKETE KVEKLLAKVLTENLPDGLRKVNDINSAAFIQDTLTSFVQDDADKRVLIQELKG KTVLMQRFLTTRITALTVWLPDRVFENFNIFIENAEKMRILLDSPLNEKIMKFD PDAEQYASLEFYGQCLSQKDIDSYNLIISGIYADDEVKNPGINEIVKEYNQQIR GDKDESPLPKLKKLHKQILMPVEKAFFVRVLSNDSDARSILEKILKDTEMLPS KIIEAMKEADAGDIAVYGSRLHELSHVIYGDHGKLSQIIYDKESKRISELMETL SPKERKESKKRLEGLEEHIRKSTYTFDELNRYAEKNVMAAYIAAVEESCAEIM RKEKDLRTLLSKEDVKIRGNRHNTLIVKNYFNAWTVFRNLIRILRRKSEAEIDS DFYDVLDDSVEVLSLTYKGENLCRSYITKKIGSDLKPEIATYGSALRPNSRWW SPGEKFNVKFHTIVRRDGRLYYFILPKGAKPVELEDMDGDTECLQMRKIPNPTT FLPKLVFKDPEAFFRDNPEADEFVFLSGMKAPVT1TRETYEAYRYKLYTVGKL RDGEVSEEEYKRALLQVLTAYKEFLENRMIYADLNFGFKDLEEYKDSSEFIKQ VETHNTFMCWAKVSSSQLDDLVKSGNGLLFEIWSERLESYYKYGNEKVLRG YEGVLLSILKDENLVSMRTLLNSRPMLVYRPKESSKPMVVHRDGSRVVDRFD KDGKYIPPEVHDELYRFFNNLL1KEKLGEKARKILDNKKVKVKVLESERVKW SKFYDEQFAVTFSVKKNADCLDTTKDLNAEVMEQYSESNRLILIRNTTDILYY LVLDKNGKVLKQRSLNIINDGARDVDWKERFRQVTKDRNEGYNEWDYSRTS 84CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NDLKEVYLNYALKEIAEAVIEYNAILIIEKMSNAFKDKYSFLDDVTFKGFETK LLAKLSDLHFRGIKDGEPCSFTNPLQLCQNDSNKILQDGVIFMVPNSMTRSLD PDTGFIFAINDHNIRTKKAKLNFLSKFDQLKVSSEGCLIMKYSGDSLPTHNTDN RVWNCCCNHPITNYDRETKKVEFIEEPVEELSRVLEENGIETDTELNKLNERE NVPGKVVDAIYSLVLNYLRGTVSGVAGQRAVYYSPVTGKKYDISFIQAMNLN RKCDYYRTGSKERGEWTDFVAQLTNKRPAATKKAGQAKKKKGSYPYDVPDY AYPYDVPDYAYPYDVPDYA (SEQ ID NO: 15)

[00120] SEQ ID NO: 15 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00121] SEQ ID NO: 15 may be encoded by the following nucleotide sequence:

[00122] ATGGATTACGGCAACGGCCAGTTTGAGCGGAGAGCCCCC CTGACCAAGACAATCACCCTGCGCCTGAAGCCTATCGGCGAGACACGGGA GACAATCCGCGAGCAGAAGCTGCTGGAGCAGGACGCCGCCTTCAGAAAG CTGGTGGAGACAGTGACCCCTATCGTGGACGATTGTATCAGGAAGATCGC CGATAACGCCCTGTGCCACTTTGGCACCGAGTATGACTTCAGCTGTCTGGG CAACGCCATCTCTAAGAATGACAGCAAGGCCATCAAGAAGGAGACAGAG AAGGTGGAGAAGCTGCTGGCCAAGGTGCTGACCGAGAATCTGCCAGATG GCCTGCGCAAGGTGAACGACATCAATTCCGCCGCCTTTATCCAGGATACA CTGACCTCTTTCGTGCAGGACGATGCCGACAAGCGGGTGCTGATCCAGGA GCTGAAGGGCAAGACCGTGCTGATGCAGCGGTTCCTGACCACACGGATCA CAGCCCTGACCGTGTGGCTGCCCGACAGAGTGTTCGAGAACTTTAATATCT TCATCGAGAACGCCGAGAAGATGAGAATCCTGCTGGACTCCCCTCTGAAT GAGAAGATCATGAAGTTTGACCCAGATGCCGAGCAGTACGCCTCTCTGGA GTTCTATGGCCAGTGCCTGTCTCAGAAGGACATCGATAGCTACAACCTGA TCATCTCCGGCATCTATGCCGACGATGAGGTGAAGAACCCTGGCATCAAT GAGATCGTGAAGGAGTACAATCAGCAGATCCGGGGCGACAAGGATGAGT CCCCACTGCCCAAGCTGAAGAAGCTGCACAAGCAGATCCTGATGCCAGTG GAGAAGGCCTTCTTTGTGCGCGTGCTGTCTAACGACAGCGATGCCCGGAG CATCCTGGAGAAGATCCTGAAGGACACAGAGATGCTGCCCTCCAAGATCA TCGAGGCCATGAAGGAGGCAGATGCAGGCGACATCGCCGTGTACGGCAG CCGGCTGCACGAGCTGAGCCACGTGATCTACGGCGATCACGGCAAGCTGT 85CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCCAGATCATCTATGACAAGGAGTCCAAGAGGATCTCTGAGCTGATGGAG ACACTGTCTCCAAAGGAGCGCAAGGAGAGCAAGAAGCGGCTGGAGGGCC TGGAGGAGCACATCAGAAAGTCTACATACACCTTCGACGAGCTGAACAGG TATGCCGAGAAGAATGTGATGGCAGCATACATCGCAGCAGTGGAGGAGTC TTGTGCCGAGATCATGAGAAAGGAGAAGGATCTGAGGACCCTGCTGAGCA AGGAGGACGTGAAGATCCGGGGCAACAGACACAATACACTGATCGTGAA GAACTACTTTAATGCCTGGACCGTGTTCCGGAACCTGATCAGAATCCTGA GGCGCAAGTCCGAGGCCGAGATCGACTCTGACTTCTACGATGTGCTGGAC GATTCCGTGGAGGTGCTGTCTCTGACATACAAGGGCGAGAATCTGTGCCG CAGCTATATCACCAAGAAGATCGGCTCCGACCTGAAGCCCGAGATCGCCA CATACGGCAGCGCCCTGAGGCCTAACAGCCGCTGGTGGTCCCCAGGAGAG AAGTTTAATGTGAAGTTCCACACCATCGTGCGGAGAGATGGCCGGCTGTA CTATTTCATCCTGCCCAAGGGCGCCAAGCCTGTGGAGCTGGAGGACATGG ATGGCGACATCGAGTGTCTGCAGATGAGAAAGATCCCTAACCCAACAATC TTTCTGCCCAAGCTGGTGTTCAAGGACCCTGAGGCCTTCTTTAGGGATAAT CCAGAGGCCGACGAGTTCGTGTTTCTGAGCGGCATGAAGGCCCCCGTGAC AATCACCAGAGAGACATACGAGGCCTACAGGTATAAGCTGTATACCGTGG GCAAGCTGCGCGATGGCGAGGTGTCCGAAGAGGAGTACAAGCGGGCCCT GCTGCAGGTGCTGACCGCCTACAAGGAGTTTCTGGAGAACAGAATGATCT ATGCCGACCTGAATTTCGGCTTTAAGGATCTGGAGGAGTATAAGGACAGC TCCGAGTTTATCAAGCAGGTGGAGACACACAACACCTTCATGTGCTGGGC CAAGGTGTCTAGCTCCCAGCTGGACGATCTGGTGAAGTCTGGCAACGGCC TGCTGTTCGAGATCTGGAGCGAGCGCCTGGAGTCCTACTATAAGTACGGC AATGAGAAGGTGCTGCGGGGCTATGAGGGCGTGCTGCTGAGCATCCTGAA GGATGAGAACCTGGTGTCCATGCGGACCCTGCTGAACAGCCGGCCCATGC TGGTGTACCGGCCAAAGGAGTCTAGCAAGCCTATGGTGGTGCACCGGGAT GGCAGCAGAGTGGTGGACAGGTTTGATAAGGACGGCAAGTACATCCCCCC TGAGGTGCACGACGAGCTGTATCGCTTCTTTAACAATCTGCTGATCAAGG AGAAGCTGGGCGAGAAGGCCCGGAAGATCCTGGACAACAAGAAGGTGAA GGTGAAGGTGCTGGAGAGCGAGAGAGTGAAGTGGTCCAAGTTCTACGAT GAGCAGTTTGCCGTGACCTTCAGCGTGAAGAAGAACGCCGATTGTCTGGA CACCACAAAGGACCTGAATGCCGAAGTGATGGAGCAGTATAGCGAGTCC AACAGACTGATCCTGATCAGGAATACCACAGATATCCTGTACTATCTGGT GCTGGACAAGAATGGCAAGGTGCTGAAGCAGAGATCCCTGAACATCATCA 86CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATGACGGCGCCAGGGATGTGGACTGGAAGGAGAGGTTCCGCCAGGTGAC AAAGGATAGAAACGAGGGCTACAATGAGTGGGATTATTCCAGGACCTCTA ACGACCTGAAGGAGGTGTACCTGAATTATGCCCTGAAGGAGATCGCCGAG GCCGTGATCGAGTACAACGCCATCCTGATCATCGAGAAGATGTCTAATGC CTTTAAGGACAAGTATAGCTTCCTGGACGACGTGACCTTCAAGGGCTTCG AGACAAAGCTGCTGGCCAAGCTGAGCGATCTGCACTTTAGGGGCATCAAG GACGGCGAGCCATGTTCCTTCACAAACCCCCTGCAGCTGTGCCAGAACGA TTCTAATAAGATCCTGCAGGACGGCGTGATCTTTATGGTGCCAAATTCTAT GACACGGAGCCTGGACCCCGACACCGGCTTCATCTTTGCCATCAACGACC ACAATATCAGGACCAAGAAGGCCAAGCTGAACTTTCTGAGCAAGTTCGAT CAGCTGAAGGTGTCCTCTGAGGGCTGCCTGATCATGAAGTACAGCGGCGA TTCCCTGCCTACACACAACACCGACAATCGCGTGTGGAACTGCTGTTGCA ATCACCCAATCACAAACTATGACCGGGAGACAAAGAAGGTGGAGTTCATC GAGGAGCCCGTGGAGGAGCTGTCCCGCGTGCTGGAGGAGAATGGCATCG AGACAGACACCGAGCTGAACAAGCTGAATGAGCGGGAGAACGTGCCTGG CAAGGTGGTGGATGCCATCTACTCTCTGGTGCTGAATTATCTGCGCGGCAC AGTGAGCGGAGTGGCAGGACAGAGGGCCGTGTACTATAGCCCTGTGACCG GCAAGAAGTACGATATCTCCTTTATCCAGGCCATGAACCTGAATAGGAAG TGTGACTACTATAGGATCGGCTCCAAGGAGAGGGGAGAGTGGACCGATTT CGTGGCCCAGCTGATCAACAAAAGGCCGGCGGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGC TTATCCCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTA TGCCTAA

[00123] Butyrivibrio proteoclasticus (BpCpfl; pY006), including NLS and HA tag:

[00124] MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEK RAKDYKKAKQIIDKYHQFFIEETLSSVCISEDLLQNYSDVYFKLKKSDDDNLQ KDFKSAKDT1KKQ1SEY1KDSEKFKNLFNQNLIDAKKGQESDL1LWLKQSKDN GIELFKANSDrrDIDEALEIIKSFKGWTTYFKGFHENRKNVYSSNDIPTSHYRIV DDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRV FSLDEVFEIANFNNYLNQSGITKFNTTTGGKFVNGENTKRKGINEYINLYSQQIN DKTLKKYKMSVLFKQ1LSDTESKSFV1DKLEDDSDVVTTMQSFYEQ1AAFKTV EEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLE YITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKLALEEFNKHRDIDKQC 87CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 RFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIK DLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNK IRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVM NKKNNKIFDDKAIKENKGEGYKKIVYKLLPGANKMLPKVFFSAKSIKFYNPSE DILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFR FSDTQRYNSIDEFYREVENQGYKLTFENISESYIDSVVNQGKLYLFQIYNKDFS AYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQS1PKKITHPAK EAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEI NLLLKEKANDVHILSIDRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNY HDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIWF EDLNFGFKRGRFKVEKQVYQKLEKML1EKLNYLVFKDNEFDKTGGVLRAYQ LTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFS KFDKICYNLDKGYFEFSFDYKNFGDKAAKGKWTIASFGSRLINFRNSDKNHN WDTREVYPTKELEKLLKDYSIEYGHGECIKAATCGESDKKFFAKLTSVLNTIL QMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDADANGAYHIGLKG LMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNNKRPAATKKAGQAKKKKG SYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 17)

[00125] SEQ ID NO: 17 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00126] SEQ ID NO: 17 may be encoded by the following nucleotide sequence:

[00127] ATGAGCATCTACCAGGAGTTCGTCAACAAGTATTCACTG AGTAAGACACTGCGGTTCGAGCTGATCCCACAGGGCAAGACACTGGAGA ACATCAAGGCCCGAGGCCTGATTCTGGACGATGAGAAGCGGGCAAAAGA CTATAAGAAAGCCAAGCAGATCATTGATAAATACCACCAGTTCTTTATCG AGGAAATTCTGAGCTCCGTGTGCATCAGTGAGGATCTGCTGCAGAATTAC TCAGACGTGTACTTCAAGCTGAAGAAGAGCGACGATGACAACCTGCAGAA GGACTTCAAGTCCGCCAAGGACACCATCAAGAAACAGATTAGCGAGTACA TCAAGGACTCCGAAAAGTTTAAAAATCTGTTCAACCAGAATCTGATCGAT GCTAAGAAAGGCCAGGAGTCCGACCTGATCCTGTGGCTGAAACAGTCTAA GGACAATGGGATTGAACTGTTCAAGGCTAACTCCGATATCACTGATATTG ACGAGGCACTGGAAATCATCAAGAGCTTCAAGGGATGGACCACATACTTT 88CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAAGGCTTCCACGAGAACCGCAAGAACGTGTACTCCAGCAACGACATTCC TACCTCCATCATCTACCGAATCGTCGATGACAATCTGCCAAAGTTCCTGGA GAACAAGGCCAAATATGAATCTCTGAAGGACAAAGCTCCCGAGGCAATTA ATTACGAACAGATCAAGAAAGATCTGGCTGAGGAACTGACATTCGATATC GACTATAAGACTAGCGAGGTGAACCAGAGGGTCTTTTCCCTGGACGAGGT GTTTGAAATCGCCAATTTCAACAATTACCTGAACCAGTCCGGCATTACTAA ATTCAATACCATCATTGGCGGGAAGTTTGTGAACGGGGAGAATACCAAGC GCAAGGGAATTAACGAATACATCAATCTGTATAGCCAGCAGATCAACGAC AAAACTCTGAAGAAATACAAGATGTCTGTGCTGTTCAAACAGATCCTGAG TGATACCGAGTCCAAGTCTTTTGTCATTGATAAACTGGAAGATGACTCAG ACGTGGTCACTACCATGCAGAGCTTTTATGAGCAGATCGCCGCTTTCAAG ACAGTGGAGGAAAAATCTATTAAGGAAACTCTGAGTCTGCTGTTCGATGA CCTGAAAGCCCAGAAGCTGGACCTGAGTAAGATCTACTTCAAAAACGATA AGAGTCTGACAGACCTGTCACAGCAGGTGTTTGATGACTATTCCGTGATTG GGACCGCCGTCCTGGAGTACATTACACAGCAGATCGCTCCAAAGAACCTG GATAATCCCTCTAAGAAAGAGCAGGAACTGATCGCTAAGAAAACCGAGA AGGCAAAATATCTGAGTCTGGAAACAATTAAGCTGGCACTGGAGGAGTTC AACAAGCACAGGGATATTGACAAACAGTGCCGCTTTGAGGAAATCCTGGC CAACTTCGCAGCCATCCCCATGATTTTTGATGAGATCGCCCAGAACAAAG ACAATCTGGCTCAGATCAGTATTAAGTACCAGAACCAGGGCAAGAAAGAC CTGCTGCAGGCTTCAGCAGAAGATGACGTGAAAGCCATCAAGGATCTGCT GGACCAGACCAACAATCTGCTGCACAAGCTGAAAATCTTCCATATTAGTC AGTCAGAGGATAAGGCTAATATCCTGGATAAAGACGAACACTTCTACCTG GTGTTCGAGGAATGTTACTTCGAGCTGGCAAACATTGTCCCCCTGTATAAC AAGATTAGGAACTACATCACACAGAAGCCTTACTCTGACGAGAAGTTTAA ACTGAACTTCGAAAATAGTACCCTGGCCAACGGGTGGGATAAGAACAAG GAGCCTGACAACACAGCTATCCTGTTCATCAAGGATGACAAGTACTATCT GGGAGTGATGAATAAGAAAAACAATAAGATCTTCGATGACAAAGCCATT AAGGAGAACAAAGGGGAAGGATACAAGAAAATCGTGTATAAGCTGCTGC CCGGCGCAAATAAGATGCTGCCTAAGGTGTTCTTCAGCGCCAAGAGTATC AAATTCTACAACCCATCCGAGGACATCCTGCGGATTAGAAATCACTCAAC ACATACTAAGAACGGGAGCCCCCAGAAGGGATATGAGAAATTTGAGTTCA ACATCGAGGATTGCAGGAAGTTTATTGACTTCTACAAGCAGAGCATCTCC AAACACCCTGAATGGAAGGATTTTGGCTTCCGGTTTTCCGACACACAGAG 89CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATATAACTCTATCGACGAGTTCTACCGCGAGGTGGAAAATCAGGGGTATA AGCTGACTTTTGAGAACATTTCTGAAAGTTACATCGACAGCGTGGTCAATC AGGGAAAGCTGTACCTGTTCCAGATCTATAACAAAGATTTTTCAGCATAC AGCAAGGGCAGACCAAACCTGCATACACTGTACTGGAAGGCCCTGTTCGA TGAGAGGAATCTGCAGGACGTGGTCTATAAACTGAACGGAGAGGCCGAA CTGTTTTACCGGAAGCAGTCTATTCCTAAGAAAATCACTCACCCAGCTAAG GAGGCCATCGCTAACAAGAACAAGGACAATCCTAAGAAAGAGAGCGTGT TCGAATACGATCTGATTAAGGACAAGCGGTTCACCGAAGATAAGTTCTTT TTCCATTGTCCAATCACCATTAACTTCAAGTCAAGCGGCGCTAACAAGTTC AACGACGAGATCAATCTGCTGCTGAAGGAAAAAGCAAACGATGTGCACA TCCTGAGCATTGACCGAGGAGAGCGGCATCTGGCCTACTATACCCTGGTG GATGGCAAAGGGAATATCATTAAGCAGGATACATTCAACATCATTGGCAA TGACCGGATGAAAACCAACTACCACGATAAACTGGCTGCAATCGAGAAG GATAGAGACTCAGCTAGGAAGGACTGGAAGAAAATCAACAACATTAAGG AGATGAAGGAAGGCTATCTGAGCCAGGTGGTCCATGAGATTGCAAAGCTG GTCATCGAATACAATGCCATTGTGGTGTTCGAGGATCTGAACTTCGGCTTT AAGAGGGGGCGCTTTAAGGTGGAAAAACAGGTCTATCAGAAGCTGGAGA AAATGCTGATCGAAAAGCTGAATTACCTGGTGTTTAAAGATAACGAGTTC GACAAGACCGGAGGCGTCCTGAGAGCCTACCAGCTGACAGCTCCCTTTGA AACTTTCAAGAAAATGGGAAAACAGACAGGCATCATCTACTATGTGCCAG CCGGATTCACTTCCAAGATCTGCCCCGTGACCGGCTTTGTCAACCAGCTGT ACCCTAAATATGAGTCAGTGAGCAAGTCCCAGGAATTTTTCAGCAAGTrC GATAAGATCTGTTATAATCTGGACAAGGGGTACTTCGAGTTTTCCTTCGAT TACAAGAACTTCGGCGACAAGGCCGCTAAGGGGAAATGGACCATTGCCTC CTTCGGATCTCGCCTGATCAACTTTCGAAATTCCGATAAAAACCACAATTG GGACACTAGGGAGGTGTACCCAACCAAGGAGCTGGAAAAGCTGCTGAAA GACTACTCTATCGAGTATGGACATGGCGAATGCATCAAGGCAGCCATCTG TGGCGAGAGTGATAAGAAATTTTTCGCCAAGCTGACCTCAGTGCTGAATA CAATCCTGCAGATGCGGAACTCAAAGACCGGGACAGAACTGGACTATCTG ATTAGCCCCGTGGCTGATGTCAACGGAAACTTCTTCGACAGCAGACAGGC ACCCAAAAATATGCCTCAGGATGCAGACGCCAACGGGGCCTACCACATCG GGCTGAAGGGACTGATGCTGCTGGGCCGGATCAAGAACAATCAGGAGGG GAAGAAGCTGAACCTGGTCATTAAGAACGAGGAATACTTCGAGTTTGTCC AGAATAGAAATAACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGC 90CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATC CCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCCT AA(SEQID NO: 18)

[00128] Peregrinibacteria bacterium GW201l_GWA_33_10 (PeCpfl; pY007), including NLS and HA tag:

[00129] MSNFFKNFTNLYELSKTLRFELKPVGDTLTNMKDHLEYDE KLQTFLKDQNIDDAYQALKPQFDE1HEEF1TDSLESKKAKEIDFSEYLDLFQEK KELNDSEKKLRNKIGETFNKAGEKWKKEKYPQYEWKKGSKIANGADILSCQ DMLQFIKYKNPEDEKIKNYIDDTLKGFFTYFGGFNQNRANYYETKKEASTAV ATRIVHENLPKFCDNVIQFKHIIKRKKDGTVEKTERKTEYLNAYQYLKNNNKI TQ1KDAETEKMIESTP1AEK1FDVYYFSSCLSQKQ1EEYNR11GHYNLLINLYNQ AKRSEGKHLSANEKKYKDLPKFKTLYKQIGCGKKKDLFYTIKCDTEEEANKS RNEGKESHSVEEIINKAQEAINKYFKSNNDCENINTVPDFINYILTKENYEGVY WSKAAMNTISDKYFANYHDLQDRLKEAKVFQKADKKSEDDIKIPEAIELSGL FGVLDSLADWQTTLFKSSILSNEDKLKIITDSQTPSEALLKMIFNDIEKNMESFL KETNDirTLKKYKGNKEGTEKIKQWFDYTLAINRMLKYFLVKENKIKGNSLDT NISEALKTLIYSDDAEWFKWYDALRNYLTQKPQDEAKENKLKLNFDNPSLAG GWDVNKECSNFCVILKDKNEKKYLAIMKKGENTLFQKEWTEGRGKNLTKKS NPLFEINNCEILSKMEYDFWADVSKMIPKCSTQLKAVVNHFKQSDNEFIFPIG YKVTSGEKFREECKISKQDFELNNKVFNKNELSVTAMRYDLSSTQEKQYIKA FQKEYWELLFKQEKRDTKLTNNEIFNEWINFCNKKYSELLSWERKYKDALTN WINFCKYFLSKYPKTTLFNYSFKESENYNSLDEFYRDVDICSYKLNINTTINKS ILDRLVEEGKLYLFEIKNQDSNDGKSIGHKNNLHTIYWNAIFENFDNRPKLNG EAEIFYRKAISKDKLGIVKGKKTKNGTEIIKNYRFSKEKFILHVPITLNFCSNNE YVNDIVNTKFYNFSNLHFLGIDRGEKHLAYYSLVNKNGEIVDQGTLNLPFTD KDGNQRSIKKEKYFYNKQEDKWEAKEVDCWNYNDLLDAMASNRDMARKN WQRIGTTKEAKNGYVSLVTRKIADLAVNNERPAFIVLEDLNTGFKRSRQKIDKS VYQKFELALAKKLNFLVDKNAKRDE1GSPTKALQLTPPVNNYGDIENKKQAG IMLYTRANYTSQTDPATGWRKTIYLKAGPEETTYKKDGKIKNKSVKDQIIETF TDIGFDGKDYYFEYDKGEFVDEKTGEIKPKKWRLYSGENGKSLDRFRGEREK DKYEWKIDKrDIVKTLDDLFVNFDKNISLLKQLKEGVELTRNNEHGTGESLRF AINUQQIRNTGNNERDNDF1LSPVRDENGKHFDSREYWDKETKGEKISMPSS GDANGAFNIARKGIIMNAHILANSDSKDLSLFVSDEEWDLHLNNKTEWKKQL 91CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NIFSSRKAMAKRKKKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYA YPYDVPDYA (SEQ ID NO: 19)

[00130] SEQ ID NO: 19 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00131] SEQ ID NO: 19 may be encoded by the following nucleotide sequence:

[00132] ATGTCCAACTTCTTTAAGAATTTCACCAACCTGTATGAGC TGTCCAAGACACTGAGGTTTGAGCTGAAGCCCGTGGGCGACACCCTGACA AACATGAAGGACCACCTGGAGTACGATGAGAAGCTGCAGACCTTCCTGAA GGATCAGAATATCGACGATGCCTATCAGGCCCTGAAGCCTCAGTTCGACG AGATCCACGAGGAGTTTATCACAGATTCTCTGGAGAGCAAGAAGGCCAAG GAGATCGACTTCTCCGAGTACCTGGATCTGTTTCAGGAGAAGAAGGAGCT GAACGACTCTGAGAAGAAGCTGCGCAACAAGATCGGCGAGACATTCAAC AAGGCCGGCGAGAAGTGGAAGAAGGAGAAGTACCCTCAGTATGAGTGGA AGAAGGGCTCCAAGATCGCCAATGGCGCCGACATCCTGTCTTGCCAGGAT ATGCTGCAGTTTATCAAGTATAAGAACCCAGAGGATGAGAAGATCAAGAA TTACATCGACGATACACTGAAGGGCTTCTTTACCTATTTCGGCGGCTTTAA TCAGAACAGGGCCAACTACTATGAGACAAAGAAGGAGGCCTCCACCGCA GTGGCAACAAGGATCGTGCACGAGAACCTGCCAAAGTTCTGTGACAATGT GATCCAGTTTAAGCACATCATCAAGCGGAAGAAGGATGGCACCGTGGAG AAAACCGAGAGAAAGACCGAGTACCTGAACGCCTACCAGTATCTGAAGA ACAATAACAAGATCACACAGATCAAGGACGCCGAGACAGAGAAGATGAT CGAGTCTACACCCATCGCCGAGAAGATCTTCGACGTGTACTACTTCAGCA GCTGCCTGAGCCAGAAGCAGATCGAGGAGTACAACCGGATCATCGGCCA CTATAATCTGCTGATCAACCTGTATAACCAGGCCAAGAGATCTGAGGGCA AGCACCTGAGCGCCAACGAGAAGAAGTATAAGGACCTGCCTAAGTTCAA GACCCTGTATAAGCAGATCGGCTGCGGCAAGAAGAAGGACCTGTTTTACA CAATCAAGTGTGATACCGAGGAGGAGGCCAATAAGTCCCGGAACGAGGG CAAGGAGTCCCACTCTGTGGAGGAGATCATCAACAAGGCCCAGGAGGCC ATCAATAAGTACTTCAAGTCTAATAACGACTGTGAGAATATCAACACCGT GCCCGACTTCATCAACTATATCCTGACAAAGGAGAATTACGAGGGCGTGT ATTGGAGCAAGGCCGCCATGAACACCATCTCCGACAAGTACTTCGCCAAT 92CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TATCACGACCTGCAGGATAGACTGAAGGAGGCCAAGGTGTTTCAGAAGGC CGATAAGAAGTCCGAGGACGATATCAAGATCCCAGAGGCCATCGAGCTGT CTGGCCTGTTCGGCGTGCTGGACAGCCTGGCCGATTGGCAGACCACACTG TTTAAGTCTAGCATCCTGAGCAACGAGGACAAGCTGAAGATCATCACAGA TTCCCAGACCCCCTCTGAGGCCCTGCTGAAGATGATCTTCAATGACATCGA GAAGAACATGGAGTCCTTTCTGAAGGAGACAAACGATATCATCACCCTGA AGAAGTATAAGGGCAATAAGGAGGGCACCGAGAAGATCAAGCAGTGGTT CGACTATACACTGGCCATCAACCGGATGCTGAAGTACTTTCTGGTGAAGG AGAATAAGATCAAGGGCAACTCCCTGGATACCAATATCTCTGAGGCCCTG AAAACCCTGATCTACAGCGACGATGCCGAGTGGTTCAAGTGGTACGACGC CCTGAGAAACTATCTGACCCAGAAGCCTCAGGATGAGGCCAAGGAGAAT AAGCTGAAGCTGAATTTCGACAACCCATCTCTGGCCGGCGGCTGGGATGT GAACAAGGAGTGCAGCAATTTTTGCGTGATCCTGAAGGACAAGAACGAG AAGAAGTACCTGGCCATCATGAAGAAGGGCGAGAATACCCTGTTCCAGAA GGAGTGGACAGAGGGCCGGGGCAAGAACCTGACAAAGAAGTCTAATCCA CTGTTCGAGATCAATAACTGCGAGATCCTGAGCAAGATGGAGTATGACTT TTGGGCCGACGTGAGCAAGATGATCCCCAAGTGTAGCACCCAGCTGAAGG CCGTGGTGAACCACTTCAAGCAGTCCGACAATGAGTTCATCTTTCCTATCG GCTACAAGGTGACAAGCGGCGAGAAGTTTAGGGAGGAGTGCAAGATCTC CAAGCAGGACTTCGAGCTGAATAACAAGGTGTTTAATAAGAACGAGCTGA GCGTGACCGCCATGCGCTACGATCTGTCCTCTACACAGGAGAAGCAGTAT ATCAAGGCCTTCCAGAAGGAGTACTGGGAGCTGCTGTTTAAGCAGGAGAA GCGGGACACCAAGCTGACAAATAACGAGATCTTCAACGAGTGGATCAATT TTTGCAACAAGAAGTATAGCGAGCTGCTGTCCTGGGAGAGAAAGTACAAG GATGCCCTGACCAATTGGATCAACTTCTGTAAGTACTTTCTGAGCAAGTAT CCCAAGACCACACTGTTCAACTACTCTTTTAAGGAGAGCGAGAATTATAA CTCCCTGGACGAGTTCTACCGGGACGTGGATATCTGTTCTTACAAGCTGAA TATCAACACCACAATCAATAAGAGCATCCTGGATAGACTGGTGGAGGAGG GCAAGCTGTACCTGTTTGAGATCAAGAATCAGGACAGCAACGATGGCAAG TCCATCGGCCACAAGAATAACCTGCACACCATCTACTGGAACGCCATCTT CGAGAATTTTGACAACAGGCCTAAGCTGAATGGCGAGGCCGAGATCTTCT ATCGCAAGGCCATCTCCAAGGATAAGCTGGGCATCGTGAAGGGCAAGAA AACCAAGAACGGCACCGAGATCATCAAGAATTACAGATTCAGCAAGGAG AAGTTTATCCTGCACGTGCCAATCACCCTGAACTTCTGCTCCAATAACGAG 93CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TATGTGAATGACATCGTGAACACAAAGTTCTACAATTTTTCCAACCTGCAC TTTCTGGGCATCGATAGGGGCGAGAAGCACCTGGCCTACTATTCTCTGGTG AATAAGAACGGCGAGATCGTGGACCAGGGCACACTGAACCTGCCTTTCAC CGACAAGGATGGCAATCAGCGCAGCATCAAGAAGGAGAAGTACTTTTATA ACAAGCAGGAGGACAAGTGGGAGGCCAAGGAGGTGGATTGTTGGAATTA TAACGACCTGCTGGATGCCATGGCCTCTAACCGGGACATGGCCAGAAAGA ATTGGCAGAGGATCGGCACCATCAAGGAGGCCAAGAACGGCTACGTGAG CCTGGTCATCAGGAAGATCGCCGATCTGGCCGTGAATAACGAGCGCCCCG CCTTCATCGTGCTGGAGGACCTGAATACAGGCTTTAAGCGGTCCAGACAG AAGATCGATAAGAGCGTGTACCAGAAGTTCGAGCTGGCCCTGGCCAAGAA GCTGAACTTTCTGGTGGACAAGAATGCCAAGCGCGATGAGATCGGCTCCC CTACAAAGGCCCTGCAGCTGACCCCCCCTGTGAATAACTACGGCGACATT GAGAACAAGAAGCAGGCCGGCATCATGCTGTATACCCGGGCCAATTATAC CTCTCAGACAGATCCAGCCACAGGCTGGAGAAAGACCATCTATCTGAAGG CCGGCCCCGAGGAGACAACATACAAGAAGGACGGCAAGATCAAGAACAA GAGCGTGAAGGACCAGATCATCGAGACATTCACCGATATCGGCTTTGACG GCAAGGATTACTATTTCGAGTACGACAAGGGCGAGTTTGTGGATGAGAAA ACCGGCGAGATCAAGCCCAAGAAGTGGCGGCTGTACTCCGGCGAGAATG GCAAGTCCCTGGACAGGTTCCGCGGAGAGAGGGAGAAGGATAAGTATGA GTGGAAGATCGACAAGATCGATATCGTGAAGATCCTGGACGATCTGTTCG TGAATTTTGACAAGAACATCAGCCTGCTGAAGCAGCTGAAGGAGGGCGTG GAGCTGACCCGGAATAACGAGCACGGCACAGGCGAGTCCCTGAGATTCG CCATCAACCTGATCCAGCAGATCCGGAATACCGGCAATAACGAGAGAGA CAACGATTTCATCCTGTCCCCAGTGAGGGACGAGAATGGCAAGCACTTTG ACTCTCGCGAGTACTGGGATAAGGAGACAAAGGGCGAGAAGATCAGCAT GCCCAGCTCCGGCGATGCCAATGGCGCCTTCAACATCGCCCGGAAGGGCA TCATCATGAACGCCCACATCCTGGCCAATAGCGACTCCAAGGATCTGTCC CTGTTCGTGTCTGACGAGGAGTGGGATCTGCACCTGAATAACAAGACCGA GTGGAAGAAGCAGCTGAACATCTTTTCTAGCAGGAAGGCCATGGCCAAGC GCAAGAAGAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAA AGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTAC GACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCCTAA (SEQID NO:20) 94CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00133] Parcubucteria bacterium GWC2011_GWC2_44_17 (PbCpfl; pY008), including NLS and HA tag:

[00134] MENIFDQFIGKYSLSKTLRFELKPVGKTEDFLKINKVFEKDQ TIDDSYNQAKFYFDSLHQKFIDAALASDKTSELSFQNFADVLEKQNKIILDKK REMGALRKRDKNAVGIDRLQKEINDAEDIIQKEKEKIYKDVRTLFDNEAESW KTYYQEREVDGKKTTFSKADLKQKGADFLTAAGTLKVLKYEFPEEKEKEFQA KNQPSLFVEEKENPGQKRYIFDSFDKFAGYLTKFQQTKKNLYAADGTSTAVA TRIADNFIIFHQNTKVFRDKYKNNHTDLGFDEENIFEIERYKNCLLQREIEHIKN ENSYNKIIGRINKKIKEYRDQKAKDTKLTKSDFPFFKNLDKQILGEVEKEKQLI EKTREKTEEDVLIERFKEFIENNEERFTAAKKLMNAFCNGEFESEYEGIYLKN KAINTISRRWFVSDRDFELKLPQQKSKNKSEKNEPKVKKFIS1AE1KNAVEELD GDIFKAVFYDKKIIAQGGSKLEQFLVIWKYEFEYLFRDIERENGEKLLGYDSCL KIAKQLGIFPQEKEAREKATAVIKNYADAGLGIFQMMKYFSLDDKDRKNTPG QLSTNFYAEYDGYYKDFEFIKYYNEFRNFITKKPFDEDKIKLNFENGALLKGW DENKEYDFMGVILKKEGRLYLGIMHKNHRKLFQSMGNAKGDNANRYQKMI YKQIADASKDVPRLLLTSKKAMEKFKPSQEILRIKKEKTFKRESKNFSLRDLH ALIEYYRNCIPQYSNWSFYDFQFQDTGKYQNIKEFTDDVQKYGYKISFRDIDD EYINQALNEGKMYLFEVVNKDIYNTKNGSKNLHTLYFEHILSAENLNDPVFK LSGMAEIFQRQPSVNEREKITTQKNQCILDKGDRAYKYRRYTEKKIMFHMSL VLNTGKGEIKQVQFNKIINQRISSSDNEMRVNVIGIDRGEKNLLYYSVVKQNG EIIEQASLNEINGVNYRDKLIEREKERLKNRQSWKPVVKIKDLKKGYISHVIHK ICQLIEKYSAIVVLEDLNMRFKQIRGGIERSVYQQFEKALIDKLGYLVFKDNRD LRAPGGVLNGYQLSAPFVSFEKMRKQTGILFYTQAEYTSKTDPITGFRKNVYI SNSASLDKIKEAVKKFDAIGWDGKEQSYFFKYNPYNLADEKYKNSTVSKEW AIFASAPRIRRQKGEDGYWKYDRVKVNEEFEKLLKVWNFVNPKATDIKQEII KKEKAGDLQGEKELDGRLRNFWHSFIYLFNLVLELRNSFSLQIKIKAGEVIAV DEGVDFIASPVKPFFTTPNPYIPSNLCWLAVENADANGAYNIARKGVMILKKI REHAKKDPEFKKLPNLF1SNAEWDEAARDWGKYAGTTALNLDHKRPAATKK AGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 21)

[00135] SEQ ID NO: 21 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13). 95CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00136] SEQ ID NO: 21 may be encoded by the following nucleotide sequence:

[00137] ATGGAGAACATCTTCGACCAGTTTATCGGCAAGTACAGC CTGTCCAAGACCCTGAGATTCGAGCTGAAGCCCGTGGGCAAGACAGAGGA CTTCCTGAAGATCAACAAGGTGTTTGAGAAGGATCAGACCATCGACGATA GCTACAATCAGGCCAAGTTCTATTTTGATTCCCTGCACCAGAAGTTTATCG ACGCCGCCCTGGCCTCCGATAAGACATCCGAGCTGTCTTTCCAGAACTTTG CCGACGTGCTGGAGAAGCAGAATAAGATCATCCTGGATAAGAAGAGAGA GATGGGCGCCCTGAGGAAGCGCGACAAGAACGCCGTGGGCATCGATAGG CTGCAGAAGGAGATCAATGACGCCGAGGATATCATCCAGAAGGAGAAGG AGAAGATCTACAAGGACGTGCGCACCCTGTTCGATAACGAGGCCGAGTCT TGGAAAACCTACTATCAGGAGCGGGAGGTGGACGGCAAGAAGATCACCT TCAGCAAGGCCGACCTGAAGCAGAAGGGCGCCGATTTTCTGACAGCCGCC GGCATCCTGAAGGTGCTGAAGTATGAGTTCCCCGAGGAGAAGGAGAAGG AGTTTCAGGCCAAGAACCAGCCCTCCCTGTTCGTGGAGGAGAAGGAGAAT CCTGGCCAGAAGAGGTACATCTTCGACTCTTTTGATAAGTTCGCCGGCTAT CTGACCAAGTTTCAGCAGACAAAGAAGAATCTGTACGCAGCAGACGGCAC CAGCACAGCAGTGGCCACCCGCATCGCCGATAACTTTATCATCTTCCACC AGAATACCAAGGTGTTCCGGGACAAGTACAAGAACAATCACACAGACCT GGGCTTCGATGAGGAGAACATCTTTGAGATCGAGAGGTATAAGAATTGCC TGCTGCAGCGCGAGATCGAGCACATCAAGAATGAGAATAGCTACAACAA GATCATCGGCCGGATCAATAAGAAGATCAAGGAGTATCGGGACCAGAAG GCCAAGGATACCAAGCTGACAAAGTCCGACTTCCCTTTCTTTAAGAACCT GGATAAGCAGATCCTGGGCGAGGTGGAGAAGGAGAAGCAGCTGATCGAG AAAACCCGGGAGAAAACCGAGGAGGACGTGCTGATCGAGCGGTTCAAGG AGTTCATCGAGAACAATGAGGAGAGGTTCACCGCCGCCAAGAAGCTGATG AATGCCTTCTGTAACGGCGAGTTTGAGTCCGAGTACGAGGGCATCTATCT GAAGAATAAGGCCATCAACACAATCTCCCGGAGATGGTTCGTGTCTGACA GAGATTTTGAGCTGAAGCTGCCTCAGCAGAAGTCCAAGAACAAGTCTGAG AAGAATGAGCCAAAGGTGAAGAAGTTCATCTCCATCGCCGAGATCAAGA ACGCCGTGGAGGAGCTGGACGGCGATATCTTTAAGGCCGTGTTCTACGAC AAGAAGATCATCGCCCAGGGCGGCTCTAAGCTGGAGCAGTTCCTGGTCAT CTGGAAGTACGAGTTTGAGTATCTGTTCCGGGACATCGAGAGAGAGAACG GCGAGAAGCTGCTGGGCTATGATAGCTGCCTGAAGATCGCCAAGCAGCTG 96CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGCATCTTCCCACAGGAGAAGGAGGCCCGCGAGAAGGCAACCGCCGTGA TCAAGAATTACGCCGACGCCGGCCTGGGCATCTTCCAGATGATGAAGTAT TTTTCTCTGGACGATAAGGATCGGAAGAACACCCCCGGCCAGCTGAGCAC AAATTTCTACGCCGAGTATGACGGCTACTACAAGGATTTCGAGTTTATCAA GTACTACAACGAGTTTAGGAACTTCATCACCAAGAAGCCTTTCGACGAGG ATAAGATCAAGCTGAACTTTGAGAATGGCGCCCTGCTGAAGGGCTGGGAC GAGAACAAGGAGTACGATTTCATGGGCGTGATCCTGAAGAAGGAGGGCC GCCTGTATCTGGGCATCATGCACAAGAACCACCGGAAGCTGTTTCAGTCC ATGGGCAATGCCAAGGGCGACAACGCCAATAGATACCAGAAGATGATCT ATAAGCAGATCGCCGACGCCTCTAAGGATGTGCCCAGGCTGCTGCTGACC AGCAAGAAGGCCATGGAGAAGTTCAAGCCTTCCCAGGAGATCCTGAGAAT CAAGAAGGAGAAAACCTTCAAGCGGGAGAGCAAGAACTTTTCCCTGAGA GATCTGCACGCCCTGATCGAGTACTATAGGAACTGCATCCCTCAGTACAG CAATTGGTCCTTTTATGACTTCCAGTTTCAGGATACCGGCAAGTACCAGAA TATCAAGGAGTTCACAGACGATGTGCAGAAGTACGGCTATAAGATCTCCT TTCGCGACATCGACGATGAGTATATCAATCAGGCCCTGAACGAGGGCAAG ATGTACCTGTTCGAGGTGGTGAACAAGGATATCTATAACACCAAGAATGG CTCCAAGAATCTGCACACACTGTACTTTGAGCACATCCTGTCTGCCGAGAA CCTGAATGACCCAGTGTTCAAGCTGTCTGGCATGGCCGAGATCTTTCAGCG GCAGCCCAGCGTGAACGAAAGAGAGAAGATCACCACACAGAAGAATCAG TGTATCCTGGACAAGGGCGATAGAGCCTACAAGTATAGGCGCTACACCGA GAAGAAGATCATGTTCCACATGAGCCTGGTGCTGAACACAGGCAAGGGCG AGATCAAGCAGGTGCAGTTTAATAAGATCATCAACCAGAGGATCAGCTCC TCTGACAACGAGATGAGGGTGAATGTGATCGGCATCGATCGCGGCGAGAA GAACCTGCTGTACTATAGCGTGGTGAAGCAGAATGGCGAGATCATCGAGC AGGCCTCCCTGAACGAGATCAATGGCGTGAACTACCGGGACAAGCTGATC GAGAGGGAGAAGGAGCGCCTGAAGAACCGGCAGAGCTGGAAGCCTGTGG TGAAGATCAAGGATCTGAAGAAGGGCTACATCTCCCACGTGATCCACAAG ATCTGCCAGCTGATCGAGAAGTATTCTGCCATCGTGGTGCTGGAGGACCT GAATATGAGATTCAAGCAGATCAGGGGAGGAATCGAGCGGAGCGTGTAC CAGCAGTTCGAGAAGGCCCTGATCGATAAGCTGGGCTATCTGGTGTTTAA GGACAACAGGGATCTGAGGGCACCAGGAGGCGTGCTGAATGGCTACCAG CTGTCTGCCCCCTTTGTGAGCTTCGAGAAGATGCGCAAGCAGACCGGCAT CCTGTTCTACACACAGGCCGAGTATACCAGCAAGACAGACCCAATCACCG 97CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCTrTCGGAAGAACGTGTATATCTCTAATAGCGCCTCCCTGGATAAGATCA AGGAGGCCGTGAAGAAGTTCGACGCCATCGGCTGGGATGGCAAGGAGCA GTCTTACTTCTTTAAGTACAACCCTTACAACCTGGCCGACGAGAAGTATAA GAACTCTACCGTGAGCAAGGAGTGGGCCATCTTTGCCAGCGCCCCAAGAA TCCGGAGACAGAAGGGCGAGGACGGCTACTGGAAGTATGATAGGGTGAA AGTGAATGAGGAGTTCGAGAAGCTGCTGAAGGTCTGGAATTTTGTGAACC CAAAGGCCACAGATATCAAGCAGGAGATCATCAAGAAGGAGAAGGCAGG CGACCTGCAGGGAGAGAAGGAGCTGGATGGCCGGCTGAGAAACTTTTGG CACTCTTTCATCTACCTGTTTAACCTGGTGCTGGAGCTGCGCAATTCTTTCA GCCTGCAGATCAAGATCAAGGCAGGAGAAGTGATCGCAGTGGACGAGGG CGTGGACTTCATCGCCAGCCCAGTGAAGCCCTTCTTTACCACACCCAACCC TTACATCCCCTCCAACCTGTGCTGGCTGGCCGTGGAGAATGCAGACGCAA ACGGAGCCTATAATATCGCCAGGAAGGGCGTGATGATCCTGAAGAAGATC CGCGAGCACGCCAAGAAGGACCCCGAGTTCAAGAAGCTGCCAAACCTGTT TATCAGCAATGCAGAGTGGGACGAGGCAGCCCGGGATTGGGGCAAGTAC GCAGGCACCACAGCCCTGAACCTGGACCACAAAAGGCCGGCGGCCACGA AAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGT TCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATATGA TGTCCCCGACTATGCCTAA (SEQ ID NO: 22)

[00138] Smithella sp. SC_K08D17 (SsCpfl; pY009), including NLS and HA tag:

[00139] MQTLFENFTNQYPVSKTLRFELIPQGKTKDFIEQKGLLKKDE DRAEKYKKVKNIIDEYHKDFIEKSLNGLKLDGLEKYKTLYLKQEKDDKDKK AFDKEKENLRKQIANAFRNNEKFKTLFAKELIKNDLMSFACEEDKKNVKEFE AFTTYFTGFHQNRANMYVADEKRTAIASRLIHENLPKFIDNIKIFEKMKKEAP ELLSPFNQTLKDMKDVIKGTTLEEIFSLDYFNKTLTQSGIDIYNSVIGGRTPEEG KTKIKGLNEYINTDFNQKQTDKKKRQPKFKQLYKQILSDRQSLSFIAEAFKND TEILEAIEKFYVNELLHFSNEGKSTNVLDA1KNAVSNLESFNLTKMYFRSGASL TDVSRKVFGEWSIINRALDNYYATTYPIKPREKSEKYEERKEKWLKQDFNVS LIQTAIDEYDNETVKGKNSGKVIADYFAKFCDDKETDLIQKVNEGYIAVKDLL NTPCPENEKLGSNKDQVKQIKAFMDSIMDIMHFVRPLSLKDTDKEKDETFYS LFTPLYDHLTQTIALYNKVRNYLTQKPYSTEKIKLNFENSTLLGGWDLNKETD NTAIILRKDNLYYLGIMDKRHNRIFRNVPKADKKDFCYEKMVYKLLPGANK MLPKVFFSQSRIQEFTPSAKLLENYANETHKKGDNFNLNHCHKLIDFFKDSIN 98CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 KHEDWKNFDFRFSATSTYADLSGFYHEVEHQGYKISFQSVADSFIDDLVNEG KLYLFQIYNKDFSPFSKGKPNLHTLYWKMLFDENNLKDVVYKLNGEAEVFY RKKSIAEKNTTIHKANESIINKNPDNPKATSTFNYDIVKDKRYTIDKFQFHIPIT MNFKAEGIFNMNQRVNQFLKANPDINIIGIDRGERHLLYYALINQKGKILKQD TLNVIANEKQKVDYHNLLDKKEGDRATARQEWGVIETIKELKEGYLSQVIHK LTDLMIENNAIIVMEDLNFGFKRGRQKVEKQVYQKFEKMLIDKLNYLVDKN KKANELGGLLNAFQLANKFESFQKMGKQNGFIFYVPAWNTSKTDPATGFIDF LKPRYENLNQAKDFFEKFDSIRLNSKADYFEFAFDFKNFTEKADGGRTKWTV CTTNEDRYAWNRALNNNRGSQEKYDITAELKSLFDGKVDYKSGKDLKQQIA SQESADFFKALMKNLSITLSLRHNNGEKGDNEQDYILSPVADSKGRFFDSRKA DDDMPKNADANGAYHIALKGLWCLEQISKTDDLKKVKLAISNKEWLEFVQT LKGKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 23)

[00140] SEQ ID NO: 23 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00141] SEQ ID NO: 23 may be encoded by the following nucleotide sequence:

[00142] ATGCAGACCCTGTTTGAGAACTTCACAAATCAGTACCCA GTGTCCAAGACCCTGCGCTTTGAGCTGATCCCCCAGGGCAAGACAAAGGA CTTCATCGAGCAGAAGGGCCTGCTGAAGAAGGATGAGGACCGGGCCGAG AAGTATAAGAAGGTGAAGAACATCATCGATGAGTACCACAAGGACTTCAT CGAGAAGTCTCTGAATGGCCTGAAGCTGGACGGCCTGGAGAAGTACAAG ACCCTGTATCTGAAGCAGGAGAAGGACGATAAGGATAAGAAGGCCTTTG ACAAGGAGAAGGAGAACCTGCGCAAGCAGATCGCCAATGCCTTCCGGAA CAATGAGAAGTTTAAGACACTGTTCGCCAAGGAGCTGATCAAGAACGATC TGATGTCTTTCGCCTGCGAGGAGGACAAGAAGAATGTGAAGGAGTTTGAG GCCTTCACCACATACTTCACCGGCTTCCACCAGAACCGCGCCAATATGTAC GTGGCCGATGAGAAGAGAACAGCCATCGCCAGCAGGCTGATCCACGAGA ACCTGCCAAAGTTTATCGACAATATCAAGATCTTCGAGAAGATGAAGAAG GAGGCCCCCGAGCTGCTGTCTCCTTTCAACCAGACCCTGAAGGATATGAA GGACGTGATCAAGGGCACCACACTGGAGGAGATCTTTAGCCTGGATTATT TCAACAAGACCCTGACACAGAGCGGCATCGACATCTACAATTCCGTGATC 99CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGCGGCAGAACCCCTGAGGAGGGCAAGACAAAGATCAAGGGCCTGAACG AGTACATCAATACCGACTTCAACCAGAAGCAGACAGACAAGAAGAAGCG GCAGCCAAAGTTCAAGCAGCTGTATAAGCAGATCCTGAGCGATAGGCAGA GCCTGTCCTTTATCGCCGAGGCCTTCAAGAACGACACCGAGATCCTGGAG GCCATCGAGAAGTTTTACGTGAATGAGCTGCTGCACTTCAGCAATGAGGG CAAGTCCACAAACGTGCTGGACGCCATCAAGAATGCCGTGTCTAACCTGG AGAGCTTTAACCTGACCAAGATGTATTTCCGCTCCGGCGCCTCTCTGACAG ACGTGAGCCGGAAGGTGTTTGGCGAGTGGAGCATCATCAATAGAGCCCTG GACAACTACTATGCCACCACATATCCAATCAAGCCCAGAGAGAAGTCTGA GAAGTACGAGGAGAGGAAGGAGAAGTGGCTGAAGCAGGACTTCAACGTG AGCCTGATCCAGACCGCCATCGATGAGTACGACAACGAGACAGTGAAGG GCAAGAACAGCGGCAAAGTGATCGCCGATTATTTTGCCAAGTTCTGCGAC GATAAGGAGACAGACCTGATCCAGAAGGTGAACGAGGGCTACATCGCCG TGAAGGATCTGCTGAATACACCCTGTCCTGAGAACGAGAAGCTGGGCAGC AATAAGGACCAGGTGAAGCAGATCAAGGCCTTTATGGATTCTATCATGGA CATCATGCACTTCGTGCGCCCCCTGAGCCTGAAGGATACCGACAAGGAGA AGGATGAGACATTCTACTCCCTGTTCACACCTCTGTACGACCACCTGACCC AGACAATCGCCCTGTATAACAAGGTGCGGAACTATCTGACCCAGAAGCCT TACAGCACAGAGAAGATCAAGCTGAACTTCGAGAACAGCACCCTGCTGGG CGGCTGGGATCTGAATAAGGAGACAGACAACACAGCCATCATCCTGAGG AAGGATAACCTGTACTATCTGGGCATCATGGACAAGAGGCACAATCGCAT CTTTCGGAACGTGCCCAAGGCCGATAAGAAGGACTTCTGCTACGAGAAGA TGGTGTATAAGCTGCTGCCTGGCGCCAACAAGATGCTGCCAAAGGTGTTC TTTTCTCAGAGCAGAATCCAGGAGTTTACCCCTTCCGCCAAGCTGCTGGAG AACTACGCCAATGAGACACACAAGAAGGGCGATAATTTCAACCTGAATCA CTGTCACAAGCTGATCGATTTCTTTAAGGACTCTATCAACAAGCACGAGG ATTGGAAGAATTTCGACTTTAGGTTCAGCGCCACCTCCACCTACGCCGACC TGAGCGGCTTTTACCACGAGGTGGAGCACCAGGGCTACAAGATCTCTTTT CAGAGCGTGGCCGATTCCTTCATCGACGATCTGGTGAACGAGGGCAAGCT GTACCTGTTCCAGATCTATAATAAGGACTTTTCCCCATTCTCTAAGGGCAA GCCCAACCTGCACACCCTGTACTGGAAGATGCTGTTTGATGAGAACAATC TGAAGGACGTGGTGTATAAGCTGAATGGCGAGGCCGAGGTGTTCTACCGC AAGAAGAGCATTGCCGAGAAGAACACCACAATCCACAAGGCCAATGAGT CCATCATCAACAAGAATCCTGATAACCCAAAGGCCACCAGCACCTTCAAC 100CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TATGATATCGTGAAGGACAAGAGATACACCATCGACAAGTTTCAGTTCCA CATCCCAATCACAATGAACTTTAAGGCCGAGGGCATCTTCAACATGAATC AGAGGGTGAATCAGTTCCTGAAGGCCAATCCCGATATCAACATCATCGGC ATCGACAGAGGCGAGAGGCACCTGCTGTACTATGCCCTGATCAACCAGAA GGGCAAGATCCTGAAGCAGGATACCCTGAATGTGATCGCCAACGAGAAG CAGAAGGTGGACTACCACAATCTGCTGGATAAGAAGGAGGGCGACCGCG CAACCGCAAGGCAGGAGTGGGGCGTGATCGAGACAATCAAGGAGCTGAA GGAGGGCTATCTGTCCCAGGTCATCCACAAGCTGACCGATCTGATGATCG AGAACAATGCCATCATCGTGATGGAGGACCTGAACTTTGGCTTCAAGCGG GGCAGACAGAAGGTGGAGAAGCAGGTGTATCAGAAGTTTGAGAAGATGC TGATCGATAAGCTGAATTACCTGGTGGACAAGAATAAGAAGGCAAACGA GCTGGGAGGCCTGCTGAACGCATTCCAGCTGGCCAATAAGTTTGAGTCCT TCCAGAAGATGGGCAAGCAGAACGGCTTTATCTTCTACGTGCCCGCCTGG AATACCTCTAAGACAGATCCTGCCACCGGCTTTATCGACTTCCTGAAGCCC CGCTATGAGAACCTGAATCAGGCCAAGGATTTCTTTGAGAAGTTTGACTCT ATCCGGCTGAACAGCAAGGCCGATTACTTTGAGTTCGCCTTTGACTTCAAG AATTTCACCGAGAAGGCCGATGGCGGCAGAACCAAGTGGACAGTGTGCA CCACAAACGAGGACAGATATGCCTGGAATAGGGCCCTGAACAATAACAG GGGCAGCCAGGAGAAGTACGACATCACAGCCGAGCTGAAGTCCCTGTTCG ATGGCAAGGTGGACTATAAGTCTGGCAAGGATCTGAAGCAGCAGATCGCC AGCCAGGAGTCCGCCGACTTCTTTAAGGCCCTGATGAAGAACCTGTCCAT CACCCTGTCTCTGAGACACAATAACGGCGAGAAGGGCGATAATGAGCAG GACTACATCCTGTCCCCTGTGGCCGATTCTAAGGGCCGCTTCTTTGACTCC CGGAAGGCCGACGATGACATGCCAAAGAATGCCGACGCCAACGGCGCCT ATCACATCGCCCTGAAGGGCCTGTGGTGTCTGGAGCAGATCAGCAAGACC GATGACCTGAAGAAGGTGAAGCTGGCCATCTCCAACAAGGAGTGGCTGG AGTTCGTGCAGACACTGAAGGGCAAAAGGCCGGCGGCCACGAAAAAGGC CGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATT ACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCG ACTATGCCTAA (SEQ ID NO: 24)

[00143] Acidaminococcus sp. BV3L6 (AsCpfl; pYOlO), including NLS and HA tag:

[00144] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKA RNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNAL 101CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 IEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGT VTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFK ENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLY NQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDR NTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHK KLETISSALCDHWDTLRNALYERRISELTGKTTKSAKEKVQRSLKHEDINLQEn SAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKE1LKSQLDSLLGLY HLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEK FKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFE PTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIE PLE1TKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKW1DFTRDFLSKY TKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLY LFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSR MKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARAL LPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEH PETPnGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAA RQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGI AEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGT QSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKT GDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPV IENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVA LIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAY HIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNKRPAATKKAGQA KKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 25 )

[00145] SEQ ID NO: 25 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00146] SEQ ID NO: 25 may be encoded by the following nucleotide sequence:

[00147] ATGACACAGTTCGAGGGCTTTACCAACCTGTATCAGGTG AGCAAGACACTGCGGTTTGAGCTGATCCCACAGGGCAAGACCCTGAAGCA CATCCAGGAGCAGGGCTTCATCGAGGAGGACAAGGCCCGCAATGATCACT ACAAGGAGCTGAAGCCCATCATCGATCGGATCTACAAGACCTATGCCGAC 102CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CAGTGCCTGCAGCTGGTGCAGCTGGATTGGGAGAACCTGAGCGCCGCCAT CGACTCCTATAGAAAGGAGAAAACCGAGGAGACAAGGAACGCCCTGATC GAGGAGCAGGCCACATATCGCAATGCCATCCACGACTACTTCATCGGCCG GACAGACAACCTGACCGATGCCATCAATAAGAGACACGCCGAGATCTAC AAGGGCCTGTTCAAGGCCGAGCTGTTTAATGGCAAGGTGCTGAAGCAGCT GGGCACCGTGACCACAACCGAGCACGAGAACGCCCTGCTGCGGAGCTTCG ACAAGTTTACAACCTACTTCTCCGGCTTTTATGAGAACAGGAAGAACGTG TTCAGCGCCGAGGATATCAGCACAGCCATCCCACACCGCATCGTGCAGGA CAACTTCCCCAAGTTTAAGGAGAATTGTCACATCTTCACACGCCTGATCAC CGCCGTGCCCAGCCTGCGGGAGCACTTTGAGAACGTGAAGAAGGCCATCG GCATCTTCGTGAGCACCTCCATCGAGGAGGTGTTTTCCTTCCCTTTTTATA ACCAGCTGCTGACACAGACCCAGATCGACCTGTATAACCAGCTGCTGGGA GGAATCTCTCGGGAGGCAGGCACCGAGAAGATCAAGGGCCTGAACGAGG TGCTGAATCTGGCCATCCAGAAGAATGATGAGACAGCCCACATCATCGCC TCCCTGCCACACAGATTCATCCCCCTGTTTAAGCAGATCCTGTCCGATAGG AACACCCTGTCTTTCATCCTGGAGGAGTTTAAGAGCGACGAGGAAGTGAT CCAGTCCTTCTGCAAGTACAAGACACTGCTGAGAAACGAGAACGTGCTGG AGACAGCCGAGGCCCTGTTTAACGAGCTGAACAGCATCGACCTGACACAC ATCTTCATCAGCCACAAGAAGCTGGAGACAATCAGCAGCGCCCTGTGCGA CCACTGGGATACACTGAGGAATGCCCTGTATGAGCGGAGAATCTCCGAGC TGACAGGCAAGATCACCAAGTCTGCCAAGGAGAAGGTGCAGCGCAGCCT GAAGCACGAGGATATCAACCTGCAGGAGATCATCTCTGCCGCAGGCAAGG AGCTGAGCGAGGCCTTCAAGCAGAAAACCAGCGAGATCCTGTCCCACGCA CACGCCGCCCTGGATCAGCCACTGCCTACAACCCTGAAGAAGCAGGAGGA GAAGGAGATCCTGAAGTCTCAGCTGGACAGCCTGCTGGGCCTGTACCACC TGCTGGACTGGTTTGCCGTGGATGAGTCCAACGAGGTGGACCCCGAGTTC TCTGCCCGGCTGACCGGCATCAAGCTGGAGATGGAGCCTTCTCTGAGCTTC TACAACAAGGCCAGAAATTATGCCACCAAGAAGCCCTACTCCGTGGAGAA GTTCAAGCTGAACTTTCAGATGCCTACACTGGCCTCTGGCTGGGACGTGA ATAAGGAGAAGAACAATGGCGCCATCCTGTTTGTGAAGAACGGCCTGTAC TATCTGGGCATCATGCCAAAGCAGAAGGGCAGGTATAAGGCCCTGAGCTT CGAGCCCACAGAGAAAACCAGCGAGGGCTTTGATAAGATGTACTATGACT ACTTCCCTGATGCCGCCAAGATGATCCCAAAGTGCAGCACCCAGCTGAAG GCCGTGACAGCCCACTTTCAGACCCACACAACCCCCATCCTGCTGTCCAA 103CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CAATTTCATCGAGCCTCTGGAGATCACAAAGGAGATCTACGACCTGAACA ATCCTGAGAAGGAGCCAAAGAAGTTTCAGACAGCCTACGCCAAGAAAAC CGGCGACCAGAAGGGCTACAGAGAGGCCCTGTGCAAGTGGATCGACTTCA CAAGGGATTTTCTGTCCAAGTATACCAAGACAACCTCTATCGATCTGTCTA GCCTGCGGCCATCCTCTCAGTATAAGGACCTGGGCGAGTACTATGCCGAG CTGAATCCCCTGCTGTACCACATCAGCTTCCAGAGAATCGCCGAGAAGGA GATCATGGATGCCGTGGAGACAGGCAAGCTGTACCTGTTCCAGATCTATA ACAAGGACTTTGCCAAGGGCCACCACGGCAAGCCTAATCTGCACACACTG TATTGGACCGGCCTGTTTTCTCCAGAGAACCTGGCCAAGACAAGCATCAA GCTGAATGGCCAGGCCGAGCTGTTCTACCGCCCTAAGTCCAGGATGAAGA GGATGGCACACCGGCTGGGAGAGAAGATGCTGAACAAGAAGCTGAAGGA TCAGAAAACCCCAATCCCCGACACCCTGTACCAGGAGCTGTACGACTATG TGAATCACAGACTGTCCCACGACCTGTCTGATGAGGCCAGGGCCCTGCTG CCCAACGTGATCACCAAGGAGGTGTCTCACGAGATCATCAAGGATAGGCG CTTTACCAGCGACAAGTTCTTTTTCCACGTGCCTATCACACTGAACTATCA GGCCGCCAATTCCCCATCTAAGTTCAACCAGAGGGTGAATGCCTACCTGA AGGAGCACCCCGAGACACCTATCATCGGCATCGATCGGGGCGAGAGAAA CCTGATCTATATCACAGTGATCGACTCCACCGGCAAGATCCTGGAGCAGC GGAGCCTGAACACCATCCAGCAGTTTGATTACCAGAAGAAGCTGGACAAC AGGGAGAAGGAGAGGGTGGCAGCAAGGCAGGCCTGGTCTGTGGTGGGCA CAATCAAGGATCTGAAGCAGGGCTATCTGAGCCAGGTCATCCACGAGATC GTGGACCTGATGATCCACTACCAGGCCGTGGTGGTGCTGGAGAACCTGAA TTTCGGCTTTAAGAGCAAGAGGACCGGCATCGCCGAGAAGGCCGTGTACC AGCAGTTCGAGAAGATGCTGATCGATAAGCTGAATTGCCTGGTGCTGAAG GACTATCCAGCAGAGAAAGTGGGAGGCGTGCTGAACCCATACCAGCTGAC AGACCAGTTCACCTCCTTTGCCAAGATGGGCACCCAGTCTGGCTTCCTGTT TTACGTGCCTGCCCCATATACATCTAAGATCGATCCCCTGACCGGCTTCGT GGACCCCTTCGTGTGGAAAACCATCAAGAATCACGAGAGCCGCAAGCACT TCCTGGAGGGCTTCGACTTTCTGCACTACGACGTGAAAACCGGCGACTTC ATCCTGCACTTTAAGATGAACAGAAATCTGTCCTTCCAGAGGGGCCTGCC CGGCTTTATGCCTGCATGGGATATCGTGTTCGAGAAGAACGAGACACAGT TTGACGCCAAGGGCACCCCTTTCATCGCCGGCAAGAGAATCGTGCCAGTG ATCGAGAATCACAGATTCACCGGCAGATACCGGGACCTGTATCCTGCCAA CGAGCTGATCGCCCTGCTGGAGGAGAAGGGCATCGTGTTCAGGGATGGCT 104CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCAACATCCTGCCAAAGCTGCTGGAGAATGACGATTCTCACGCCATCGAC ACCATGGTGGCCCTGATCCGCAGCGTGCTGCAGATGCGGAACTCCAATGC CGCCACAGGCGAGGACTATATCAACAGCCCCGTGCGCGATCTGAATGGCG TGTGCTTCGACTCCCGGTTTCAGAACCCAGAGTGGCCCATGGACGCCGAT GCCAATGGCGCCTACCACATCGCCCTGAAGGGCCAGCTGCTGCTGAATCA CCTGAAGGAGAGCAAGGATCTGAAGCTGCAGAACGGCATCTCCAATCAG GACTGGCTGGCCTACATCCAGGAGCTGCGCAACAAAAGGCCGGCGGCCA CGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGA TGTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATA TGATGTCCCCGACTATGCCTAA (SEQ ID NO: 26)

[00148] Lachnospiraceae bacterium MA2020 (Lb2Cpfl; pYOl1), including NLS and HA tag:

[00149] MYYESLTKQYPVSKTIRNELIPIGKTLDNIRQNNILESDVKR KQNYEHVKGILDEYHKQLINEALDNCTLPSLKIAAEIYLKNQKEVSDREDFNK TQDLLRKEVVEKLKAHENFTKIGKKDILDLLEKLPSISEDDYNALESFRNFYT YFTSYNKVRENLYSDKEKSSTVAYRLINENFPKFLDNVKSYRFVKTAGILADG LGEEEQDSLFIVETFNKTLTQDGIDTYNSQVGKINSSINLYNQKNQKANGFRKI PKMKMLYKQILSDREESFIDEFQSDEVLIDNVESYGSVLIESLKSSKVSAFFDA LRESKGKNVYVKNDLAKTAMSNIVFENWRTFDDLLNQEYDLANENKKKDD KYFEKRQKELKKNKSYSLEHLCNLSEDSCNLIENYIHQISDDIENIIINNETFLRI VINEHDRSRKLAKNRKAVKAIKDFLDSIKVLERELKLINSSGQELEKDLIVYSA HEELLVELKQVDSLYNMTRNYLTKKPFSTEKVKLNFNRSTLLNGWDRNKET DNLGVLLLKDGKYYLGIMNTSANKAFVNPPVAKTEKVFKKVDYKLLPVPNQ MLPKVFFAKSNIDFYNPSSEIYSNYKKGTHKKGNMFSLEDCHNLIDFFKESISK HEDWSKFGFKFSDTASYNDISEFYREVEKQGYKLTYTDIDETYINDLIERNEL YLFQIYNKDFSMYSKGKLNLHTLYFMMLFDQRNIDDVVYKLNGEAEVFYRP ASISEDELITHKAGEEIKNKNPNRARTKETSTFSYDIVKDKRYSKDKFTLHIPIT MNFGVDEVKRFNDAVNSAIRIDENVNV1GIDRGERNLLYVVVIDSKGNILEQ1S LNSIINKEYDIETDYHALLDEREGGRDKARKDWNTVENIRDLKAGYLSQVVN VVAKLVLKYNAIICLEDLNFGFKRGRQKVEKQVYQKFEKMLIDKLNYLVIDK SREQTSPKELGGALNALQLTSKFKSFKELGKQSGVIYYVPAYLTSKIDPTTGF ANLFYMKCENVEKSKRFFDGFDHRFNALENVFEFGFDYRSFTQRACGINSK WTVCTNGERIIKYRNPDKNNMFDEKVVVVTDEMKNLFEQYKIPYEDGRNVK DMIISNEEAEFYRRLYRLLQQTLQMRNSTSDGTRDYIISPVKNKREAYFNSELS 105CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 DGSVPKDADANGAYNIARKGLWVLEQIRQKSEGEKINLAMTNAEWLEYAQT HLLKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 27)

[00150] SEQ ID NO: 27 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00151] SEQ ID NO: 27 may be encoded by the following nucleotide sequence:

[00152] ATGTACTATGAGTCCCTGACCAAGCAGTACCCCGTGTCTA AGACAATCCGGAATGAGCTGATCCCTATCGGCAAGACACTGGATAACATC CGCCAGAACAATATCCTGGAGAGCGACGTGAAGCGGAAGCAGAACTACG AGCACGTGAAGGGCATCCTGGATGAGTATCACAAGCAGCTGATCAACGAG GCCCTGGACAATTGCACCCTGCCATCCCTGAAGATCGCCGCCGAGATCTA CCTGAAGAATCAGAAGGAGGTGTCTGACAGAGAGGATTTCAACAAGACA CAGGACCTGCTGAGGAAGGAGGTGGTGGAGAAGCTGAAGGCCCACGAGA ACTTTACCAAGATCGGCAAGAAGGACATCCTGGATCTGCTGGAGAAGCTG CCTTCCATCTCTGAGGACGATTACAATGCCCTGGAGAGCTTCCGCAACTTT TACACCTATTTCACATCCTACAACAAGGTGCGGGAGAATCTGTATTCTGAT AAGGAGAAGAGCTCCACAGTGGCCTACAGACTGATCAACGAGAATTTCCC AAAGTTTCTGGACAATGTGAAGAGCTATAGGTTTGTGAAAACCGCAGGCA TCCTGGCAGATGGCCTGGGAGAGGAGGAGCAGGACTCCCTGTTCATCGTG GAGACATTCAACAAGACCCTGACACAGGACGGCATCGATACCTACAATTC TCAAGTGGGCAAGATCAACTCTAGCATCAATCTGTATAACCAGAAGAATC AGAAGGCCAATGGCTTCAGAAAGATCCCCAAGATGAAGATGCTGTATAAG CAGATCCTGTCCGATAGGGAGGAGTCTTTCATCGACGAGTTTCAGAGCGA TGAGGTGCTGATCGACAACGTGGAGTCTTATGGCAGCGTGCTGATCGAGT CTCTGAAGTCCTCTAAGGTGAGCGCCTTCTTTGATGCCCTGAGAGAGTCTA AGGGCAAGAACGTGTACGTGAAGAATGACCTGGCCAAGACAGCCATGAG CAACATCGTGTTCGAGAATTGGAGGACCTTTGACGATCTGCTGAACCAGG AGTACGACCTGGCCAACGAGAACAAGAAGAAGGACGATAAGTATTTCGA GAAGCGCCAGAAGGAGCTGAAGAAGAATAAGAGCTACTCCCTGGAGCAC CTGTGCAACCTGTCCGAGGATTCTTGTAACCTGATCGAGAATTATATCCAC CAGATCTCCGACGATATCGAGAATATCATCATCAACAATGAGACATTCCT 106CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCGCATCGTGATCAATGAGCACGACAGGTCCCGCAAGCTGGCCAAGAACC GGAAGGCCGTGAAGGCCATCAAGGACTTTCTGGATTCTATCAAGGTGCTG GAGCGGGAGCTGAAGCTGATCAACAGCTCCGGCCAGGAGCTGGAGAAGG ATCTGATCGTGTACTCTGCCCACGAGGAGCTGCTGGTGGAGCTGAAGCAG GTGGACAGCCTGTATAACATGACCAGAAATTATCTGACAAAGAAGCCTTT CTCTACCGAGAAGGTGAAGCTGAACTTTAATCGCAGCACACTGCTGAACG GCTGGGATCGGAATAAGGAGACAGACAACCTGGGCGTGCTGCTGCTGAA GGACGGCAAGTACTATCTGGGCATCATGAACACAAGCGCCAATAAGGCCT TCGTGAATCCCCCTGTGGCCAAGACCGAGAAGGTGTTTAAGAAGGTGGAT TACAAGCTGCTGCCAGTGCCCAACCAGATGCTGCCAAAGGTGTTCTTTGCC AAGAGCAATATCGACTTCTATAACCCCTCTAGCGAGATCTACTCCAATTAT AAGAAGGGCACCCACAAGAAGGGCAATATGTTTTCCCTGGAGGATTGTCA CAACCTGATCGACTTCTTTAAGGAGTCTATCAGCAAGCACGAGGACTGGA GCAAGTTCGGCTTTAAGTTCAGCGATACAGCCTCCTACAACGACATCTCCG AGTTCTATCGCGAGGTGGAGAAGCAGGGCTACAAGCTGACCTATACAGAC ATCGATGAGACATACATCAATGATCTGATCGAGCGGAACGAGCTGTACCT GTTCCAGATCTATAATAAGGACTTTAGCATGTACTCCAAGGGCAAGCTGA ACCTGCACACACTGTATTTCATGATGCTGTTTGATCAGCGCAATATCGACG ACGTGGTGTATAAGCTGAACGGAGAGGCAGAGGTGTTCTATAGGCCAGCC TCCATCTCTGAGGACGAGCTGATCATCCACAAGGCCGGCGAGGAGATCAA GAACAAGAATCCTAACCGGGCCAGAACCAAGGAGACAAGCACCTTCAGC TACGACATCGTGAAGGATAAGCGGTATAGCAAGGATAAGTTTACCCTGCA CATCCCCATCACAATGAACTTCGGCGTGGATGAGGTGAAGCGGTTCAACG ACGCCGTGAACAGCGCCATCCGGATCGATGAGAATGTGAACGTGATCGGC ATCGACCGGGGCGAGAGAAATCTGCTGTACGTGGTGGTCATCGACTCTAA GGGCAACATCCTGGAGCAGATCTCCCTGAACTCTATCATCAATAAGGAGT ACGACATCGAGACAGATTATCACGCACTGCTGGATGAGAGGGAGGGCGG CAGAGATAAGGCCCGGAAGGACTGGAACACCGTGGAGAATATCAGGGAC CTGAAGGCCGGCTACCTGAGCCAGGTGGTGAACGTGGTGGCCAAGCTGGT GCTGAAGTATAATGCCATCATCTGCCTGGAGGACCTGAACTTTGGCTTCAA GAGGGGCCGCCAGAAGGTGGAGAAGCAGGTGTACCAGAAGTTCGAGAAG ATGCTGATCGATAAGCTGAATTACCTGGTCATCGACAAGAGCCGCGAGCA GACATCCCCTAAGGAGCTGGGAGGCGCCCTGAACGCACTGCAGCTGACCT CTAAGTTCAAGAGCTTTAAGGAGCTGGGCAAGCAGTCCGGCGTGATCTAC 107CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TATGTGCCTGCCTACCTGACCTCTAAGATCGATCCAACCACAGGCTTCGCC AATCTGTTTTATATGAAGTGTGAGAACGTGGAGAAGTCCAAGAGATTCTT TGACGGCTTTGATTTCATCAGGTTCAACGCCCTGGAGAACGTGTTCGAGTT CGGCTTTGACTACCGGAGCTTCACCCAGAGGGCCTGCGGCATCAATTCCA AGTGGACCGTGTGCACCAACGGCGAGCGCATCATCAAGTATCGGAATCCA GATAAGAACAATATGTTCGACGAGAAGGTGGTGGTGGTGACCGATGAGAT GAAGAACCTGTTTGAGCAGTACAAGATCCCCTATGAGGATGGCAGAAATG TGAAGGACATGATCATCAGCAACGAGGAGGCCGAGTTCTACCGGAGACTG TATAGGCTGCTGCAGCAGACCCTGCAGATGAGAAACAGCACCTCCGACGG CACAAGGGATTACATCATCTCCCCTGTGAAGAATAAGAGAGAGGCCTACT TCAACAGCGAGCTGTCCGACGGCTCTGTGCCAAAGGACGCCGATGCCAAC GGCGCCTACAATATCGCCAGAAAGGGCCTGTGGGTGCTGGAGCAGATCAG GCAGAAGAGCGAGGGCGAGAAGATCAATCTGGCCATGACCAACGCCGAG TGGCTGGAGTATGCCCAGACACACCTGCTGAAAAGGCCGGCGGCCACGA AAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGT TCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATATGA TGTCCCCGACTATGCCTAA (SEQ ID NO: 28)

[00153] Candidatus Methanuplasma termitum (CMtCpfl; pY012), including NLS and HA tag:

[00154] MNNYDEFTKLYPIQKTIRFELKPQGRTMEHLETFNFFEEDRD RAEKYKILKEAIDEYHKKFIDEHLTNMSLDWNSLKQISEKYYKSREEKDKKV FLSEQKRMRQEIVSEFKKDDRFKDLFSKKLFSELLKEEIYKKGNHQEIDALKSF DKFSGYFIGLHENRKNMYSDGDEITAISNRIVNENFPKFLDNLQKYQEARKKY PEWIIKAESALVAHNIKMDEVFSLEYFNKVLNQEGIQRYNLALGGYVTKSGE KMMGLNDALNLAHQSEKSSKGRIHMTPLFKQILSEKESFSYIPDVFTEDSQLL PSIGGFFAQIENDKDGNIFDRALELISSYAEYDTERIYIRQADINRVSNVIFGEW GTLGGLMREYKADSINDINLERTCKKVDKWLDSKEFALSDVLEAIKRTGNND AFNEYISKMRTAREKIDAARKEMKFISEKISGDEESIH1IKTLLDSVQQFLHFFN LFKARQDIPLDGAFYAEFDEVHSKLFAIVPLYNKVRNYLTKNNLNTKKIKLNF KNPTLANGWDQNKVYDYASLIFLRDGNYYLGIINPKRKKNIKFEQGSGNGPF YRKMVYKQIPGPNKNLPRVFLTSTKGKKEYKPSKEIIEGYEADKHTRGDKFDL DFCHKLIDFFKESIEKHKDWSKFNFYFSPTESYGDISEFYLDVEKQGYRMHFE NISAETIDEYVEKGDLFLFQIYNKDFVKAATGKKDMHTIYWNAAFSPENLQD VVVKLNGEAELFYRDKSDIKEIVHREGEILVNRTYNGRTPVPDKIHKKLTDYH 108CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NGRTKDLGEAKEYLDKVRYFKAHYDITKDRRYLNDKIYFHVPLTLNFKANG KKNLNKMVIEKFLSDEKAHIIGIDRGERNLLYYSIIDRSGKIIDQQSLNVIDGFD YREKLNQREIEMKDARQSWNAIGKIKDLKEGYLSKAVHEITKMAIQYNAIVV MEELNYGFKRGRFKVEKQIYQKFENMLIDKMNYLVFKDAPDESPGGVLNAY QLTNPLESFAKLGKQTGILFYVPAAYTSKIDPTTGFVNLFNTSSKTNAQERKEF LQKFESISYSAKDGGIFAFAFDYRKFGTSKTDHKNVWTAYTNGERMRYIKEK KRNELFDPSKE1KEALTSSGIKYDGGQNILPD1LRSNNNGL1YTMYSSFIAAIQM RVYDGKEDYIISPIKNSKGEFFRTDPKRRELPIDADANGAYNIALRGELTMRAI AEKFDPDSEKMAKLELKHKDWFEFMQTRGDKRPAATKKAGQAKKKKGSYP YDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 29)

[00155] SEQ ID NO: 29 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00156] SEQ ID NO: 29 may be encoded by the following nucleotide sequence:

[00157] ATGAACAATTACGACGAGTTCACCAAGCTGTATCCTATC CAGAAAACCATCCGGTTTGAGCTGAAGCCACAGGGCAGAACCATGGAGC ACCTGGAGACATTCAACTTCTTTGAGGAGGACCGGGATAGAGCCGAGAAG TATAAGATCCTGAAGGAGGCCATCGACGAGTACCACAAGAAGTTTATCGA TGAGCACCTGACCAATATGTCCCTGGATTGGAACTCTCTGAAGCAGATCA GCGAGAAGTACTATAAGAGCAGGGAGGAGAAGGACAAGAAGGTGTTCCT GTCCGAGCAGAAGAGGATGCGCCAGGAGATCGTGTCTGAGTTTAAGAAG GACGATCGCTTCAAGGACCTGTTTTCCAAGAAGCTGTTCTCTGAGCTGCTG AAGGAGGAGATCTACAAGAAGGGCAACCACCAGGAGATCGACGCCCTGA AGAGCTTCGATAAGTTTTCCGGCTATTTCATCGGCCTGCACGAGAATAGG AAGAACATGTACTCCGACGGCGATGAGATCACCGCCATCTCCAATCGCAT CGTGAATGAGAACTTCCCCAAGTTTCTGGATAACCTGCAGAAGTACCAGG AGGCCAGGAAGAAGTATCCTGAGTGGATCATCAAGGCCGAGAGCGCCCT GGTGGCCCACAATATCAAGATGGACGAGGTGTTCTCCCTGGAGTACTTTA ATAAGGTGCTGAACCAGGAGGGCATCCAGCGGTACAACCTGGCCCTGGGC GGCTATGTGACCAAGAGCGGCGAGAAGATGATGGGCCTGAATGATGCCCT GAACCTGGCCCACCAGTCCGAGAAGAGCTCCAAGGGCAGAATCCACATG ACCCCCCTGTTCAAGCAGATCCTGTCCGAGAAGGAGTCCTTCTCTTACATC 109CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCCGACGTGTTTACAGAGGATTCTCAGCTGCTGCCTAGCATCGGCGGCTTC TTTGCCCAGATCGAGAATGACAAGGATGGCAACATCTTCGACCGGGCCCT GGAGCTGATCTCTAGCTACGCCGAGTATGATACCGAGCGGATCTATATCA GACAGGCCGACATCAATAGAGTGTCCAACGTGATCTTTGGAGAGTGGGGC ACCCTGGGAGGCCTGATGAGGGAGTACAAGGCCGACTCTATCAATGATAT CAACCTGGAGCGCACATGCAAGAAGGTGGACAAGTGGCTGGATTCTAAG GAGTTTGCCCTGAGCGATGTGCTGGAGGCCATCAAGAGGACCGGCAACAA TGACGCCTTCAACGAGTATATCTCCAAGATGCGGACAGCCAGAGAGAAGA TCGATGCCGCCCGCAAGGAGATGAAGTTCATCAGCGAGAAGATCTCCGGC GATGAGGAGTCTATCCACATCATCAAGACCCTGCTGGACAGCGTGCAGCA GTTCCTGCACTTCTTTAATCTGTTTAAGGCAAGGCAGGACATCCCACTGGA TGGAGCCTTCTACGCCGAGTTTGACGAGGTGCACAGCAAGCTGTTTGCCA TCGTGCCCCTGTATAACAAGGTGCGGAACTATCTGACCAAGAACAATCTG AACACAAAGAAGATCAAGCTGAATTTCAAGAACCCTACACTGGCCAATGG CTGGGACCAGAACAAGGTGTACGATTATGCCTCCCTGATCTTTCTGCGGG ACGGCAATTACTATCTGGGCATCATCAATCCTAAGAGAAAGAAGAACATC AAGTTCGAGCAGGGCTCTGGCAACGGCCCCTTCTACCGGAAGATGGTGTA TAAGCAGATCCCCGGCCCTAATAAGAACCTGCCAAGAGTGTTCCTGACCT CCACAAAGGGCAAGAAGGAGTATAAGCCCTCTAAGGAGATCATCGAGGG CTACGAGGCCGACAAGCACATCAGGGGCGATAAGTTCGACCTGGATTTTT GTCACAAGCTGATCGATTTCTTTAAGGAGTCCATCGAGAAGCACAAGGAC TGGTCTAAGTTCAACTTCTACTTCAGCCCAACCGAGAGCTATGGCGACATC TCTGAGTTCTACCTGGATGTGGAGAAGCAGGGCTATCGCATGCACTTTGA GAATATCAGCGCCGAGACAATCGACGAGTATGTGGAGAAGGGCGATCTGT TTCTGTTCCAGATCTACAACAAGGATTTTGTGAAGGCCGCCACCGGCAAG AAGGACATGCACACAATCTACTGGAATGCCGCCTTCAGCCCCGAGAACCT GCAGGACGTGGTGGTGAAGCTGAACGGCGAGGCCGAGCTGTTTTATAGGG ACAAGTCCGATATCAAGGAGATCGTGCACCGCGAGGGCGAGATCCTGGTG AATAGGACCTACAACGGCCGCACACCAGTGCCCGACAAGATCCACAAGA AGCTGACCGATTATCACAATGGCCGGACAAAGGACCTGGGCGAGGCCAA GGAGTACCTGGATAAGGTGAGATACTTCAAGGCCCACTATGACATCACCA AGGATCGGAGATACCTGAACGACAAGATCTATTTCCACGTGCCTCTGACC CTGAACTTCAAGGCCAACGGCAAGAAGAATCTGAACAAGATGGTCATCGA GAAGTTCCTGTCCGATGAGAAGGCCCACATCATCGGCATCGACAGGGGCG 110CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGCGCAATCTGCTGTACTATTCCATCATCGACAGGTCTGGCAAGATCATCG ATCAGCAGAGCCTGAATGTGATCGACGGCTTTGATTATCGGGAGAAGCTG AACCAGAGAGAGATCGAGATGAAGGATGCCCGCCAGTCTTGGAACGCCA TCGGCAAGATCAAGGACCTGAAGGAGGGCTACCTGAGCAAGGCCGTGCA CGAGATCACCAAGATGGCCATCCAGTATAATGCCATCGTGGTCATGGAGG AGCTGAACTACGGCTTCAAGCGGGGCCGGTTCAAGGTGGAGAAGCAGATC TATCAGAAGTTCGAGAATATGCTGATCGATAAGATGAACTACCTGGTGTT TAAGGACGCACCTGATGAGTCCCCAGGAGGCGTGCTGAATGCCTACCAGC TGACAAACCCACTGGAGTCTTTCGCCAAGCTGGGCAAGCAGACCGGCATC CTGTTTTACGTGCCAGCCGCCTATACATCCAAGATCGACCCCACCACAGG CTTCGTGAATCTGTTTAACACCTCCTCTAAGACAAACGCCCAGGAGCGGA AGGAGTTCCTGCAGAAGTTTGAGAGCATCTCCTATTCTGCCAAGGATGGC GGCATCTTTGCCTTCGCCTTTGACTACAGAAAGTTCGGCACCAGCAAGAC AGATCACAAGAACGTGTGGACCGCCTATACAAACGGCGAGAGGATGCGC TACATCAAGGAGAAGAAGCGGAATGAGCTGTTTGACCCTTCTAAGGAGAT CAAGGAGGCCCTGACCAGCTCCGGCATCAAGTACGATGGCGGCCAGAAC ATCCTGCCAGACATCCTGAGGAGCAACAATAACGGCCTGATCTACACAAT GTATTCTAGCTTCATCGCCGCCATCCAGATGCGCGTGTACGACGGCAAGG AGGATTATATCATCAGCCCCATCAAGAACTCCAAGGGCGAGTTCTTTAGG ACCGACCCCAAGAGGCGCGAGCTGCCTATCGACGCCGATGCCAATGGCGC CTACAACATCGCCCTGAGGGGAGAGCTGACAATGAGGGCAATCGCAGAG AAGTTCGACCCTGATAGCGAGAAGATGGCCAAGCTGGAGCTGAAGCACA AGGATTGGTTCGAGTTTATGCAGACCAGAGGCGACAAAAGGCCGGCGGCC ACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACG ATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCAT ATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 30)

[00158] Euhacterium eligens (EeCpfl ; pY013), including NLS and HA tag:

[00159] MNGNRS1VYREFVGVIPVAKTLRNELRPVGHTQEHIIQNGL1 QEDELRQEKSTELKNIMDDYYREYIDKSLSGVTDLDFTLLFELMNLVQSSPSK DNKKALEKEQSKMREQICTHLQSDSNYKNIFNAKLLKEILPDFIKNYNQYDV KDKAGKLETLALFNGFSTYFTDFFEKRKNVFTKEAVSTSTAYRIVHENSLIFLA NMTSYKKISEKALDEIEV1EKNNQDKMGDWELNQ1FNPDFYNMVLIQSGIDFY NEICGWNAHMNLYCQQTKNNYNLFKMRKLHKQILAYTSTSFEVPKMFEDD MSVYNAVNAFIDETEKGNIIGKLKDIVNKYDELDEKRIYISKDFYETLSCFMSG 111CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NWNLITGCVENFYDENIHAKGKSKEEKVKKAVKEDKYKSINDVNDLVEKYI DEKERNEFKNSNAKQYIREISNIITDTETAHLEYDDHISLIESEEKADEMKKRL DMYMNMYHWAKAFIVDEVLDRDEMFYSDIDDIYNILENIVPLYNRVRNYVT QKPYNSKKIKLNFQSPTLANGWSQSKEFDNNAIILIRDNKYYLAIFNAKNKPD KKIIQGNSDKKNDNDYKKMVYNLLPGANKMLPKVFLSKKGIETFKPSDYIISG YNAHKHIKTSENFDISFCRDLIDYFKNSIEKHAEWRKYEFKFSATDSYSDISEF YREVEMQGYR1DWTY1SEADINKLDEEGK1YLFQ1YNKDFAENSTGKENLHT MYFKNIFSEENLKDIIIKLNGQAELFYRRASVKNPVKHKKDSVLVNKTYKNQL DNGDWRIPIPDDIYNEIYKMYNGYIKESDLSEAAKEYLDKVEVRTAQKDIVK DYRYTVDKYFIHTPITINYKVTARNNVNDMVVKYIAQNDDIHVIGIDRGERNL IYISVIDSHGNIVKQKSYNILNNYDYKKKLVEKEKTREYARKNWKS1GNIKEL KEGYISGVVHEIAMLIVEYNAIIAMEDLNYGFKRGRFKVERQVYQKFESMLIN KLNYFASKEKSVDEPGGLLKGYQLTYVPDNIKNLGKQCGVIFYVPAAFTSKID PSTGFISAFNFKSISTNASRKQFFMQFDEIRYCAEKDMFSFGFDYNNFDTYNIT MGKTQWTVYTNGERLQSEFNNARRTGKTKSINLTETIKLLLEDNEINYADGH DIRIDMEKMDEDKKSEFFAQLLSLYKLTVQMRNSYTEAEEQENGISYDKIISP VINDEGEFFDSDNYKESDDKECKMPKDADANGAYCIALKGLYEVLKIKSEWT EDGFDRNCLKLPHAEWLDFIQNKRYEKRPAATKKAGQAKKKKGSYPYDVPD YAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 31)

[00160] SEQ ID NO: 31 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00161] SEQ ID NO: 31 may be encoded by the following nucleotide sequence:

[00162] ATGAACGGCAATAGGTCCATCGTGTACCGCGAGTTCGTG GGCGTGATCCCCGTGGCCAAGACCCTGAGGAATGAGCTGCGCCCTGTGGG CCACACACAGGAGCACATCATCCAGAACGGCCTGATCCAGGAGGACGAG CTGCGGCAGGAGAAGAGCACCGAGCTGAAGAACATCATGGACGATTACT ATAGAGAGTACATCGATAAGTCTCTGAGCGGCGTGACCGACCTGGACTTC ACCCTGCTGTTCGAGCTGATGAACCTGGTGCAGAGCTCCCCCTCCAAGGA CAATAAGAAGGCCCTGGAGAAGGAGCAGTCTAAGATGAGGGAGCAGATC TGCACCCACCTGCAGTCCGACTCTAACTACAAGAATATCTTTAACGCCAA GCTGCTGAAGGAGATCCTGCCTGATTTCATCAAGAACTACAATCAGTATG 112CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ACGTGAAGGATAAGGCCGGCAAGCTGGAGACACTGGCCCTGTTTAATGGC TTCAGCACATACTTTACCGACTTCTTTGAGAAGAGGAAGAACGTGTTCACC AAGGAGGCCGTGAGCACATCCATCGCCTACCGCATCGTGCACGAGAACTC CCTGATCTTCCTGGCCAATATGACCTCTTATAAGAAGATCAGCGAGAAGG CCCTGGATGAGATCGAAGTGATCGAGAAGAACAATCAGGACAAGATGGG CGATTGGGAGCTGAATCAGATCTTTAACCCTGACTTCTACAATATGGTGCT GATCCAGTCCGGCATCGACTTCTACAACGAGATCTGCGGCGTGGTGAATG CCCACATGAACCTGTACTGTCAGCAGACCAAGAACAATTATAACCTGTTC AAGATGCGGAAGCTGCACAAGCAGATCCTGGCCTACACCAGCACCAGCTT CGAGGTGCCCAAGATGTTCGAGGACGATATGAGCGTGTATAACGCCGTGA ACGCCTTCATCGACGAGACAGAGAAGGGCAACATCATCGGCAAGCTGAA GGATATCGTGAATAAGTACGACGAGCTGGATGAGAAGAGAATCTATATCA GCAAGGACTTTTACGAGACACTGAGCTGCTTCATGTCCGGCAACTGGAAT CTGATCACAGGCTGCGTGGAGAACTTCTACGATGAGAACATCCACGCCAA GGGCAAGTCCAAGGAGGAGAAGGTGAAGAAGGCCGTGAAGGAGGACAA GTACAAGTCTATCAATGACGTGAACGATCTGGTGGAGAAGTATATCGATG AGAAGGAGAGGAATGAGTTCAAGAACAGCAATGCCAAGCAGTACATCCG CGAGATCTCCAACATCATCACCGACACAGAGACAGCCCACCTGGAGTATG ACGATCACATCTCTCTGATCGAGAGCGAGGAGAAGGCCGACGAGATGAA GAAGCGGCTGGATATGTATATGAACATGTACCACTGGGCCAAGGCCTTTA TCGTGGACGAGGTGCTGGACAGAGATGAGATGTTCTACAGCGATATCGAC GATATCTATAATATCCTGGAGAACATCGTGCCACTGTATAATCGGGTGAG AAACTACGTGACCCAGAAGCCCTACAACTCTAAGAAGATCAAGCTGAATT TCCAGAGCCCTACACTGGCCAATGGCTGGTCCCAGTCTAAGGAGTTCGAC AACAATGCCATCATCCTGATCAGAGATAACAAGTACTATCTGGCCATCTTC AATGCCAAGAACAAGCCAGACAAGAAGATCATCCAGGGCAACTCCGATA AGAAGAACGACAACGATTACAAGAAGATGGTGTATAACCTGCTGCCAGG CGCCAACAAGATGCTGCCCAAGGTGTTTCTGTCTAAGAAGGGCATCGAGA CATTCAAGCCCTCCGACTATATCATCTCTGGCTACAACGCCCACAAGCAC ATCAAGACAAGCGAGAATTTTGATATCTCCTTCTGTCGGGACCTGATCGAT TACTTCAAGAACAGCATCGAGAAGCACGCCGAGTGGAGAAAGTATGAGTT CAAGTTTTCCGCCACCGACAGCTACTCCGATATCTCTGAGTTCTATCGGGA GGTGGAGATGCAGGGCTACAGAATCGACTGGACATATATCAGCGAGGCC GACATCAACAAGCTGGATGAGGAGGGCAAGATCTATCTGTTTCAGATCTA 113CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CAATAAGGATTTCGCCGAGAACAGCACCGGCAAGGAGAATCTGCACACA ATGTACTTTAAGAACATCTTCTCCGAGGAGAATCTGAAGGACATCATCAT CAAGCTGAACGGCCAGGCCGAGCTGTTTTATCGGAGAGCCTCTGTGAAGA ATCCCGTGAAGCACAAGAAGGATAGCGTGCTGGTGAACAAGACCTACAA GAATCAGCTGGACAACGGCGACGTGGTGAGAATCCCCATCCCTGACGATA TCTATAACGAGATCTACAAGATGTATAATGGCTACATCAAGGAGTCCGAC CTGTCTGAGGCCGCCAAGGAGTACCTGGATAAGGTGGAGGTGAGGACCGC CCAGAAGGACATCGTGAAGGATTACCGCTATACAGTGGACAAGTACTTCA TCCACACACCTATCACCATCAACTATAAGGTGACCGCCCGCAACAATGTG AATGATATGGTGGTGAAGTACATCGCCCAGAACGACGATATCCACGTGAT CGGCATCGACCGGGGCGAGAGAAACCTGATCTACATCTCCGTGATCGATT CTCACGGCAACATCGTGAAGCAGAAATCCTACAACATCCTGAACAACTAC GACTACAAGAAGAAGCTGGTGGAGAAGGAGAAAACCCGGGAGTACGCCA GAAAGAACTGGAAGAGCATCGGCAATATCAAGGAGCTGAAGGAGGGCTA TATCTCCGGCGTGGTGCACGAGATCGCCATGCTGATCGTGGAGTACAACG CCATCATCGCCATGGAGGACCTGAATTATGGCTTTAAGAGGGGCCGCTTC AAGGTGGAGCGGCAGGTGTACCAGAAGTTTGAGAGCATGCTGATCAATAA GCTGAACTATTTCGCCAGCAAGGAGAAGTCCGTGGACGAGCCAGGAGGCC TGCTGAAGGGCTATCAGCTGACCTACGTGCCCGATAATATCAAGAACCTG GGCAAGCAGTGCGGCGTGATCTTTTACGTGCCTGCCGCCTTCACCAGCAA GATCGACCCATCCACAGGCTTTATCTCTGCCTTCAACTTTAAGTCTATCAG CACAAATGCCTCTCGGAAGCAGTTCTTTATGCAGTTTGACGAGATCAGAT ACTGTGCCGAGAAGGATATGTTCAGCTTTGGCTTCGACTACAACAACTTCG ATACCTACAACATCACAATGGGCAAGACACAGTGGACCGTGTATACAAAC GGCGAGAGACTGCAGTCTGAGTTCAACAATGCCAGGCGCACCGGCAAGA CAAAGAGCATCAATCTGACAGAGACAATCAAGCTGCTGCTGGAGGACAAT GAGATCAACTACGCCGACGGCCACGATATCAGGATCGATATGGAGAAGAT GGACGAGGATAAGAAGAGCGAGTTCTTTGCCCAGCTGCTGAGCCTGTATA AGCTGACCGTGCAGATGCGCAATTCCTATACAGAGGCCGAGGAGCAGGA GAACGGCATCTCTTACGACAAGATCATCAGCCCTGTGATCAATGATGAGG GCGAGTTCTTTGACTCCGATAACTATAAGGAGTCTGACGATAAGGAGTGC AAGATGCCAAAGGACGCCGATGCCAACGGCGCCTACTGTATCGCCCTGAA GGGCCTGTATGAGGTGCTGAAGATCAAGAGCGAGTGGACCGAGGACGGC TTTGATAGGAATTGCCTGAAGCTGCCACACGCAGAGTGGCTGGACTTCAT 114CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCAGAACAAGCGGTACGAGAAAAGGCCGGCGGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGC TTATCCCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTA TGCCTAA (SEQ ID NO: 32)

[00163] Moraxella bovoculi 237 (MbCpfl; pY014). including NLS and HA tag:

[00164] MLFQDFTHLYPLSKTVRFELKPIDRTLEH1HAKNFLSQDETM ADMHQKVKVILDDYHRDFIADMMGEVKLTKLAEFYDVYLKFRKNPKDDEL QKQLKDLQAVLRKEIVKPIGNGGKYKAGYDRLFGAKLFKDGKELGDLAKFVI AQEGESSPKLAHLAHFEKFSTYFTGFHDNRKNMYSDEDKHTAIAYRLIHENLP RFIDNLQILTT1KQKHSALYDQ1INELTASGLDVSLASHLDGYHKLLTQEGITA YNTLLGGISGEAGSPKIQGINELINSHHNQHCHKSERIAKLRPLHKQILSDGMS VSFLPSKFADDSEMCQAVNEFYRHYADVFAKVQSLFDGFDDHQKDGIYVEH KNLNELSKQAFGDFALLGRVLDGYYVDVVNPEFNERFAKAKTDNAKAKLTK EKDKFIKGVHSLASLEQAIEHYTARHDDESVQAGKLGQYFKHGLAGVDNPIQ KIHNNHSTIKGFLERERPAGERALPKIKSGKNPEMTQLRQLKELLDNALNVAH FAKLLTTKTTLDNQDGNFYGEFGVLYDELAKIPTLYNKVRDYLSQKPFSTEK YKLNFGNPTLLNGWDLNKEKDNFGVILQKDGCYYLALLDKAHKKVFDNAP NTGKSIYQKMIYKYLEVRKQFPKVFFSKEAIAINYHPSKELVEIKDKGRQRSD DERLKLYRHLECLKIHPKYDKKFEGAIGDIQLFKKDKKGREVPISEKDLFDKI NGIFSSKPKLEMEDFFIGEFKRYNPSQDLVDQYNIYKKIDSNDNRKKENFYNN HPKFKKDLVRYYYESMCKHEEWEESFEFSKKLQDIGCYVDVNELFTEIETRRL NYKISFCNINADYIDELVEQGQLYLFQIYNKDFSPKAHGKPNLHTLYFKALFSE DNLADPIYKLNGEAQIFYRKASLDMNETTIHRAGEVLENKNPDNPKKRQFVY DIIKDKRYTQDKFMLHVPITMNFGVQGMTIKEFNKKVNQSIQQYDEVNVIGID RGERHLLYLTVINSKGEILEQCSLNDITTASANGTQMTTPYHKILDKREIERLN ARVGWGEIETIKELKSGYLSHVVHQISQLMLKYNAIVVLEDLNFGFKRGRFK VEKQIYQNFENALIKKLNHLVLKDKADDEIGSYKNALQLTNNFTDLKSIGKQT GFLFYVPAWNTSKIDPETGFVDLLKPRYENIAQSQAFFGKFDKICYNADKDYF EFHIDYAKFTDKAKNSRQIWTICSHGDKRYVYDKTANQNKGAAKGINVNDE LKSLFARHHINEKQPNLVMDICQNNDKEFHKSLMYLLKTLLALRYSNASSDE DFILSPVANDEGVFFNSALADDTQPQNADANGAYHIALKGLWLLNELKNSDD LNKVKLAIDNQTWLNFAQNRKRPAATKKAGQAKKKKGSYPYDVPDYAYPY DVPDYAYPYDVPDYA (SEQ ID NO: 33) 115CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00165] SEQ ID NO: 33 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00166] SEQ ID NO: 33 may be encoded by the following nucleotide sequence:

[00167] ATGCTGTTCCAGGACTTTACCCACCTGTATCCACTGTCCA AGACAGTGAGATTTGAGCTGAAGCCCATCGATAGGACCCTGGAGCACATC CACGCCAAGAACTTCCTGTCTCAGGACGAGACAATGGCCGATATGCACCA GAAGGTGAAAGTGATCCTGGACGATTACCACCGCGACTTCATCGCCGATA TGATGGGCGAGGTGAAGCTGACCAAGCTGGCCGAGTTCTATGACGTGTAC CTGAAGTTTCGGAAGAACCCAAAGGACGATGAGCTGCAGAAGCAGCTGA AGGATCTGCAGGCCGTGCTGAGAAAGGAGATCGTGAAGCCCATCGGCAAT GGCGGCAAGTATAAGGCCGGCTACGACAGGCTGTTCGGCGCCAAGCTGTT TAAGGACGGCAAGGAGCTGGGCGATCTGGCCAAGTTCGTGATCGCACAGG AGGGAGAGAGCTCCCCAAAGCTGGCCCACCTGGCCCACTTCGAGAAGTTT TCCACCTATTTCACAGGCTTTCACGATAACCGGAAGAATATGTATTCTGAC GAGGATAAGCACACCGCCATCGCCTACCGCCTGATCCACGAGAACCTGCC CCGGTTTATCGACAATCTGCAGATCCTGACCACAATCAAGCAGAAGCACT CTGCCCTGTACGATCAGATCATCAACGAGCTGACCGCCAGCGGCCTGGAC GTGTCTCTGGCCAGCCACCTGGATGGCTATCACAAGCTGCTGACACAGGA GGGCATCACCGCCTACAATACACTGCTGGGAGGAATCTCCGGAGAGGCAG GCTCTCCTAAGATCCAGGGCATCAACGAGCTGATCAATTCTCACCACAAC CAGCACTGCCACAAGAGCGAGAGAATCGCCAAGCTGAGGCCACTGCACA AGCAGATCCTGTCCGACGGCATGAGCGTGTCCTTCCTGCCCTCTAAGTTTG CCGACGATAGCGAGATGTGCCAGGCCGTGAACGAGTTCTATCGCCACTAC GCCGACGTGTTCGCCAAGGTGCAGAGCCTGTTCGACGGCTTTGACGATCA CCAGAAGGATGGCATCTACGTGGAGCACAAGAACCTGAATGAGCTGTCCA AGCAGGCCTTCGGCGACTTTGCACTGCTGGGACGCGTGCTGGACGGATAC TATGTGGATGTGGTGAATCCAGAGTTCAACGAGCGGTTTGCCAAGGCCAA GACCGACAATGCCAAGGCCAAGCTGACAAAGGAGAAGGATAAGTTCATC AAGGGCGTGCACTCCCTGGCCTCTCTGGAGCAGGCCATCGAGCACTATAC CGCAAGGCACGACGATGAGAGCGTGCAGGCAGGCAAGCTGGGACAGTAC TTCAAGCACGGCCTGGCCGGAGTGGACAACCCCATCCAGAAGATCCACAA 116CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CAATCACAGCACCATCAAGGGCTTTCTGGAGAGGGAGCGCCCTGCAGGAG AGAGAGCCCTGCCAAAGATCAAGTCCGGCAAGAATCCTGAGATGACACA GCTGAGGCAGCTGAAGGAGCTGCTGGATAACGCCCTGAATGTGGCCCACT TCGCCAAGCTGCTGACCACAAAGACCACACTGGACAATCAGGATGGCAAC TTCTATGGCGAGTTTGGCGTGCTGTACGACGAGCTGGCCAAGATCCCCAC CCTGTATAACAAGGTGAGAGATTACCTGAGCCAGAAGCCTTTCTCCACCG AGAAGTACAAGCTGAACTTTGGCAATCCAACACTGCTGAATGGCTGGGAC CTGAACAAGGAGAAGGATAATTTCGGCGTGATCCTGCAGAAGGACGGCTG CTACTATCTGGCCCTGCTGGACAAGGCCCACAAGAAGGTGTTTGATAACG CCCCTAATACAGGCAAGAGCATCTATCAGAAGATGATCTATAAGTACCTG GAGGTGAGGAAGCAGTTCCCCAAGGTGTTCTTTTCCAAGGAGGCCATCGC CATCAACTACCACCCTTCTAAGGAGCTGGTGGAGATCAAGGACAAGGGCC GGCAGAGATCCGACGATGAGCGCCTGAAGCTGTATCGGTTTATCCTGGAG TGTCTGAAGATCCACCCTAAGTACGATAAGAAGTTCGAGGGCGCCATCGG CGACATCCAGCTGTTTAAGAAGGATAAGAAGGGCAGAGAGGTGCCAATC AGCGAGAAGGACCTGTTCGATAAGATCAACGGCATCTTTTCTAGCAAGCC TAAGCTGGAGATGGAGGACTTCTTTATCGGCGAGTTCAAGAGGTATAACC CAAGCCAGGACCTGGTGGATCAGTATAATATCTACAAGAAGATCGACTCC AACGATAATCGCAAGAAGGAGAATTTCTACAACAATCACCCCAAGTTTAA GAAGGATCTGGTGCGGTACTATTACGAGTCTATGTGCAAGCACGAGGAGT GGGAGGAGAGCTTCGAGTTTTCCAAGAAGCTGCAGGACATCGGCTGTTAC GTGGATGTGAACGAGCTGTTTACCGAGATCGAGACACGGAGACTGAATTA TAAGATCTCCTTCTGCAACATCAATGCCGACTACATCGATGAGCTGGTGG AGCAGGGCCAGCTGTATCTGTTCCAGATCTACAACAAGGACTTTTCCCCA AAGGCCCACGGCAAGCCCAATCTGCACACCCTGTACTTCAAGGCCCTGTT TTCTGAGGACAACCTGGCCGATCCTATCTATAAGCTGAATGGCGAGGCCC AGATCTTCTACAGAAAGGCCTCCCTGGACATGAACGAGACAACAATCCAC AGGGCCGGCGAGGTGCTGGAGAACAAGAATCCCGATAATCCTAAGAAGA GACAGTTCGTGTACGACATCATCAAGGATAAGAGGTACACACAGGACAA GTTCATGCTGCACGTGCCAATCACCATGAACTTTGGCGTGCAGGGCATGA CAATCAAGGAGTTCAATAAGAAGGTGAACCAGTCTATCCAGCAGTATGAC GAGGTGAACGTGATCGGCATCGATCGGGGCGAGAGACACCTGCTGTACCT GACCGTGATCAATAGCAAGGGCGAGATCCTGGAGCAGTGTTCCCTGAACG ACATCACCACAGCCTCTGCCAATGGCACACAGATGACCACACCTTACCAC 117CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AAGATCCTGGATAAGAGGGAGATCGAGCGCCTGAACGCCCGGGTGGGAT GGGGCGAGATCGAGACAATCAAGGAGCTGAAGTCTGGCTATCTGAGCCAC GTGGTGCACCAGATCAGCCAGCTGATGCTGAAGTACAACGCCATCGTGGT GCTGGAGGACCTGAATTTCGGCTTTAAGAGGGGCCGCTTTAAGGTGGAGA AGCAGATCTATCAGAACTTCGAGAATGCCCTGATCAAGAAGCTGAACCAC CTGGTGCTGAAGGACAAGGCCGACGATGAGATCGGCTCTTACAAGAATGC CCTGCAGCTGACCAACAATTTCACAGATCTGAAGAGCATCGGCAAGCAGA CCGGCTTCCTGTTTTATGTGCCCGCCTGGAACACCTCTAAGATCGACCCTG AGACAGGCTTTGTGGATCTGCTGAAGCCAAGATACGAGAACATCGCCCAG AGCCAGGCCTTCTTTGGCAAGTTCGACAAGATCTGCTATAATGCCGACAA GGATTACTTCGAGTTTCACATCGACTACGCCAAGTTTACCGATAAGGCCA AGAATAGCCGCCAGATCTGGACAATCTGTTCCCACGGCGACAAGCGGTAC GTGTACGATAAGACAGCCAACCAGAATAAGGGCGCCGCCAAGGGCATCA ACGTGAATGATGAGCTGAAGTCCCTGTTCGCCCGCCACCACATCAACGAG AAGCAGCCCAACCTGGTCATGGACATCTGCCAGAACAATGATAAGGAGTT TCACAAGTCTCTGATGTACCTGCTGAAAACCCTGCTGGCCCTGCGGTACAG CAACGCCTCCTCTGACGAGGATTTCATCCTGTCCCCCGTGGCAAACGACG AGGGCGTGTTCTTTAATAGCGCCCTGGCCGACGATACACAGCCTCAGAAT GCCGATGCCAACGGCGCCTACCACATCGCCCTGAAGGGCCTGTGGCTGCT GAATGAGCTGAAGAACTCCGACGATCTGAACAAGGTGAAGCTGGCCATCG ACAATCAGACCTGGCTGAATTTCGCCCAGAACAGGAAAAGGCCGGCGGC CACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATAC GATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCA TATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 34)

[00168] Leptospira inadai (LiCpfl; pY015), including NLS and HA tag:

[00169] MEDYSGFVNIYSIQKTLRFELKPVGKTLEHIEKKGFLKKDKI RAEDYKAVKKIIDKYHRAYIEEVFDSVLHQKKKKDKTRFSTQFIKEIKEFSELY YKTEKNIPDKERLEALSEKLRKMLVGAFKGEFSEEVAEKYKNLFSKELIRNEI EKFCETDEERKQVSNFKSFTTYFTGFHSNRQNIYSDEKKSTAIGYRIIHQNLPK FLDNLKIIESIQRRFKDFPWSDLKKNLKKIDKNIKLTEYFSIDGFVNVLNQKGID AYNTILGGKSEESGEKIQGLNEYINLYRQKNNIDRKNLPNVKILFKQILGDRET KSFIPEAFPDDQSVLNSITEFAKYLKLDKKKKSI1AELKKFLSSFNRYELDGIYL ANDNSLASISTFLFDDWSFIKKSVSFKYDESVGDPKKKIKSPLKYEKEKEKWL KQKYYTISFLNDAIESYSKSQDEKRVKIRLEAYFAEFKSKDDAKKQFDLLERIE 118CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 EAYAIVEPLLGAEYPRDRNLKADKKEVGKIKDFLDSIKSLQFFLKPLLSAEIFD EKDLGFYNQLEGYYEEIDSIGHLYNKVRNYLTGKIYSKEKFKLNFENSTLLKG WDENREVANLCVIFREDQKYYLGVMDKENNTILSDIPKVKPNELFYEKMVY KLIPTPHMQLPRIIFSSDNLSIYNPSKSILKIREAKSFKEGKNFKLKDCHKFIDFY KESISKNEDWSRFDFKFSKTSSYENISEFYREVERQGYNLDFKKVSKFYIDSLV EDGKLYLFQIYNKDFSIFSKGKPNLHTIYFRSLFSKENLKDVCLKLNGEAEMFF RKKSINYDEKKKREGHHPELFEKLKYP1LKDKRYSEDKFQFHLPISLNFKSKER LNFNLKVNEFLKRNKDINIIGIDRGERNLLYLVMINQKGEILKQTLLDSMQSG KGRPEIN YKEKLQEKEIERDKARKSWGTVENIKELKEGYLSIVIHQISKLMVE NNAIVVLEDLNIGFKRGRQKVERQVYQKFEKMLIDKLNFLVFKENKPTEPGG VLKAYQLTDEFQSFEKLSKQTGFLFYVPSWNTSKIDPRTGF1DFLHPAYENIEK AKQWINKFDSIRFNSKMDWFEFTADTRKFSENLMLGKNRVWVICTTNVERYF TSKTANSSIQYNSIQITEKLKELFVDIPFSNGQDLKPEILRKNDAVFFKSLLFYIK TTLSLRQNNGKKGEEEKDFILSPVVDSKGRFFNSLEASDDEPKDADANGAYHI ALKGLMNLLVLNETKEENLSRPKWKIKNKDWLEFVWERNRKRPAATKKAG QAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 35)

[00170] SEQ ID NO: 35 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00171] SEQ ID NO: 35 may be encoded by the following nucleotide sequence:

[00172] ATGGAGGACTATTCCGGCTTTGTGAACATCTACTCTATCC AGAAAACCCTGAGGTTCGAGCTGAAGCCAGTGGGCAAGACACTGGAGCA CATCGAGAAGAAGGGCTTCCTGAAGAAGGACAAGATCCGGGCCGAGGAT TACAAGGCCGTGAAGAAGATCATCGATAAGTACCACAGAGCCTATATCGA GGAGGTGTTTGATTCCGTGCTGCACCAGAAGAAGAAGAAGGACAAGACC CGCTTTTCTACACAGTTCATCAAGGAGATCAAGGAGTTCAGCGAGCTGTA CTATAAGACCGAGAAGAACATCCCCGACAAGGAGAGGCTGGAGGCCCTG AGCGAGAAGCTGCGCAAGATGCTGGTGGGCGCCTTTAAGGGCGAGTTCTC CGAGGAGGTGGCCGAGAAGTATAAGAACCTGTTTTCTAAGGAGCTGATCA GGAATGAGATCGAGAAGTTCTGCGAGACAGACGAGGAGCGCAAGCAGGT GTCTAACTTCAAGAGCTTCACCACATACTTTACCGGCTTCCACTCCAACAG GCAGAATATCTATTCCGACGAGAAGAAGTCTACAGCCATCGGCTACCGCA 119CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TCATCCACCAGAACCTGCCTAAGTTCCTGGATAATCTGAAGATCATCGAGT CCATCCAGCGGCGGTTCAAGGACTTCCCATGGTCTGATCTGAAGAAGAAC CTGAAGAAGATCGATAAGAATATCAAGCTGACCGAGTACTTCAGCATCGA CGGCTTCGTGAACGTGCTGAATCAGAAGGGCATCGATGCCTACAACACAA TCCTGGGCGGCAAGTCCGAGGAGTCTGGCGAGAAGATCCAGGGCCTGAAC GAGTACATCAATCTGTATCGGCAGAAGAACAATATCGACAGAAAGAACCT GCCCAATGTGAAGATCCTGTTTAAGCAGATCCTGGGCGATAGGGAGACAA AGAGCTTTATCCCTGAGGCCTTCCCAGACGATCAGTCCGTGCTGAACTCTA TCACAGAGTTCGCCAAGTACCTGAAGCTGGATAAGAAGAAGAAGAGCAT CATCGCCGAGCTGAAGAAGTTTCTGAGCTCCTTCAATCGCTACGAGCTGG ACGGCATCTATCTGGCCAACGATAATAGCCTGGCCTCTATCAGCACCTTCC TGTTTGACGATTGGTCCTTTATCAAGAAGTCCGTGTCTTTCAAGTATGACG AGTCCGTGGGCGACCCCAAGAAGAAGATCAAGTCTCCCCTGAAGTACGAG AAGGAGAAGGAGAAGTGGCTGAAGCAGAAGTACTATACAATCTCTTTCCT GAACGATGCCATCGAGAGCTATTCCAAGTCTCAGGACGAGAAGAGGGTG AAGATCCGCCTGGAGGCCTACTTTGCCGAGTTCAAGAGCAAGGACGATGC CAAGAAGCAGTTCGACCTGCTGGAGAGGATCGAGGAGGCCTATGCCATCG TGGAGCCTCTGCTGGGAGCAGAGTACCCAAGGGACCGCAACCTGAAGGC CGATAAGAAGGAAGTGGGCAAGATCAAGGACTTCCTGGATAGCATCAAG TCCCTGCAGTTCTTTCTGAAGCCTCTGCTGTCCGCCGAGATCTTTGACGAG AAGGATCTGGGCTTCTACAATCAGCTGGAGGGCTACTATGAGGAGATCGA TTCTATCGGCCACCTGTATAACAAGGTGCGGAATTATCTGACCGGCAAGA TCTACAGCAAGGAGAAGTTTAAGCTGAACTTCGAGAACAGCACCCTGCTG AAGGGCTGGGACGAGAACCGGGAGGTGGCCAATCTGTGCGTGATCTTCAG AGAGGACCAGAAGTACTATCTGGGCGTGATGGATAAGGAGAACAATACC ATCCTGTCCGACATCCCCAAGGTGAAGCCTAACGAGCTGTTTTACGAGAA GATGGTGTATAAGCTGATCCCCACACCTCACATGCAGCTGCCCCGGATCA TCTTCTCTAGCGACAACCTGTCTATCTATAATCCTAGCAAGTCCATCCTGA AGATCAGAGAGGCCAAGAGCTTTAAGGAGGGCAAGAACTTCAAGCTGAA GGACTGTCACAAGTTTATCGATTTCTACAAGGAGTCTATCAGCAAGAATG AGGACTGGAGCAGATTCGACTTCAAGTTCAGCAAGACCAGCAGCTACGAG AACATCAGCGAGTTTTACCGGGAGGTGGAGAGACAGGGCTATAACCTGGA CTTCAAGAAGGTGTCTAAGTTCTACATCGACAGCCTGGTGGAGGATGGCA AGCTGTACCTGTTCCAGATCTATAACAAGGACTTTTCTATCTTCAGCAAGG 120CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCAAGCCCAATCTGCACACCATCTATTTTCGGTCCCTGTTCTCTAAGGAGA ACCTGAAGGACGTGTGCCTGAAGCTGAATGGCGAGGCCGAGATGTTCTTT CGGAAGAAGTCCATCAACTACGATGAGAAGAAGAAGCGGGAGGGCCACC ACCCCGAGCTGTTTGAGAAGCTGAAGTATCCTATCCTGAAGGACAAGAGA TACAGCGAGGATAAGTTTCAGTTCCACCTGCCCATCAGCCTGAACTTCAA GTCCAAGGAGCGGCTGAACTTTAATCTGAAAGTGAATGAGTTCCTGAAGA GAAACAAGGACATCAATATCATCGGCATCGATCGGGGCGAGAGAAACCT GCTGTACCTGGTCATGATCAATCAGAAGGGCGAGATCCTGAAGCAGACCC TGCTGGACAGCATGCAGTCCGGCAAGGGCCGGCCTGAGATCAACTACAAG GAGAAGCTGCAGGAGAAGGAGATCGAGAGGGATAAGGCCCGCAAGAGCT GGGGCACAGTGGAGAATATCAAGGAGCTGAAGGAGGGCTATCTGTCTATC GTGATCCACCAGATCAGCAAGCTGATGGTGGAGAACAATGCCATCGTGGT GCTGGAGGACCTGAACATCGGCTTTAAGCGGGGCAGACAGAAGGTGGAG CGGCAGGTGTACCAGAAGTTCGAGAAGATGCTGATCGATAAGCTGAACTT TCTGGTGTTCAAGGAGAATAAGCCAACCGAGCCAGGAGGCGTGCTGAAG GCCTATCAGCTGACAGACGAGTTTCAGTCTTTCGAGAAGCTGAGCAAGCA GACCGGCTTTCTGTTCTACGTGCCAAGCTGGAACACCTCCAAGATCGACC CCAGAACAGGCTTTATCGATTTCCTGCACCCTGCCTACGAGAATATCGAG AAGGCCAAGCAGTGGATCAACAAGTTTGATTCCATCAGGTTCAATTCTAA GATGGACTGGTTTGAGTTCACCGCCGATACACGCAAGTTTTCCGAGAACC TGATGCTGGGCAAGAATCGGGTGTGGGTCATCTGCACCACAAATGTGGAG CGGTACTTCACCAGCAAGACCGCCAACAGCTCCATCCAGTACAATAGCAT CCAGATCACCGAGAAGCTGAAGGAGCTGTTTGTGGACATCCCTTTCAGCA ACGGCCAGGATCTGAAGCCAGAGATCCTGAGGAAGAATGACGCCGTGTTC TTTAAGAGCCTGCTGTTTTACATCAAGACCACACTGTCCCTGCGCCAGAAC AATGGCAAGAAGGGCGAGGAGGAGAAGGACTTCATCCTGAGCCCAGTGG TGGATTCCAAGGGCCGGTTCTTTAACTCTCTGGAGGCCAGCGACGATGAG CCCAAGGACGCCGATGCCAATGGCGCCTACCACATCGCCCTGAAGGGCCT GATGAACCTGCTGGTGCTGAATGAGACAAAGGAGGAGAACCTGAGCAGA CCAAAGTGGAAGATCAAGAATAAGGACTGGCTGGAGTTCGTGTGGGAGA GGAACCGCAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAA AGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTAC GACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 36) 121CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00173] Lachnospiraceae bacterium ND2006 (LbCpfl; pY016), including NLS and HA tag:

[00174] MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDE KRAEDYKGVKKLLDRYYLSFINDVLHSIKLKNLNNYISLFRKKTRTEKENKEL ENLEINLRKEIAKAFKGNEGYKSLFKKDIIETILPEFLDDKDEIALVNSFNGFTT AFTGFFDNRENMFSEEAKSTSIAFRCINENLTRYISNMDIFEKVDAIFDKHEVQ E1KEKILNSDYDVEDFFEGEFFNFVLTQEGIDVYNAI1GGFVTESGEK1KGLNEY INLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNKN SEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNVIRDKWNAEY DDIHLKKKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEinQ KVDEIYKVYGSSEKLFDADFVLEKSLKKNDAVVAIMKDLLDSVKSFENYIKA FFGEGKETNRDESFYGDFVLAYDILLKVDHIYDAIRNYVTQKPYSKDKFKLYF QNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKKYAKCLQKIDKDDVN GNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDIQKIYKNGTFKKGDM FNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYK VSFESASKKEVDKLVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDEN NHGQIRLSGGAELFMRRASLKKEELVVHPANSPIANKNPDNPKKTTTLSYDV YKDKRFSEDQYELHIPIAINKCPKNIFKINTEVRVLLKHDDNPYVIGIDRGERN LLYIVWDGKGNIVEQYSLNEIINNFNGIRIKTDYHSLLDKKEKERFEARQNW TSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSGFKNSRVKVEKQVY QKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGFIFY IPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISSFDRIMYVPEEDLFEFALDYK NFSRTDADYIKKWKLYSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKY GINYQQGDIRALLCEQSDKAFYSSFMALMSLMLQMRNSITGRTDVDFLISPVK NSDGIFYDSRNYEAQENAILPKNADANGAYNIARKVLWAIGQFKKAEDEKLD KVKIAISNKEWLEYAQTSVKHKRPAATKKAGQAKKKKGSYPYDVPDYAYPY DVPDYAYPYDVPDYA (SEQ ID NO: 37)

[00175] SEQ ID NO: 37 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00176] SEQ ID NO: 37 may be encoded by the following nucleotide sequence: 122CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00177] ATGAGCAAGCTGGAGAAGTTTACAAACTGCTACTCCCTG TCTAAGACCCTGAGGTTCAAGGCCATCCCTGTGGGCAAGACCCAGGAGAA CATCGACAATAAGCGGCTGCTGGTGGAGGACGAGAAGAGAGCCGAGGAT TATAAGGGCGTGAAGAAGCTGCTGGATCGCTACTATCTGTCTTTTATCAAC GACGTGCTGCACAGCATCAAGCTGAAGAATCTGAACAATTACATCAGCCT GTTCCGGAAGAAAACCAGAACCGAGAAGGAGAATAAGGAGCTGGAGAAC CTGGAGATCAATCTGCGGAAGGAGATCGCCAAGGCCTTCAAGGGCAACG AGGGCTACAAGTCCCTGTTTAAGAAGGATATCATCGAGACAATCCTGCCA GAGTTCCTGGACGATAAGGACGAGATCGCCCTGGTGAACAGCTTCAATGG CTTTACCACAGCCTTCACCGGCTTCTTTGATAACAGAGAGAATATGTTTTC CGAGGAGGCCAAGAGCACATCCATCGCCTTCAGGTGTATCAACGAGAATC TGACCCGCTACATCTCTAATATGGACATCTTCGAGAAGGTGGACGCCATCT TTGATAAGCACGAGGTGCAGGAGATCAAGGAGAAGATCCTGAACAGCGA CTATGATGTGGAGGATTTCTTTGAGGGCGAGTTCTTTAACTTTGTGCTGAC ACAGGAGGGCATCGACGTGTATAACGCCATCATCGGCGGCTTCGTGACCG AGAGCGGCGAGAAGATCAAGGGCCTGAACGAGTACATCAACCTGTATAA TCAGAAAACCAAGCAGAAGCTGCCTAAGTTTAAGCCACTGTATAAGCAGG TGCTGAGCGATCGGGAGTCTCTGAGCTTCTACGGCGAGGGCTATACATCC GATGAGGAGGTGCTGGAGGTGTTTAGAAACACCCTGAACAAGAACAGCG AGATCTTCAGCTCCATCAAGAAGCTGGAGAAGCTGTTCAAGAATTTTGAC GAGTACTCTAGCGCCGGCATCTTTGTGAAGAACGGCCCCGCCATCAGCAC AATCTCCAAGGATATCTTCGGCGAGTGGAACGTGATCCGGGACAAGTGGA ATGCCGAGTATGACGATATCCACCTGAAGAAGAAGGCCGTGGTGACCGAG AAGTACGAGGACGATCGGAGAAAGTCCTTCAAGAAGATCGGCTCCTTTTC TCTGGAGCAGCTGCAGGAGTACGCCGACGCCGATCTGTCTGTGGTGGAGA AGCTGAAGGAGATCATCATCCAGAAGGTGGATGAGATCTACAAGGTGTAT GGCTCCTCTGAGAAGCTGTTCGACGCCGATTTTGTGCTGGAGAAGAGCCT GAAGAAGAACGACGCCGTGGTGGCCATCATGAAGGACCTGCTGGATTCTG TGAAGAGCTTCGAGAATTACATCAAGGCCTTCTTTGGCGAGGGCAAGGAG ACAAACAGGGACGAGTCCTTCTATGGCGATTTTGTGCTGGCCTACGACAT CCTGCTGAAGGTGGACCACATCTACGATGCCATCCGCAATTATGTGACCC AGAAGCCCTACTCTAAGGATAAGTTCAAGCTGTATTTTCAGAACCCTCAGT TCATGGGCGGCTGGGACAAGGATAAGGAGACAGACTATCGGGCCACCAT CCTGAGATACGGCTCCAAGTACTATCTGGCCATCATGGATAAGAAGTACG 123CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 CCAAGTGCCTGCAGAAGATCGACAAGGACGATGTGAACGGCAATTACGA GAAGATCAACTATAAGCTGCTGCCCGGCCCTAATAAGATGCTGCCAAAGG TGTTCTTTTCTAAGAAGTGGATGGCCTACTATAACCCCAGCGAGGACATCC AGAAGATCTACAAGAATGGCACATTCAAGAAGGGCGATATGTTTAACCTG AATGACTGTCACAAGCTGATCGACTTCTTTAAGGATAGCATCTCCCGGTAT CCAAAGTGGTCCAATGCCTACGATTTCAACTTTTCTGAGACAGAGAAGTA TAAGGACATCGCCGGCTTTTACAGAGAGGTGGAGGAGCAGGGCTATAAG GTGAGCTTCGAGTCTGCCAGCAAGAAGGAGGTGGATAAGCTGGTGGAGG AGGGCAAGCTGTATATGTTCCAGATCTATAACAAGGACTTTTCCGATAAG TCTCACGGCACACCCAATCTGCACACCATGTACTTCAAGCTGCTGTTTGAC GAGAACAATCACGGACAGATCAGGCTGAGCGGAGGAGCAGAGCTGTTCA TGAGGCGCGCCTCCCTGAAGAAGGAGGAGCTGGTGGTGCACCCAGCCAA CTCCCCTATCGCCAACAAGAATCCAGATAATCCCAAGAAAACCACAACCC TGTCCTACGACGTGTATAAGGATAAGAGGTTTTCTGAGGACCAGTACGAG CTGCACATCCCAATCGCCATCAATAAGTGCCCCAAGAACATCTTCAAGAT CAATACAGAGGTGCGCGTGCTGCTGAAGCACGACGATAACCCCTATGTGA TCGGCATCGATAGGGGCGAGCGCAATCTGCTGTATATCGTGGTGGTGGAC GGCAAGGGCAACATCGTGGAGCAGTATTCCCTGAACGAGATCATCAACAA CTTCAACGGCATCAGGATCAAGACAGATTACCACTCTCTGCTGGACAAGA AGGAGAAGGAGAGGTTCGAGGCCCGCCAGAACTGGACCTCCATCGAGAA TATCAAGGAGCTGAAGGCCGGCTATATCTCTCAGGTGGTGCACAAGATCT GCGAGCTGGTGGAGAAGTACGATGCCGTGATCGCCCTGGAGGACCTGAAC TCTGGCTTTAAGAATAGCCGCGTGAAGGTGGAGAAGCAGGTGTATCAGAA GTTCGAGAAGATGCTGATCGATAAGCTGAACTACATGGTGGACAAGAAGT CTAATCCTTGTGCAACAGGCGGCGCCCTGAAGGGCTATCAGATCACCAAT AAGTTCGAGAGCTTTAAGTCCATGTCTACCCAGAACGGCTTCATCTTTTAC ATCCCTGCCTGGCTGACATCCAAGATCGATCCATCTACCGGCTTTGTGAAC CTGCTGAAAACCAAGTATACCAGCATCGCCGATTCCAAGAAGTTCATCAG CTCCTTTGACAGGATCATGTACGTGCCCGAGGAGGATCTGTTCGAGTTTGC CCTGGACTATAAGAACTTCTCTCGCACAGACGCCGATTACATCAAGAAGT GGAAGCTGTACTCCTACGGCAACCGGATCAGAATCTTCCGGAATCCTAAG AAGAACAACGTGTTCGACTGGGAGGAGGTGTGCCTGACCAGCGCCTATAA GGAGCTGTTCAACAAGTACGGCATCAATTATCAGCAGGGCGATATCAGAG CCCTGCTGTGCGAGCAGTCCGACAAGGCCTTCTACTCTAGCTTTATGGCCC 124CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TGATGAGCCTGATGCTGCAGATGCGGAACAGCATCACAGGCCGCACCGAC GTGGATTTTCTGATCAGCCCTGTGAAGAACTCCGACGGCATCTTCTACGAT AGCCGGAACTATGAGGCCCAGGAGAATGCCATCCTGCCAAAGAACGCCG ACGCCAATGGCGCCTATAACATCGCCAGAAAGGTGCTGTGGGCCATCGGC CAGTTCAAGAAGGCCGAGGACGAGAAGCTGGATAAGGTGAAGATCGCCA TCTCTAACAAGGAGTGGCTGGAGTACGCCCAGACCAGCGTGAAGCACAAA AGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGA TCCTACCCATACGATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGAT TATGCATACCCATATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 38)

[00178] Porphyromonas crevioricanis (PcCpfl ; pYOl 7), including NLS and HA tag:

[00179] MDSLKDFTNLYPVSKTLRFELKPVGKTLENIEKAGILKEDEH RAESYRRVKKIIDTYHKVFIDSSLENMAKMGIENEIKAMLQSFCELYKKDHRT EGEDKALDKIRAVLRGLTVGAFTGVCGRRENTVQNEKYESLFKEKLIKEILPD FVLSTEAESLPFSVEEATRSLKEFDSFTSYFAGFYENRKNIYSTKPQSTAIAYRL IHENLPKFIDNILVFQKIKEPIAKELEHIRADFSAGGYIKKDERLEDIFSLNYYIH VLSQAGIEKYNALIGKIVTEGDGEMKGLNEHINLYNQQRGREDRLPLFRPLYK QILSDREQLSYLPESFEKDEELLRALKEFYDHIAEDILGRTQQLMTSISEYDLSR IYVRNDSQLTDISKKMLGDWNAIYMARERAYDHEQAPKRITAKYERDRIKAL KGEESISLANLNSCIAFLDNVRDCRVDTYLSTLGQKEGPHGLSNLVENVFASY HEAEQLLSFPYPEENNLIQDKDNVVLIKNLLDNISDLQRFLKPLWGMGDEPDK DERFYGEYNYIRGALDQVIPLYNKVRNYLTRKPYSTRKVKLNFGNSQLLSGW DRNKEKDNSCVILRKGQNFYLAIMNNRHKRSFENKMLPEYKEGEPYFEKMD YKFLPDPNKMLPKVFLSKKGIEIYKPSPKLLEQYGHGTHKKGDTFSMDDLHE LIDFFKHSIEAHEDWKQFGFKFSDTATYENVSSFYREVEDQGYKLSFRKVSES YVYSLIDQGKLYLFQIYNKDFSPCSKGTPNLHTLYWRMLFDERNLADVIYKL DGKAEIFFREKSLKNDHPTHPAGKPIKKKSRQKKGEESLFEYDLVKDRRYTM DKFQFHVPITMNFKCSAGSKVNDMVNAH1REAKDMHVIGIDRGERNLLYICV1 DSRGTILDQISLNTINDIDYHDLLESRDKDRQQEHRNWQTIEGIKELKQGYLSQ AVHRIAELMVAYKAVVALEDLNMGFKRGRQKVESSVYQQFEKQLIDKLNYL VDKKKRPEDIGGLLRAYQFTAPFKSFKEMGKQNGFLFYIPAWNTSNIDPTTGF VNLFHVQYENVDKAKSFFQKFDSISYNPKKDWFEFAFDYKNFTKKAEGSRS MWILCTHGSRIKNFRNSQKNGQWDSEEFALTEAFKSLFVRYEIDYTADLKTAI VDEKQKDFFVDLLKLFKLTVQMRNSWKEKDLDYLISPVAGADGRFFDTREG 125CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NKSLPKDADANGAYNIALKGLWALRQIRQTSEGGKLKLAISNKEWLQFVQER SYEKDKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 39)

[00180] SEQ ID NO: 39 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00181] SEQ ID NO: 39 may be encoded by the following nucleotide sequence:

[00182] ATGGACAGCCTGAAGGATTTCACCAACCTGTACCCCGTG TCCAAGACACTGCGGTTTGAGCTGAAGCCTGTGGGCAAGACCCTGGAGAA TATCGAGAAGGCCGGCATCCTGAAGGAGGATGAGCACAGAGCCGAGAGC TACCGGAGAGTGAAGAAGATCATCGATACATATCACAAGGTGTTCATCGA CAGCTCCCTGGAGAACATGGCCAAGATGGGCATCGAGAATGAGATCAAG GCCATGCTGCAGTCCTTTTGCGAGCTGTATAAGAAGGACCACAGGACCGA GGGAGAGGACAAGGCCCTGGATAAGATCAGGGCCGTGCTGAGGGGCCTG ATCGTGGGAGCCTTCACCGGCGTGTGCGGCCGGCGGGAGAACACAGTGCA GAATGAGAAGTATGAGAGCCTGTTTAAGGAGAAGCTGATCAAGGAGATC CTGCCAGATTTCGTGCTGTCTACAGAGGCCGAGTCCCTGCCCTTTTCTGTG GAGGAGGCCACCAGAAGCCTGAAGGAGTTCGACTCCTTTACATCTTACTT CGCCGGCTTTTATGAGAACCGGAAGAATATCTACTCTACCAAGCCCCAGA GCACAGCCATCGCCTATAGACTGATCCACGAGAACCTGCCTAAGTTCATC GATAATATCCTGGTGTTTCAGAAGATCAAGGAGCCAATCGCCAAGGAGCT GGAGCACATCAGGGCAGACTTCAGCGCCGGCGGCTACATCAAGAAGGAT GAGCGCCTGGAGGACATCTTTTCCCTGAACTACTATATCCACGTGCTGTCT CAGGCCGGCATCGAGAAGTACAATGCCCTGATCGGCAAGATCGTGACCGA GGGCGATGGCGAGATGAAGGGCCTGAACGAGCACATCAACCTGTATAATC AGCAGAGGGGCCGCGAGGACCGGCTGCCACTGTTCAGACCCCTGTATAAG CAGATCCTGTCTGATAGGGAGCAGCTGTCCTATCTGCCAGAGTCTTTCGAG AAGGACGAGGAGCTGCTGAGGGCCCTGAAGGAGTTTTACGATCACATCGC AGAGGACATCCTGGGAAGGACCCAGCAGCTGATGACAAGCATCTCCGAGT ACGATCTGTCCCGGATCTATGTGAGAAACGATAGCCAGCTGACCGACATC TCCAAGAAGATGCTGGGCGATTGGAATGCCATCTACATGGCCCGGGAGAG AGCCTATGACCACGAGCAGGCCCCCAAGCGCATCACAGCCAAGTACGAG 126CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 AGGGACCGCATCAAGGCCCTGAAGGGCGAGGAGTCTATCAGCCTGGCCA ACCTGAACAGCTGCATCGCCTTCCTGGACAACGTGAGGGATTGTCGCGTG GACACCTATCTGTCTACACTGGGACAGAAGGAGGGACCTCACGGCCTGAG CAACCTGGTGGAGAACGTGTTCGCCTCCTACCACGAGGCCGAGCAGCTGC TGTCTTTTCCCTATCCTGAGGAGAACAATCTGATCCAGGACAAGGATAAC GTGGTGCTGATCAAGAACCTGCTGGATAATATCAGCGACCTGCAGAGGTT CCTGAAGCCACTGTGGGGCATGGGCGATGAGCCCGACAAGGATGAGAGG TTTTACGGCGAGTACAATTATATCAGGGGCGCCCTGGACCAGGTCATCCCT CTGTATAACAAGGTGCGGAATTATCTGACCCGCAAGCCATACTCCACACG CAAGGTGAAGCTGAACTTCGGCAATAGCCAGCTGCTGTCCGGCTGGGATA GGAACAAGGAGAAGGACAATTCTTGCGTGATCCTGCGCAAGGGCCAGAA CTTCTACCTGGCCATCATGAACAATCGGCACAAGCGGAGCTTCGAGAATA AGATGCTGCCCGAGTATAAGGAGGGCGAGCCTTACTTCGAGAAGATGGAT TATAAGTTTCTGCCAGACCCCAACAAGATGCTGCCCAAGGTGTTCCTGTCT AAGAAGGGCATCGAGATCTACAAGCCTAGCCCAAAGCTGCTGGAGCAGT ATGGCCACGGCACCCACAAGAAGGGCGATACCTTCAGCATGGACGATCTG CACGAGCTGATCGACTTCTTTAAGCACTCCATCGAGGCCCACGAGGATTG GAAGCAGTTCGGCTTTAAGTTCAGCGACACCGCCACATACGAGAACGTGA GCAGCTTCTACCGGGAGGTGGAGGACCAGGGCTACAAGCTGTCTTTTAGA AAGGTGTCCGAGTCTTACGTGTATAGCCTGATCGATCAGGGCAAGCTGTA CCTGTTCCAGATCTATAACAAGGACTTTAGCCCTTGTTCCAAGGGCACCCC AAATCTGCACACACTGTACTGGCGGATGCTGTTCGATGAGAGAAACCTGG CCGACGTGATCTATAAGCTGGATGGCAAGGCCGAGATCTTCTTTCGGGAG AAGTCCCTGAAGAATGACCACCCAACCCACCCTGCAGGCAAGCCCATCAA GAAGAAGAGCCGGCAGAAGAAGGGCGAGGAGAGCCTGTTCGAGTACGAT CTGGTGAAGGACCGGAGATATACCATGGATAAGTTTCAGTTCCACGTGCC AATCACAATGAACTTTAAGTGCTCTGCCGGCAGCAAGGTGAACGACATGG TGAATGCCCACATCAGGGAGGCCAAGGACATGCACGTGATCGGCATCGAT AGGGGCGAGCGCAATCTGCTGTATATCTGCGTGATCGACAGCCGCGGCAC CATCCTGGATCAGATCTCCCTGAACACAATCAATGACATCGATTATCACG ATCTGCTGGAGTCCAGGGACAAGGATCGCCAGCAGGAGCACAGGAACTG GCAGACCATCGAGGGCATCAAGGAGCTGAAGCAGGGCTACCTGTCTCAGG CCGTGCACCGCATCGCCGAGCTGATGGTGGCCTATAAGGCCGTGGTGGCC CTGGAGGACCTGAACATGGGCTTCAAGCGGGGCAGACAGAAGGTGGAGA 127CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GCAGCGTGTACCAGCAGTTTGAGAAGCAGCTGATCGACAAGCTGAATTAT CTGGTGGATAAGAAGAAGCGGCCCGAGGACATCGGAGGCCTGCTGAGAG CCTACCAGTTCACCGCCCCTTTCAAGAGCTTTAAGGAGATGGGCAAGCAG AACGGCTTTCTGTTCTATATCCCTGCCTGGAACACATCCAATATCGACCCA ACCACAGGCTTCGTGAACCTGTTTCACGTGCAGTACGAGAATGTGGATAA GGCCAAGAGCTTCTTTCAGAAGTTCGACAGCATCTCCTACAACCCTAAGA AGGATTGGTTTGAGTTCGCCTTTGACTATAAGAACTTCACCAAGAAGGCC GAGGGCTCTAGGAGCATGTGGATTCTGTGCACCCACGGCTCCCGGATCAA GAACTTCAGAAATTCTCAGAAGAATGGCCAGTGGGATAGCGAGGAGTTTG CCCTGACCGAGGCCTTCAAGTCCCTGTTTGTGCGGTACGAGATCGATTATA CCGCCGACCTGAAAACCGCCATCGTGGACGAGAAGCAGAAGGATTTCTTT GTGGACCTGCTGAAGCTGTTCAAGCTGACCGTGCAGATGAGAAACTCCTG GAAGGAGAAGGACCTGGATTACCTGATCTCTCCAGTGGCCGGCGCCGATG GCAGGTTCTTTGACACACGCGAGGGCAATAAGAGCCTGCCCAAGGACGCA GATGCAAACGGAGCCTATAATATCGCCCTGAAGGGCCTGTGGGCACTGAG GCAGATCAGACAGACCTCCGAGGGCGGCAAGCTGAAGCTGGCCATCTCTA ACAAGGAGTGGCTGCAGTTTGTGCAGGAGAGATCCTACGAGAAGGACAA AAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGG ATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGA TTATGCATACCCATATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 40)

[00183] Prevotella disiens (PdCpfl; pY018), including NLS and HA tag:

[00184] MENYQEFTNLFQLNKTLRFELKPIGKTCELLEEGKIFASGSF LEKDKVRADNVSYVKKEIDKKHKIFIEETLSSFSISNDLLKQYFDCYNELKAFK KDCKSDEEEVKKTALRNKCTSIQRAMREAISQAFLKSPQKKLLAIKNLIENVF KADENVQHFSEFTSYFSGFETNRENFYSDEEKSTSIAYRLVHDNLPIFIKNIYIF EKLKEQFDAKTLSEIFENYKLYVAGSSLDEVFSLEYFNNTLTQKGIDNYNAVI GKIVKEDKQEIQGLNEHINLYNQKHKDRRLPFFTSLKKQILSDREALSWLPDM FKNDSEV1KALKGFY1EDGFENNVLTPLATLLSSLDKYNLNGIF1RNNEALSSLS QNVYRNFSIDEAIDANAELQTFNNYELIANALRAKIKKETKQGRKSFEKYEEY IDKKVKAIDSLSIQEINELVENYVSEFNSNSGNMPRKVEDYFSLMRKGDFGSN DLTENIKTKLSAAEKLLGTKYQETAKDTFKKDENSKLIKELLDATKQFQHFTKP LLGTGEEADRDLVFYGDFLPLYEKFEELTLLYNKVRNRLTQKPYSKDKIRLCF NKPKLMTGWVDSKTEKSDNGTQYGGYLFRKKNEIGEYDYFLGISSKAQLFRK NEAVIGDYERLDYYQPKANTIYGSAYEGENSYKEDKKRLNKVIIAYIEQIKQT 128CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 NIKKSIIESISKYPNISDDDKVTPSSLLEKIKKVSIDSYNGILSFKSFQSVNKEVID NLLKTISPLKNKAEFLDLINKDYQIFTEVQAVIDEICKQKTFIYFPISNVELEKE MGDKDKPLCLFQISNKDLSFAKTFSANLRKKRGAENLHTMLFKALMEGNQD NLDLGSGAIFYRAKSLDGNKPTHPANEAIKCRNVANKDKVSLFTYDIYKNRR YMENKFLFHLSIVQNYKAANDSAQLNSSATEYIRKADDLHIIGIDRGERNLLY YSVIDMKGNIVEQDSLNIIRNNDLETDYHDLLDKREKERKANRQNWEAVEGI KDLKKGYLSQAVHQIAQLMLKYNAIIALEDLGQMFVTRGQK1EKAVYQQFE KSLVDKLSYLVDKKRPYNELGGILKAYQLASSITKNNSDKQNGFLFYVPAWN TSKIDPVTGFTDLLRPKAMTIKEAQDFFGAFDNISYNDKGYFEFETNYDKFKIR MKSAQTRWTICTFGNRIKRKKDKNYWNYEEVELTEEFKKLFKDSNIDYENCN LKEEIQNKDNRKFFDDL1KLLQLTLQMRNSDDKGNDYIISPVANAEGQFFDSR NGDKKLPLDADANGAYNIARKGLWNIRQIKQTKNDKKLNLSISSTEWLDFVR EKPYLKKRPAATKKAGQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDY A (SEQ ID NO: 41)

[00185] SEQ ID NO: 41 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13).

[00186] SEQ ID NO: 41 may be encoded by the following nucleotide sequence:

[00187] ATGGAGAACTATCAGGAGTTCACCAACCTGTTTCAGCTG AATAAGACACTGAGATTCGAGCTGAAGCCCATCGGCAAGACCTGCGAGCT GCTGGAGGAGGGCAAGATCTTCGCCAGCGGCTCCTTTCTGGAGAAGGACA AGGTGAGGGCCGATAACGTGAGCTACGTGAAGAAGGAGATCGACAAGAA GCACAAGATCTTTATCGAGGAGACACTGAGCTCCTTCTCTATCAGCAACG ATCTGCTGAAGCAGTACTTTGACTGCTATAATGAGCTGAAGGCCTTCAAG AAGGACTGTAAGAGCGATGAGGAGGAGGTGAAGAAAACCGCCCTGCGCA ACAAGTGTACCTCCATCCAGAGGGCCATGCGCGAGGCCATCTCTCAGGCC TTTCTGAAGAGCCCCCAGAAGAAGCTGCTGGCCATCAAGAACCTGATCGA GAACGTGTTCAAGGCCGACGAGAATGTGCAGCACTTCTCCGAGTTTACCA GCTATTTCTCCGGCTTTGAGACAAACAGAGAGAATTTCTACTCTGACGAG GAGAAGTCCACATCTATCGCCTATAGGCTGGTGCACGATAACCTGCCTAT CTTCATCAAGAACATCTACATCTTCGAGAAGCTGAAGGAGCAGTTCGACG CCAAGACCCTGAGCGAGATCTTCGAGAACTACAAGCTGTATGTGGCCGGC 129CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 TCTAGCCTGGATGAGGTGTTCTCCCTGGAGTACTTTAACAATACCCTGACA CAGAAGGGCATCGACAACTATAATGCCGTGATCGGCAAGATCGTGAAGG AGGATAAGCAGGAGATCCAGGGCCTGAACGAGCACATCAACCTGTATAAT CAGAAGCACAAGGACCGGAGACTGCCCTTCTTTATCTCCCTGAAGAAGCA GATCCTGTCCGATCGGGAGGCCCTGTCTTGGCTGCCTGACATGTTCAAGAA TGATTCTGAAGTGATCAAGGCCCTGAAGGGCTTCTACATCGAGGACGGCT TTGAGAACAATGTGCTGACACCTCTGGCCACCCTGCTGTCCTCTCTGGATA AGTACAACCTGAATGGCATCTTTATCCGCAACAATGAGGCCCTGAGCTCC CTGTCCCAGAACGTGTATCGGAATTTTTCTATCGACGAGGCCATCGATGCC AACGCCGAGCTGCAGACCTTCAACAATTACGAGCTGATCGCCAATGCCCT GCGCGCCAAGATCAAGAAGGAGACAAAGCAGGGCCGGAAGTCTTTCGAG AAGTACGAGGAGTATATCGATAAGAAGGTGAAGGCCATCGACAGCCTGTC CATCCAGGAGATCAACGAGCTGGTGGAGAATTACGTGAGCGAGTTTAACT CTAATAGCGGCAACATGCCAAGAAAGGTGGAGGACTACTTCAGCCTGATG AGGAAGGGCGACTTCGGCTCCAACGATCTGATCGAAAATATCAAGACCAA GCTGAGCGCCGCAGAGAAGCTGCTGGGCACAAAGTACCAGGAGACAGCC AAGGACATCTTCAAGAAGGATGAGAACTCCAAGCTGATCAAGGAGCTGCT GGACGCCACCAAGCAGTTCCAGCACTTTATCAAGCCACTGCTGGGCACAG GCGAGGAGGCAGATCGGGACCTGGTGTTCTACGGCGATTTTCTGCCCCTG TATGAGAAGTTTGAGGAGCTGACCCTGCTGTATAACAAGGTGCGGAATAG ACTGACACAGAAGCCCTATTCCAAGGACAAGATCCGCCTGTGCTTCAACA AGCCTAAGCTGATGACAGGCTGGGTGGATTCCAAGACCGAGAAGTCTGAC AACGGCACACAGTACGGCGGCTATCTGTTTCGGAAGAAGAATGAGATCGG CGAGTACGATTATTTTCTGGGCATCTCTAGCAAGGCCCAGCTGTTCAGAAA GAACGAGGCCGTGATCGGCGACTACGAGAGGCTGGATTACTATCAGCCAA AGGCCAATACCATCTACGGCTCTGCCTATGAGGGCGAGAACAGCTACAAG GAGGACAAGAAGCGGCTGAACAAAGTGATCATCGCCTATATCGAGCAGA TCAAGCAGACAAACATCAAGAAGTCTATCATCGAGTCCATCTCTAAGTAT CCTAATATCAGCGACGATGACAAGGTGACCCCATCCTCTCTGCTGGAGAA GATCAAGAAGGTGTCTATCGACAGCTACAACGGCATCCTGTCCTTCAAGT cttttcagagcgtgaacaaggaagtgatcgataacctgctgaaaaccatc AGCCCCCTGAAGAACAAGGCCGAGTTTCTGGACCTGATCAATAAGGATTA TCAGATCTTCACCGAGGTGCAGGCCGTGATCGACGAGATCTGCAAGCAGA AAACCTTCATCTACTTTCCAATCTCCAACGTGGAGCTGGAGAAGGAGATG 130CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GGCGATAAGGACAAGCCCCTGTGCCTGTTCCAGATCAGCAATAAGGATCT GTCCTTCGCCAAGACCTTTAGCGCCAACCTGCGGAAGAAGAGAGGCGCCG AGAATCTGCACACAATGCTGTTTAAGGCCCTGATGGAGGGCAACCAGGAT AATCTGGACCTGGGCTCTGGCGCCATCTTCTACAGAGCCAAGAGCCTGGA CGGCAACAAGCCCACACACCCTGCCAATGAGGCCATCAAGTGTAGGAAC GTGGCCAATAAGGATAAGGTGTCCCTGTTCACCTACGACATCTATAAGAA CAGGCGCTACATGGAGAATAAGTTCCTGTTTCACCTGAGCATCGTGCAGA ACTATAAGGCCGCCAATGACTCCGCCCAGCTGAACAGCTCCGCCACCGAG TATATCAGAAAGGCCGATGACCTGCACATCATCGGCATCGATAGGGGCGA GCGCAATCTGCTGTACTATTCCGTGATCGATATGAAGGGCAACATCGTGG AGCAGGACTCTCTGAATATCATCAGGAACAATGACCTGGAGACAGATTAC CACGACCTGCTGGATAAGAGGGAGAAGGAGCGCAAGGCCAACCGGCAGA ATTGGGAGGCCGTGGAGGGCATCAAGGACCTGAAGAAGGGCTACCTGAG CCAGGCCGTGCACCAGATCGCCCAGCTGATGCTGAAGTATAACGCCATCA TCGCCCTGGAGGATCTGGGCCAGATGTTTGTGACCCGCGGCCAGAAGATC GAGAAGGCCGTGTACCAGCAGTTCGAGAAGAGCCTGGTGGATAAGCTGTC CTACCTGGTGGACAAGAAGCGGCCTTATAATGAGCTGGGCGGCATCCTGA AGGCCTACCAGCTGGCCTCTAGCATCACCAAGAACAATTCTGACAAGCAG AACGGCTTCCTGTTTTATGTGCCAGCCTGGAATACAAGCAAGATCGATCCC GTGACCGGCTTTACAGACCTGCTGCGGCCCAAGGCCATGACCATCAAGGA GGCCCAGGACTTCTTTGGCGCCTTCGATAACATCTCTTACAATGACAAGGG CTATTTCGAGTTTGAGACAAACTACGACAAGTTTAAGATCAGAATGAAGA GCGCCCAGACCAGGTGGACAATCTGCACCTTCGGCAATCGGATCAAGAGA AAGAAGGATAAGAACTACTGGAATTATGAGGAGGTGGAGCTGACCGAGG AGTTCAAGAAGCTGTTTAAGGACAGCAACATCGATTACGAGAACTGTAAT CTGAAGGAGGAGATCCAGAACAAGGACAATCGCAAGTTCTTTGATGACCT GATCAAGCTGCTGCAGCTGACACTGCAGATGCGGAACTCCGATGACAAGG GCAATGATTATATCATCTCTCCTGTGGCCAACGCCGAGGGCCAGTTCTTTG ACTCCCGCAATGGCGATAAGAAGCTGCCACTGGATGCAGACGCAAACGG AGCCTACAATATCGCCCGCAAGGGCCTGTGGAACATCCGGCAGATCAAGC AGACCAAGAACGACAAGAAGCTGAATCTGAGCATCTCCTCTACAGAGTGG CTGGATTTCGTGCGGGAGAAGCCTTACCTGAAGAAAAGGCCGGCGGCCAC GAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGAT 131CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 GTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATAT GATGTCCCCGACTATGCCTAA (SEQ ID NO: 42)

[00188] Porphyromonas macacae (PmCpfl; pY09), including NLS and HA tag:

[00189] MKTQHFFEDFTSLYSLSKTIRFELKPIGKTLENIKKNGLIRRD EQRLDDYEKLKKVIDEYHEDFIANILSSFSFSEEILQSYIQNLSESEARAKIEKT MRDTLAKAFSEDERYKSIFKKELVKKDIPVWCPAYKSLCKKFDNFTTSLVPFH ENRKNLYTSNEITASIPYRIVHVNLPKFIQNIEALCELQKKMGADLYLEMMEN LRNVWPSFVKTPDDLCNLKTYNHLMVQSSISEYNRFVGGYSTEDGTKHQGIN EWINIYRQRNKEMRLPGLVFLHKQILAKVDSSSFISDTLENDDQVFCVLRQFR KLFWNTVSSKEDDAASLKDLFCGLSGYDPEAIYVSDAHLAT1SKNIFDRWNY1 SDAIRRKTEVLMPRKKESVERYAEKISKQIKKRQSYSLAELDDLLAHYSEESL PAGFSLLSYFTSLGGQKYLVSDGEVILYEEGSNIWDEVLIAFRDLQVILDKDFT EKKLGKDEEAVSVIKKALDSALRLRKFFDLLSGTGAEIRRDSSFYALYTDRMD KLKGLLKMYDKVRNYLTKKPYSIEKFKLHFDNPSLLSGWDKNKELNNLSVIF RQNGYYYLGIMTPKGKNLFKTLPKLGAEEMFYEKMEYKQIAEPMLMLPKVF FPKKTKPAFAPDQSVVDIYNKKTFKTGQKGFNKKDLYRLIDFYKEALTVHEW KLFNFSFSPTEQYRNIGEFFDEVREQAYKVSMVNVPASYIDEAVENGKLYLFQ IYNKDFSPYSKGIPNLHTLYWKALFSEQNQSRVYKLCGGGELFYRKASLHMQ DTTVHPKGISIHKKNLNKKGETSLFNYDLVKDKRFTEDKFFFHVPISINYKNK KITNVNQMVRDYIAQNDDLQIIGIDRGERNLLYISRIDTRGNLLEQFSLNVIESD KGDLRTDYQKILGDREQERLRRRQEWKSIESIKDLKDGYMSQVVHKICNMV VEHKAIVVLENLNLSFMKGRKKVEKSVYEKFERMLVDKLNYLVVDKKNLSN EPGGLYAAYQLTNPLFSFEELHRYPQSGILFFVDPWNTSLTDPSTGFVNLLGRI NYTNVGDARKFFDRFNAIRYDGKGNILFDLDLSRFDVRVETQRKLWTLTTFG SRIAKSKKSGKWMVERIENLSLCFLELFEQFNIGYRVEKDLKKAILSQDRKEF YVRLIYLFNLMMQIRNSDGEEDYILSPALNEKNLQFDSRLIEAKDLPVDADAN GAYNVARKGLMVVQRIKRGDHES1HRIGRAQWLRYVQEG1VEKRPAATKKA GQAKKKKGSYPYDVPDYAYPYDVPDYAYPYDVPDYA (SEQ ID NO: 43)

[00190] SEQ ID NO: 43 includes a nuclear localization signal (KRPAATKKAGQAKKKK) (SEQ ID NO: 12), followed by a glycine-serine linker (GS), followed by a HA tag (YPYDVPDYAYPYDVPDYAYPYDVPDYA) (SEQ ID NO: 13). 132CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00191] SEQ ID NO: 43 may be encoded by the following nucleotide sequence:

[00192] ATGAAAACCCAGCACTTCTTTGAGGACTTCACAAGCCTG TACTCTCTGAGCAAGACCATCCGGTTTGAGCTGAAGCCAATCGGCAAGAC CCTGGAGAACATCAAGAAGAATGGCCTGATCCGGAGAGATGAGCAGAGA CTGGACGATTACGAGAAGCTGAAGAAAGTGATCGACGAGTATCACGAGG ATTTCATCGCCAACATCCTGAGCTCCTTTTCCTTCTCTGAGGAGATCCTGC AGTCCTACATCCAGAATCTGAGCGAGTCCGAGGCCAGGGCCAAGATCGAG AAAACCATGCGCGACACACTGGCCAAGGCCTTCTCTGAGGATGAGAGGTA CAAGAGCATCTTTAAGAAGGAGCTGGTGAAGAAGGACATCCCCGTGTGGT GCCCTGCCTATAAGAGCCTGTGCAAGAAGTTCGATAACTTTACCACATCTC TGGTGCCCTTCCACGAGAACAGGAAGAACCTGTATACCAGCAATGAGATC ACAGCCTCTATCCCTTATCGCATCGTGCACGTGAACCTGCCAAAGTTTATC CAGAATATCGAGGCCCTGTGCGAGCTGCAGAAGAAGATGGGCGCCGACCT GTACCTGGAGATGATGGAGAACCTGCGCAACGTGTGGCCCAGCTTCGTGA AAACCCCAGACGACCTGTGCAACCTGAAAACCTATAATCACCTGATGGTG CAGTCTAGCATCAGCGAGTACAACAGGTTTGTGGGCGGCTATTCCACCGA GGACGGCACAAAGCACCAGGGCATCAACGAGTGGATCAATATCTACAGA CAGAGGAATAAGGAGATGCGCCTGCCTGGCCTGGTGTTCCTGCACAAGCA GATCCTGGCCAAGGTGGACTCCTCTAGCTTCATCAGCGATACACTGGAGA ACGACGATCAGGTGTTTTGCGTGCTGAGACAGTTCAGGAAGCTGTTTTGG AATACCGTGTCCTCTAAGGAGGACGATGCCGCCTCCCTGAAGGACCTGTT CTGTGGCCTGTCTGGCTATGACCCTGAGGCCATCTACGTGAGCGATGCCCA CCTGGCCACAATCTCCAAGAACATCTTTGACAGATGGAATTACATCTCCG ATGCCATCAGGCGCAAGACCGAGGTGCTGATGCCACGGAAGAAGGAGAG CGTGGAGAGATATGCCGAGAAGATCTCCAAGCAGATCAAGAAGAGACAG TCTTACAGCCTGGCCGAGCTGGACGATCTGCTGGCCCACTATAGCGAGGA GTCCCTGCCCGCAGGCTTCTCTCTGCTGAGCTACTTTACATCTCTGGGCGG CCAGAAGTATCTGGTGAGCGACGGCGAAGTGATCCTGTACGAGGAGGGC AGCAACATCTGGGACGAGGTGCTGATCGCCTTCAGGGATCTGCAGGTCAT CCTGGACAAGGACTTCACCGAGAAGAAGCTGGGCAAGGATGAGGAGGCC GTGTCTGTGATCAAGAAGGCCCTGGACAGCGCCCTGCGCCTGCGGAAGTT CTTTGATCTGCTGTCCGGCACAGGCGCAGAGATCAGGAGAGACAGCTCCT TCTATGCCCTGTATACCGACCGGATGGATAAGCTGAAGGGCCTGCTGAAG 133CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 ATGTATGATAAGGTGAGAAACTACCTGACCAAGAAGCCTTATTCCATCGA GAAGTTCAAGCTGCACTTTGACAACCCATCCCTGCTGTCTGGCTGGGATAA GAATAAGGAGCTGAACAATCTGTCTGTGATCTTCCGGCAGAACGGCTACT ATTACCTGGGCATCATGACACCCAAGGGCAAGAATCTGTTCAAGACCCTG CCTAAGCTGGGCGCCGAGGAGATGTTTTATGAGAAGATGGAGTACAAGCA GATCGCCGAGCCTATGCTGATGCTGCCAAAGGTGTTCTTTCCCAAGAAAA CCAAGCCAGCCTTCGCCCCAGACCAGAGCGTGGTGGATATCTACAACAAG AAAACCTTCAAGACAGGCCAGAAGGGCTTTAATAAGAAGGACCTGTACCG GCTGATCGACTTCTACAAGGAGGCCCTGACAGTGCACGAGTGGAAGCTGT TTAACTTCTCCTTTTCTCCAACCGAGCAGTATCGGAATATCGGCGAGTTCT TTGACGAGGTGAGAGAGCAGGCCTACAAGGTGTCCATGGTGAACGTGCCC GCCTCTTATATCGACGAGGCCGTGGAGAACGGCAAGCTGTATCTGTTCCA GATCTACAATAAGGACTTCAGCCCCTACTCCAAGGGCATCCCTAACCTGC ACACACTGTATTGGAAGGCCCTGTTCAGCGAGCAGAATCAGAGCCGGGTG TATAAGCTGTGCGGAGGAGGAGAGCTGTTTTATAGAAAGGCCAGCCTGCA CATGCAGGACACCACAGTGCACCCCAAGGGCATCTCTATCCACAAGAAGA ACCTGAATAAGAAGGGCGAGACAAGCCTGTTCAACTACGACCTGGTGAAG GATAAGAGGTTTACCGAGGACAAGTTCTTTTTCCACGTGCCTATCTCTATC AACTACAAGAATAAGAAGATCACCAACGTGAATCAGATGGTGCGCGATTA TATCGCCCAGAACGACGATCTGCAGATCATCGGCATCGACCGCGGCGAGC GGAATCTGCTGTATATCAGCCGGATCGATACAAGGGGCAACCTGCTGGAG CAGTTCAGCCTGAATGTGATCGAGTCCGACAAGGGCGATCTGAGAACCGA CTATCAGAAGATCCTGGGCGATCGCGAGCAGGAGCGGCTGAGGCGCCGG CAGGAGTGGAAGTCTATCGAGAGCATCAAGGACCTGAAGGATGGCTACAT GAGCCAGGTGGTGCACAAGATCTGTAACATGGTGGTGGAGCACAAGGCC ATCGTGGTGCTGGAGAACCTGAATCTGAGCTTCATGAAGGGCAGGAAGAA GGTGGAGAAGTCCGTGTACGAGAAGTTTGAGCGCATGCTGGTGGACAAGC TGAACTATCTGGTGGTGGATAAGAAGAACCTGTCCAATGAGCCAGGAGGC CTGTATGCAGCATACCAGCTGACCAATCCACTGTTCTCTTTTGAGGAGCTG CACAGATACCCCCAGAGCGGCATCCTGTTTTTCGTGGACCCATGGAACAC CTCTCTGACAGATCCCAGCACAGGCTTCGTGAATCTGCTGGGCAGAATCA ACTACACCAATGTGGGCGACGCCCGCAAGTTTTTCGATCGGTTTAACGCC ATCAGATATGACGGCAAGGGCAATATCCTGTTCGACCTGGATCTGTCCAG ATTTGATGTGAGGGTGGAGACACAGAGGAAGCTGTGGACACTGACCACAT 134TCGGCTCTCGCATCGCCAAATCCAAGAAGTCTGGCAAGTGGATGGTGGAG CGGATCGAGAACCTGAGCCTGTGCTTTCTGGAGCTGTTCGAGCAGTTTAAT ATCGGCTACAGAGTGGAGAAGGACCTGAAGAAGGCCATCCTGAGCCAGG ATAGGAAGGAGTTCTATGTGCGCCTGATCTACCTGTTTAACCTGATGATGC AGATCCGGAACAGCGACGGCGAGGAGGATTATATCCTGTCTCCCGCCCTG AACGAGAAGAATCTGCAGTTCGACAGCAGGCTGATCGAGGCCAAGGATCT GCCTGTGGACGCAGATGCAAACGGAGCATACAATGTGGCCCGCAAGGGC CTGATGGTGGTGCAGAGAATCAAGAGGGGCGACCACGAGTCCATCCACA GGATCGGAAGGGCACAGTGGCTGAGATATGTGCAGGAGGGCATCGTGGA GAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAA GGGATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTACGACGTGCC TGATTATGCATACCCATATGATGTCCCCGACTATGCCTAA (SEQ ID NO: 44)

[00193] Some of the non-limiting sequences shown above include a sequence such as a nuclear localization signal and/or a tag sequence (such as a HA tags). In various embodiments, a different nuclear localization signal may be present. In some embodiments, no nuclear localization signal is used. In certain embodiments no tag (e.g., no HA tag) is used.

[00194] In various embodiments relating to a protein (such as a protein within a gene-editing complex) the protein may include a nuclear localization signal. For example, the protein (e.g., a Cas protein) may comprise a nuclear localization signal (NLS). Such signals are known in the art, and non-limiting examples are described in Kalderon el al., (1984) Cell 39 (3 Pt 2): 499-509; Makkerh et al., (1996) CurrBiol. 6 (8): 1025-7; and Dingwall et al., (1991) Trends in Biochemical Sciences 16 (12): 478-81. Specific non-limiting examples of nuclear localization signals include GGSGPPKKKRKV (SEQ ID NO: 5), KRPAATKKAGQAKKKK (SEQ ID NO: 12), PKKKRKV (SEQ ID NO: 45), KR[PAATKKAGQA]KKKK (SEQ ID NO: 46), KR[XXXXXXXXXXJKKKK (SEQ ID NO: 47), KKXK (SEQ ID NO: 48), KRXK (SEQ ID NO: 49), KKXR (SEQ ID NO: 50), KRXR (SEQ ID NO: 51), AVKRPAATKKAGQAKKKKLD (SEQ ID NO: 52), MSRRRKANPTKLSENAKKLAKEVEN (SEQ ID NO: 53), PAAKRVKLD (SEQ ID NO: 54), and KLKIKRPVK (SEQ ID NO: 55). 135 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 General Definitions and General Techniques

[00195] Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, and biochemistry).

[00196] As used herein, the term “about” in the context of a numerical value or range means ±10% of the numerical value or range recited or claimed, unless the context requires a more limited range.

[00197] In the descriptions above and in the claims, phrases such as “at least one of’ or “one or more of’ may occur followed by a conjunctive list of elements or features. The term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features. For example, the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation is also intended for lists including three or more items. For example, the phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.” In addition, use of the term “based on,” above and in the claims is intended to mean, “based at least in part on,” such that an unrecited feature or element is also permissible.

[00198] The terms “plasma membrane” and “cell membrane” are used interchangeably herein, and refer to the semipermeable membrane that separates the interior of a cell from the environment outside the cell.

[00199] As used herein, an “expression vector” is a DNA or RNA vector that is capable of effecting expression of one or more polynucleotides. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in host cells of the present invention, including in one of the prokaryotic or eukaryotic cells described herein, e.g., protozoan, algal, fungi, yeast, plant, animal, vertebrate, invertebrate, arthropod, mammalian, rodent, primate, or human cells. 136Expression vectors of the present invention contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the host cell and that control the expression of a polynucleotide. In particular, expression vectors of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. In preferred embodiments, the methods do not comprise the use of viral vectors such as adenoviruses to deliver nucleic acid molecules or constructs.

[00200] It is understood that where a parameter range is provided, all integers within that range, and tenths thereof, are also provided by the invention. For example, “0.2-5 mg” is a disclosure of 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg etc. up to 5.0 mg.

[00201] Unless otherwise implicitly or explicitly contradicted by the context in which it is used, references to cell “squeeze” “squeezing” “deformation” and the like refer to a process used to deliver macromolecules directly into the cytosol of cells with minimal cytotoxicity. The principle underlying this approach is temporary membrane disruption by rapid mechanical deformation, or squeezing, of the target cell, which permits the uptake by diffusion of macromolecules in the fluid medium and is followed by cell membrane repair (see, e.g., U.S. Patent Application Publication No. 2014/0287509, published September 25, 2014; PCT International Patent Application No. PCT/US2015/058489, filed October 30, 2015; and PCT International Patent Application No. PCT/2015/060689, filed November 13, 2015).

[00202] As used herein, “gRNA” refers to a CRISPR-Cas system guide RNA.

[00203] As used herein the term “protein complex” refers to a composite unit arising from the specific binding of a protein with a binding partner, wherein said binding partner can be one or more proteins, one or more nucleic acids, or a combination of one or more proteins and one or more nucleic acids, and the like, to 137 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 form said protein complex. Protein complexes may be protein-protein complexes, protein-nucleic acid complexes, and the like. In certain embodiments, a protein complex may comprise protein-protein interactions, e.g. interactions between different proteins, or dimers, trimers, tetramers or higher oligomers of the same protein. Interactions between subunits of protein complexes (e.g., in protein-protein complexes or protein-nucleic acid complexes that comprise more than one protein) or between proteins and nucleic acids (e.g., in protein-nucleic acid complexes) are usually non-binding interactions, such as those interactions caused by hydrogen bridges, pi electron systems such as (optionally conjugated) C—C double bonds or aromatic rings, e.g. phenyl, and heteroaromatic rings, e.g. pyrrole, imidazole, indole, pyrimidine or purine rings, and interactions between metal atoms and oxygen, nitrogen or sulfur atoms, but may also be weak, and in particular reversible, covalent binding interactions, e.g. sulfur-sulfur bridges.

[00204] A “protein-protein complex” means a composite unit that is a combination of two or more proteins formed by interaction between the proteins. Typically but not necessarily, a “protein complex” is formed by the binding of two or more proteins together through specific non-covalent binding affinities. However, covalent bonds may also be present between the interacting partners. For instance, the two interacting partners can be covalently crosslinked so that the protein complex becomes more stable.

[00205] Similarly, a “protein-nucleic acid complex” means a composite unit that is a combination of at least one protein and at least one nucleic acid formed by interactions that include an interaction between a protein and a nucleic acid. Typically but not necessarily, a “protein-nucleic acid complex” is formed by the binding of a protein and a nucleic acid through non-covalent binding affinities.

[00206] In various embodiments, a gene-editing complex is a proteinnucleic acid complex, such as a RNP. A non-limiting example of an RNP is a CRISPR-Cas RNP comprising a Cas protein and a gRNA.

[00207] Methods and devices described herein deliver an intact and functional gene-editing complex into cells. The components of the gene-editing complex do not disassociate during delivery and remain functional after delivery into the cell.

[00208] Various assays are available to determine whether an intact and functional gene-editing complex has been delivered to a cell. For example, the 138CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 detection of gene editing by the gene-editing complex may be used to indicate that an intact and functional gene-editing complex was delivered into a cell. Alternatively or in addition, cells to which the gene-editing complex has been delivered may be lysed using non-denaturing conditions (such as a non-denaturing buffer or a French press), and the lysate may be analyzed using a non-denaturing gel to determine whether the gene-editing complex was intact within the cells. Alternatively or in addition, the cells may be lysed using non-denaturing conditions and then immunoprecipitation may be used to isolate the gene-editing complex from the lysate (i.e., to verify that one component of the complex can be co-isolated with another using immunoprecipitation). The isolated gene-editing complex can be assayed before or after delivery to a cell using a non-denaturing gel or a denaturing assay (such as sodium dodecyl sulfate polyacrylamide gel electrophoresis) to determine whether the gene-editing complex was present in a pre-delivery/pre-cell squeeze buffer as well as whether the complex is present after microfluidic/squeeze processing and found intact and/or functional in the treated cells. In some embodiments relating to CRISPR-Cas9 RNPs, a band on a non-denaturing gel of about 145, 150, 155, or 145-160 kDa may indicate that the RNP was delivered as a complete and functional gene-editing complex into the cell.

[00209] As used herein, device dimensions are denoted by a series of numbers indicating length, width, and optionally number of constrictions (e.g., 30pm- 6mx5 denotes a device with a 30pm length, 6pm width, and 5 constrictions). Exemplary Embodiments

[00210] Aspects of the present subject matter provide a method for delivering a protein and a nucleic acid into a cell, the method comprising: providing a cell in a solution; passing the solution through a microfluidic channel that includes a cell-deforming constriction; passing the cell through the constriction such that a pressure is applied to the cell causing perturbations of the cell large enough for the protein and the nucleic acid to pass through; and contacting the cell with the protein and the nucleic acid before, during, and/or after the cell passes through the constriction.

[00211] In some embodiments, said solution comprises the protein and the nucleic acid before, during, and/or after the cell passes through the constriction. 139CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00212] In some embodiments, the protein and the nucleic acid form a protein-nucleic acid complex.

[00213] In some embodiments, the protein and the nucleic acid are the components of the protein-nucleic acid complex but are not complexed when delivered to the cell.

[00214] In some embodiments, the protein and the nucleic acid form a protein-nucleic acid complex after delivery into the cell.

[00215] In some embodiments, the protein and the nucleic acid form a protein-nucleic acid complex before delivery into the cell.

[00216] In some embodiments, the protein and the nucleic acid comprise gene editing components.

[00217] In some embodiments, said protein-nucleic acid complex comprises a ribonucleoprotein (RNP).

[00218] In some embodiments, (a) the protein is a Cas protein or a Cpfl protein; and (b) the nucleic acid is a single guide RNA (sgRNA) or a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA).

[00219] In some embodiments, the complex is a RNP comprising a Cas protein or a Cpfl protein and a sgRNA, wherein the Cas protein or the Cpfl protein and the sgRNA were complexed using about a 0.5, 2.0, 2.5, or 3.0 molar excess of the Cas protein or Cpfl protein.

[00220] In some embodiments, the Cas protein comprises a Cas9 protein.

[00221] In some embodiments, said protein-nucleic acid complex comprises a first RNP and a second RNP.

[00222] In some embodiments, the first RNP and the second RNP are both nickases.

[00223] In some embodiments, the first RNP nicks a target sequence different from the target sequence of the second RNP.

[00224] In some embodiments, said protein-nucleic acid complex comprises a TALEN protein, Zinc finger nuclease, mega nuclease, or Cre recombinase.

[00225] In some embodiments, the nucleic acid comprises an mRNA encoding a TALEN protein, a Zinc finger nuclease, a mega nuclease, or a Cre recombinase 140CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00226] In some embodiments, said protein-nucleic acid complex comprises (a) a nucleic acid molecule that is complexed with a protein via electrostatic attraction; (b) a nucleic acid molecule wrapped around a protein; (c) DNA and a histone; (d) a ribonucleoprotein (RNP); (e) a ribosome, an enzyme telomerase, a vault ribonucleoprotein, RNase P, hnRNP, or a small nuclear RNP (snRNP); or (f) a chromosome comprising a protein.

[00227] In some embodiments, the solution further comprises donor DNA.

[00228] In some embodiments, the solution further comprises donor DNA before, during, and/or after the cell passes through the constriction.

[00229] In some embodiments, said cell comprises a mammalian cell.

[00230] In some embodiments, said cell comprises a human cell.

[00231] In some embodiments, the diameter of the constriction is selected to induce temporary perturbations of the cell membrane large enough for the protein and the nucleic acid to pass through.

[00232] In some embodiments, a diameter of the constriction is about 20- 99% of the diameter of the cell.

[00233] In some embodiments, a diameter of the constriction is about 60% of the diameter of the cell.

[00234] In some embodiments, the microfluidic channel is one of a plurality of parallel microfluidic channels in the microfluidic system.

[00235] In some embodiments, the plurality of parallel microfluidic channels comprises at least about 2, 5, 10, 20, 25, 30, 40, 45, 50, 75, 100, 500, 1,000, or 2-1,000 microfluidic channels.

[00236] In some embodiments, the cell is a plurality of cells, and each cell is passed through one of a plurality of parallel microfluidic channels, and wherein each microfluidic channel of the plurality of parallel microfluidic channels includes a cell-deforming constriction.

[00237] In some embodiments, (a) the diameter of the constriction is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 2-10pm, or 10-20pm; (b) the length of the constriction is about 10, 15, 20, 24, 30, 40, 50, 60, 70, 80, 90, 100, 10-40, 10-50, 10-60, or 10- 100pm; (c) apressure of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or 10-100 psi is used to pass the solution through the microfluidic channel; (d) the cell passes through the microfluidic channel at a speed of about 300, 400, 500, 600, 700, 800, 900, 100- 300, 200-700, 250-400, lOO-lOOOmm/s, l-1000mm/s, Im/s, 2m/s, 3m/s, 4m/s, 5m/s, 141CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 6m/s, 7m/s, 8m/s, 9m/s, lOm/s, 0.01-5m/s, 5-10m/s, or 0.01-10m/s; (e) said microfluidic channel comprises multiple cell-deforming constrictions in series; (1) said microfluidic channel comprises a single cell-deforming constriction; (g) the perturbations of the cell membrane include a maximum diameter of about 1-20, 1- 600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm; and/or (h) perturbations of the cell membrane having a maximum diameter of about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm persist on the cell membrane for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 1-10 minutes.

[00238] In some embodiments, (a) the expression of a target gene in the cell is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more, after the protein and the nucleic acid are delivered to the cell.

[00239] In some embodiments, (a) the expression of a target gene in the cell is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more, about 1, 2, 5, 12, 24, 1-12, 6-12, 6- 18, 12-24, or 1-24 hours after the protein and the nucleic acid are delivered to the cell.

[00240] In some embodiments, (a) the expression of a target gene in the cell is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more, after the protein and the nucleic acid are delivered to the cell.

[00241] In some embodiments, (a) the expression of a target gene in the cell is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more, about 1, 2, 5, 12, 24, 1-12, 6-12, 6-18, 12-24, or 1-24 hours after the protein and the nucleic acid are delivered to the cell.

[00242] Aspects of the present subject matter provide a device for delivering a protein-nucleic acid complex to a cell, comprising at least one 142CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 microfluidic channel, wherein said channel comprises a constriction length of about 30 pm and a constriction width of about 4 pm.

[00243] Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results. Example 1: Editing of the B2M locus in primary human T cells using CellSqueeze (SQZ) to deliver CRISPR/Cas9 gene editing complex

[00244] A series of experiments have been undertaken in unstimulated human T cells to demonstrate the ability of the SQZ platform to deliver Cas9 ribonucleoproteins (RNPs; recombinant Cas9 protein complexed with a single-guide RNA) and accomplish efficient genome editing of a model locus, the p2 microglobulin component of MHC class 1 (B2M). Delivery of Cas9 RNP to Unstimulated Human T cells

[00245] Fresh PBMCs were isolated from human blood using a standard Ficoll gradient. Next, T cells were negatively selected (Human T cell enrichment kit (StemCell Technologies)) counted, washed and resuspended at 10-20 xlO6 cells/mL in OptiMEM for delivery. Ten pg of recombinant CAS9 (PNA Bio) was pre-complexed with a 2.5 molar excess of unmodified gRNA (PNA Bio) designed to specifically target the B2M locus. Recombinant CAS9 is reconstituted to a solution with a final concentration of 20mM Hepes, 150mM KC1, 1% sucrose. gRNA is added directly to the CAS9 solution and incubated on ice for 20 minutes to form the complex. The complex is added directly to resuspended cells. RNP complexes were incubated on ice 20 minutes prior to SQZ-mediated delivery. The RNP (2.2uM) was co-delivered with a 3kD-Cascade Blue Dextran (0.15mg/mL) used as a proxy for delivery efficiency. Two different chips, 10-4 and 30-4 were used to deliver the complex at a pressures of 60 and 90 psi. The chips have constrictions of the same width (4 microns) but have two different constriction lengths (30 vs. 10 microns).

[00246] At 48 hours post-delivery, a FACS based readout was used to determine B2M protein levels. Reduced B2M expression was used as a measure of functional editing. Two controls were used; 1) T cells incubated with the RNP 143CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113 complex at room temperature for the same time as the delivery process using the Cell Squeeze process (endocytosis control; “endo control”), and 2) T cells squeezed with Cas9 protein but no gRNA. Plots of B2M expression vs. delivered dextran are shown (FIG. 4) for the four different cell populations. B2M expression on the Cas9 control was not significantly different than the endocytosis control. The delivery of the RNP using the 30-4 chip at 90 psi resulted in a 54.4% reduction in B2M expression as compared to the endo control whereas the 10-4 chip at 90 psi resulted in a 25.2% reduction in B2M expression. The longer constriction chip resulted in more delivery of the RNP complex and a larger reduction in B2M expression.

[00247] Dextran delivery was used to define low, mid and high delivered populations. The differences in efficiency of B2M knockdown for these specific populations was then determined using the mean fluorescence intensity (MFI) of B2M staining. For the 10-4 chip, the MFI of the highly delivered population was 18,637 versus 71,173 for the mid delivered populations and 83,676 for the low or non¬ delivered populations. This nearly 5-fold intensity drop in B2M staining for the high delivered populations demonstrates the degree to which delivery influences RNP activity. Similarly, for the 30-4 chip, the MFI of the highly delivered population was 16,460 versus 44,207 for the mid delivered populations and 54,159 for the low delivered population. These data demonstrated the importance that the cell squeezing delivery system of gene editing complexes to the cytosol of a cell has on editing efficiency, even within a single population.

[00248] To confirm the FACS readout, a second, sequence based analysis, was also employed in which DNA was extracted and amplified using primers flanking the target region thereby generating an amplicon of the edited region for Next Generation Sequencing (NGS). Sequencing results were analyzed using a simple algorithm designed to detect CRISPR variants from NGS reads. As expected, the sequence-based readout showed higher editing efficiencies. Indeed, some of the indels identified in sequencing still resulted in a functional, full length protein (i.e. single base substitutions that did not change the resultant amino acid). 144Table: Comparison of FACS- and Sequence-based readouts from 10-4 editing experiment. Endo Cas9 RNP FACS 0.3 8.15 20.4 Sequencing 3.87 3.04 27.18

[00249] These data demonstrated successful editing ability of the RNP complex when delivered by the Cell Squeeze platform. Effect of RNP complex amount on editing efficiency

[00250] RNP complex was delivered to unstimulated human T cells using the 30-4 chip and at two different RNP amounts: 1) the standard IX RNP complex (lOug Cas9, 2.5 molar excess of gRNA) and, 2) 0.1X the standard RNP complex amount. At 48 hours post-delivery, a FACS based readout was used to determine B2M protein levels. Reduced B2M expression was used as a measure of functional editing. Plots of B2M expression vs. delivered dextran are shown below for the four different cell populations. Two controls were used; 1) T cells incubated in IX RNP complex at room temperature for the same time as the delivery process using the Cell Squeeze process (endocytosis control), and 2) T cells squeezed with Cas9 protein but no gRNA (FIG. 5).

[00251] B2M expression on the Cas9 control (Cas9 protein with no gRNA) is not significantly different than the endocytosis control. The lower amount of the RNP complex (0.1XRNP) resulted in a 20.7% reduction of B2M positive cells as compared to the 55.4% reduction in B2M positive cells at the higher amount of RNP complex (IX RNP complex (lOug CAS9, 2.5 molar excess of gRNA)). This experiment demonstrates a dose-dependent response directly related to the delivery of the RNP. [00252] 145 Date Regue/Date Received 2022-04-22CA 02971626 2017-06-19 WO 2016/115179 PCT/US2016/013113

[00253] Further, while the description above refers to the invention, the description may include more than one invention.

[00254] The subject matter described herein can be embodied in systems, apparatus, methods, and/or articles depending on the desired configuration. The implementations set forth in the foregoing description do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the described subject matter. Although a few variations have been described in detail above, other modifications or additions are possible. In particular, further features and/or variations can be provided in addition to those set forth herein. For example, the implementations described above can be directed to various combinations and subcombinations of the disclosed features and/or combinations and subcombinations of several further features disclosed above. In addition, the logic flows depicted in the accompanying figures and/or described herein do not necessarily require the particular order shown, or sequential order, to achieve desirable results. Other implementations may be within the scope of the following claims. 146

Claims (55)

1. WHAT IS CLAIMED IS: 1. A method for delivering a protein-nucleic acid complex into a cell, the method comprising: providing a cell in a suspension; passing the suspension through a microfluidic channel that includes a celldeforming constriction, wherein a diameter of the cell-deforming constriction is between 20% to 99% of a diameter of the cell, and wherein the cell-deforming constriction induces perturbations within a membrane of die cell as the cell passes through the cell-deforming constriction, such that die protein-nucleic acid complex enters the cell through die perturbations when contacted with the cell; and contacting the cell comprising the perturbations with the protein-nucleic acid complex; and wherein the diameter of the cell-deforming constriction is between 2 pm and 20 pm, and a pressure between 10 psi and 200 psi is used to pass the suspension through the microfluidic channel.
2. 2. The method of claim 1, wherein the suspension comprises the protein-nucleic acid complex before die passing of the suspension through the microfluidic channel, such that the cell is in contact with the protein-nucleic acid complex when the cell-deforming constriction induces perturbations within the membrane of the cell.
3. 3. The method of claim 1 or 2, wherein the suspension comprises the protein-nucleic acid complex during die passing of the suspension through the microfluidic channel, such that the cell is in contact with the protein-nucleic acid complex when the cell-deforming constriction induces perturbations within the membrane of the cell.
4. 4. The method of any one of claims 1 to 3, wherein the suspension comprises die proteinnucleic acid complex after the passing of the suspension through the microfluidic channel, such that the cell comprising the perturbations is in contact with the protein-nucleic acid complex. 147 Date Refue/Date Received 2023-04-275.
5. The method of any one of claims 1 to 4, wherein the protein-nucleic acid complex comprises one or more gene editing components.
6. 6. The method of any one of claims 1 to 5, wherein the protein-nucleic acid complex comprises a ribonucleoprotein (RNP).
7. 7. The method of claim 6, wherein the RNP comprises: (a) a Cas protein or a Cpfl protein; and (b) a single guide RNA (sgRNA), or a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA).
8. 8. The method of claim 7, wherein the RNP comprises a Cas protein and a sgRNA, and wherein the Cas protein and the sgRNA are complexed at a molar ratio between about 1:10 and about 10:1, respectively.
9. 9. The method of claim 7 or 8, wherein the Cas protein is a Cas9 protein.
10. 10. The method of claim 7, wherein the RNP comprises a Cpfl protein and a sgRNA, and wherein the Cpfl protein and the sgRNA are complexed at a molar ratio between about 1:10 and about 10:1, respectively.
11. 11. The method of any one of claims 6 to 10, wherein the protein-nucleic acid complex comprises a first RNP and a second RNP.
12. 12. The method of claim 11 , wherein the first RNP and the second RNP are both nickases.
13. 13. The method of claim 11 or 12, wherein the first RNP nicks a target sequence different from the target sequence of the second RNP. 148 Date Re^ue/Date Received 2023-04-2714.
14. The method of any one of claims 1 to 5, wherein the protein-nucleic acid complex comprises a transcription activator-like effector nuclease (TALEN) protein, a Zinc finger nuclease, a mega nuclease, or a Cre recombinase.
15. 15. The method of any one of claims 1 to 5, wherein the protein-nucleic acid complex comprises (a) a nucleic acid molecule that is complexed with a protein via electrostatic attraction; (b) a nucleic acid molecule wrapped around a protein; (c) DNA and a histone; (d) a ribosome, an enzyme telomerase, a vault ribonucleoprotein, RNase P, hnRNP, or a small nuclear RNP (snRNP); or (e) a chromosome comprising a protein.
16. 16. The method of any one of claims 1 to 15, wherein the suspension comprises a donor DNA.
17. 17. The method of claim 16, wherein the suspension comprises the donor DNA before the passing of the suspension through the microfluidic channel.
18. 18. The method of claim 16 or 17, wherein the suspension comprises the donor DNA during the passing of die suspension through the microfluidic channel.
19. 19. The method of any one of claims 16 to 18, wherein the suspension comprises the donor DNA after the passing of the suspension through the microfluidic channel.
20. 20. A method for delivering a complex, comprising a small molecule and a RNA, into a cell, the method comprising: providing a cell in a suspension; passing the suspension through a microfluidic channel that includes a cell¬ deforming constriction, wherein a diameter of the cell-deforming constriction is 20-99% of a 149 Date Refue/Date Received 2023-04-27diameter of the cell, and wherein the cell-deforming constriction induces perturbations within a membrane of the cell as the cell passes through the cell-deforming constriction, such that the complex enters the cell through the perturbations when contacted with the cell; and contacting the cell comprising the perturbations with the complex; and wherein the diameter of the cell-deforming constriction is between 2 pm and 20 pm, and a pressure between 10 psi and 200 psi is used to pass the suspension through the microfluidic channel.
21. 21. The method of claim 20, wherein the suspension comprises the complex before the passing of the suspension through the microfluidic channel, such that the cell is in contact with die complex when the cell-deforming constriction induces perturbations within the membrane of the cell.
22. 22. The method of claim 20 or 21, wherein the suspension comprises the complex during the passing of the suspension through the microfluidic channel, such that the cell is in contact with tiie complex when the cell-deforming constriction induces perturbations within the membrane of the cell.
23. 23. The method of any one of claims 20 to 22, wherein the suspension comprises the complex after the passing of the suspension through the microfluidic channel, such that the cell comprising the perturbations is in contact with the complex.
24. 24. The method of any one of claims 1 to 23, wherein the cell is a mammalian cell.
25. 25. The method of any one of claims 1 to 24, wherein the cell is a human cell.
26. 26. The method of any one of claims 1 to 25, wherein the cell is an immune cell.
27. 27. The method of any one of claims 1 to 25, wherein the cell is a stem cell.
28. 28. The method of any one of claims 1 to 25, wherein the cell is an oocyte. 150 Date Refue/Date Received 2023-04-2729.
29. The method of any one of claims 1 to 25, wherein the cell is a zygote.
30. 30. The method of claim 27, wherein the stem cell is a hematopoietic stem cell, an embryonic stem cell, or an induced pluripotent stem cell.
31. 31. The method of claim 26, wherein the immune cell is a T cell, a B cell, a monocyte, or a dendritic cell.
32. 32. The method of claim 26 or 31, wherein the immune cell is a component of circulating blood cells or a component of whole blood.
33. 33. The method of claim 31 or 32, wherein the immune cell is a T cell, and wherein the protein-nucleic acid complex or the complex comprising a small molecule and aRNA comprises gene editing components that are capable of reducing the activity or expression of SHP2.
34. 34. The method of any one of claims 1 to 33, wherein the diameter of tire constriction is between 20% to 60% of the diameter of the cell.
35. 35. The method of any one of claims 1 to 34, wherein the microfluidic channel is one of a plurality of microfluidic channels in a microfluidic system.
36. 36. The method of claim 35, wherein the plurality of microfluidic channels is arranged in parallel.
37. 37. The method of claim 35 or 36, wherein the plurality of microfluidic channels comprises at least 2, 5, 10, 20, 25, 30, 40, 45, 50, 75, 100, 500, 1,000, or 2,000 microfluidic channels.
38. 38. The method of any one of claims 35 to 37, wherein the cell is one of a plurality of cells, and each cell of the plurality of cells is passed through one of the plurality of microfluidic 151 Date Refue/Date Received 2023-04-27channels, and wherein each microfluidic channel of the plurality of microfluidic channels includes a cell-deforming constriction.
39. 39. The method of any one of claims 1 to 38, wherein the diameter of die cell-deforming constriction is 2 pm, 3 pm, 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm, 15 pm, 20 pm.
40. 40. The method of claim 39, wherein the diameter of the cell-deforming constriction is between 2 pm and 10 pm or between 10 pm to 20 pm.
41. 41. The method of any one of claims 1 to 40, wherein a length of the cell-deforming constriction is at least 10 pm, 15 pm, 20 pm, 24 pm, 30 pm, 40 pm, 50 pm, 60 pm, 70 pm, 80 pm, 90 pm, or 100 pm.
42. 42. The method of claim 41, wherein the length of the cell-deforming constriction is between 10 pm and 40 pm, between 10 pm and 50 pm, between 10 pm and 60 pm, or between 10 pm and 100 pm.
43. 43. The method of any one of claims 1 to 42, wherein the pressure is about 10 psi, 20 psi, 30 psi, 40 psi, 50 psi, 60 psi, 70 psi, 80 psi, 90 psi, 100 psi, 110 psi, 120 psi, 130 psi, 140 psi, 150 psi, 160 psi, 170 psi, 180 psi, 190 psi, or 200 psi.
44. 44. The method of claim 43, wherein the pressure is between 10 psi and 100 psi.
45. 45. The method of any one of claims 1 to 44, wherein the cell passes through the cell¬ deforming constriction at a speed of at least 300 mm/s, 400 mm/s, 500 mm/s, 600 mm/s, 700 mm/s, 800 mm/s, 900 mm/s, 100-300 mm/s, 200-700 mm/s, 250-400 mm/s, 100-1000 mm/s, 1- 1000 mm/s, 1 m/s, 2 m/s, 3 m/s, 4 m/s, 5 m/s, 6 m/s, 7 m/s, 8 m/s, 9 m/s, 10 m/s, 0.01-5 m/s, 5- 10 m/s, or 0.01-10 m/s. 152 Date Refue/Date Received 2023-04-2746.
46. The method of any one of claims 1 to 45, wherein the microfluidic channel comprises multiple cell-deforming constrictions.
47. 47. The method of claim 46, wherein the multiple cell-deforming constrictions are in series.
48. 48. The method of claim 46 or 47, wherein the multiple cell-deforming constrictions are in parallel.
49. 49. The method of any one of claims 1 to 45, wherein the microfluidic channel comprises a single cell-deforming constriction.
50. 50. The method of any one of claims 1 to 49, wherein the perturbations include a maximum diameter of between 1-20 nm, between 1-600 nm, at least 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 12 nm, 14 nm, 16 nm, 18 nm, 20 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, or 600 nm.
51. 51. The method of any one of claims 1 to 50, wherein the perturbations persist for at least 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, or between 1-10 minutes.
52. 52. The method of any one of claims 1 to 51, wherein (a) the expression of a target gene in the cell is reduced by at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is reduced by at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more, after the protein-nucleic acid complex or the complex comprising the small molecule and RNA is delivered to the cell. 153 Date Refue/Date Received 2023-04-2753.
53. The method of claim 52, wherein (a) the expression of a target gene in the cell is reduced by at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is reduced by at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more, about 1, 2, 5, 12, 24, 1-12, 6-12, 6-18, 12-24, or 1-24 hours after the protein-nucleic acid complex or the complex comprising the small molecule and RNA is delivered to the cell.
54. 54. The method of any one of claims 1 to 51, wherein (a) the expression of a target gene in the cell is increased by at least 5, 10, 25, 50, 75, 100, 250, 500% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is increased by at least 5, 10, 25, 50, 75, 100, 250, 500% or more, after the protein-nucleic acid complex or the complex comprising the small molecule and RNA is delivered to the cell.
55. 55. The method of claim 54, wherein (a) the expression of a target gene in the cell is increased by at least 5, 10, 25, 50, 75, 100, 250, 500% or more; or (b) the cell is a plurality of cells and the expression of a target gene in the plurality of cells is increased by at least 5, 10, 25, 50, 75, 100, 250, 500% or more, about 1, 2, 5, 12, 24, 1-12, 6-12, 6-18, 12-24, or 1-24 hours after die protein-nucleic acid complex or the complex comprising the small molecule and RNA is delivered to die cell. 154 Date Refue/Date Received 2023-04-27